

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

**CUMULATIVE
SUPPLEMENT 11
NOVEMBER 2013**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

33rd EDITION

Department of Health and Human Services

**Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs**

2013

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

33rd EDITION

Cumulative Supplement 11

November 2013

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition	vi
1.6 Report of Counts for the Prescription Drug Product List	vii
1.7 Cumulative Supplement Legend	viii
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

33rd EDITION

**CUMULATIVE SUPPLEMENT 11
November 2013**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 32nd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 33rd Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
BIONICHE PHARMA USA LLC (BIONICHE PHARMA USA)	MYLAN INSTITUTIONAL LLC (MYLAN LLC)
BOCA PHARMACAL INC (BOCA PHARMA)	BOCA PHARMACAL LLC (BOCA PHARMA LLC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2012) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2012</u>	<u>MAR 2013</u>	<u>JUN 2013</u>	<u>SEPT 2013</u>	<u>DEC 2013</u>
DRUG PRODUCTS LISTED	15343	15445	15408	15472	
SINGLE SOURCE	2400 (15.9%)	2467 (16.0%)	2440 (15.8%)	2502 (16.2)	
MULTISOURCE	12825 (83.6%)	12900 (83.5%)	12890 (83.7%)	12970 (83.8%)	
THERAPEUTICALLY EQUIVALENT	12683 (82.7%)	12758 (82.6%)	12750 (82.7%)	12827 (82.9%)	
NOT THERAPEUTICALLY EQUIVALENT	142 (0.9%)	142 (0.9%)	140 (0.9%)	143 (0.9%)	
EXCEPTIONS ¹	78 (0.5%)	78 (0.5%)	78 (0.5%)	78 (0.5%)	
NEW MOLECULAR ENTITIES APPROVED	17	9	5	8	
NUMBER OF APPLICANTS	835	844	841	832	

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.

CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ABACAVIR SULFATE

TABLET; ORAL						
ABACAVIR SULFATE						
AB	HETERO LABS LTD III	EQ 300MG BASE	A091560	001	Sep 13, 2013	Aug NEWA

ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL						
>A>	ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE					
>A> AB	LUPIN LTD	EQ 300MG BASE;150MG;300MG	A202912	001	Dec 05, 2013	Nov NEWA
	TRIZIVIR					
>D>	+ VIIV HLTHCARE	EQ 300MG BASE;150MG;300MG	N021205	001	Nov 14, 2000	Nov CFTG
>A> AB	+	EQ 300MG BASE;150MG;300MG	N021205	001	Nov 14, 2000	Nov CFTG

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE; ORAL						
ACAMPROSATE CALCIUM						
>A> AB	BARR LABS DIV TEVA	333MG	A200143	001	Nov 18, 2013	Nov NEWA
AB	GLENMARK GENERICS	333MG	A202229	001	Jul 16, 2013	Jul NEWA
	CAMPRAL					
AB	+ FOREST LABS	333MG	N021431	001	Jul 29, 2004	Jul CFTG

ACARBOSE

TABLET; ORAL						
ACARBOSE						
AB	VIRTUS PHARM	25MG	A091343	001	Oct 17, 2013	Sep NEWA
AB		50MG	A091343	002	Oct 17, 2013	Sep NEWA
AB		100MG	A091343	003	Oct 17, 2013	Sep NEWA

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL						
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE						
	@ WEST WARD	500MG;50MG;40MG	A040261	001	Oct 28, 1998	Jul DISC
	ESGIC-PLUS					
	+ MIKART	500MG;50MG;40MG	A040085	001	Mar 28, 1996	Jul CTEC
TABLET; ORAL						
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE						
	@ MIRROR PHARMS LLC	500MG;50MG;40MG	A040883	001	Dec 23, 2008	Feb DISC
	@ WEST WARD	500MG;50MG;40MG	A040336	001	Aug 18, 1999	Aug DISC

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL						
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE						
	@ MIKART	356.4MG;30MG;16MG	A040109	001	Aug 26, 1997	Feb DISC
	@ WRASER PHARMS LLC	356.4MG;30MG;16MG	A040688	001	Apr 03, 2007	Jun DISC
TABLET; ORAL						
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE						
	@ MIKART	712.8MG;60MG;32MG	A040316	001	Apr 28, 1999	Feb DISC

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL						
ACETAMINOPHEN AND CODEINE PHOSPHATE						
AA	AUROLIFE PHARMA LLC	300MG;15MG	A202800	001	Apr 15, 2013	Apr NEWA
AA		300MG;30MG	A202800	002	Apr 15, 2013	Apr NEWA
AA		300MG;60MG	A202800	003	Apr 15, 2013	Apr NEWA
	@ MIKART	300MG;30MG	A089238	001	Feb 25, 1986	Jun DISC
	@	650MG;30MG	A089231	001	Mar 03, 1986	Feb DISC
	@	650MG;60MG	A089363	001	Sep 09, 1991	Feb DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL						
HYDROCODONE BITARTRATE AND ACETAMINOPHEN						
	@ MIKART	500MG;5MG	A081067	001	Nov 30, 1989	Feb DISC
	@	500MG;5MG	A089008	001	Feb 21, 1986	Jun DISC
SOLUTION; ORAL						
HYDROCODONE BITARTRATE AND ACETAMINOPHEN						
AA	PAI	325MG/15ML;7.5MG/15ML	A040838	001	May 10, 2013	Apr NEWA
TABLET; ORAL						
CO-GESIC						
>D> AA	UCB INC	500MG;5MG	A087757	001	May 03, 1982	Nov DISC

TABLET;ORAL							
CO-GESIC							
>A>	@	500MG;5MG	A087757	001	May 03, 1982	Nov	DISC
	HYDROCODONE BITARTRATE AND ACETAMINOPHEN						
AA	CARACO	325MG;5MG	A090118	001	Dec 23, 2008	May	CAHN
AA		325MG;7.5MG	A090118	002	Dec 23, 2008	May	CAHN
AA		325MG;10MG	A090118	003	Dec 23, 2008	May	CAHN
AA		500MG;5MG	A090265	001	Dec 23, 2008	May	CAHN
AA		500MG;7.5MG	A090265	002	Dec 23, 2008	May	CAHN
AA		500MG;10MG	A090265	003	Dec 23, 2008	May	CAHN
AA		650MG;7.5MG	A090380	001	Dec 23, 2008	Jun	CAHN
AA		650MG;10MG	A090380	002	Dec 23, 2008	Jun	CAHN
AA		660MG;10MG	A090380	003	Dec 23, 2008	Jun	CAHN
AA		750MG;7.5MG	A090380	004	Dec 23, 2008	Jun	CAHN
	+ MIKART	325MG;2.5MG	A040846	001	Jun 09, 2010	Jul	CRLD
	@	500MG;2.5MG	A089698	001	Aug 25, 1989	Feb	DISC
	@	650MG;5MG	A040849	001	Jun 09, 2010	Feb	DISC
AA	TRIS PHARMA INC	325MG;5MG	A202214	001	Mar 27, 2013	Mar	NEWA
AA		325MG;7.5MG	A202214	002	Mar 27, 2013	Mar	NEWA
AA		325MG;10MG	A202214	003	Mar 27, 2013	Mar	NEWA
<u>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE</u>							
TABLET;ORAL							
OXYCODONE AND ACETAMINOPHEN							
AA	ACTAVIS ELIZABETH	325MG;2.5MG	A201447	001	Apr 12, 2013	Apr	NEWA
AA		325MG;5MG	A201447	002	Apr 12, 2013	Apr	NEWA
AA		325MG;7.5MG	A201447	003	Apr 12, 2013	Apr	NEWA
AA		325MG;10MG	A201447	004	Apr 12, 2013	Apr	NEWA
AA	AUROLIFE PHARMA LLC	325MG;2.5MG	A201972	001	Jul 15, 2013	Jul	NEWA
AA		325MG;5MG	A201972	002	Jul 15, 2013	Jul	NEWA
AA		325MG;7.5MG	A201972	003	Jul 15, 2013	Jul	NEWA
AA		325MG;10MG	A201972	004	Jul 15, 2013	Jul	NEWA
	@ MIKART	400MG;2.5MG	A040679	001	May 16, 2006	Jul	DISC
AA	VINTAGE PHARMS	325MG;2.5MG	A090733	001	Jul 11, 2013	Jul	NEWA
AA		325MG;7.5MG	A090734	001	Jul 11, 2013	Jul	NEWA
AA		325MG;10MG	A090734	002	Jul 11, 2013	Jul	NEWA
	ROXICET 5/500						
	@ ROXANE	500MG;5MG	A089775	001	Jan 12, 1989	Aug	DISC
<u>ACETAZOLAMIDE</u>							
TABLET;ORAL							
ACETAZOLAMIDE							
	@ WATSON LABS	250MG	A088882	001	Oct 22, 1985	Jan	DISC
<u>ACETAZOLAMIDE SODIUM</u>							
INJECTABLE;INJECTION							
ACETAZOLAMIDE SODIUM							
AP	SAGENT AGILA	EQ 500MG BASE/VIAL	A200880	001	May 09, 2012	Jan	CAHN
<u>ACITRETIN</u>							
CAPSULE;ORAL							
ACITRETIN							
AB	BARR LABS INC	10MG	A091455	001	Apr 04, 2013	Mar	NEWA
AB		25MG	A091455	002	Apr 04, 2013	Mar	NEWA
AB	TEVA PHARMS USA	17.5MG	A202897	001	Apr 04, 2013	Mar	NEWA
AB		22.5MG	A202897	002	Apr 04, 2013	Mar	NEWA
SORIATANE							
AB	STIEFEL LABS INC	10MG	N019821	001	Oct 28, 1996	Mar	CFTG
AB		17.5MG	N019821	003	Aug 06, 2009	Mar	CFTG
AB		22.5MG	N019821	004	Aug 06, 2009	Mar	CFTG
AB	+	25MG	N019821	002	Oct 28, 1996	Mar	CFTG
<u>ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE</u>							
CAPSULE;ORAL							
SEMPREX-D							
	+ ACTIENT PHARMS	8MG;60MG	N019806	001	Mar 25, 1994	May	CAHN

ACYCLOVIR

	CAPSULE;ORAL						
	ACYCLOVIR						
	@ MYLAN	200MG	A074977	001	Apr 13, 1998	Aug	DISC
	@ WATSON LABS	200MG	A075101	001	Apr 15, 1998	Sep	DISC
	CREAM;TOPICAL						
	ZOVIRAX						
	+ VALEANT BERMUDA	5%	N021478	001	Dec 30, 2002	Jul	CAHN
	OINTMENT;TOPICAL						
	ACYCLOVIR						
AB	MYLAN PHARMS INC	5%	A202459	001	Apr 03, 2013	Mar	NEWA
	ZOVIRAX						
AB	+ VALEANT BERMUDA	5%	N018604	001	Mar 29, 1982	May	CAHN
AB	+ VALEANT INTL	5%	N018604	001	Mar 29, 1982	Mar	CFTG
	SUSPENSION;ORAL						
	ZOVIRAX						
AB	+ DELCOR ASSET	200MG/5ML	N019909	001	Dec 22, 1989	Jun	CAHN
	TABLET;BUCCAL						
	SITAVIG						
	@ BIOALLIANCE PHARMA	50MG	N203791	001	Apr 12, 2013	Sep	DISC
	+	50MG	N203791	001	Apr 12, 2013	Apr	NEWA
	TABLET;ORAL						
	ACYCLOVIR						
AB	CADILA PHARMS LTD	400MG	A202168	001	Nov 15, 2013	Oct	NEWA
AB		800MG	A202168	002	Nov 15, 2013	Oct	NEWA
AB	HETERO LABS LTD V	400MG	A203834	001	Oct 29, 2013	Oct	NEWA
AB		800MG	A203834	002	Oct 29, 2013	Oct	NEWA
	@ MYLAN	400MG	A074976	001	Apr 13, 1998	Aug	DISC
	@	800MG	A074976	002	Apr 13, 1998	Aug	DISC

ACYCLOVIR SODIUM

	INJECTABLE;INJECTION						
	ACYCLOVIR SODIUM						
AP	AUROBINDO PHARMA LTD	EQ 50MG BASE/ML	A203701	001	Oct 11, 2013	Sep	NEWA

ACYCLOVIR; HYDROCORTISONE

	CREAM;TOPICAL						
	XERESE						
	+ VALEANT BERMUDA	5%;1%	N022436	001	Jul 31, 2009	Apr	CAHN

ADEFOVIR DIPIVOXIL

	TABLET;ORAL						
	ADEFOVIR DIPIVOXIL						
AB	SIGMAPHARM LABS LLC	10MG	A202051	001	Aug 29, 2013	Aug	NEWA
	HEPSERA						
AB	+ GILEAD	10MG	N021449	001	Sep 20, 2002	Aug	CFTG

ADENOSINE

	INJECTABLE;INJECTION						
	ADENOSCAN						
AP	+ ASTELLAS	3MG/ML	N020059	001	May 18, 1995	Aug	CTEC
	ADENOSINE						
	@ TEVA PHARMS USA	3MG/ML	A076564	001	Jun 16, 2004	Apr	CAHN
AP		3MG/ML	A077425	001	Aug 29, 2013	Aug	NEWA
	@	3MG/ML	A078676	001	Jul 31, 2008	Apr	CAHN

AFATINIB DIMALEATE

	TABLET;ORAL						
	GILOTRIF						
	BOEHRINGER INGELHEIM	EQ 20MG BASE	N201292	001	Jul 12, 2013	Jul	NEWA
		EQ 30MG BASE	N201292	002	Jul 12, 2013	Jul	NEWA
	+	EQ 40MG BASE	N201292	003	Jul 12, 2013	Jul	NEWA

ALBENDAZOLE

	TABLET;ORAL						
	ALBENZA						
	+ AMEDRA PHARMS	200MG	N020666	001	Jun 11, 1996	Feb	CAHN

ALBUTEROL SULFATEAEROSOL, METERED; INHALATION
PROAIR HFA

BX	+	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N021457	001	Oct 29, 2004	Apr CAHN
		VENTOLIN HFA					
BX	+	GLAXO GRP LTD	EQ 0.09MG BASE/INH	N020983	001	Apr 19, 2001	May CAHN
		SOLUTION; INHALATION					
		ALBUTEROL SULFATE					
		@ APOTEX INC	EQ 0.021% BASE	A078623	001	Apr 05, 2010	Apr DISC
		@	EQ 0.042% BASE	A078623	002	Apr 05, 2010	Apr DISC
		@	EQ 0.083% BASE	A075717	001	Feb 02, 2007	Apr DISC
		@	EQ 0.5% BASE	A076391	001	Apr 01, 2003	Apr DISC
AN	+	MYLAN SPECLT	EQ 0.083% BASE	A072652	001	Feb 21, 1992	Jan CAHN
		@ WOCKHARDT EU OPERATN	EQ 0.083% BASE	A075394	001	Nov 22, 1999	Mar DISC

ALBUTEROL SULFATE; IPRATROPIUM BROMIDESOLUTION; INHALATION
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

		@ APOTEX INC	EQ 0.083% BASE; 0.017%	A077117	001	Dec 31, 2007	Apr DISC
AN		CIPLA LTD	EQ 0.083% BASE; 0.017%	A077559	001	Dec 31, 2007	Aug CAHN

ALENDRONATE SODIUMSOLUTION; ORAL
ALENDRONATE SODIUM

AA		ROXANE	EQ 70MG BASE/75ML	A090520	001	Feb 25, 2013	Feb NEWA
		FOSAMAX					
AA	+	MERCK	EQ 70MG BASE/75ML	N021575	001	Sep 17, 2003	Feb CFTG
		TABLET; ORAL					
		ALENDRONATE SODIUM					
AB		CIPLA LTD	EQ 5MG BASE	A076768	001	Aug 04, 2008	Jul CAHN
AB			EQ 10MG BASE	A076768	002	Aug 04, 2008	Jul CAHN
AB			EQ 35MG BASE	A076768	003	Aug 04, 2008	Jul CAHN
AB			EQ 40MG BASE	A076768	004	Aug 04, 2008	Jul CAHN
AB			EQ 70MG BASE	A076768	005	Aug 04, 2008	Jul CAHN
		@ MYLAN	EQ 35MG BASE	A078638	001	Aug 04, 2008	Aug DISC
		@	EQ 70MG BASE	A078638	002	Aug 04, 2008	Aug DISC
		FOSAMAX					
>D> AB		MERCK AND CO INC	EQ 5MG BASE	N020560	003	Apr 25, 1997	Nov DISC
>A>		@	EQ 5MG BASE	N020560	003	Apr 25, 1997	Nov DISC
>D> AB			EQ 10MG BASE	N020560	001	Sep 29, 1995	Nov DISC
>A>		@	EQ 10MG BASE	N020560	001	Sep 29, 1995	Nov DISC
>D> AB			EQ 35MG BASE	N020560	004	Oct 20, 2000	Nov DISC
>A>		@	EQ 35MG BASE	N020560	004	Oct 20, 2000	Nov DISC
>D> AB			EQ 40MG BASE	N020560	002	Sep 29, 1995	Nov DISC
>A>		@	EQ 40MG BASE	N020560	002	Sep 29, 1995	Nov DISC

ALFUZOSIN HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL
UROXATRAL

AB	+	COVIS PHARMA SARL	10MG	N021287	001	Jun 12, 2003	Apr CAHN
----	---	-------------------	------	---------	-----	--------------	----------

ALLOPURINOLTABLET; ORAL
ALLOPURINOL

AB		ACCORD HLTHCARE	100MG	A203154	001	May 06, 2013	Apr NEWA
AB			300MG	A203154	002	May 06, 2013	Apr NEWA

ALOGLIPTIN BENZOATETABLET; ORAL
NESINA

		TAKEDA PHARMS USA	EQ 6.25MG BASE	N022271	001	Jan 25, 2013	Jan NEWA
			EQ 12.5MG BASE	N022271	002	Jan 25, 2013	Jan NEWA
	+		EQ 25MG BASE	N022271	003	Jan 25, 2013	Jan NEWA

ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDETABLET; ORAL
KAZANO

	+	TAKEDA PHARMS USA	EQ 12.5MG BASE; 1GM	N203414	002	Jan 25, 2013	Jan NEWA
			EQ 12.5MG BASE; 500MG	N203414	001	Jan 25, 2013	Jan NEWA

ALOGLIPTIN BENZOATE; PIOGLITAZONE

TABLET; ORAL

OSEN

TAKEDA PHARMS USA	EQ 12.5MG BASE;15MG	N022426	004	Jan 25, 2013	Jan NEWA
	EQ 12.5MG BASE;30MG	N022426	005	Jan 25, 2013	Jan NEWA
	EQ 12.5MG BASE;45MG	N022426	006	Jan 25, 2013	Jan NEWA
	EQ 25MG BASE;15MG	N022426	001	Jan 25, 2013	Jan NEWA
	EQ 25MG BASE;30MG	N022426	002	Jan 25, 2013	Jan NEWA
+	EQ 25MG BASE;45MG	N022426	003	Jan 25, 2013	Jan NEWA

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

OSEN

TAKEDA PHARMS USA	EQ 12.5MG BASE;EQ 15MG BASE	N022426	004	Jan 25, 2013	Feb CAIN
	EQ 12.5MG BASE;EQ 30MG BASE	N022426	005	Jan 25, 2013	Feb CAIN
	EQ 12.5MG BASE;EQ 45MG BASE	N022426	006	Jan 25, 2013	Feb CAIN
	EQ 25MG BASE;EQ 15MG BASE	N022426	001	Jan 25, 2013	Feb CAIN
	EQ 25MG BASE;EQ 30MG BASE	N022426	002	Jan 25, 2013	Feb CAIN
+	EQ 25MG BASE;EQ 45MG BASE	N022426	003	Jan 25, 2013	Feb CAIN

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

@ TEVA PHARMS USA	0.5MG	A077979	001	Feb 28, 2007	Jun DISC
@	1MG	A077979	002	Feb 28, 2007	Jun DISC
@	2MG	A077979	003	Feb 28, 2007	Jun DISC
@	3MG	A077979	004	Feb 28, 2007	Jun DISC

ALPROSTADIL

INJECTABLE; INJECTION

ALPROSTADIL

AP	TEVA PHARMS USA	0.5MG/ML	A075196	001	Apr 30, 1999	Apr CAHN
----	-----------------	----------	---------	-----	--------------	----------

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

	@ HOSPIRA	EQ 250MG BASE/ML	A063264	001	Nov 30, 1994	Mar DISC
	@ TEVA PHARMS USA	EQ 50MG BASE/ML	A064045	001	Sep 28, 1993	Jun CAHN
AP		EQ 250MG BASE/ML	A064045	002	Sep 28, 1993	Jun CAHN

AMINO ACIDS

INJECTABLE; INJECTION

AMINOSYN-HF 8%

>D>	HOSPIRA	8% (8GM/100ML)	1020345	001	Apr 04, 1996	Nov CMS2
>A>		8% (8GM/100ML)	A020345	001	Apr 04, 1996	Nov CMS2

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE

@ INTL MEDICATION	25MG/ML	A087209	001	Feb 01, 1982	Jun DISC
@ PHARMA SERVE NY	25MG/ML	A087392	001	Dec 15, 1983	Jun DISC

TABLET; ORAL

AMINOPHYLLINE

@ WEST WARD	100MG	A084540	001		Jul DISC
@	200MG	A085003	001		Jul DISC

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

	@ AGILA SPECLTS	50MG/ML	A076394	001	Apr 25, 2003	Aug CAHN
	@ APOTEX INC	50MG/ML	A076394	001	Apr 25, 2003	Apr DISC
>A> AP	HOSPIRA INC	50MG/ML	A203884	001	Nov 25, 2013	Nov NEWA
>A> AP		50MG/ML	A203885	001	Nov 25, 2013	Nov NEWA
AP	+	MYLAN INSTITUTIONAL	A076217	001	Oct 15, 2002	Apr CAHN
	@ TEVA PHARMS USA	50MG/ML	A076163	001	Sep 05, 2003	Apr CAHN

AMLEXANOX

PASTE;DENTAL
APHTHASOL
@ ULURU

5%

N020511 001 Dec 17, 1996 Jun DISC

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

AB	ACCORD HLTHCARE	EQ 2.5MG BASE	A202553	001	Apr 29, 2013	Apr	NEWA
AB		EQ 5MG BASE	A202553	002	Apr 29, 2013	Apr	NEWA
AB		EQ 10MG BASE	A202553	003	Apr 29, 2013	Apr	NEWA
AB	CIPLA LTD	EQ 2.5MG BASE	A077073	001	Sep 26, 2007	Aug	CAHN
AB		EQ 5MG BASE	A077073	002	Sep 26, 2007	Aug	CAHN
AB		EQ 10MG BASE	A077073	003	Sep 26, 2007	Aug	CAHN
AB	UNICHEM LABS LTD	EQ 2.5MG BASE	A203245	001	Oct 21, 2013	Oct	NEWA
AB		EQ 5MG BASE	A203245	002	Oct 21, 2013	Oct	NEWA
AB		EQ 10MG BASE	A203245	003	Oct 21, 2013	Oct	NEWA

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET;ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

>A>	MYLAN PHARMS INC	EQ 2.5MG BASE;EQ 10MG BASE	A200465	001	Nov 29, 2013	Nov	NEWA
>A> AB		EQ 2.5MG BASE;EQ 20MG BASE	A200465	002	Nov 29, 2013	Nov	NEWA
>A> AB		EQ 2.5MG BASE;EQ 40MG BASE	A200465	003	Nov 29, 2013	Nov	NEWA
>A> AB		EQ 5MG BASE;EQ 10MG BASE	A200465	004	Nov 29, 2013	Nov	NEWA
>A> AB		EQ 5MG BASE;EQ 20MG BASE	A200465	005	Nov 29, 2013	Nov	NEWA
>A> AB		EQ 5MG BASE;EQ 40MG BASE	A200465	006	Nov 29, 2013	Nov	NEWA
>A> AB		EQ 5MG BASE;EQ 80MG BASE	A200465	007	Nov 29, 2013	Nov	NEWA
>A> AB		EQ 10MG BASE;EQ 10MG BASE	A200465	008	Nov 29, 2013	Nov	NEWA
>A> AB		EQ 10MG BASE;EQ 20MG BASE	A200465	009	Nov 29, 2013	Nov	NEWA
>A> AB		EQ 10MG BASE;EQ 40MG BASE	A200465	010	Nov 29, 2013	Nov	NEWA
>A> AB		EQ 10MG BASE;EQ 80MG BASE	A200465	011	Nov 29, 2013	Nov	NEWA
>D>	CADUET						
>D>	PFIZER	EQ 2.5MG BASE;EQ 10MG BASE	N021540	009	Jul 29, 2004	Nov	CFTG
>A> AB		EQ 2.5MG BASE;EQ 10MG BASE	N021540	009	Jul 29, 2004	Nov	CFTG
>D>		EQ 2.5MG BASE;EQ 20MG BASE	N021540	010	Jul 29, 2004	Nov	CFTG
>A> AB		EQ 2.5MG BASE;EQ 20MG BASE	N021540	010	Jul 29, 2004	Nov	CFTG
>D>		EQ 2.5MG BASE;EQ 40MG BASE	N021540	011	Jul 29, 2004	Nov	CFTG
>A> AB		EQ 2.5MG BASE;EQ 40MG BASE	N021540	011	Jul 29, 2004	Nov	CFTG
>D>		EQ 5MG BASE;EQ 10MG BASE	N021540	001	Jan 30, 2004	Nov	CFTG
>A> AB		EQ 5MG BASE;EQ 10MG BASE	N021540	001	Jan 30, 2004	Nov	CFTG
>D>		EQ 5MG BASE;EQ 20MG BASE	N021540	002	Jan 30, 2004	Nov	CFTG
>A> AB		EQ 5MG BASE;EQ 20MG BASE	N021540	002	Jan 30, 2004	Nov	CFTG
>D>		EQ 5MG BASE;EQ 40MG BASE	N021540	003	Jan 30, 2004	Nov	CFTG
>A> AB		EQ 5MG BASE;EQ 40MG BASE	N021540	003	Jan 30, 2004	Nov	CFTG
>D>		EQ 5MG BASE;EQ 80MG BASE	N021540	004	Jan 30, 2004	Nov	CFTG
>A> AB		EQ 5MG BASE;EQ 80MG BASE	N021540	004	Jan 30, 2004	Nov	CFTG
>D>		EQ 10MG BASE;EQ 10MG BASE	N021540	005	Jan 30, 2004	Nov	CFTG
>A> AB		EQ 10MG BASE;EQ 10MG BASE	N021540	005	Jan 30, 2004	Nov	CFTG
>D>		EQ 10MG BASE;EQ 20MG BASE	N021540	006	Jan 30, 2004	Nov	CFTG
>A> AB		EQ 10MG BASE;EQ 20MG BASE	N021540	006	Jan 30, 2004	Nov	CFTG
>D>		EQ 10MG BASE;EQ 40MG BASE	N021540	007	Jan 30, 2004	Nov	CFTG
>A> AB		EQ 10MG BASE;EQ 40MG BASE	N021540	007	Jan 30, 2004	Nov	CFTG
>D>	+	EQ 10MG BASE;EQ 80MG BASE	N021540	008	Jan 30, 2004	Nov	CFTG
>A> AB	+	EQ 10MG BASE;EQ 80MG BASE	N021540	008	Jan 30, 2004	Nov	CFTG

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB	PAR PHARM INC	EQ 5MG BASE;160MG	A090011	001	Mar 28, 2013	Mar	NEWA
AB		EQ 5MG BASE;320MG	A090144	001	Mar 28, 2013	Mar	NEWA
AB		EQ 10MG BASE;160MG	A090011	002	Mar 28, 2013	Mar	NEWA
AB		EQ 10MG BASE;320MG	A090011	004	Mar 28, 2013	Mar	NEWA
	EXFORGE						
AB	NOVARTIS	EQ 5MG BASE;160MG	N021990	002	Jun 20, 2007	Mar	CFTG
AB		EQ 5MG BASE;320MG	N021990	004	Jun 20, 2007	Mar	CFTG
AB	+	EQ 10MG BASE;160MG	N021990	003	Jun 20, 2007	Mar	CFTG
AB	+	EQ 10MG BASE;320MG	N021990	005	Jun 20, 2007	Mar	CFTG

AMMONIA N-13INJECTABLE; INTRAVENOUS
AMMONIA N 13

AP	CARDINAL HEALTH 414	30MCI-300MCI/8ML (3.75-37.5MCI/ML)	A203700	001	Feb 25, 2013	Feb NEWA
AP	+ FEINSTEIN	30MCI-300MCI/8ML (3.75-37.5MCI/ML)	N022119	001	Aug 23, 2007	Feb CFTG
>A> AP	KREITCHMAN PET CTR	30MCI-300MCI/8ML (3.75-37.5MCI/ML)	A203938	001	Dec 09, 2013	Nov NEWA
AP	MCPRF	30MCI-300MCI/8ML (3.75-37.5MCI/ML)	A203321	001	Feb 25, 2013	Feb NEWA
AP	UCLA BIOMEDICAL	30MCI-300MCI/8ML (3.75-37.5MCI/ML)	A203812	001	Jun 27, 2013	Jun NEWA

AMOXICILLINFOR SUSPENSION; ORAL
AMOXICILLIN

@ RANBAXY	200MG/5ML	A065113	001	Nov 29, 2002	Feb DISC
@	400MG/5ML	A065113	002	Nov 29, 2002	Feb DISC

TABLET; ORAL

@ DAVA PHARMS INC	875MG	A065344	001	Jan 15, 2009	Jun DISC
-------------------	-------	---------	-----	--------------	----------

TABLET, CHEWABLE; ORAL

@ DAVA PHARMS INC	125MG	A064139	001	Jan 29, 1996	Mar DISC
@	250MG	A064139	002	Jan 29, 1996	Mar DISC
@ RANBAXY	200MG	A065060	001	Nov 29, 2000	Feb DISC
@	400MG	A065060	002	Nov 29, 2000	Feb DISC

AMOXIL

@ DR REDDYS LABS INC	200MG	N050761	001	Apr 15, 1999	Feb DISC
@	400MG	N050761	002	Apr 15, 1999	Feb DISC

TABLET, FOR SUSPENSION; ORAL

@ AUROBINDO PHARMA LTD	200MG	A065324	001	Jan 17, 2007	Jan DISC
@	400MG	A065324	002	Jan 17, 2007	Jan DISC

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLECAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET; ORAL
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

AB	TEVA PHARMS USA	500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, 30MG	A200218	001	Aug 30, 2013	Aug NEWA
AB	+ PREVPAC					
AB	+ TAKEDA PHARMS USA	500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, 30MG	N050757	001	Dec 02, 1997	Aug CFTG

AMOXICILLIN; CLAVULANATE POTASSIUMFOR SUSPENSION; ORAL
AMOXICILLIN AND CLAVULANATE POTASSIUM

>A> AB	WOCKHARDT EU OPERATN	600MG/5ML; EQ 42.9MG BASE/5ML	A065420	001	Dec 02, 2013	Nov NEWA
	TABLET; ORAL					
	AMOXICILLIN AND CLAVULANATE POTASSIUM					
	@ APOTEX INC	250MG; EQ 125MG BASE	A065333	001	Feb 24, 2009	Apr DISC
	@	500MG; EQ 125MG BASE	A065333	002	Feb 24, 2009	Apr DISC
	@	875MG; EQ 125MG BASE	A065317	003	Oct 20, 2008	Apr DISC
	@ RANBAXY LABS	500MG; EQ 125MG BASE	A065109	001	Nov 04, 2002	Apr DISC
AB	TEVA PHARMS USA	875MG; EQ 125MG BASE	A065096	001	Oct 29, 2002	Apr CRLD
	AUGMENTIN '250'					
AB	+ DR REDDYS LABS INC	250MG; EQ 125MG BASE	N050564	001	Aug 06, 1984	Apr CRLD
	AUGMENTIN '500'					
AB	+ DR REDDYS LABS INC	500MG; EQ 125MG BASE	N050564	002	Aug 06, 1984	Apr CRLD
	AUGMENTIN '875'					
AB	+ DR REDDYS LABS INC	875MG; EQ 125MG BASE	N050720	001	Feb 13, 1996	Apr CRLD

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

AMPHETAMINE ASP AMPHETAMINE SULF DEXTROAMPHET SACCHARATE & DEXTR SULF

AB	TEVA	1.25MG; 1.25MG; 1.25MG; 1.25MG	A077488	001	Apr 29, 2013	Apr NEWA
AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A077488	002	Apr 29, 2013	Apr NEWA
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A077488	003	Apr 29, 2013	Apr NEWA
AB		5MG; 5MG; 5MG; 5MG	A077488	004	Apr 29, 2013	Apr NEWA
AB		6.25MG; 6.25MG; 6.25MG; 6.25MG	A077488	005	Apr 29, 2013	Apr NEWA
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A077488	006	Apr 29, 2013	Apr NEWA
	DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE					
AB	BARR LABS INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A076536	001	Feb 12, 2013	Jan NEWA
AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A076536	002	Feb 12, 2013	Jan NEWA
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A076536	003	Feb 12, 2013	Jan NEWA

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE,AMP ASPARTATE,DEXTROAMP SULFATE AND AMP SULFATE

AB		5MG;5MG;5MG;5MG	A076536	004	Feb 12, 2013	Jan NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A076536	005	Feb 12, 2013	Jan NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A076536	006	Feb 12, 2013	Jan NEWA

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

>A>	AB	AUROLIFE PHARMA LLC	1.25MG;1.25MG;1.25MG;1.25MG	A202424	001	Nov 27, 2013	Nov NEWA
>A>	AB		1.875MG;1.875MG;1.875MG;1.875MG	A202424	002	Nov 27, 2013	Nov NEWA
>A>	AB		2.5MG;2.5MG;2.5MG;2.5MG	A202424	003	Nov 27, 2013	Nov NEWA
>A>	AB		3.125MG;3.125MG;3.125MG;3.125MG	A202424	004	Nov 27, 2013	Nov NEWA
>A>	AB		3.75MG;3.75MG;3.75MG;3.75MG	A202424	005	Nov 27, 2013	Nov NEWA
>A>	AB		5MG;5MG;5MG;5MG	A202424	006	Nov 27, 2013	Nov NEWA
>A>	AB		7.5MG;7.5MG;7.5MG;7.5MG	A202424	007	Nov 27, 2013	Nov NEWA
	AB	MALLINCKRODT INC	1.25MG;1.25MG;1.25MG;1.25MG	A040440	001	Oct 07, 2003	Sep CMFD
	AB		1.875MG;1.875MG;1.875MG;1.875MG	A040440	002	Oct 07, 2003	Sep CMFD
	AB		2.5MG;2.5MG;2.5MG;2.5MG	A040440	003	Oct 07, 2003	Sep CMFD
	AB		3.125MG;3.125MG;3.125MG;3.125MG	A040440	004	Oct 07, 2003	Sep CMFD
	AB		3.75MG;3.75MG;3.75MG;3.75MG	A040440	005	Oct 07, 2003	Sep CMFD
	AB		5MG;5MG;5MG;5MG	A040440	006	Oct 07, 2003	Sep CMFD
	AB		7.5MG;7.5MG;7.5MG;7.5MG	A040440	007	Oct 07, 2003	Sep CMFD
	AB	MUTUAL PHARM	1.25MG;1.25MG;1.25MG;1.25MG	A040480	001	Sep 09, 2003	Oct CMFD
	AB		1.875MG;1.875MG;1.875MG;1.875MG	A040480	002	Sep 09, 2003	Oct CMFD
	AB		2.5MG;2.5MG;2.5MG;2.5MG	A040480	003	Sep 09, 2003	Oct CMFD
	AB		3.125MG;3.125MG;3.125MG;3.125MG	A040480	004	Sep 09, 2003	Oct CMFD
	AB		3.75MG;3.75MG;3.75MG;3.75MG	A040480	005	Sep 09, 2003	Oct CMFD
	AB		5MG;5MG;5MG;5MG	A040480	006	Sep 09, 2003	Oct CMFD
	AB		7.5MG;7.5MG;7.5MG;7.5MG	A040480	007	Sep 09, 2003	Oct CMFD
		@ TEVA PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A040472	001	Sep 30, 2003	Jan DISC
		@	2.5MG;2.5MG;2.5MG;2.5MG	A040472	002	Sep 30, 2003	Jan DISC
		@	5MG;5MG;5MG;5MG	A040472	003	Sep 30, 2003	Jan DISC
		@	7.5MG;7.5MG;7.5MG;7.5MG	A040472	004	Sep 30, 2003	Jan DISC

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

AP		ACS DOBFAR SPA	EQ 1GM BASE/VIAL	A090884	002	Apr 03, 2013	Mar NEWA
AP			EQ 2GM BASE/VIAL	A090884	003	Apr 03, 2013	Mar NEWA
AP			EQ 10GM BASE/VIAL	A090889	001	Apr 03, 2013	Mar NEWA
AP			EQ 500MG BASE/VIAL	A090884	001	Apr 03, 2013	Mar NEWA
		@ ANTIBIOTICE	EQ 1GM BASE/VIAL	A090354	003	Dec 28, 2009	Jun DISC
		@	EQ 2GM BASE/VIAL	A090354	004	Dec 28, 2009	Jun DISC
		@	EQ 250MG BASE/VIAL	A090354	001	Dec 28, 2009	Jun DISC
		@	EQ 500MG BASE/VIAL	A090354	002	Dec 28, 2009	Jun DISC

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

UNASYN

AP	+	PFIZER	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A062901	002	Feb 27, 1992	Jul NEWA
AP	+		EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A062901	001	Nov 23, 1988	Jul CRLD

ANAGRELIDE HYDROCHLORIDE

CAPSULE;ORAL

ANAGRELIDE HYDROCHLORIDE

	@	WATSON LABS	EQ 0.5MG BASE	A076417	001	Apr 18, 2005	Sep DISC
	@		EQ 1MG BASE	A076417	002	Apr 18, 2005	Sep DISC

ANASTROZOLE

TABLET;ORAL

ANASTROZOLE

AB		ACCORD HLTHCARE	1MG	A090568	001	Jun 28, 2010	Apr CAHN
	@	IMPAX LABS INC	1MG	A091242	001	May 31, 2012	Oct DISC
	@	KUDCO IRELAND	1MG	A091331	001	Jan 05, 2011	Feb DISC

ARIPIPIRAZOLE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

ABILIFY MAINTENA KIT

		OTSUKA PHARM CO LTD	300MG/VIAL	N202971	001	Feb 28, 2013	Feb NEWA
+			400MG/VIAL	N202971	002	Feb 28, 2013	Feb NEWA

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATEINJECTABLE; INJECTION
ORABLOC

PIERREL	4%;EQ 0.009MG BASE/1.8ML (EQ 0.005MG BASE/ML)	N022466	001	Feb 26, 2010	Oct CTNA
+	4%;EQ 0.018MG BASE/1.8ML (EQ 0.01MG BASE/ML)	N022466	002	Feb 26, 2010	Oct CTNA

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATEFOR SOLUTION; ORAL
MOVIPREP

@ NOVEL LABS INC	4.7GM;100GM;1.015GM;5.9GM;2.691GM; 7.5GM	A090145	001	Jan 25, 2012	Aug DISC	
+	SALIX PHARMS	4.7GM;100GM;1.015GM;5.9GM;2.691GM; 7.5GM	N021881	001	Aug 02, 2006	Aug CTEC

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

ORPHENGESIC

@ PRINSTON INC	385MG;30MG;25MG	A075141	001	May 29, 1998	Apr CAHN
----------------	-----------------	---------	-----	--------------	----------

ORPHENGESIC FORTE

@ PRINSTON INC	770MG;60MG;50MG	A075141	002	May 29, 1998	Apr CAHN
----------------	-----------------	---------	-----	--------------	----------

ATENOLOL

TABLET; ORAL

ATENOLOL

@ MYLAN	25MG	A074126	003	Aug 26, 1998	Aug DISC
@	50MG	A074126	001	Mar 23, 1994	Aug DISC
@	100MG	A074126	002	Mar 23, 1994	Aug DISC
@ WATSON LABS	50MG	A073352	001	Dec 27, 1991	Mar DISC
@	100MG	A073353	001	Dec 27, 1991	Mar DISC

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

AB	KUDCO IRELAND	EQ 10MG BASE	A091624	001	Apr 05, 2013	Mar NEWA
AB		EQ 20MG BASE	A091624	002	Apr 05, 2013	Mar NEWA
AB		EQ 40MG BASE	A091624	003	Apr 05, 2013	Mar NEWA
AB		EQ 80MG BASE	A091624	004	Apr 05, 2013	Mar NEWA

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET; ORAL

LIPTRUZET

MERCK SHARP DOHME	EQ 10MG BASE;10MG	N200153	001	May 03, 2013	May NEWA
	EQ 20MG BASE;10MG	N200153	002	May 03, 2013	May NEWA
	EQ 40MG BASE;10MG	N200153	003	May 03, 2013	May NEWA
+	EQ 80MG BASE;10MG	N200153	004	May 03, 2013	May NEWA

AZACITIDINE

INJECTABLE; IV-SC

AZACITIDINE

AP	DR REDDYS LABS LTD	100MG/VIAL	A201537	001	Sep 16, 2013	Aug NEWA
AP	VIDAZA					
+	CELGENE	100MG/VIAL	N050794	001	May 19, 2004	Aug CFTG

AZELAIC ACID

GEL; TOPICAL

FINACEA

+	BAYER HLTHCARE	15%	N021470	001	Dec 24, 2002	Jun CAHN
---	----------------	-----	---------	-----	--------------	----------

AZILSARTAN KAMEDOXOMIL

TABLET; ORAL

EDARBI

+	ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Sep CAHN
		EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Sep CAHN

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET; ORAL
EDARBYCLOR

ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL;12.5MG	N202331	001	Dec 20, 2011	Sep CAHN
+	EQ 40MG MEDOXOMIL;25MG	N202331	002	Dec 20, 2011	Sep CAHN

AZITHROMYCIN

FOR SUSPENSION, EXTENDED RELEASE; ORAL
ZMAX

PF PRISM CV	EQ 2GM BASE/BOT	N050797	001	Jun 10, 2005	Aug CAHN
-------------	-----------------	---------	-----	--------------	----------

INJECTABLE; INJECTION
AZITHROMYCIN

AP	SUN PHARM INDS LTD	EQ 500MG BASE/VIAL	A090923	001	Apr 02, 2013	Mar NEWA
----	--------------------	--------------------	---------	-----	--------------	----------

SOLUTION/DROPS; OPHTHALMIC
AZASITE

>D>	+	INSPIRE	1%	N050810	001	Apr 27, 2007	Nov CAHN
>A>	+	OAK PHARMS AKORN	1%	N050810	001	Apr 27, 2007	Nov CAHN

BACITRACIN

OINTMENT; OPHTHALMIC
BACITRACIN

+	PERRIGO CO TENNESSEE	500 UNITS/GM	A061212	001		Jun CAHN
---	----------------------	--------------	---------	-----	--	----------

POWDER; FOR RX COMPOUNDING
BACI-RX

@ X GEN PHARMS	5,000,000 UNITS/BOT	A061580	001		Mar DISC
----------------	---------------------	---------	-----	--	----------

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
CORTISPORIN

>A>	@ CITRON PHARMA LLC	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050416	002		Nov CAHN
>D>	@ MONARCH PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050416	002		Nov CAHN

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

AT	PERRIGO CO TENNESSEE	400 UNITS/GM;EQ 3.5MG BASE;10,000 UNITS/GM	A060764	002		Jun CAHN
----	----------------------	---	---------	-----	--	----------

NEOSPORIN

>A>	@ CITRON PHARMA LLC	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050417	001		Nov CAHN
>D>	@ MONARCH PHARMS	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050417	001		Nov CAHN

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT	PERRIGO CO TENNESSEE	500 UNITS/GM;10,000 UNITS/GM	A065022	001	Feb 27, 2002	Jun CAHN
----	----------------------	------------------------------	---------	-----	--------------	----------

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

+	PERRIGO CO TENNESSEE	400 UNITS/GM;1%;EQ 3.5MG BASE;10,000 UNITS/GM	A062166	002		Jun CAHN
---	----------------------	--	---------	-----	--	----------

BACLOFEN

INJECTABLE; INTRATHECAL
GABLOFEN

AP	MALLINCKRODT INC	0.05MG/ML	N022462	001	Nov 19, 2010	May CAHN
AP		0.5MG/ML	N022462	002	Nov 19, 2010	May CAHN
		1MG/ML	N022462	004	Jun 22, 2012	May CAHN
AP		2MG/ML	N022462	003	Nov 19, 2010	May CAHN

LIORESAL

>D>	AP	+	MEDTRONIC	0.05MG/ML	N020075	003	Nov 07, 1996	Nov CAHN
>D>	AP	+		0.5MG/ML	N020075	001	Jun 17, 1992	Nov CAHN
>D>	AP	+		2MG/ML	N020075	002	Jun 17, 1992	Nov CAHN
>A>	AP	+	MEDTRONIC NEURO	0.05MG/ML	N020075	003	Nov 07, 1996	Nov CAHN
>A>	AP	+		0.5MG/ML	N020075	001	Jun 17, 1992	Nov CAHN
>A>	AP	+		2MG/ML	N020075	002	Jun 17, 1992	Nov CAHN

BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED

TABLET; ORAL

DUAVEE

+	WYETH PHARMS PFIZER	EQ 20MG BASE;0.45MG	N022247	001	Oct 03, 2013	Oct	NEWA
---	---------------------	---------------------	---------	-----	--------------	-----	------

BENDAMUSTINE HYDROCHLORIDE

SOLUTION; IV (INFUSION)

TREANDA

+	CEPHALON	45MG/0.5ML (90MG/ML)	N022249	003	Sep 13, 2013	Oct	CMS2
+		45MG/0.5ML (90MG/ML)	N022249	003	Oct 13, 2013	Sep	NEWA
+		180MG/2ML (90MG/ML)	N022249	004	Sep 13, 2013	Oct	CMS2
+		180MG/2ML (90MG/ML)	N022249	004	Oct 13, 2013	Sep	NEWA

BENZONATATE

CAPSULE; ORAL

BENZONATATE

AA	CARACO	100MG	A040587	001	Mar 19, 2008	May	CAHN
AA		200MG	A040587	002	Mar 19, 2008	May	CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

ACANYA

+	DOW PHARM	2.5%;1.2%	N050819	001	Oct 23, 2008	Apr	CAHN
---	-----------	-----------	---------	-----	--------------	-----	------

BENZACLIN

AB	VALEANT BERMUDA	5%;EQ 1% BASE	N050756	001	Dec 21, 2000	Apr	CAHN
BT	+	5%;EQ 1% BASE	N050756	002	Apr 20, 2007	Apr	CAHN

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

BENZAMYCIN PAK

+	VALEANT LUXEMBOURG	5%;3%	N050769	001	Nov 27, 2000	Jun	CAHN
---	--------------------	-------	---------	-----	--------------	-----	------

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

@ COREPHARMA 50MG

A040714	001	Oct 29, 2007	Feb	DISC
---------	-----	--------------	-----	------

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

AP	NAVINTA LLC	1MG/ML	A091525	001	Feb 05, 2013	Jan	NEWA
----	-------------	--------	---------	-----	--------------	-----	------

TABLET; ORAL

BENZTROPINE MESYLATE

@ PROSAM LABS 0.5MG

A040699	001	Feb 14, 2008	Mar	DISC
---------	-----	--------------	-----	------

@ 1MG

A040705	001	Feb 14, 2008	Mar	DISC
---------	-----	--------------	-----	------

@ 2MG

A040706	001	Feb 14, 2008	Mar	DISC
---------	-----	--------------	-----	------

BETAMETHASONE

SYRUP; ORAL

CELESTONE

@ MERCK SHARP DOHME 0.6MG/5ML

N014215	002		Apr	CAHN
---------	-----	--	-----	------

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

CELESTONE SOLUSPAN

AB	+	MERCK SHARP DOHME	3MG/ML;EQ 3MG BASE/ML	N014602	001		Apr	CAHN
----	---	-------------------	-----------------------	---------	-----	--	-----	------

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE

SUSPENSION; TOPICAL

TACLONEX

+	LEO PHARMA AS	0.064%;0.005%	N022185	001	May 09, 2008	Sep	CAHN
---	---------------	---------------	---------	-----	--------------	-----	------

BETAMETHASONE VALERATE

AEROSOL, FOAM; TOPICAL

BETAMETHASONE VALERATE

AB	PERRIGO	0.12%	A078337	001	Nov 26, 2012	Apr	CPOT
----	---------	-------	---------	-----	--------------	-----	------

LUXIQ

AB	+	DELCOR ASSET	0.12%	N020934	001	Feb 28, 1999	Sep	CAHN
----	---	--------------	-------	---------	-----	--------------	-----	------

AB	+	STIEFEL	0.12%	N020934	001	Feb 28, 1999	Apr	CPOT
----	---	---------	-------	---------	-----	--------------	-----	------

BETAXOLOL HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
BETAXOLOL HYDROCHLORIDE

@ APOTEX INC	EQ 0.5% BASE	A075446	001	Sep 28, 2000	Apr DISC
--------------	--------------	---------	-----	--------------	----------

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

AA	CARACO	5MG	A040897	001	Apr 22, 2009	Jun CAHN
AA		10MG	A040897	002	Apr 22, 2009	Jun CAHN
AA		25MG	A040897	003	Apr 22, 2009	Jun CAHN
AA		50MG	A040897	004	Apr 22, 2009	Jun CAHN
	@ LANNETT HOLDINGS INC	5MG	A040703	001	Mar 27, 2008	Jun DISC
	@	50MG	A040677	001	Mar 27, 2008	Jun DISC

BEXAROTENE

CAPSULE;ORAL

TARGRETIN

+	VALEANT LUXEMBOURG	75MG	N021055	001	Dec 29, 1999	Jun CAHN
---	--------------------	------	---------	-----	--------------	----------

GEL;TOPICAL
TARGRETIN

+	VALEANT LUXEMBOURG	1%	N021056	001	Jun 28, 2000	Jun CAHN
+	VALEANT PHARMS INC	1%	N021056	001	Jun 28, 2000	Feb CAHN

BICALUTAMIDE

TABLET;ORAL

BICALUTAMIDE

AB	ACCORD HLTHCARE	50MG	A078917	001	Jul 06, 2009	Apr CAHN
>D> AB	KUDCO IRELAND	50MG	A077995	001	Jul 06, 2009	Nov DISC
>A>	@	50MG	A077995	001	Jul 06, 2009	Nov DISC
	@ SYNTHON PHARMS	50MG	A077973	001	Jul 06, 2009	Sep DISC

BLEOMYCIN SULFATE

INJECTABLE;INJECTION

BLEOMYCIN SULFATE

@ PHARMACHEMIE BV	EQ 15 UNITS BASE/VIAL	A065201	001	Dec 13, 2007	Feb DISC
-------------------	-----------------------	---------	-----	--------------	----------

BRIMONIDINE TARTRATE

GEL;TOPICAL

MIRVASO

+	GALDERMA LABS LP	EQ 0.33% BASE	N204708	001	Aug 23, 2013	Oct CPOT
+		0.33%	N204708	001	Aug 23, 2013	Sep CAHN
+	GALDERMA R AND D	0.33%	N204708	001	Aug 23, 2013	Aug NEWA

BRIMONIDINE TARTRATE; BRINZOLAMIDE

SUSPENSION/DROPS;OPHTHALMIC

SIMBRINZA

+	ALCON RES LTD	0.2%;1%	N204251	001	Apr 19, 2013	Apr NEWA
---	---------------	---------	---------	-----	--------------	----------

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

COMBIGAN

+	ALLERGAN	0.2%;EQ 0.5% BASE	N021398	001	Oct 30, 2007	Oct CPOT
---	----------	-------------------	---------	-----	--------------	----------

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

BROMDAY

+	ISTA PHARMS INC	EQ 0.09% ACID	N021664	002	Oct 16, 2010	Apr CPOT
---	-----------------	---------------	---------	-----	--------------	----------

BROMFENAC SODIUM

AT	COASTAL PHARMS	EQ 0.09% ACID	A201211	001	May 11, 2011	Apr CPOT
AT	LUITPOLD	EQ 0.09% ACID	A202030	001	Jan 09, 2013	Apr CPOT
AT		0.09%	A202030	001	Jan 09, 2013	Feb CAHN

PROLENSA

+	BAUSCH AND LOMB	EQ 0.07% ACID	N203168	001	Apr 05, 2013	Apr NEWA
---	-----------------	---------------	---------	-----	--------------	----------

XIBROM

@ ISTA PHARMS INC	EQ 0.09% ACID	N021664	001	Mar 24, 2005	Apr CPOT
-------------------	---------------	---------	-----	--------------	----------

BUDESONIDE

SUSPENSION; INHALATION							
BUDESONIDE							
	@ APOTEX INC	0.25MG/2ML	A078202	001	Mar 30, 2009	Apr	DISC
	@	0.5MG/2ML	A078202	002	Mar 30, 2009	Apr	DISC
AN	SANDOZ	0.25MG/2ML	A201966	003	Sep 27, 2013	Sep	NEWA
AN		0.5MG/2ML	A201966	002	Sep 27, 2013	Sep	NEWA
AN		1MG/2ML	A201966	001	Sep 27, 2013	Sep	NEWA
PULMICORT RESPULES							
AN	+ ASTRAZENECA	1MG/2ML	N020929	003	Aug 08, 2000	Sep	CTEC
TABLET, EXTENDED RELEASE; ORAL							
UCERIS							
	+ SANTARUS	9MG	N203634	001	Jan 14, 2013	Jan	NEWA

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION							
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE							
AP	AUROBINDO PHARMA LTD	0.25%	A203895	001	Nov 05, 2013	Oct	NEWA
AP		0.5%	A203895	002	Nov 05, 2013	Oct	NEWA
AP		0.75%	A203895	003	Nov 05, 2013	Oct	NEWA
	@ INTL MEDICATED	0.25%	A076012	001	Jan 09, 2002	Jun	DISC
	@	0.5%	A076012	002	Jan 09, 2002	Jun	DISC
	@	0.75%	A076012	003	Jan 09, 2002	Jun	DISC

BUPRENORPHINE

FILM, EXTENDED RELEASE; TRANSDERMAL							
BUTRANS							
	PURDUE PHARMA LP	15MCG/HR	N021306	004	Jul 25, 2013	Aug	NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM; SUBLINGUAL							
SUBOXONE							
	RECKITT BENCKISER	EQ 8MG BASE; EQ 2MG BASE	N022410	002	Aug 30, 2010	Jul	CRLD
	+	EQ 12MG BASE; EQ 3MG BASE	N022410	004	Aug 10, 2012	Jul	CRLD
TABLET; SUBLINGUAL							
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE							
AB	ACTAVIS ELIZABETH	EQ 2MG BASE; EQ 0.5MG BASE	A091422	001	Feb 22, 2013	Jul	CTNA
AB	+	EQ 8MG BASE; EQ 2MG BASE	A091422	002	Feb 22, 2013	Jul	CTNA
AB	AMNEAL PHARMS	EQ 8MG BASE; EQ 2MG BASE	A203136	002	Feb 22, 2013	Aug	CTNA
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE							
AB	AMNEAL PHARMS	EQ 2MG BASE; EQ 0.5MG BASE	A203136	001	Feb 22, 2013	Aug	CTNA
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE							
AB	ACTAVIS ELIZABETH	EQ 2MG BASE; EQ 0.5MG BASE	A091422	001	Feb 22, 2013	Feb	NEWA
AB	+	EQ 8MG BASE; EQ 2MG BASE	A091422	002	Feb 22, 2013	Apr	CRLD
AB		EQ 8MG BASE; EQ 2MG BASE	A091422	002	Feb 22, 2013	Feb	NEWA
AB	AMNEAL PHARMS	EQ 2MG BASE; EQ 0.5MG BASE	A203136	001	Feb 22, 2013	Feb	NEWA
AB		EQ 8MG BASE; EQ 2MG BASE	A203136	002	Feb 22, 2013	Feb	NEWA
ZUBSOLV							
	OREXO AB	EQ 1.4MG BASE; EQ 0.36MG BASE	N204242	001	Jul 03, 2013	Jul	NEWA
	+	EQ 5.7MG BASE; EQ 1.4MG BASE	N204242	002	Jul 03, 2013	Jul	NEWA

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL							
APLENZIN							
	VALEANT BERMUDA	174MG	N022108	001	Apr 23, 2008	Apr	CAHN
>D>	+	348MG	N022108	002	Apr 23, 2008	Nov	CRLD
>A>		348MG	N022108	002	Apr 23, 2008	Nov	CRLD
	+	348MG	N022108	002	Apr 23, 2008	Apr	CAHN
>D>		522MG	N022108	003	Apr 23, 2008	Nov	CRLD
>A>	+	522MG	N022108	003	Apr 23, 2008	Nov	CRLD
		522MG	N022108	003	Apr 23, 2008	Apr	CAHN

BUPROPION HYDROCHLORIDE

TABLET; ORAL							
BUPROPION HYDROCHLORIDE							
	@ TEVA	75MG	A075310	001	Nov 29, 1999	Feb	CDFR
	@	100MG	A075310	002	Nov 29, 1999	Feb	DISC
TABLET, EXTENDED RELEASE; ORAL							
BUPROPION HYDROCHLORIDE							
	@ IMPAX LABS	300MG	A077415	002	Dec 15, 2006	Apr	DISC
AB1	JUBILANT LIFE	100MG	A202774	001	Oct 11, 2013	Sep	NEWA

TABLET, EXTENDED RELEASE;ORAL
BUPROPION HYDROCHLORIDE

AB1		150MG	A202774	002	Oct 11, 2013	Sep NEWA
AB2		150MG	A202775	001	Oct 11, 2013	Sep NEWA
AB1		200MG	A202774	003	Oct 11, 2013	Sep NEWA
BX	WATSON LABS	300MG	A077715	002	Jun 13, 2007	Sep CTEC
AB1	WATSON LABS INC	100MG	A077455	001	Jul 19, 2010	Apr CAHN
AB3		150MG	A077285	001	Nov 26, 2008	Apr CAHN
AB1		150MG	A077455	002	Mar 12, 2008	Apr CAHN
AB1		200MG	A077455	003	Jul 19, 2010	Apr CAHN
AB3		300MG	A077285	002	Aug 15, 2008	Apr CAHN

BUTOCONAZOLE NITRATE

CREAM;VAGINAL

BUTOCONAZOLE NITRATE

+	PERRIGO ISRAEL	2%	A200923	001	May 18, 2012	Mar CRLD
	GYNAZOLE-1					
@	KV PHARM	2%	N019881	001	Feb 07, 1997	Mar DISC

BUTORPHANOL TARTRATE

INJECTABLE;INJECTION

BUTORPHANOL TARTRATE

@ APOTEX INC 2MG/ML

A075697 001 Oct 23, 2001 Apr DISC

BUTORPHANOL TARTRATE PRESERVATIVE FREE

@ APOTEX INC 1MG/ML

A075695 001 Oct 23, 2001 Apr DISC

@ 2MG/ML

A075695 002 Oct 23, 2001 Apr DISC

STADOL

@ APOTHECON 2MG/ML

N017857 004 Jun DISC

STADOL PRESERVATIVE FREE

@ APOTHECON 1MG/ML

N017857 001 Jun DISC

@ 2MG/ML

N017857 002 Jun DISC

CABERGOLINE

TABLET;ORAL

CABERGOLINE

AB APOTEX CORP 0.5MG

A201503 001 Mar 08, 2013 Feb NEWA

>A> AB MYLAN PHARMS INC 0.5MG

A202947 001 Dec 02, 2013 Nov NEWA

CAFFEINE; ERGOTAMINE TARTRATE

TABLET;ORAL

ERGOTAMINE TARTRATE AND CAFFEINE

AA MIKART 100MG;1MG

A040590 001 Sep 16, 2005 Mar CMFD

@ 100MG;1MG

A040590 001 Sep 16, 2005 Jan DISC

CALCIPOTRIENE

OINTMENT;TOPICAL

DOVONEX

@ LEO PHARMA AS 0.005%

N020273 001 Dec 29, 1993 Sep CAHN

CALCITRIOL

CAPSULE;ORAL

CALCITRIOL

AB BANNER PHARMACAPS 0.25MCG

A091174 001 May 24, 2013 May NEWA

AB 0.5MCG

A091174 002 May 24, 2013 May NEWA

CALCIUM ACETATE

CAPSULE;ORAL

CALCIUM ACETATE

AB INVAGEN PHARMS EQ 169MG CALCIUM

A203135 001 Feb 07, 2013 Jan NEWA

TABLET;ORAL

CALCIUM ACETATE

AB INVAGEN PHARMS EQ 169MG CALCIUM

A202420 001 Feb 05, 2013 Jan NEWA

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE;INJECTION

ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER

@ B BRAUN 35MG/100ML;5GM/100ML;30MG/100ML;74 MG/100ML;640MG/100ML;500MG/100ML;7 4MG/100ML

N019867 001 Dec 20, 1993 Mar DISC

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

>D>	@ FRESenius	18.4MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	1020374	001	Jun 13, 1994	Nov	CMS2
>A>	@	18.4MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	A020374	001	Jun 13, 1994	Nov	CMS2
	@	18.4MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	A020374	001	Jun 13, 1994	Feb	DISC
INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER							
>D>	@ FRESenius	18.4MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	1020374	002	Jun 13, 1994	Nov	CMS2
>A>	@	18.4MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	A020374	002	Jun 13, 1994	Nov	CMS2
	@	18.4MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	A020374	002	Jun 13, 1994	Feb	DISC
INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER							
>D>	@ FRESenius	18.4MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020374	003	Jun 13, 1994	Nov	CMS2
>A>	@	18.4MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	A020374	003	Jun 13, 1994	Nov	CMS2
	@	18.4MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	A020374	003	Jun 13, 1994	Feb	DISC
INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER							
>D>	@ FRESenius	18.4MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020374	004	Jun 13, 1994	Nov	CMS2
>A>	@	18.4MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	A020374	004	Jun 13, 1994	Nov	CMS2
	@	18.4MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	A020374	004	Jun 13, 1994	Feb	DISC

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INTRATHECAL

ELLIOTTS B SOLUTION

+	LUKARE MEDICAL LLC	0.2MG/ML; 0.8MG/ML; 0.3MG/ML; 0.3MG/ML; 1.9MG/ML; 7.3MG/ML; 0.2MG/ML	N020577	001	Sep 27, 1996	Jun	CAHN
---	--------------------	--	---------	-----	--------------	-----	------

CANAGLIFLOZIN

TABLET; ORAL

INVOKANA

	JANSSEN PHARMS	100MG	N204042	001	Mar 29, 2013	Apr	CAHN
+		300MG	N204042	002	Mar 29, 2013	Apr	CAHN
	JANSSEN RES AND DEV	100MG	N204042	001	Mar 29, 2013	Mar	NEWA
+		300MG	N204042	002	Mar 29, 2013	Mar	NEWA

CANDESARTAN CILEXETIL

TABLET; ORAL

ATACAND

AB	ASTRAZENECA	4MG	N020838	001	Jun 04, 1998	Apr	CFTG
AB		8MG	N020838	002	Jun 04, 1998	Apr	CFTG
AB		16MG	N020838	003	Jun 04, 1998	Apr	CFTG
AB	+	32MG	N020838	004	Jun 04, 1998	Apr	CFTG
CANDESARTAN CILEXETIL							
AB	SANDOZ	4MG	A078702	001	May 03, 2013	Apr	NEWA
AB		8MG	A078702	002	May 03, 2013	Apr	NEWA
AB		16MG	A078702	003	May 03, 2013	Apr	NEWA
AB		32MG	A078702	004	May 03, 2013	Apr	NEWA

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

AB	APOTEX INC	32MG; 25MG	A202884	003	Jun 03, 2013	May	NEWA
AB	DR REDDYS LABS LTD	16MG; 12.5MG	A202965	001	Jun 03, 2013	May	NEWA
AB		32MG; 12.5MG	A202965	002	Jun 03, 2013	May	NEWA
AB		32MG; 25MG	A202965	003	Jun 03, 2013	May	NEWA

CAPECITABINE

TABLET; ORAL

CAPECITABINE

AB	TEVA PHARMS USA	150MG	A091649	001	Sep 16, 2013	Aug	NEWA
AB		500MG	A091649	002	Sep 16, 2013	Aug	NEWA
XELODA							
AB	HOFFMANN LA ROCHE	150MG	N020896	001	Apr 30, 1998	Aug	CFTG

TABLET; ORAL							
XELODA							
AB	+	500MG	N020896	002	Apr 30, 1998	Aug	CFTG
<u>CAPSAICIN</u>							
PATCH; TOPICAL							
QUTENZA							
	+	ACORDA	8%	N022395	001	Nov 16, 2009	Jul CAHN
<u>CAPTOPRIL</u>							
TABLET; ORAL							
CAPTOPRIL							
	@	PRINSTON INC	12.5MG	A074477	001	Feb 13, 1996	Jun DISC
	@		25MG	A074477	002	Feb 13, 1996	Jun DISC
	@		50MG	A074477	003	Feb 13, 1996	Jun DISC
	@		100MG	A074477	004	Feb 13, 1996	Jun DISC
	@	TEVA	12.5MG	A074483	001	Feb 13, 1996	Jun DISC
	@		25MG	A074483	002	Feb 13, 1996	Jun DISC
	@		50MG	A074483	003	Feb 13, 1996	Jun DISC
	@		100MG	A074483	004	Feb 13, 1996	Jun DISC
<u>CARBAMAZEPINE</u>							
CAPSULE, EXTENDED RELEASE; ORAL							
CARBAMAZEPINE							
AB		TARO	100MG	A201106	001	Jun 21, 2013	Jun NEWA
AB			200MG	A201106	002	Jun 21, 2013	Jun NEWA
AB			300MG	A201106	003	Jun 21, 2013	Jun NEWA
<u>CARBIDOPA; LEVODOPA</u>							
TABLET, EXTENDED RELEASE; ORAL							
CARBIDOPA AND LEVODOPA							
AB		ACCORD HLTHCARE	25MG; 100MG	A202323	001	Feb 08, 2013	Jan NEWA
AB			50MG; 200MG	A202323	002	Feb 08, 2013	Jan NEWA
<u>CARBINOXAMINE MALEATE</u>							
SUSPENSION, EXTENDED RELEASE; ORAL							
KARBINAL ER							
	+	TRIS PHARMA INC	4MG/5ML	N022556	001	Mar 28, 2013	Mar NEWA
<u>CARBOPLATIN</u>							
INJECTABLE; INJECTION							
CARBOPLATIN							
	@	PLIVA	50MG/VIAL	A076602	001	Nov 16, 2004	Feb DISC
	@		150MG/VIAL	A076602	002	Nov 16, 2004	Feb DISC
	@		450MG/VIAL	A076602	003	Nov 16, 2004	Feb DISC
INJECTABLE; IV (INFUSION)							
CARBOPLATIN							
	@	FRESENIUS KABI USA	50MG/5ML (10MG/ML)	A077266	001	Feb 15, 2006	Mar DISC
	@		150MG/15ML (10MG/ML)	A077266	002	Feb 15, 2006	Mar DISC
	@	PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077679	001	Feb 25, 2009	Apr DISC
	@		150MG/15ML (10MG/ML)	A077679	002	Feb 25, 2009	Apr DISC
	@		450MG/45ML (10MG/ML)	A077679	003	Feb 25, 2009	Apr DISC
AP		SAGENT PHARMS	50MG/5ML (10MG/ML)	A077096	001	Jun 14, 2005	Oct CMFD
AP			150MG/15ML (10MG/ML)	A077096	002	Jun 14, 2005	Oct CMFD
AP			450MG/45ML (10MG/ML)	A077096	003	Jun 14, 2005	Oct CMFD
AP			600MG/60ML (10MG/ML)	A077096	004	Jun 03, 2013	Oct NEWA
PARAPLATIN							
	@	CORDENPHARMA	50MG/5ML (10MG/ML)	N020452	001	Jul 14, 2003	Mar CAHN
	@		150MG/15ML (10MG/ML)	N020452	002	Jul 14, 2003	Mar CAHN
	@		450MG/45ML (10MG/ML)	N020452	003	Jul 14, 2003	Mar CAHN
	@		600MG/60ML (10MG/ML)	N020452	004	Jan 15, 2004	Mar CAHN
<u>CARISOPRODOL</u>							
TABLET; ORAL							
CARISOPRODOL							
AA		ACCELRX LABS	350MG	A040576	001	Jun 07, 2005	May CAHN
	@	COREPHARMA	350MG	A040397	001	Sep 21, 2000	Feb DISC
	@	PROSAM LABS	350MG	A040188	001	Mar 07, 1997	Jun DISC

CARMUSTINE

IMPLANT; INTRACRANIAL
GLIADEL

+ ARBOR PHARMS LLC 7.7MG N020637 001 Sep 23, 1996 Mar CAHN

INJECTABLE; INJECTION
BICNU

+ EMCURE PHARMS LTD 100MG/VIAL N017422 001 Jan CAHN

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
CARTEOLOL HYDROCHLORIDE

@ APOTEX INC 1% A076097 001 Feb 06, 2002 Apr DISC

CARVEDILOL

TABLET; ORAL
CARVEDILOL

AB	CIPLA LTD	3.125MG	A077474	001	Sep 05, 2007	Aug CAHN
AB		6.25MG	A077474	002	Sep 05, 2007	Aug CAHN
AB		12.5MG	A077474	003	Sep 05, 2007	Aug CAHN
AB		25MG	A077474	004	Sep 05, 2007	Aug CAHN
	@ WOCKHARDT LTD	3.125MG	A078786	001	Dec 22, 2009	Feb DISC
	@	6.25MG	A078786	002	Dec 22, 2009	Feb DISC
	@	12.5MG	A078786	003	Dec 22, 2009	Feb DISC
	@	25MG	A078786	004	Dec 22, 2009	Feb DISC

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION; ORAL

CEFADROXIL

AB	AUROBINDO	EQ 250MG BASE/5ML	A065349	001	Apr 25, 2013	Apr NEWA
AB		EQ 500MG BASE/5ML	A065349	002	Apr 25, 2013	Apr NEWA
	@ TEVA PHARMS USA	EQ 250MG BASE/5ML	A065278	001	Jan 20, 2006	Mar DISC
	@	EQ 500MG BASE/5ML	A065278	002	Jan 20, 2006	Mar DISC

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

	@ AUROBINDO PHARMA	EQ 1GM BASE/VIAL	A065395	002	Aug 08, 2008	Aug DISC
	@	EQ 500MG BASE/VIAL	A065395	001	Aug 08, 2008	Aug DISC
AP	+ HOSPIRA INC	EQ 1GM BASE/VIAL	A065226	002	Apr 21, 2005	Feb CRLD
AP	+	EQ 1GM BASE/VIAL	A065244	001	Aug 12, 2005	Feb CRLD
AP	+	EQ 10GM BASE/VIAL	A065247	001	Aug 12, 2005	Feb CRLD
AP	+	EQ 500MG BASE/VIAL	A065226	001	Apr 21, 2005	Feb CRLD
AP	+ STERI PHARMA	EQ 20GM BASE/VIAL	A063209	002	Apr 30, 1999	Jul CRLD

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION
CEFEPIME HYDROCHLORIDE

	@ SANDOZ	EQ 1GM BASE/VIAL	A090291	002	Dec 21, 2010	Mar DISC
	@	EQ 2GM BASE/VIAL	A090291	003	Dec 21, 2010	Mar DISC
	@	EQ 500MG BASE/VIAL	A090291	001	Dec 21, 2010	Mar DISC

CEFIXIME

FOR SUSPENSION; ORAL
SUPRAX

+	LUPIN LTD	500MG/5ML	N202091	001	Feb 20, 2013	Feb CDFR
	LUPIN PHARMS	100MG/5ML	A065129	001	Feb 23, 2004	Feb CDFR
		200MG/5ML	A065355	001	Apr 10, 2007	Feb CDFR

CEFOTAXIME SODIUM

INJECTABLE; INJECTION
CEFOTAXIME SODIUM

	@ AUROBINDO PHARMA	EQ 1GM BASE/VIAL	A065517	002	Nov 06, 2009	Aug DISC
	@	EQ 2GM BASE/VIAL	A065517	003	Nov 06, 2009	Aug DISC
	@	EQ 500MG BASE/VIAL	A065517	001	Nov 06, 2009	Aug DISC
	@ AUROBINDO PHARMA LTD	EQ 10GM BASE/VIAL	A065516	001	Nov 06, 2009	Jun DISC

CEFOXITIN SODIUM

INJECTABLE;INJECTION
CEFOXITIN

AP	+	ACS DOBFAR	EQ 1GM BASE/VIAL	A065414	001	Jun 12, 2009	Oct CRLD
AP	+		EQ 2GM BASE/VIAL	A065414	002	Jun 12, 2009	Oct CRLD
AP	+		EQ 10GM BASE/VIAL	A065415	001	May 19, 2010	Oct CRLD

CEFTAZIDIME

INJECTABLE;INJECTION
CEFTAZIDIME

@	AUROBINDO PHARMA LTD	1GM/VIAL	A065481	002	May 28, 2010	Jun DISC
@		2GM/VIAL	A065481	003	May 28, 2010	Jun DISC
@		6GM/VIAL	A065482	001	May 28, 2010	Jun DISC
@		500MG/VIAL	A065481	001	May 28, 2010	Jun DISC

CEFTRIAXONE SODIUM

INJECTABLE;IM-IV
CEFTRIAXONE

@	AUROBINDO PHARMA LTD	EQ 1GM BASE/VIAL	A065505	003	Jul 31, 2008	May DISC
@		EQ 2GM BASE/VIAL	A065505	004	Jul 31, 2008	May DISC
@		EQ 250MG BASE/VIAL	A065505	001	Jul 31, 2008	May DISC
@		EQ 500MG BASE/VIAL	A065505	002	Jul 31, 2008	May DISC
@	STERI PHARMA	EQ 1GM BASE/VIAL	A065268	001	Feb 28, 2007	Sep DISC
@		EQ 2GM BASE/VIAL	A065268	002	Feb 28, 2007	Sep DISC
@	TEVA	EQ 1GM BASE/VIAL	A065262	001	Jun 29, 2006	Jul DISC
@		EQ 2GM BASE/VIAL	A065262	002	Jun 29, 2006	Jul DISC
AP	TEVA PHARMS USA	EQ 1GM BASE/VIAL	A065227	003	Mar 15, 2007	May CAHN
AP		EQ 2GM BASE/VIAL	A065227	004	Mar 15, 2007	May CAHN
AP		EQ 250MG BASE/VIAL	A065227	001	Mar 15, 2007	May CAHN
AP		EQ 500MG BASE/VIAL	A065227	002	Mar 15, 2007	May CAHN

INJECTABLE;INJECTION
CEFTRIAXONE

@	AUROBINDO PHARMA LTD	EQ 10GM BASE/VIAL	A065504	001	Jul 31, 2008	May DISC
@	TEVA	EQ 10GM BASE/VIAL	A065274	001	May 01, 2006	Oct DISC

CEFUROXIME SODIUM

INJECTABLE;IM-IV
CEFUROXIME SODIUM

@	TEVA PHARMS	EQ 1.5GM BASE/VIAL	A064192	001	Apr 16, 1998	Jul DISC
@		EQ 750MG BASE/VIAL	A064192	002	Apr 16, 1998	Jul DISC

INJECTABLE;INJECTION

CEFUROXIME SODIUM IN PLASTIC CONTAINER

@	SAMSON MEDCL	EQ 75GM BASE/VIAL	A065251	001	Dec 30, 2009	Aug DISC
@		EQ 225GM BASE/VIAL	A065251	002	Dec 30, 2009	Aug DISC

ZINACEF IN PLASTIC CONTAINER

@	COVIS PHARMA SARL	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	Jun DISC
---	-------------------	-----------------	---------	-----	--------------	----------

CEPHALEXIN

CAPSULE;ORAL
CEPHALEXIN

AB		ALKEM LABS LTD	EQ 333MG BASE	A090836	003	Mar 29, 2013	Mar NEWA
			EQ 750MG BASE	A090836	004	Mar 29, 2013	Mar NEWA
AB	+	SHIONOGI INC	EQ 750MG BASE	N050405	005	May 12, 2006	Mar CTEC

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL
CETIRIZINE HYDROCHLORIDE

@	APOTEX INC	5MG/5ML	A078412	001	Jun 18, 2008	Apr DISC
@	AUROBINDO PHARMA LTD	5MG/5ML	A090751	001	Dec 16, 2009	Feb DISC
AA	BIO PHARM INC	5MG/5ML	A078870	001	Apr 27, 2009	May CAHN
AA	BRECKENRIDGE PHARM	5MG/5ML	A078488	001	Oct 06, 2008	Sep CAHN
AA	CARACO	5MG/5ML	A090191	001	Nov 12, 2009	Jun CAHN

CETRORELIX

INJECTABLE;INJECTION
CETROTIDE

@	EMD SERONO INC	EQ 3MG BASE/ML	N021197	002	Aug 11, 2000	Jun DISC
---	----------------	----------------	---------	-----	--------------	----------

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL					
CEVIMELINE HYDROCHLORIDE					
AB	ROXANE	30MG	A091591	001	Jul 08, 2013 Jun NEWA
EVOXAC					
AB	+ DAIICHI SANKYO	30MG	N020989	002	Jan 11, 2000 Sep CAHN

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL					
CHLORHEXIDINE GLUCONATE					
	@ APOTEX INC	0.12%	A075561	001	Nov 14, 2000 Apr DISC
PAROEX					
AT	SUNSTAR AMERICAS	0.12%	A076434	001	Nov 29, 2005 Apr CTNA

CHLOROTHIAZIDE

TABLET; ORAL					
CHLOROTHIAZIDE					
+	MYLAN	250MG	A084388	001	Jul CTEC
		500MG	A084217	001	Jul CTEC
	@ WEST WARD	250MG	A086028	001	Jul 14, 1982 Jul DISC
	@	500MG	A087736	001	Jul 14, 1982 Jul DISC
DIURIL					
	@ OAK PHARMS AKORN	250MG	N011145	004	Jan CAHN
	@	500MG	N011145	002	Jan CAHN

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION					
CHLOROTHIAZIDE SODIUM					
AP	LUITPOLD	EQ 500MG BASE/VIAL	A202561	001	Apr 22, 2013 Jun CAHN
AP	PHARMAFORCE	EQ 500MG BASE/VIAL	A202561	001	Apr 22, 2013 Apr NEWA
DIURIL					
AP	+ OAK PHARMS AKORN	EQ 500MG BASE/VIAL	N011145	005	Jan CAHN

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION; ORAL					
VITUZ					
	+ CYPRESS PHARM	4MG/5ML; 5MG/5ML	N204307	001	Feb 20, 2013 Feb NEWA

CHLORPROPAMIDE

TABLET; ORAL					
CHLORPROPAMIDE					
	@ WATSON LABS INC	100MG	A088852	001	Sep 26, 1984 Jan DISC
	@	250MG	A088826	001	Sep 26, 1984 Jan DISC

CHLORTHALIDONE

TABLET; ORAL					
CHLORTHALIDONE					
	@ BARR LABS INC	25MG	A088902	001	Sep 19, 1985 Sep DISC
AB		25MG	A088902	001	Sep 19, 1985 Sep CAHN
	@	50MG	A088903	001	Sep 19, 1985 Sep DISC
AB		50MG	A088903	001	Sep 19, 1985 Sep CAHN
	MYLAN	25MG	A086831	002	Sep CTEC
	+	50MG	A086831	001	Sep CTEC
THALITONE					
>A>	+ CITRON PHARMA LLC	15MG	N019574	001	Dec 20, 1988 Nov CAHN
>A>	@	25MG	N019574	002	Feb 12, 1992 Nov CAHN
>D>	+ MONARCH PHARMS	15MG	N019574	001	Dec 20, 1988 Nov CAHN
>D>	@	25MG	N019574	002	Feb 12, 1992 Nov CAHN

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL					
FENOFIBRIC ACID					
AB	ANCHEN PHARMS	EQ 45MG FENOFIBRIC ACID	A201573	002	Jul 18, 2013 Jul NEWA
AB		EQ 135MG FENOFIBRIC ACID	A201573	001	Jul 18, 2013 Jul NEWA
>A>	AB	EQ 45MG FENOFIBRIC ACID	A200750	001	Dec 04, 2013 Nov NEWA
>A>	AB	EQ 135MG FENOFIBRIC ACID	A200750	002	Dec 04, 2013 Nov NEWA
AB	MYLAN PHARMS INC	EQ 45MG FENOFIBRIC ACID	A200913	001	Mar 25, 2013 Mar NEWA
AB		EQ 135MG FENOFIBRIC ACID	A200913	002	Mar 25, 2013 Mar NEWA
TRILIPIX					
AB	ABBVIE	EQ 45MG FENOFIBRIC ACID	N022224	001	Dec 15, 2008 Mar CFTG
AB	+	EQ 135MG FENOFIBRIC ACID	N022224	002	Dec 15, 2008 Mar CFTG

CICLOPIROX

CREAM; TOPICAL							
LOPROX							
AB	+ MEDIMETRIKS PHARMS	0.77%	N018748	001	Dec 30, 1982	Sep	CAHN
SOLUTION; TOPICAL							
CICLOPIROX							
	@ APOTEX INC	8%	A078172	001	Sep 18, 2007	Apr	DISC
AT	CIPLA LTD	8%	A078124	001	Sep 18, 2007	Aug	CAHN
	@ TEVA PHARMS	8%	A078079	001	Sep 18, 2007	Jan	DISC
PENLAC							
AT	+ VALEANT BERMUDA	8%	N021022	001	Dec 17, 1999	May	CAHN
AT	+ VALEANT INTL	8%	N021022	001	Dec 17, 1999	Feb	CAHN
SUSPENSION; TOPICAL							
LOPROX							
AB	+ MEDIMETRIKS PHARMS	0.77%	N019824	001	Dec 30, 1988	Oct	CAHN

CIMETIDINE

TABLET; ORAL							
CIMETIDINE							
	@ WATSON LABS INC	200MG	A074349	001	Aug 30, 1996	May	DISC
	@	300MG	A074349	002	Aug 30, 1996	May	DISC
	@	400MG	A074349	003	Aug 30, 1996	May	DISC
	@	800MG	A074316	001	Feb 28, 1996	Jun	DISC

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL							
CIMETIDINE HYDROCHLORIDE							
	@ APOTEX INC	EQ 300MG BASE/5ML	A075560	001	Mar 15, 2000	Apr	DISC

CIPROFLOXACIN

INJECTABLE; INJECTION							
CIPROFLOXACIN							
	@ TEVA PHARMS USA	200MG/20ML (10MG/ML)	A077782	001	Aug 28, 2006	Apr	CAHN
	@	400MG/40ML (10MG/ML)	A077782	002	Aug 28, 2006	Apr	CAHN

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC							
CIPROFLOXACIN HYDROCHLORIDE							
	@ APOTEX INC	EQ 0.3% BASE	A075928	001	Jun 09, 2004	Apr	DISC

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL							
CIPRO XR							
	@ BAYER HLTHCARE	212.6MG; EQ 287.5MG BASE	N021473	001	Dec 13, 2002	May	DISC
	@	425.2MG; EQ 574.9MG BASE	N021473	002	Aug 28, 2003	May	DISC
CIPROFLOXACIN EXTENDED RELEASE							
	@ DR REDDYS LABS LTD	212.6MG; EQ 287.5MG BASE	A077701	002	Oct 31, 2007	Jun	DISC
AB	+ MYLAN PHARMS INC	212.6MG; EQ 287.5MG BASE	A078183	001	Mar 22, 2007	May	CRLD
AB	+	425.2MG; EQ 574.9MG BASE	A078183	002	Mar 22, 2007	May	CRLD

CISPLATIN

INJECTABLE; INJECTION							
CISPLATIN							
AP	HQ SPCLT PHARMA	1MG/ML	N018057	004	Nov 08, 1988	Oct	CMFD
	@ TEVA PHARMS USA	1MG/ML	A074814	001	May 16, 2000	Sep	CAHN
PLATINOL							
	@ HQ SPCLT PHARMA	10MG/VIAL	N018057	001		Jan	CAHN
	@	50MG/VIAL	N018057	002		Jan	CAHN
PLATINOL-AQ							
	@ HQ SPCLT PHARMA	0.5MG/ML	N018057	003	Jul 18, 1984	Jan	CAHN
	@	1MG/ML	N018057	004	Nov 08, 1988	Jan	CAHN

CITALOPRAM HYDROBROMIDE

SOLUTION; ORAL							
CITALOPRAM HYDROBROMIDE							
	@ APOTEX INC	EQ 10MG BASE/5ML	A077601	001	Nov 15, 2005	Apr	DISC
TABLET; ORAL							
CITALOPRAM HYDROBROMIDE							
AB	CIPLA LTD	EQ 10MG BASE	A077044	001	Nov 05, 2004	Aug	CAHN
AB		EQ 20MG BASE	A077044	002	Nov 05, 2004	Aug	CAHN

TABLET;ORAL							
CITALOPRAM HYDROBROMIDE							
AB		EQ 40MG BASE	A077044	003	Nov 05, 2004	Aug	CAHN
	@ COREPHARMA	EQ 10MG BASE	A077036	001	Oct 28, 2004	Feb	DISC
	@	EQ 20MG BASE	A077036	002	Oct 28, 2004	Feb	DISC
	@	EQ 40MG BASE	A077036	003	Oct 28, 2004	Feb	DISC
	@ NATCO PHARMA LTD	EQ 20MG BASE	A077141	002	Apr 10, 2008	Jun	DISC
	@	EQ 40MG BASE	A077141	001	Apr 10, 2008	Jun	DISC
<u>CLARITHROMYCIN</u>							
TABLET;ORAL							
CLARITHROMYCIN							
AB	ALLIED PHARMA INC	250MG	A202710	001	Jun 10, 2013	May	NEWA
AB		500MG	A202710	002	Jun 10, 2013	May	NEWA
<u>CLEMASTINE FUMARATE</u>							
SYRUP;ORAL							
CLEMASTINE FUMARATE							
	@ APOTEX INC	EQ 0.5MG BASE/5ML	A075703	001	Nov 27, 2000	Apr	DISC
	@ SILARX	EQ 0.5MG BASE/5ML	A074884	001	Dec 17, 1997	Mar	DISC
<u>CLEVIDIPINE</u>							
EMULSION;INTRAVENOUS							
CLEVIPREX							
+	MEDICINES CO	25MG/50ML (0.5MG/ML)	N022156	001	Aug 01, 2008	Feb	CAIN
+		50MG/100ML (0.5MG/ML)	N022156	002	Aug 01, 2008	Feb	CAIN
<u>CLINDAMYCIN PALMITATE HYDROCHLORIDE</u>							
FOR SOLUTION;ORAL							
CLINDAMYCIN PALMITATE HYDROCHLORIDE							
AA	AUROBINDO PHARMA LTD	EQ 75MG BASE/5ML	A202409	001	Apr 30, 2013	Apr	NEWA
<u>CLINDAMYCIN PHOSPHATE</u>							
AEROSOL, FOAM;TOPICAL							
EVOCLIN							
AT	+ DELCOR ASSET	1%	N050801	001	Oct 22, 2004	Sep	CAHN
GEL;TOPICAL							
CLINDAGEL							
BT	+ PRECISION DERMAT	EQ 1% BASE	N050782	001	Nov 27, 2000	Oct	CAHN
INJECTABLE;INJECTION							
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER							
AP	AKORN INC	EQ 6MG BASE/ML	A203048	001	Apr 04, 2013	Mar	NEWA
AP		EQ 12MG BASE/ML	A203048	002	Apr 04, 2013	Mar	NEWA
AP		EQ 18MG BASE/ML	A203048	003	Apr 04, 2013	Mar	NEWA
SOLUTION;TOPICAL							
CLINDAMYCIN PHOSPHATE							
	@ ACTAVIS MID ATLANTIC	EQ 1% BASE	A062811	001	Sep 01, 1988	May	CAHN
AT	PERRIGO NEW YORK	EQ 1% BASE	A064050	001	Nov 30, 1995	Aug	CMFD
	@	EQ 1% BASE	A064050	001	Nov 30, 1995	Feb	DISC
<u>CLOBAZAM</u>							
TABLET;ORAL							
ONFI							
	@ LUNDBECK LLC	5MG	N202067	001	Oct 21, 2011	Jul	DISC
<u>CLOBETASOL PROPIONATE</u>							
AEROSOL, FOAM;TOPICAL							
OLUX E							
AB2	+ DELCOR ASSET	0.05%	N022013	001	Jan 12, 2007	Jun	CAHN
CREAM;TOPICAL							
CLOBETASOL PROPIONATE							
	@ TEVA PHARMS USA	0.05%	A074087	001	Feb 16, 1994	Jun	DISC
SOLUTION;TOPICAL							
EMBELINE							
AT	+ HI TECH PHARMA	0.05%	A074222	001	Dec 06, 1995	Jul	CRLD
TEMOVATE							
	@ FOUGERA PHARMS	0.05%	N019966	001	Feb 22, 1990	Jul	DISC

CLONAZEPAMTABLET; ORAL
CLONAZEPAM

AB	ACCORD HLTHCARE	0.5MG	A077147	001	May 02, 2005	Apr CAHN
AB		1MG	A077147	002	May 02, 2005	Apr CAHN
AB		2MG	A077147	003	May 02, 2005	Apr CAHN
	@ APOTEX INC	0.5MG	A075468	001	Oct 06, 2000	Feb DISC
	@	1MG	A075468	002	Oct 06, 2000	Feb DISC
	@	2MG	A075468	003	Oct 06, 2000	Feb DISC

CLONIDINE HYDROCHLORIDEINJECTABLE; INJECTION
CLONIDINE HYDROCHLORIDE

AP	EXELA PHARMA SCS LLC	1MG/10ML (0.1MG/ML)	A203167	001	Oct 29, 2013	Oct NEWA
AP		5MG/10ML (0.5MG/ML)	A203167	002	Oct 29, 2013	Oct NEWA

TABLET; ORAL
CLONIDINE HYDROCHLORIDE

>D> AB	ALEMBIC PHARMS LTD	0.1MG	A091368	001	Dec 06, 2011	Nov DISC
>A>	@	0.1MG	A091368	001	Dec 06, 2011	Nov DISC
>D> AB		0.2MG	A091368	002	Dec 06, 2011	Nov DISC
>A>	@	0.2MG	A091368	002	Dec 06, 2011	Nov DISC
>D> AB		0.3MG	A091368	003	Dec 06, 2011	Nov DISC
>A>	@	0.3MG	A091368	003	Dec 06, 2011	Nov DISC
AB	CARLSBAD	0.1MG	A202297	001	Jun 13, 2013	May NEWA
AB		0.2MG	A202297	002	Jun 13, 2013	May NEWA
AB		0.3MG	A202297	003	Jun 13, 2013	May NEWA

TABLET, EXTENDED RELEASE; ORAL
CLONIDINE HYDROCHLORIDE

AB	ANCHEN PHARMS	0.1MG	A202984	001	Sep 30, 2013	Sep NEWA
AB		0.2MG	A202984	002	Sep 30, 2013	Sep NEWA
	JENLOGA					
	@ CONCORDIA PHARMS INC	0.1MG	N022331	001	Sep 30, 2009	May CAHN
	@	0.2MG	N022331	002	May 25, 2010	May CAHN
	KAPVAY					
AB	+ CONCORDIA PHARMS INC	0.1MG	N022331	003	Sep 28, 2010	Sep CFTG
	+	0.1MG	N022331	003	Sep 28, 2010	May CAHN
AB		0.2MG	N022331	004	Sep 28, 2010	Sep CFTG
		0.2MG	N022331	004	Sep 28, 2010	May CAHN

CLOPIDOGREL BISULFATETABLET; ORAL
CLOPIDOGREL BISULFATE

AB	ACCORD HLTHCARE	EQ 75MG BASE	A202925	001	Mar 27, 2013	Mar NEWA
AB		EQ 300MG BASE	A202925	002	Mar 27, 2013	Mar NEWA
AB	ACTAVIS TOTOWA	EQ 75MG BASE	A090307	001	May 28, 2013	May NEWA
AB	MUTUAL PHARM	EQ 75MG BASE	A078133	001	Jun 10, 2013	May NEWA

CLORAZEPATE DIPOTASSIUMCAPSULE; ORAL
TRANXENE

@ RECORDATI RARE	3.75MG	N017105	001		May CAHN
@	7.5MG	N017105	002		May CAHN
@	15MG	N017105	003		May CAHN

TABLET; ORAL
TRANXENE

AB	RECORDATI RARE	3.75MG	N017105	006		May CAHN
AB		7.5MG	N017105	007		May CAHN
AB	+	15MG	N017105	008		May CAHN
	TRANXENE SD					
@ RECORDATI RARE	11.25MG	N017105	005		May CAHN	
@	22.5MG	N017105	004		May CAHN	

CLOTTRIMAZOLECREAM; TOPICAL
MYCELEX

@ BAYER	1%	N018183	001		Sep CAHN
---------	----	---------	-----	--	----------

CLOZAPINESUSPENSION; ORAL
VERSACLOZ

+	DOUGLAS PHARMS	50MG/ML	N203479	001	Feb 06, 2013	Feb NEWA
+	JAZZ PHARMS III	50MG/ML	N203479	001	Feb 06, 2013	Mar CAHN

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA	AMNEAL PHARMS	10MG/5ML; 6.25MG/5ML	A200894	001	Apr 24, 2013	Apr NEWA
AA	CARACO	10MG/5ML; 6.25MG/5ML	A090180	001	Mar 17, 2010	May CAHN
	@ PHARM ASSOC	10MG/5ML; 6.25MG/5ML	A089647	001	Dec 22, 1988	Aug DISC

CRIZOTINIB

CAPSULE; ORAL

XALKORI

	PF PRISM CV	200MG	N202570	001	Aug 26, 2011	Sep CAHN
+		250MG	N202570	002	Aug 26, 2011	Sep CAHN

CROMOLYN SODIUM

CONCENTRATE; ORAL

CROMOLYN SODIUM

AA	MICRO LABS LTD INDIA	100MG/5ML	A202745	001	Apr 04, 2013	Mar NEWA
----	----------------------	-----------	---------	-----	--------------	----------

SOLUTION; INHALATION

CROMOLYN SODIUM

@ APOTEX INC 10MG/ML

A075333	001	Apr 30, 2002	Apr DISC
---------	-----	--------------	----------

SOLUTION/DROPS; OPHTHALMIC

CROMOLYN SODIUM

@ APOTEX INC 4%

A075615	001	Jan 26, 2001	Apr DISC
---------	-----	--------------	----------

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

AMRIX

AB	IVAX INTL	15MG	N021777	001	Feb 01, 2007	Jan CAHN
AB	+	30MG	N021777	002	Feb 01, 2007	Jan CAHN
	CYCLOBENZAPRINE HYDROCHLORIDE					
AB	TWI PHARMS INC	15MG	A091281	001	Jan 31, 2013	Jan NEWA
AB		30MG	A091281	002	Jan 31, 2013	Jan NEWA

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB	MYLAN PHARMS INC	7.5MG	A073144	003	Mar 25, 2013	Mar NEWA
	@ PROSAM LABS	5MG	A077291	001	Feb 03, 2006	Mar DISC
	@ SANDOZ	5MG	A072854	002	Feb 03, 2006	Apr DISC
	@	10MG	A072854	001	Nov 19, 1991	Apr DISC

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKPENTOLATE

@ AKORN 2%

A040165	001	Jan 13, 1997	Mar DISC
---------	-----	--------------	----------

CYCLOGYL

+	ALCON LABS INC	2%	A084108	001		Mar CTEC
---	----------------	----	---------	-----	--	----------

CYCLOPHOSPHAMIDE

CAPSULE; ORAL

CYCLOPHOSPHAMIDE

ROXANE 25MG

N203856	001	Sep 16, 2013	Sep NEWA
---------	-----	--------------	----------

+ 50MG

N203856	002	Sep 16, 2013	Sep NEWA
---------	-----	--------------	----------

INJECTABLE; INJECTION

CYTOXAN (LYOPHILIZED)

AP	+	BAXTER HLTHCARE	1GM/VIAL	N012142	004	Aug 30, 1982	Mar CTNA
	@		1GM/VIAL	N012142	010	Sep 24, 1985	Jan CTNA
AP	+		2GM/VIAL	N012142	005	Aug 30, 1982	Mar CTNA
	@		2GM/VIAL	N012142	009	Dec 10, 1985	Jan CTNA
AP	+		500MG/VIAL	N012142	003		Mar CTNA
	@		500MG/VIAL	N012142	008	Jan 04, 1984	Jan CTNA

CYCLOSPORINESOLUTION;ORAL
CYCLOSPORINE

@ APOTEX INC	100MG/ML	A065167	001	Jan 05, 2005	Apr DISC
--------------	----------	---------	-----	--------------	----------

CYPROHEPTADINE HYDROCHLORIDE

SYRUP;ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA	PHARM ASSOC	2MG/5ML	A091295	001	Mar 28, 2013	Mar NEWA
----	-------------	---------	---------	-----	--------------	----------

CYSTEAMINE BITARTRATE

CAPSULE, DELAYED RELEASE;ORAL

PROCYSBI

	RAPTOR PHARMS	EQ 25MG BASE	N203389	001	Apr 30, 2013	Apr NEWA
+		EQ 75MG BASE	N203389	002	Apr 30, 2013	Apr NEWA

CYTARABINE

INJECTABLE;INJECTION

CYTOSAR-U

AP	+	TEVA PHARMS USA	1GM/VIAL	A075206	004	Dec 30, 1998	Jun CAHN
AP	+		2GM/VIAL	A075206	003	Dec 30, 1998	Jun CAHN
AP			100MG/VIAL	A075206	001	Dec 30, 1998	Jun CAHN
AP	+		500MG/VIAL	A075206	002	Dec 30, 1998	Jun CAHN

DABRAFENIB MESYLATE

CAPSULE;ORAL

TAFINLAR

	GLAXOSMITHKLINE	EQ 50MG BASE	N202806	001	May 29, 2013	May NEWA
+		EQ 75MG BASE	N202806	002	May 29, 2013	May NEWA

DACARBAZINE

INJECTABLE;INJECTION

DACARBAZINE

AP		TEVA PHARMS USA	200MG/VIAL	A075259	002	Aug 27, 1998	Apr CAHN
AP	+		500MG/VIAL	A075259	001	Sep 22, 2000	Apr CAHN

DACTINOMYCIN

INJECTABLE;INJECTION

COSMEGEN

AP	+	RECORDATI RARE	0.5MG/VIAL	N050682	001		May CAHN
----	---	----------------	------------	---------	-----	--	----------

DACTINOMYCIN

>A>	AP	LUITPOLD	0.5MG/VIAL	A202562	001	Aug 23, 2013	Nov CAHN
>D>	AP	PHARMAFORCE	0.5MG/VIAL	A202562	001	Aug 23, 2013	Nov CAHN
	AP		0.5MG/VIAL	A202562	001	Aug 23, 2013	Aug NEWA

DALTEPARIN SODIUM

INJECTABLE;SUBCUTANEOUS

FRAGMIN

@ EISAI INC	10,000IU/0.4ML (25,000IU/ML)	N020287	002	May 01, 2007	Jun DISC
@	95,000IU/9.5ML (10,000IU/ML)	N020287	007	Apr 04, 2002	Jun DISC

DANTROLENE SODIUM

CAPSULE;ORAL

DANTROLENE SODIUM

AB	MIKAH PHARMA	25MG	A076686	001	Oct 24, 2005	Jul CMFD
AB		50MG	A076686	002	Oct 24, 2005	Jul CMFD
AB		100MG	A076686	003	Oct 24, 2005	Jul CMFD

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

DAUNORUBICIN HYDROCHLORIDE

AP	TEVA PHARMS USA	EQ 5MG BASE/ML	A065035	001	Jan 24, 2000	Apr CAHN
----	-----------------	----------------	---------	-----	--------------	----------

DECITABINE

INJECTABLE;INTRAVENOUS

DACOGEN

AP	+	EISAI INC	50MG/VIAL	N021790	001	May 02, 2006	Jul CFTG
----	---	-----------	-----------	---------	-----	--------------	----------

DECITABINE

AP		DR REDDYS LABS LTD	50MG/VIAL	A203131	001	Jul 11, 2013	Jul NEWA
----	--	--------------------	-----------	---------	-----	--------------	----------

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

>A>	@ BARR LABS INC	150MG	A071804	001	May 29, 1997	Nov CAHN
>D>	@ PLIVA	150MG	A071804	001	May 29, 1997	Nov CAHN

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DESMOPRESSIN ACETATE

AP	SUN PHARM INDS LTD	0.004MG/ML	A091280	001	Jan 25, 2013	Jan NEWA
AP	TEVA PHARMS USA	0.004MG/ML	A074888	001	Oct 15, 1997	Apr CAHN

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

DESOGESTREL AND ETHINYL ESTRADIOL

AB	FAMY CARE LTD	0.15MG, N/A; 0.02MG, 0.01MG	A202296	001	Aug 30, 2013	Aug NEWA
AB	NOVAST LABS LTD	0.15MG; 0.03MG	A091234	001	Jul 12, 2013	Jul NEWA
	ENSKYCE					
AB	LUPIN LTD	0.15MG; 0.03MG	A201887	001	Mar 07, 2013	Feb NEWA
	PIMTREA					
AB	NOVAST LABS LTD	0.15MG, N/A; 0.02MG, 0.01MG	A091247	001	Aug 01, 2013	Jul NEWA

DESONIDE

GEL; TOPICAL

DESONATE

+	BAYER HLTHCARE	0.05%	N021844	001	Oct 20, 2006	Jun CAHN
---	----------------	-------	---------	-----	--------------	----------

DESOXIMETASONE

OINTMENT; TOPICAL

DESOXIMETASONE

AB	GLENMARK GENERICS	0.25%	A202838	001	Sep 20, 2013	Sep NEWA
----	-------------------	-------	---------	-----	--------------	----------

SPRAY; TOPICAL

TOPICORT

+	TARO	0.25%	N204141	001	Apr 11, 2013	Apr NEWA
---	------	-------	---------	-----	--------------	----------

DESVENLAFAXINE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE

BC	+	ALEMBIC PHARMS LTD	50MG	N204150	001	Mar 04, 2013	Jul CTEC
	+		50MG	N204150	001	Mar 04, 2013	Apr CRLD
			50MG	N204150	001	Mar 04, 2013	Mar NEWA
BC	+		100MG	N204150	002	Mar 04, 2013	Jul CTEC
	+		100MG	N204150	002	Mar 04, 2013	Mar NEWA
		KHEDEZLA					
BC		OSMOTICA PHARM CORP	50MG	N204683	001	Jul 10, 2013	Jul NEWA
BC			100MG	N204683	002	Jul 10, 2013	Jul NEWA

DESVENLAFAXINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE FUMARATE

+	TEVA PHARMS USA	EQ 50MG BASE	N205208	001	Oct 11, 2013	Oct NEWA
+		EQ 100MG BASE	N205208	002	Oct 11, 2013	Oct NEWA

DEXAMETHASONE

ELIXIR; ORAL

DEXAMETHASONE

AA	WOCKHARDT EU OPERATN	0.5MG/5ML	A088254	001	Jul 27, 1983	May CRLD
----	----------------------	-----------	---------	-----	--------------	----------

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

>A>	AP	AGILA SPECLTS	EQ 4MG PHOSPHATE/ML	A040803	001	Aug 29, 2008	Nov CAHN
>A>	AP		EQ 10MG PHOSPHATE/ML	A040802	001	Aug 29, 2008	Nov CAHN
>D>	AP	PFIZER	EQ 4MG PHOSPHATE/ML	A040803	001	Aug 29, 2008	Nov CAHN
>D>	AP		EQ 10MG PHOSPHATE/ML	A040802	001	Aug 29, 2008	Nov CAHN

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

AT	NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE						
	PERRIGO CO TENNESSEE	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062938	001	Jul 31, 1989	Jun	CAHN

SUSPENSION/DROPS;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

	@ ALCON PHARMS LTD	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062721	001	Nov 17, 1986	Jan	DISC
--	--------------------	---------------------------------------	---------	-----	--------------	-----	------

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

PRECEDEX

+	HOSPIRA	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	N021038	002	Mar 13, 2013	Mar	NEWA
+		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	N021038	003	Mar 13, 2013	Mar	NEWA

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

>A>	AB	INTELLIPHARMACEUTICS	15MG	A078992	003	Nov 18, 2013	Nov	NEWA
>A>	AB		30MG	A078992	004	Nov 18, 2013	Nov	NEWA
	AB	MYLAN PHARMS INC	30MG	A202580	001	Aug 28, 2013	Aug	NEWA
>A>	AB	TEVA PHARMS USA	5MG	A078908	001	Nov 19, 2013	Nov	NEWA
>A>	AB		10MG	A078908	002	Nov 19, 2013	Nov	NEWA
>A>	AB		20MG	A078908	003	Nov 19, 2013	Nov	NEWA
>A>	AB		40MG	A202731	002	Nov 19, 2013	Nov	NEWA
>A>	AB	WATSON LABS INC	30MG	A079108	005	Nov 21, 2013	Nov	NEWA
		FOCALIN XR						
>D>		NOVARTIS	5MG	N021802	001	May 26, 2005	Nov	CTEC
>A>	AB		5MG	N021802	001	May 26, 2005	Nov	CTEC
>D>			10MG	N021802	002	May 26, 2005	Nov	CTEC
>A>	AB		10MG	N021802	002	May 26, 2005	Nov	CTEC
>D>			15MG	N021802	004	Aug 01, 2006	Nov	CTEC
>A>	AB		15MG	N021802	004	Aug 01, 2006	Nov	CTEC
>D>			20MG	N021802	003	May 26, 2005	Nov	CTEC
>A>	AB		20MG	N021802	003	May 26, 2005	Nov	CTEC
	AB		30MG	N021802	005	Oct 23, 2009	Aug	CFTG
>D>	+		40MG	N021802	006	Aug 11, 2010	Nov	CTEC
>A>	AB	+	40MG	N021802	006	Aug 11, 2010	Nov	CTEC

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE;INJECTION

TOTECT

+	BIOCODEX INC	EQ 500MG BASE/VIAL	N022025	001	Sep 06, 2007	May	CAHN
---	--------------	--------------------	---------	-----	--------------	-----	------

DEXTROAMPHETAMINE SULFATE

SOLUTION;ORAL

DEXTROAMPHETAMINE SULFATE

AA	+	OUTLOOK PHARMS	5MG/5ML	A040776	001	Jan 29, 2008	May	CFTG
AA		TRIS PHARMA INC	5MG/5ML	A203644	001	May 29, 2013	May	NEWA

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

AA		AUROLIFE PHARMA LLC	5MG	A202893	001	Jul 31, 2013	Jul	NEWA
AA			10MG	A202893	002	Jul 31, 2013	Jul	NEWA

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER

@	B BRAUN	5GM/100ML;220MG/100ML	N018744	003	Nov 09, 1982	Jan	DISC
---	---------	-----------------------	---------	-----	--------------	-----	------

DIAZEPAM

INJECTABLE;INJECTION

DIAZEPAM

@	WATSON LABS	5MG/ML	A070296	001	Feb 12, 1986	Jun	DISC
---	-------------	--------	---------	-----	--------------	-----	------

DIAZOXIDESUSPENSION;ORAL
PROGLYCEM

+ TEVA BRANDED PHARM 50MG/ML N017453 001 Apr CAHN

DICLOFENACCAPSULE;ORAL
ZORVOLEXIROKO PHARMS LLC 18MG N204592 001 Oct 18, 2013 Oct NEWA
+ 35MG N204592 002 Oct 18, 2013 Oct NEWADICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

AB TOLMAR 3% A200936 001 Oct 28, 2013 Oct NEWA
SOLARAZE

AB + FOUGERA PHARMS 3% N021005 001 Oct 16, 2000 Oct CFTG

SOLUTION/DROPS;OPHTHALMIC

DICLOFENAC SODIUM

@ APOTEX INC 0.1% A077600 001 Nov 13, 2008 Apr DISC

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL

DICLOFENAC SODIUM AND MISOPROSTOL

AB SANDOZ 50MG;0.2MG A200158 001 May 09, 2013 Apr NEWA

AB 75MG;0.2MG A200158 002 May 09, 2013 Apr NEWA

DICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL

DICYCLOMINE HYDROCHLORIDE

@ WEST WARD 10MG A040204 001 Feb 28, 1997 Jul DISC

DIDANOSINE

TABLET, FOR SUSPENSION;ORAL

DIDANOSINE

AUROBINDO 100MG A077275 001 Aug 14, 2012 Apr CDFR

150MG A077275 002 Aug 14, 2012 Apr CDFR

+ 200MG A077275 003 Aug 14, 2012 Apr CDFR

DIFLORASONE DIACETATE

CREAM;TOPICAL

DIFLORASONE DIACETATE

@ FOUGERA PHARMS 0.05% A075187 001 Mar 30, 1998 May DISC

BX + TARO 0.05% A075508 001 Apr 24, 2000 May CRLD

PSORCON

@ TARO PHARMS NORTH 0.05% N020205 001 Nov 20, 1992 Jun CAHN

DIGOXIN

TABLET;ORAL

DIGOXIN

@ CARACO 0.125MG A076363 001 Jan 31, 2003 Jun DISC

@ 0.25MG A076363 002 Jan 31, 2003 Jun DISC

AB HIKMA PHARMS 0.125MG A077002 002 Oct 30, 2007 Oct CAHN

AB 0.25MG A077002 001 Oct 30, 2007 Oct CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE

AB3 PAR PHARM 120MG A074984 001 Dec 20, 1999 Jan CAHN

AB3 180MG A074984 002 Dec 20, 1999 Jan CAHN

AB3 240MG A074984 003 Dec 20, 1999 Jan CAHN

AB3 300MG A074984 004 Dec 20, 1999 Jan CAHN

AB4 SANDOZ 120MG A091022 001 Sep 28, 2012 Feb CAHN

AB4 180MG A091022 002 Sep 28, 2012 Feb CAHN

AB4 240MG A091022 003 Sep 28, 2012 Feb CAHN

AB4 300MG A091022 004 Sep 28, 2012 Feb CAHN

AB4 360MG A091022 005 Sep 28, 2012 Feb CAHN

AB4 420MG A091022 006 Sep 28, 2012 Feb CAHN

INJECTABLE; INJECTION							
DILTIAZEM HYDROCHLORIDE							
AP	AKORN INC	5MG/ML	A075086	001	Apr 09, 1998	Jul	CAHN
	@ APOTEX INC	5MG/ML	A075375	001	Sep 30, 1999	Apr	DISC
	@ TEVA PHARMS USA	5MG/ML	A074894	001	Aug 26, 1997	Apr	CAHN
+		10MG/ML	A074894	002	Apr 19, 2002	Apr	CAHN
TABLET; ORAL							
DILTIAZEM HYDROCHLORIDE							
	@ DAVA PHARMS INC	30MG	A074093	001	Nov 05, 1992	Jan	DISC
	@	60MG	A074093	002	Nov 05, 1992	Jan	DISC
	@	90MG	A074093	003	Nov 05, 1992	Jan	DISC
	@	120MG	A074093	004	Nov 05, 1992	Jan	DISC
<u>DIMENHYDRINATE</u>							
INJECTABLE; INJECTION							
DIMENHYDRINATE							
+	FRESENIUS KABI USA	50MG/ML	A040519	001	Jun 23, 2004	Apr	CRLD
	@ WATSON LABS	50MG/ML	A080615	001		Apr	DISC
<u>DIMETHYL FUMARATE</u>							
CAPSULE, DELAYED RELEASE; ORAL							
TECFIDERA							
	BIOMGEN IDEC INC	120MG	N204063	001	Mar 27, 2013	Mar	NEWA
+		240MG	N204063	002	Mar 27, 2013	Mar	NEWA
<u>DIPHENHYDRAMINE HYDROCHLORIDE</u>							
INJECTABLE; INJECTION							
DIPHENHYDRAMINE HYDROCHLORIDE							
	@ WATSON LABS INC	10MG/ML	A080873	001		Mar	DISC
	@	50MG/ML	A080873	002		Mar	DISC
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE							
AP	BD RX	50MG/ML	A091526	001	Mar 26, 2013	Mar	NEWA
	@ WATSON LABS INC	50MG/ML	A080873	003		Mar	DISC
<u>DIPYRIDAMOLE</u>							
INJECTABLE; INJECTION							
DIPYRIDAMOLE							
	@ AGILA SPECLTS	5MG/ML	A075769	001	Nov 27, 2002	Aug	CAHN
	@ APOTEX INC	5MG/ML	A075769	001	Nov 27, 2002	Apr	DISC
	@ TEVA PHARMS USA	5MG/ML	A074952	001	Nov 26, 1997	May	CAHN
TABLET; ORAL							
DIPYRIDAMOLE							
	@ PROSAM LABS	25MG	A040542	001	Apr 21, 2006	Jun	DISC
	@	50MG	A040542	002	Apr 21, 2006	Jun	DISC
	@	75MG	A040542	003	Apr 21, 2006	Jun	DISC
<u>DISULFIRAM</u>							
TABLET; ORAL							
DISULFIRAM							
AB	ALVOGEN PINE BROOK	250MG	A091681	001	Aug 08, 2013	Jul	NEWA
<u>DIVALPROEX SODIUM</u>							
TABLET, DELAYED RELEASE; ORAL							
DIVALPROEX SODIUM							
	@ MYLAN	EQ 125MG VALPROIC ACID	A077254	001	Jul 29, 2008	Aug	DISC
	@	EQ 250MG VALPROIC ACID	A077254	002	Jul 29, 2008	Aug	DISC
	@	EQ 500MG VALPROIC ACID	A077254	003	Jul 29, 2008	Aug	DISC
TABLET, EXTENDED RELEASE; ORAL							
DIVALPROEX SODIUM							
	@ TEVA PHARMS USA	EQ 500MG VALPROIC ACID	A078700	001	Aug 03, 2009	Mar	DISC
<u>DOCETAXEL</u>							
INJECTABLE; INJECTION							
DOCETAXEL							
AP	ACCORD HLTHCARE	160MG/8ML (20MG/ML)	N201195	005	Apr 20, 2012	Aug	CTEC
AP	ACTAVIS INC	20MG/ML (20MG/ML)	N203551	001	Apr 12, 2013	Apr	NEWA
AP		80MG/4ML (20MG/ML)	N203551	002	Apr 12, 2013	Apr	NEWA
		140MG/7ML (20MG/ML)	N203551	003	Apr 12, 2013	Apr	NEWA
	@ APOTEX INC	20MG/0.5ML (40MG/ML)	N022312	001	Jan 11, 2012	May	DISC
	@	80MG/2ML (40MG/ML)	N022312	002	Jan 11, 2012	May	DISC

INJECTABLE;INJECTION
TAXOTERE

AP + SANOFI AVENTIS US 160MG/8ML (20MG/ML) N020449 005 Apr 13, 2012 Aug NEWA

DOLUTEGRAVIR SODIUM

TABLET;ORAL
TIVICAY

+ VIIV HLTHCARE EQ 50MG BASE N204790 001 Aug 12, 2013 Aug NEWA

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL
ARICEPT

AB + EISAI INC 23MG N022568 001 Jul 23, 2010 Jul CTEC
 DONEPEZIL HYDROCHLORIDE
 @ ACCORD HLTHCARE 5MG A201335 001 Aug 29, 2011 Jan DISC
 @ 10MG A201335 002 Aug 29, 2011 Jan DISC
 AB ACTAVIS GRP PTC 5MG A090551 001 May 31, 2011 Apr CAHN
 AB 10MG A090551 002 May 31, 2011 Apr CAHN
 AB ALEMBIC PHARMS LTD 5MG A201724 001 Feb 25, 2013 Feb NEWA
 AB 10MG A201724 002 Feb 25, 2013 Feb NEWA
 AB ALVOGEN PINE BROOK 5MG A202114 001 Jul 05, 2013 Jun NEWA
 AB 10MG A202114 002 Jul 05, 2013 Jun NEWA
 AB CSPC OUYI PHARM CO 5MG A202114 001 Jul 05, 2013 Sep CAHN
 AB 10MG A202114 002 Jul 05, 2013 Sep CAHN
 AB DR REDDYS LABS LTD 23MG A202723 001 Jul 24, 2013 Jul NEWA
 AB PAR PHARM 23MG A202542 001 Jul 24, 2013 Jul NEWA

DORIPENEM

INJECTABLE;IV (INFUSION)
DORIBAX

SHIONOGI INC 250MG/VIAL N022106 002 Oct 05, 2010 Oct CAHN
 + 500MG/VIAL N022106 001 Oct 12, 2007 Oct CAHN

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE

@ APOTEX INC EQ 2% BASE A078395 001 Oct 28, 2008 Apr DISC
 >A> AT ZACH SYSTEMS EQ 2% BASE A091034 001 Dec 04, 2013 Nov NEWA

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC
COSOPT

>D> AT + MERCK EQ 2% BASE;EQ 0.5% BASE N020869 001 Apr 07, 1998 Nov CAHN
 >A> AT + OAK PHARMS AKORN EQ 2% BASE;EQ 0.5% BASE N020869 001 Apr 07, 1998 Nov CAHN
 COSOPT PF
 >D> + MERCK SHARP DOHME EQ 2% BASE;EQ 0.5% BASE N202667 001 Feb 01, 2012 Nov CAHN
 >A> + OAK PHARMS AKORN EQ 2% BASE;EQ 0.5% BASE N202667 001 Feb 01, 2012 Nov CAHN
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE
 @ APOTEX INC EQ 2% BASE;EQ 0.5% BASE A078201 001 Oct 28, 2008 Apr DISC
 >A> AT ZACH SYSTEMS EQ 2% BASE;EQ 0.5% BASE A091180 001 Dec 04, 2013 Nov NEWA

DOXAPRAM HYDROCHLORIDE

INJECTABLE;INJECTION
DOPRAM

AP + HIKMA MAPLE 20MG/ML N014879 001 Jul CAHN

DOXAZOSIN MESYLATE

TABLET;ORAL

DOXAZOSIN MESYLATE

@ WATSON LABS INC EQ 1MG BASE A075426 001 Oct 18, 2000 Jan DISC
 @ EQ 2MG BASE A075426 002 Oct 18, 2000 Jan DISC
 @ EQ 4MG BASE A075426 003 Oct 18, 2000 Jan DISC
 @ EQ 8MG BASE A075426 004 Oct 18, 2000 Jan DISC

DOXEPIH HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIH HYDROCHLORIDE

AB MYLAN PHARMS INC EQ 10MG BASE A070791 002 May 13, 1986 Jun CRLD
 AB EQ 10MG BASE A070791 002 May 13, 1986 May CRLD
 AB + EQ 25MG BASE A070791 003 May 13, 1986 Jun CRLD
 @ PAR PHARM EQ 10MG BASE A071697 001 Nov 09, 1987 May DISC
 @ EQ 25MG BASE A071437 001 Nov 09, 1987 May DISC

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

@	EQ 50MG BASE	A071595	001	Nov 09, 1987	May DISC
@	EQ 75MG BASE	A071608	001	Nov 09, 1987	May DISC
@	EQ 100MG BASE	A071422	001	Nov 09, 1987	May DISC
@ WATSON LABS	EQ 10MG BASE	A071485	001	Apr 30, 1987	May DISC
@	EQ 25MG BASE	A071486	001	Apr 30, 1987	May DISC
@	EQ 50MG BASE	A071238	001	Apr 30, 1987	May DISC
@	EQ 75MG BASE	A071326	001	Apr 30, 1987	May DISC
@	EQ 100MG BASE	A071239	001	Apr 30, 1987	May DISC

CONCENTRATE;ORAL

DOXEPIN HYDROCHLORIDE

@ PHARM ASSOC	EQ 10MG BASE/ML	A075924	001	Jan 15, 2004	Mar DISC
---------------	-----------------	---------	-----	--------------	----------

TABLET;ORAL

DOXEPIN HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	EQ 3MG BASE	A201951	001	Jul 26, 2013	Jul NEWA
AB		EQ 6MG BASE	A201951	002	Jul 26, 2013	Jul NEWA
	SILENOR					
AB	PERNIX THERAPS LLC	EQ 3MG BASE	N022036	001	Mar 17, 2010	Jul CFTG
		EQ 3MG BASE	N022036	001	Mar 17, 2010	Apr CAHN
AB	+	EQ 6MG BASE	N022036	002	Mar 17, 2010	Jul CFTG
	+	EQ 6MG BASE	N022036	002	Mar 17, 2010	Apr CAHN

DOXERCALCIFEROL

INJECTABLE;INJECTION

DOXERCALCIFEROL

AP	HIKMA PHARMS LLC	4MCG/2ML (2MCG/ML)	A091101	001	Aug 30, 2013	Oct CAHN
AP	INNOPHARMA INC	4MCG/2ML (2MCG/ML)	A091101	001	Aug 30, 2013	Aug NEWA
	HECTOROL					
AP	+ GENZYME CORP	4MCG/2ML (2MCG/ML)	N021027	001	Apr 06, 2000	Aug CFTG

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

DOXORUBICIN HYDROCHLORIDE

AP	SAGENT PHARMS	2MG/ML	A091495	001	Mar 18, 2013	Mar NEWA
AP	TEVA PHARMS USA	2MG/ML	A064140	001	Jul 28, 1995	Jun CAHN
AP		200MG/100ML	A064140	002	Jul 28, 1995	Jun CAHN

INJECTABLE, LIPOSOMAL;INJECTION

DOXIL

AB	+	JANSSEN RES AND DEV	20MG/10ML (2MG/ML)	N050718	001	Nov 17, 1995	Jan CFTG
AB	+		50MG/25ML (2MG/ML)	N050718	002	Jun 13, 2000	Jan CFTG

DOXIL (LIPOSOMAL)

AB		JANSSEN RES AND DEV	20MG/10ML (2MG/ML)	N050718	001	Nov 17, 1995	Jun CRLD
AB	+		20MG/10ML (2MG/ML)	N050718	001	Nov 17, 1995	Apr CTNA
AB			50MG/25ML (2MG/ML)	N050718	002	Jun 13, 2000	Jun CRLD
AB	+		50MG/25ML (2MG/ML)	N050718	002	Jun 13, 2000	Apr CTNA

DOXORUBICIN HYDROCHLORIDE

AB		SUN PHARMA GLOBAL	20MG/10ML (2MG/ML)	A203263	001	Feb 04, 2013	Jan NEWA
AB			50MG/25ML (2MG/ML)	A203263	002	Feb 04, 2013	Jan NEWA

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

AB	+	SUN PHARMA GLOBAL	20MG/10ML (2MG/ML)	A203263	001	Feb 04, 2013	Jun CRLD
AB	+		20MG/10ML (2MG/ML)	A203263	001	Feb 04, 2013	Apr CTNA
AB	+		50MG/25ML (2MG/ML)	A203263	002	Feb 04, 2013	Jun CRLD
AB	+		50MG/25ML (2MG/ML)	A203263	002	Feb 04, 2013	Apr CTNA

DOXYCYCLINE

FOR SUSPENSION;ORAL

DOXYCYCLINE

AB		CHARTWELL LIFE SCI	EQ 25MG BASE/5ML	A065454	001	Jul 16, 2008	Sep CAHN
AB		LUPIN LTD	EQ 25MG BASE/5ML	A201678	001	Mar 18, 2013	Mar NEWA

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

DOXYCYCLINE HYCLATE

AB		CHARTWELL LIFE SCI	EQ 50MG BASE	A062500	001	Sep 11, 1984	Sep CAHN
AB			EQ 100MG BASE	A062500	002	Sep 11, 1984	Sep CAHN
AB		HIKMA PHARMS	EQ 50MG BASE	A062396	002	Nov 07, 1984	May CAHN
AB			EQ 100MG BASE	A062396	001	May 07, 1984	May CAHN

INJECTABLE;INJECTION

DOXYCYCLINE

>A>	AP	AGILA SPECLTS	EQ 100MG BASE/VIAL	A091406	001	Aug 21, 2012	Nov CAHN
>D>	AP	PFIZER	EQ 100MG BASE/VIAL	A091406	001	Aug 21, 2012	Nov CAHN

TABLET;ORAL

DOXYCYCLINE HYCLATE

	@ BLU CARIBE INC	EQ 50MG BASE	A062269	003		Mar CAHN
>D>	@	EQ 100MG BASE	A062269	002	Nov 08, 1982	Nov CMFD
>A> AB		EQ 100MG BASE	A062269	002	Nov 08, 1982	Nov CMFD
	@	EQ 100MG BASE	A062269	002	Nov 08, 1982	Mar CAHN
AB	CHARTWELL LIFE SCI	EQ 100MG BASE	A062505	001	Sep 11, 1984	Jul CAHN
AB	+ HIKMA PHARMS	EQ 100MG BASE	A065095	001	Jul 02, 2003	May CAHN
TABLET, DELAYED RELEASE;ORAL						
DORYX						
	MAYNE PHARMA	EQ 80MG BASE	N050795	004	Apr 11, 2013	Apr NEWA
		EQ 200MG BASE	N050795	005	Apr 11, 2013	Apr NEWA
DOXYCYCLINE HYCLATE						
AB	HERITAGE PHARMS INC	EQ 75MG BASE	A200856	001	Apr 30, 2013	Apr NEWA
AB		EQ 100MG BASE	A200856	002	Apr 30, 2013	Apr NEWA
AB		EQ 150MG BASE	A200856	003	Apr 30, 2013	Apr NEWA

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, DELAYED RELEASE;ORAL

DICLEGIS

	+ DUCHESNAY	10MG;10MG	N021876	001	Apr 08, 2013	Apr NEWA
--	-------------	-----------	---------	-----	--------------	----------

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

CYMBALTA

>D>	LILLY	EQ 20MG BASE	N021427	001	Aug 03, 2004	Nov CFTG
>A> AB		EQ 20MG BASE	N021427	001	Aug 03, 2004	Nov CFTG
>D>		EQ 30MG BASE	N021427	002	Aug 03, 2004	Nov CFTG
>A> AB		EQ 30MG BASE	N021427	002	Aug 03, 2004	Nov CFTG
>D>	+	EQ 60MG BASE	N021427	004	Aug 03, 2004	Nov CFTG
>A> AB	+	EQ 60MG BASE	N021427	004	Aug 03, 2004	Nov CFTG
DULOXETINE HYDROCHLORIDE						
>A> AB	AUROBINDO PHARMA LTD	EQ 20MG BASE	A090778	001	Dec 11, 2013	Nov NEWA
>A> AB		EQ 30MG BASE	A090778	002	Dec 11, 2013	Nov NEWA
>A> AB		EQ 60MG BASE	A090778	003	Dec 11, 2013	Nov NEWA
>A> AB	DR REDDYS LABS LTD	EQ 20MG BASE	A090723	001	Dec 11, 2013	Nov NEWA
>A> AB		EQ 30MG BASE	A090723	002	Dec 11, 2013	Nov NEWA
>A> AB		EQ 60MG BASE	A090723	003	Dec 11, 2013	Nov NEWA
>A> AB	LUPIN LTD	EQ 20MG BASE	A090694	001	Dec 11, 2013	Nov NEWA
>A> AB		EQ 30MG BASE	A090694	002	Dec 11, 2013	Nov NEWA
>A>		EQ 40MG BASE	A090694	003	Dec 11, 2013	Nov NEWA
>A> AB		EQ 60MG BASE	A090694	004	Dec 11, 2013	Nov NEWA
>A> AB	SUN PHARMA GLOBAL	EQ 20MG BASE	A090745	001	Dec 11, 2013	Nov NEWA
>A> AB		EQ 30MG BASE	A090745	002	Dec 11, 2013	Nov NEWA
>A> AB		EQ 60MG BASE	A090745	003	Dec 11, 2013	Nov NEWA
>A> AB	TEVA PHARMS USA	EQ 20MG BASE	A090783	001	Dec 11, 2013	Nov NEWA
>A> AB		EQ 30MG BASE	A090783	002	Dec 11, 2013	Nov NEWA
>A> AB		EQ 60MG BASE	A090783	003	Dec 11, 2013	Nov NEWA
>A> AB	TORRENT PHARMS LTD	EQ 20MG BASE	A090774	001	Dec 11, 2013	Nov NEWA
>A> AB		EQ 30MG BASE	A090774	002	Dec 11, 2013	Nov NEWA
>A> AB		EQ 60MG BASE	A090774	003	Dec 11, 2013	Nov NEWA

DUTASTERIDE

CAPSULE;ORAL

DUTASTERIDE

AB	BANNER PHARMACAPS	0.5MG	A200899	001	May 30, 2013	May NEWA
----	-------------------	-------	---------	-----	--------------	----------

ECONAZOLE NITRATE

AEROSOL, FOAM;TOPICAL

ECOZA

	+ AMDERMA PHARMS	1%	N205175	001	Oct 24, 2013	Oct NEWA
--	------------------	----	---------	-----	--------------	----------

CREAM;TOPICAL

ECONAZOLE NITRATE

AB	IGI LABS INC	1%	A076574	001	Dec 17, 2004	Mar CAHN
----	--------------	----	---------	-----	--------------	----------

EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION

TENSILON

AP	+ VALEANT PHARMS	10MG/ML	N007959	001		Jul CAHN
----	------------------	---------	---------	-----	--	----------

TENSILON PRESERVATIVE FREE

AP	+ VALEANT PHARMS	10MG/ML	N007959	002		Jul CAHN
----	------------------	---------	---------	-----	--	----------

ENALAPRIL MALEATEFOR SOLUTION;ORAL
EPANED KIT

+ SILVERGATE PHARMS 1MG/ML

N204308 001 Aug 13, 2013 Aug NEWA

TABLET;ORAL

ENALAPRIL MALEATE

@ MYLAN 2.5MG

A075472 001 Aug 22, 2000 Aug DISC

@ 5MG

A075472 002 Aug 22, 2000 Aug DISC

@ 10MG

A075472 003 Aug 22, 2000 Aug DISC

@ 20MG

A075472 004 Aug 22, 2000 Aug DISC

ENALAPRILAT

INJECTABLE;INJECTION

ENALAPRILAT

AP TEVA PHARMS USA 1.25MG/ML

A075578 001 Aug 22, 2000 May CAHN

ENTACAPONE

TABLET;ORAL

ENTACAPONE

AB MYLAN PHARMS INC 200MG

A202394 001 May 13, 2013 Apr NEWA

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

EPINASTINE HYDROCHLORIDE

>A> AT BRECKENRIDGE PHARM 0.05%

A090870 001 Mar 14, 2011 Nov CAHN

>D> AT CYPRESS PHARM 0.05%

A090870 001 Mar 14, 2011 Nov CAHN

EPINEPHRINE

INJECTABLE;IM-SC

EPIPEN

BX + MERIDIAN MEDCL TECHN 0.3MG/DELIVERY

N019430 001 Dec 22, 1987 Jul CDFR

BX + MYLAN SPECLT 0.3MG/DELIVERY

N019430 001 Dec 22, 1987 Sep CAHN

EPIPEN JR.

BX + MERIDIAN MEDCL TECHN 0.15MG/DELIVERY

N019430 002 Dec 22, 1987 Jul CDFR

BX + MYLAN SPECLT 0.15MG/DELIVERY

N019430 002 Dec 22, 1987 Sep CAHN

INJECTABLE;INTRAMUSCULAR

EPI E Z PEN JR

@ MYLAN SPECLT 0.15MG/DELIVERY

N019430 004 Aug 03, 1995 Sep CAHN

EPIPEN E Z PEN

@ MYLAN SPECLT 0.3MG/DELIVERY

N019430 003 Aug 03, 1995 Sep CAHN

EPIRUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

EPIRUBICIN HYDROCHLORIDE

AP TEVA PHARMS USA 50MG/25ML (2MG/ML)

A065331 001 Aug 09, 2007 Apr CAHN

AP 200MG/100ML (2MG/ML)

A065331 002 Aug 09, 2007 Apr CAHN

EPOPROSTENOL SODIUM

INJECTABLE;INJECTION

EPOPROSTENOL SODIUM

AP TEVA PHARMS USA EQ 0.5MG BASE/VIAL

A078396 001 Apr 23, 2008 Apr CAHN

AP EQ 1.5MG BASE/VIAL

A078396 002 Apr 23, 2008 Apr CAHN

ERTAPENEM SODIUM

INJECTABLE;INTRAMUSCULAR, IV (INFUSION)

INVANZ

+ MERCK SHARP DOHME EQ 1GM BASE/VIAL

N021337 001 Nov 21, 2001 Jun CAHN

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS;ORAL

ERYC

AB + MAYNE PHARMA 250MG

N050536 001 Mar CAHN

@ WARNER CHILCOTT LLC 250MG

A062338 001 Apr DISC

GEL;TOPICAL

ERYGEL

AT + DELCOR ASSET CORP 2%

N050617 001 Oct 21, 1987 Jul CAHN

OINTMENT;OPHTHALMIC

ERYTHROMYCIN

AT + PERRIGO CO TENNESSEE 0.5%

A062447 001 Sep 26, 1983 Jun CAHN

SOLUTION; TOPICAL
SANSAC

@ DOW PHARM	2%	A062522	001	Jan 24, 1985	Apr CAHN
-------------	----	---------	-----	--------------	----------

ESCITALOPRAM OXALATESOLUTION; ORAL
ESCITALOPRAM OXALATE

AA	SILARX PHARMS INC	EQ 5MG BASE/5ML	A090477	001	Jun 12, 2013	May NEWA
----	-------------------	-----------------	---------	-----	--------------	----------

>A> ESLICARBAZEPINE ACETATE

>A> TABLET; ORAL

>A> APTIOM

>A>	SUNOVION PHARMS INC	200MG	N022416	001	Nov 08, 2013	Nov NEWA
>A>		400MG	N022416	002	Nov 08, 2013	Nov NEWA
>A>		600MG	N022416	003	Nov 08, 2013	Nov NEWA
>A>	+	800MG	N022416	004	Nov 08, 2013	Nov NEWA

ESOMEPRAZOLE MAGNESIUM; NAPROXENTABLET, DELAYED RELEASE; ORAL
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

AB	DR REDDYS LABS LTD	EQ 20MG BASE; 375MG	A202461	001	Sep 27, 2013	Sep NEWA
AB		EQ 20MG BASE; 500MG	A202461	002	Sep 27, 2013	Sep NEWA
	VIMOVO					
AB	ASTRAZENECA LP	EQ 20MG BASE; 375MG	N022511	002	Apr 30, 2010	Sep CFTG
AB	+	EQ 20MG BASE; 500MG	N022511	001	Apr 30, 2010	Sep CFTG

ESOMEPRAZOLE SODIUMINJECTABLE; INTRAVENOUS
ESOMEPRAZOLE SODIUM

AP	SUN PHARMA GLOBAL	EQ 20MG BASE/VIAL	A200882	001	Mar 18, 2013	Mar NEWA
AP		EQ 40MG BASE/VIAL	A200882	002	Mar 18, 2013	Mar NEWA
	NEXIUM IV					
AP	+	ASTRAZENECA	N021689	001	Mar 31, 2005	Mar CFTG
AP	+		N021689	002	Mar 31, 2005	Mar CFTG

ESOMEPRAZOLE STRONTIUMCAPSULE, DELAYED RELEASE; ORAL
ESOMEPRAZOLE STRONTIUM

	HANMI PHARM CO LTD	EQ 20MG BASE	N202342	001	Aug 06, 2013	Sep CAHN
+		EQ 40MG BASE	N202342	002	Aug 06, 2013	Sep CAHN
	HANMI USA	EQ 20MG BASE	N202342	001	Aug 06, 2013	Aug NEWA
+		EQ 40MG BASE	N202342	002	Aug 06, 2013	Aug NEWA

ESTRADIOL VALERATEINJECTABLE; INJECTION
ESTRADIOL VALERATE

@ WATSON LABS	40MG/ML	A083714	001		Jun DISC
@ WATSON LABS INC	20MG/ML	A083547	001		Jun DISC

ESTROGENS, CONJUGATED SYNTHETIC ACREAM; VAGINAL
SYNTHETIC CONJUGATED ESTROGENS A

@ TEVA WOMENS	0.625MG/GM	N021788	001	Nov 28, 2008	Sep DISC
---------------	------------	---------	-----	--------------	----------

ESTRONEINJECTABLE; INJECTION
ESTRONE

@ WATSON LABS	5MG/ML	A085239	001		Jun DISC
---------------	--------	---------	-----	--	----------

ESTROPIPATETABLET; ORAL
ORTHO-EST

@ CARACO	0.75MG	A089567	001	Feb 27, 1991	Apr DISC
@	1.5MG	A089582	001	Jul 17, 1991	Apr DISC

ESZOPICLONETABLET; ORAL
ESZOPICLONE

AB	MYLAN PHARMS INC	1MG	A091151	001	Mar 26, 2013	Mar NEWA
AB		2MG	A091151	002	Mar 26, 2013	Mar NEWA
AB		3MG	A091151	003	Mar 26, 2013	Mar NEWA
AB	SUN PHARMA GLOBAL	1MG	A091103	001	Apr 03, 2013	Mar NEWA

TABLET;ORAL
ESZOPICLONE

AB		2MG	A091103	002	Apr 03, 2013	Mar NEWA
AB		3MG	A091103	003	Apr 03, 2013	Mar NEWA
LUNESTA						
AB	SUNOVION PHARMS INC	1MG	N021476	001	Dec 15, 2004	Mar CTEC
AB		2MG	N021476	002	Dec 15, 2004	Mar CTEC
AB	+	3MG	N021476	003	Dec 15, 2004	Mar CTEC

ETHAMBUTOL HYDROCHLORIDE

TABLET;ORAL
ETHAMBUTOL HYDROCHLORIDE
@ WEST WARD
@
MYAMBUTOL

		100MG	A075095	001	Nov 30, 1999	Jul DISC
		400MG	A075095	002	Nov 30, 1999	Jul DISC
AB	+	STI PHARMA LLC	400MG	N016320	003	Jul CRLD

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL
DAYSEE

AB	LUPIN LTD	0.03MG,0.01MG;0.15MG,N/A	A091467	001	Apr 10, 2013	Mar NEWA
	QUARTETTE					
+	TEVA BRANDED PHARM	0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A	N204061	001	Mar 28, 2013	Mar NEWA

TABLET;ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB1	FAMY CARE LTD	0.02MG;0.1MG	A200245	001	Oct 09, 2013	Sep NEWA
AB1	LUPIN LTD	0.02MG;0.1MG	A091425	001	Jan 18, 2013	Jan NEWA

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-28
NORETHINDRONE AND ETHINYL ESTRADIOL

AB	+	FAMY CARE LTD	0.05MG;1MG	A203006	001	Aug 05, 2013	Oct CRLD
AB			0.05MG;1MG	A203006	001	Aug 05, 2013	Jul NEWA
OVCON-50							
	@	WARNER CHILCOTT LLC	0.05MG;1MG	N017576	001		Oct DISC
AB	+		0.05MG;1MG	N017576	001		Jul CFTG
PIRMELLA 1/35							
AB		LUPIN LTD	0.035MG;1MG	A201512	001	Apr 24, 2013	Apr NEWA
PIRMELLA 7/7/7							
AB		LUPIN LTD	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A201510	001	Apr 24, 2013	Apr NEWA
VYFEMLA							
AB		LUPIN LTD	0.035MG;0.4MG	A201886	001	Sep 26, 2013	Sep NEWA
TABLET, CHEWABLE;ORAL							
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
AB		AMNEAL PHARMS	0.035MG;0.4MG	A078892	001	Sep 26, 2011	Sep CAHN

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE;ORAL
MINASTRIN 24 FE

+	WARNER CHILCOTT	0.02MG;1MG	N204426	001	Apr 19, 2013	Apr NEWA
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
@	WARNER CHILCOTT	0.02MG;1MG	N204426	001	Apr 19, 2013	May DISC

TABLET;ORAL

FEMHRT
@ WARNER CHILCOTT LLC
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

	@ WARNER CHILCOTT LLC	0.005MG;1MG	N021065	002	Oct 15, 1999	Jan DISC
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL					
+	BARR LABS INC	0.005MG;1MG	A076221	001	Nov 06, 2009	Jan CRLD
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
AB	AMNEAL PHARMS	0.02MG;1MG	A078267	001	Sep 01, 2009	Sep CAHN

TABLET;ORAL-21

LARIN 1/20

>A>	AB	NOVAST LABS LTD	0.02MG;1MG	A202995	001	Dec 04, 2013	Nov NEWA
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL							
AB		FAMY CARE LTD	0.02MG;1MG	A202771	001	Nov 06, 2013	Oct NEWA

TABLET;ORAL-28

LARIN FE 1.5/30

AB		NOVAST LABS LTD	0.03MG;1.5MG	A091453	001	Aug 23, 2013	Aug NEWA
LARIN FE 1/20							
AB		NOVAST LABS LTD	0.02MG;1MG	A091454	001	Aug 26, 2013	Aug NEWA

TABLET;ORAL-28							
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL							
AB	FAMY CARE LTD	0.02MG;1MG	A202772	001	Nov 14, 2013	Oct	NEWA
TABLET, CHEWABLE;ORAL							
MINASTRIN 24 FE							
+	WARNER CHILCOTT LLC	0.02MG;1MG	N203667	001	May 08, 2013	Oct	CTNA
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
+	WARNER CHILCOTT LLC	0.02MG;1MG	N203667	001	May 08, 2003	May	NEWA
TABLET, CHEWABLE, TABLET;ORAL							
LO MINASTRIN FE							
+	WARNER CHILCOTT	0.01MG,0.01MG,N/A;1MG,N/A,N/A	N204654	001	Jul 24, 2013	Jul	NEWA

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28							
ESTARYLLA							
AB	SANDOZ	0.035MG;0.25MG	A090794	001	Jan 30, 2013	Jan	NEWA
TRI LO SPRINTEC							
@	BARR LABS INC	0.025MG,0.025MG,0.025MG;0.18MG,0.2	A076784	001	Jun 29, 2009	Apr	DISC
15MG,0.25MG							
TRI-ESTARYLLA							
AB	SANDOZ	0.035MG,0.035MG,0.035MG;0.18MG,0.2	A090793	001	Jan 30, 2013	Jan	NEWA
15MG,0.25MG							

ETHOTOIN

TABLET;ORAL							
PEGANONE							
+	RECORDATI RARE	250MG	N010841	001		May	CAHN

ETODOLAC

TABLET;ORAL							
ETODOLAC							
@	PROSAM LABS	400MG	A074819	001	Feb 28, 1997	Mar	DISC
@		500MG	A074819	002	Apr 28, 1998	Mar	DISC

ETOPOSIDE

INJECTABLE;INJECTION							
ETOPOSIDE							
AP	ACCORD HLTHCARE	20MG/ML	A074513	001	Mar 14, 1996	Apr	CAHN
@	PHARMACHEMIE	20MG/ML	A074227	001	Feb 22, 1996	Apr	DISC
AP	TEVA PHARMS USA	20MG/ML	A074284	001	Feb 10, 1994	May	CAHN
AP		20MG/ML	A074529	001	Jul 24, 1996	Apr	CAHN

FAMCICLOVIR

TABLET;ORAL							
FAMCICLOVIR							
AB	CIPLA LTD	125MG	A078278	001	Mar 21, 2011	Jul	CAHN
AB		250MG	A078278	002	Mar 21, 2011	Jul	CAHN
AB		500MG	A078278	003	Mar 21, 2011	Jul	CAHN

FAMOTIDINE

INJECTABLE;INJECTION							
FAMOTIDINE							
>A>	AP	AGILA SPECLTS	10MG/ML	A078641	001	Jun 25, 2008	Nov CAHN
	@	APOTEX INC	10MG/ML	A075942	001	Aug 02, 2002	Apr DISC
	@	HIKMA MAPLE	10MG/ML	A075799	001	Apr 30, 2002	Oct DISC
>D>	AP	PFIZER	10MG/ML	A078641	001	Jun 25, 2008	Nov CAHN
FAMOTIDINE PRESERVATIVE FREE							
>A>	AP	AGILA SPECLTS	10MG/ML	A078642	001	Jun 25, 2008	Nov CAHN
AP	AKORN INC	10MG/ML	A076324	001	Nov 27, 2002	Mar CAHN	
	@	APOTEX INC	10MG/ML	A076324	001	Nov 27, 2002	Apr DISC
	@	HIKMA MAPLE	10MG/ML	A075789	001	Apr 30, 2002	Oct DISC
>D>	AP	PFIZER	10MG/ML	A078642	001	Jun 25, 2008	Nov CAHN
FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)							
AP	AKORN INC	10MG/ML	A076322	001	Nov 27, 2002	Mar CAHN	
	@	APOTEX INC	10MG/ML	A076322	001	Nov 27, 2002	Apr DISC
PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER							
	@	MERCK SHARP DOHME	0.4MG/ML	N020249	001	Feb 18, 1994	Apr CAHN
TABLET;ORAL							
FAMOTIDINE							
	@	WATSON LABS	20MG	A075062	002	Apr 16, 2001	Sep DISC
	@		40MG	A075062	001	Apr 16, 2001	Sep DISC

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL
FELODIPINE

AB	HERITAGE PHARMS INC	2.5MG	A201964	001	Nov 08, 2013	Oct NEWA
AB		5MG	A201964	002	Nov 08, 2013	Oct NEWA
AB		10MG	A201964	003	Nov 08, 2013	Oct NEWA

FENOFIBRATE

CAPSULE;ORAL

ANTARA (MICRONIZED)

LUPIN ATLANTIS 30MG
90MG

N021695	004	Oct 18, 2013	Oct NEWA
N021695	005	Oct 18, 2013	Oct NEWA

FENOFIBRATE (MICRONIZED)

AB	APOTEX INC	43MG
AB		130MG

A202252	001	Jul 26, 2013	Jul NEWA
A202252	002	Jul 26, 2013	Jul NEWA

FENOFIBRIC ACID

TABLET;ORAL

FIBRICOR

MUTUAL PHARM CO INC 35MG
+ 105MG

N022418	001	Aug 14, 2009	Feb CAHN
N022418	002	Aug 14, 2009	Feb CAHN

FENOPROFEN CALCIUM

TABLET;ORAL

FENOPROFEN CALCIUM

@ IVAX SUB TEVA PHARMS EQ 600MG BASE
+ MYLAN PHARMS INC EQ 600MG BASE

A072557	001	Aug 29, 1988	Mar DISC
A072267	001	Aug 17, 1988	Mar CTEC

FENTANYL

SPRAY;SUBLINGUAL
SUBSYS

INSYS THERAP 1.2MG
1.6MG

N202788	006	Aug 30, 2012	Aug NEWA
N202788	007	Aug 30, 2012	Aug NEWA

FENTANYL CITRATE

FILM;BUCCAL

ONSOLIS

@ MEDA PHARMS EQ 0.2MG BASE
@ EQ 0.4MG BASE
@ EQ 0.6MG BASE
@ EQ 0.8MG BASE
@ EQ 1.2MG BASE

N022266	001	Jul 16, 2009	May DISC
N022266	002	Jul 16, 2009	May DISC
N022266	003	Jul 16, 2009	May DISC
N022266	004	Jul 16, 2009	May DISC
N022266	005	Jul 16, 2009	May DISC

INJECTABLE;INJECTION

FENTANYL CITRATE PRESERVATIVE FREE

AP	+ HIKMA MAPLE	EQ 0.05MG BASE/ML
	SPRAY, METERED;NASAL	
	LAZANDA	

N019101	001	Jul 11, 1984	Jul CAHN
---------	-----	--------------	----------

DEPOMED INC EQ 0.1MG BASE
+ EQ 0.4MG BASE

N022569	001	Jun 30, 2011	Sep CAHN
N022569	002	Jun 30, 2011	Sep CAHN

TABLET;BUCCAL, SUBLINGUAL

FENTORA

AB	CEPHALON	EQ 0.1MG BASE
AB		EQ 0.2MG BASE
	@	EQ 0.3MG BASE
AB	+	EQ 0.4MG BASE
AB		EQ 0.6MG BASE
AB		EQ 0.8MG BASE

N021947	001	Sep 25, 2006	Feb CDFR
N021947	002	Sep 25, 2006	Feb CDFR
N021947	006	Mar 02, 2007	Feb CDFR
N021947	003	Sep 25, 2006	Feb CDFR
N021947	004	Sep 25, 2006	Feb CDFR
N021947	005	Sep 25, 2006	Feb CDFR

TABLET;SUBLINGUAL

ABSTRAL

GALENA BIOPHARMA EQ 0.1MG BASE
EQ 0.2MG BASE
EQ 0.3MG BASE
+ EQ 0.4MG BASE
EQ 0.6MG BASE
EQ 0.8MG BASE

N022510	001	Jan 07, 2011	May CAHN
N022510	002	Jan 07, 2011	May CAHN
N022510	003	Jan 07, 2011	May CAHN
N022510	004	Jan 07, 2011	May CAHN
N022510	005	Jan 07, 2011	May CAHN
N022510	006	Jan 07, 2011	May CAHN

FERRIC CARBOXYMALTOSE

INJECTABLE;IV

INJECTAFER

+	LUITPOLD	750MG IRON/15ML (50MG IRON/ML)	N203565	001	Jul 25, 2013	Jul NEWA
---	----------	--------------------------------	---------	-----	--------------	----------

FERUMOXSYL

SUSPENSION;ORAL

GASTROMARK

@	AMAG PHARMS INC	EQ 0.175MG IRON/ML	N020410	001	Dec 06, 1996	Feb DISC
---	-----------------	--------------------	---------	-----	--------------	----------

FINASTERIDE

TABLET;ORAL

FINASTERIDE

AB	ACCORD HLTHCARE	5MG	A090121	001	Feb 23, 2010	Apr CAHN
AB	ACCORD HLTHCARE INC	1MG	A091643	001	Nov 05, 2013	Oct NEWA
AB	ACTAVIS TOTOWA	1MG	A078371	001	Nov 05, 2013	Oct NEWA
AB	AUROBINDO PHARMA LTD	1MG	A203687	001	Nov 05, 2013	Oct NEWA
AB	HETERO LABS LTD III	1MG	A090060	001	Jul 01, 2013	Jun NEWA
AB		5MG	A090061	001	Jun 07, 2010	Apr CAHN
AB	MYLAN PHARMS INC	1MG	A078161	001	Nov 05, 2013	Oct NEWA
AB	SUN PHARMA GLOBAL	1MG	A090508	001	Jul 01, 2013	Jun NEWA
AB	TEVA	1MG	A076905	001	Nov 05, 2013	Oct NEWA

FLECAINIDE ACETATE

TABLET;ORAL

FLECAINIDE ACETATE

	@	APOTEX INC	50MG	A079164	001	Jul 09, 2009	Apr DISC
	@		100MG	A079164	002	Jul 09, 2009	Apr DISC
	@		150MG	A079164	003	Jul 09, 2009	Apr DISC
AB	+	ROXANE	150MG	A076278	003	Jan 14, 2003	May CRLD
		TAMBOCOR					
	@	MEDICIS	50MG	N018830	004	Aug 23, 1988	May DISC
	@		100MG	N018830	001	Oct 31, 1985	May DISC
	@		150MG	N018830	003	Jun 03, 1988	May DISC

FLUCONAZOLE

FOR SUSPENSION;ORAL

FLUCONAZOLE

@	TARO PHARM INDS	50MG/5ML	A076918	001	Dec 18, 2006	Mar DISC
@		200MG/5ML	A076918	002	Dec 18, 2006	Mar DISC

INJECTABLE;INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

	@	AGILA SPECLTS	200MG/100ML (2MG/ML)	A076888	001	Mar 25, 2005	Aug CAHN
	@		400MG/200ML (2MG/ML)	A076888	002	Mar 25, 2005	Aug CAHN
	@	APOTEX INC	200MG/100ML (2MG/ML)	A076888	001	Mar 25, 2005	Apr DISC
	@		400MG/200ML (2MG/ML)	A076888	002	Mar 25, 2005	Apr DISC

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

AP		TEVA PHARMS USA	200MG/100ML (2MG/ML)	A076653	001	Jul 29, 2004	May CAHN
AP			400MG/200ML (2MG/ML)	A076653	002	Jul 29, 2004	May CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	@	AGILA SPECLTS	200MG/100ML (2MG/ML)	A076889	001	Mar 25, 2005	Aug CAHN
	@		400MG/200ML (2MG/ML)	A076889	002	Mar 25, 2005	Aug CAHN
	@	APOTEX INC	200MG/100ML (2MG/ML)	A076889	001	Mar 25, 2005	Apr DISC
	@		400MG/200ML (2MG/ML)	A076889	002	Mar 25, 2005	Apr DISC

TABLET;ORAL

FLUCONAZOLE

@	HARRIS PHARM	50MG	A078423	001	Mar 07, 2011	Sep DISC
@		100MG	A078423	002	Mar 07, 2011	Sep DISC
@		150MG	A078423	003	Mar 07, 2011	Sep DISC
@		200MG	A078423	004	Mar 07, 2011	Sep DISC

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION

FLUDARABINE PHOSPHATE

AP	+	FRESENIUS KABI USA	50MG/2ML (25MG/ML)	A078393	001	Oct 15, 2007	Jan CRLD
AP		TEVA PARENTERAL	50MG/2ML (25MG/ML)	A076661	001	Apr 28, 2004	Jan CRLD
AP		TEVA PHARMS USA	50MG/VIAL	A076349	001	Aug 28, 2003	Apr CAHN
AP			50MG/2ML (25MG/ML)	A076661	001	Apr 28, 2004	Apr CAHN

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS
FLUDEOXYGLUCOSE F18

+	HOUSTON CYCLOTRON	20-500mCi/ML	A203665	001	Feb 14, 2013	Jun CRLD
+		20-500mCi/ML	A203665	001	Feb 14, 2013	Jan NEWA
	MCPRF	20-240mCi/ML	A203612	001	Aug 05, 2013	Jul NEWA
+	UCLA BIOMEDICAL	4-40mCi/ML	A203811	001	Jun 27, 2013	Jun NEWA

FLUDROCORTISONE ACETATE

TABLET;ORAL
FLORINEF

>A>	@ CITRON PHARMA LLC	0.1MG	N010060	001		Nov CAHN
>D>	@ KING PHARMS	0.1MG	N010060	001		Nov CAHN

FLUMAZENIL

INJECTABLE;INJECTION
FLUMAZENIL

>A>	AP	AGILA SPECLTS	0.5MG/5ML (0.1MG/ML)	A078595	001	May 13, 2008	Nov CAHN
>A>	AP	+	1MG/10ML (0.1MG/ML)	A078595	002	May 13, 2008	Nov CAHN
		@ APOTEX INC	0.5MG/5ML (0.1MG/ML)	A076755	002	Oct 12, 2004	Apr DISC
		@	1MG/10ML (0.1MG/ML)	A076755	001	Oct 12, 2004	Apr DISC
>D>	AP	PFIZER	0.5MG/5ML (0.1MG/ML)	A078595	001	May 13, 2008	Nov CAHN
>D>	AP	+	1MG/10ML (0.1MG/ML)	A078595	002	May 13, 2008	Nov CAHN
	AP	+	1MG/10ML (0.1MG/ML)	A078595	002	May 13, 2008	Oct CRLD
		@ TEVA PHARMS USA	0.5MG/5ML (0.1MG/ML)	A076589	002	Oct 12, 2004	Apr CAHN
		@	1MG/10ML (0.1MG/ML)	A076589	001	Oct 12, 2004	Apr CAHN
		ROMAZICON					
		@ HOFFMANN LA ROCHE	1MG/10ML (0.1MG/ML)	N020073	001	Dec 20, 1991	Sep DISC
		@	0.5MG/5ML (0.1MG/ML)	N020073	002	Dec 20, 1991	Sep DISC

FLUNISOLIDE

AEROSOL, METERED;INHALATION
AEROBID

@	ROCHE PALO	0.25MG/INH	N018340	001	Aug 17, 1984	Sep DISC
---	------------	------------	---------	-----	--------------	----------

FLUOCINOLONE ACETONIDE

OIL;TOPICAL
FLUOCINOLONE ACETONIDE

AT		PERRIGO ISRAEL	0.01%	A202847	001	Aug 09, 2013	Jul NEWA
AT			0.01%	A202848	001	Aug 09, 2013	Jul NEWA

FLUOCINONIDE

CREAM;TOPICAL
LIDEX

@	CNTY LINE PHARMS	0.05%	N016908	002		Jan CAHN
---	------------------	-------	---------	-----	--	----------

LIDEX-E

@	CNTY LINE PHARMS	0.05%	N016908	003		Jan CAHN
---	------------------	-------	---------	-----	--	----------

GEL;TOPICAL

FLUOCINONIDE

AB	+	TARO	0.05%	A074935	001	Jul 29, 1997	Jan CRLD
----	---	------	-------	---------	-----	--------------	----------

LIDEX

@	CNTY LINE PHARMS	0.05%	N017373	001		Jan CAHN
---	------------------	-------	---------	-----	--	----------

OINTMENT;TOPICAL

FLUOCINONIDE

AB	+	TARO	0.05%	A075008	001	Jun 30, 1999	Jan CRLD
----	---	------	-------	---------	-----	--------------	----------

LIDEX

@	CNTY LINE PHARMS	0.05%	N016909	002		Jan CAHN
---	------------------	-------	---------	-----	--	----------

SOLUTION;TOPICAL

FLUOCINONIDE

AT		ACTAVIS MID ATLANTIC	0.05%	A071535	001	Dec 02, 1988	May CAHN
----	--	----------------------	-------	---------	-----	--------------	----------

AT	+	TARO	0.05%	A074799	001	Dec 31, 1996	Jan CRLD
----	---	------	-------	---------	-----	--------------	----------

LIDEX

@	CNTY LINE PHARMS	0.05%	N018849	001	Apr 06, 1984	May CAHN
---	------------------	-------	---------	-----	--------------	----------

@	MEDICIS	0.05%	N018849	001	Apr 06, 1984	Jan DISC
---	---------	-------	---------	-----	--------------	----------

FLUORESCEIN SODIUM

INJECTABLE; INTRAVENOUS
AK-FLUOR 25%

	+	AKORN	EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	N022186	002	Aug 08, 2008	Oct	CRLD
--	---	-------	--------------------------------------	---------	-----	--------------	-----	------

FLUOROURACIL

INJECTABLE; INJECTION
FLUOROURACIL

AP	+	TEVA PHARMS USA	2.5GM/50ML (50MG/ML)	A040334	001	Feb 25, 2000	May	CAHN
AP	+		5GM/100ML (50MG/ML)	A040334	002	Feb 25, 2000	May	CAHN
AP	+		500MG/10ML (50MG/ML)	A040333	001	Jan 27, 2000	May	CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

	@	CARLSBAD	EQ 10MG BASE	A076022	001	Jan 30, 2002	Mar	DISC
	@		EQ 20MG BASE	A076022	002	Jan 30, 2002	Mar	DISC
	@	CR DOUBLE CRANE	EQ 10MG BASE	A076165	001	Feb 01, 2002	Apr	DISC
AB1			EQ 10MG BASE	A076165	001	Feb 01, 2002	Mar	CAHN
	@		EQ 20MG BASE	A076165	002	Feb 01, 2002	Apr	DISC
AB1			EQ 20MG BASE	A076165	002	Feb 01, 2002	Mar	CAHN
AB1		DR REDDYS LABS LTD	EQ 10MG BASE	A075465	001	Jan 29, 2002	Sep	CAHN
AB1			EQ 20MG BASE	A075465	002	Jan 29, 2002	Sep	CAHN
AB			EQ 40MG BASE	A075465	003	Aug 02, 2001	Sep	CAHN
AB1		TEVA PHARMS USA	EQ 10MG BASE	A076001	001	Jan 29, 2002	Jul	CAHN
AB1			EQ 20MG BASE	A076001	002	Jan 29, 2002	Jul	CAHN
	@	WOCKHARDT LTD	EQ 10MG BASE	A078143	001	Jan 16, 2008	Feb	DISC
	@		EQ 20MG BASE	A078143	002	Jan 16, 2008	Feb	DISC
	@		EQ 40MG BASE	A078143	003	Jan 16, 2008	Feb	DISC

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

	@	APOTEX INC	EQ 20MG BASE/5ML	A075292	001	Feb 07, 2002	Apr	DISC
--	---	------------	------------------	---------	-----	--------------	-----	------

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

AB		TEVA PHARMS	EQ 25MG BASE; EQ 3MG BASE	A202074	001	Mar 25, 2013	Mar	NEWA
----	--	-------------	---------------------------	---------	-----	--------------	-----	------

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

	@	AGILA SPECLTS	25MG/ML	A075918	001	Aug 17, 2001	Aug	CAHN
	@	APOTEX INC	25MG/ML	A075918	001	Aug 17, 2001	Apr	DISC

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HYDROCHLORIDE

	@	WEST WARD	15MG	A071107	001	Dec 08, 1986	Jul	DISC
	@		30MG	A071108	001	Dec 08, 1986	Jul	DISC

FLUTEMETAMOL F-18

INJECTABLE; INTRAVENOUS

VIZAMYL

+	GE HEALTHCARE	40.5mCi/10ML (4.05mCi/ML)	N203137	001	Oct 25, 2013	Oct	NEWA
+		121.5mCi/30ML (4.05mCi/ML)	N203137	002	Oct 25, 2013	Oct	NEWA

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

POWDER; INHALATION

BREO ELLIPTA

+	GLAXO GRP LTD	0.1MG/INH; EQ 0.025MG BASE/INH	N204275	001	May 10, 2013	May	NEWA
---	---------------	--------------------------------	---------	-----	--------------	-----	------

FLUTICASONE PROPIONATE

CREAM; TOPICAL

CUTIVATE

	@	FOUGERA PHARMS	0.05%	N019958	001	Dec 18, 1990	Aug	DISC
--	---	----------------	-------	---------	-----	--------------	-----	------

LOTION; TOPICAL

FLUTICASONE PROPIONATE

AB		PERRIGO ISRAEL	0.05%	A091553	001	Jul 30, 2013	Jul	NEWA
----	--	----------------	-------	---------	-----	--------------	-----	------

POWDER; INHALATION

FLOVENT DISKUS 100

+	GLAXO GRP LTD	0.1MG/INH	N020833	002	Sep 29, 2000	May CAHN
---	---------------	-----------	---------	-----	--------------	----------

FLOVENT DISKUS 250

+	GLAXO GRP LTD	0.25MG/INH	N020833	003	Sep 29, 2000	May CAHN
---	---------------	------------	---------	-----	--------------	----------

FLOVENT DISKUS 50

+	GLAXO GRP LTD	0.05MG/INH	N020833	001	Sep 29, 2000	May CAHN
---	---------------	------------	---------	-----	--------------	----------

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

AEROSOL, METERED; INHALATION

ADVAIR HFA

+	GLAXO GRP LTD	0.045MG/INH;EQ 0.021MG BASE/INH	N021254	001	Jun 08, 2006	May CAHN
---	---------------	---------------------------------	---------	-----	--------------	----------

+		0.115MG/INH;EQ 0.021MG BASE/INH	N021254	002	Jun 08, 2006	May CAHN
---	--	---------------------------------	---------	-----	--------------	----------

+		0.23MG/INH;EQ 0.021MG BASE/INH	N021254	003	Jun 08, 2006	May CAHN
---	--	--------------------------------	---------	-----	--------------	----------

POWDER; INHALATION

ADVAIR DISKUS 100/50

+	GLAXO GRP LTD	0.1MG/INH;EQ 0.05MG BASE/INH	N021077	001	Aug 24, 2000	May CAHN
---	---------------	------------------------------	---------	-----	--------------	----------

ADVAIR DISKUS 250/50

+	GLAXO GRP LTD	0.25MG/INH;EQ 0.05MG BASE/INH	N021077	002	Aug 24, 2000	May CAHN
---	---------------	-------------------------------	---------	-----	--------------	----------

ADVAIR DISKUS 500/50

+	GLAXO GRP LTD	0.5MG/INH;EQ 0.05MG BASE/INH	N021077	003	Aug 24, 2000	May CAHN
---	---------------	------------------------------	---------	-----	--------------	----------

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

FLUVOXAMINE MALEATE

AB	ACTAVIS ELIZABETH	100MG	A091482	001	Apr 23, 2013	Apr NEWA
----	-------------------	-------	---------	-----	--------------	----------

>A> AB		150MG	A091482	002	Nov 18, 2013	Nov NEWA
--------	--	-------	---------	-----	--------------	----------

AB	ANCHEN PHARMS	100MG	A091476	001	Mar 13, 2013	Mar NEWA
----	---------------	-------	---------	-----	--------------	----------

AB		150MG	A091476	002	Mar 13, 2013	Mar NEWA
----	--	-------	---------	-----	--------------	----------

LUVOX CR

AB	JAZZ PHARMS	100MG	N022033	001	Feb 28, 2008	Mar CFTG
----	-------------	-------	---------	-----	--------------	----------

AB	+	150MG	N022033	002	Feb 28, 2008	Mar CFTG
----	---	-------	---------	-----	--------------	----------

TABLET; ORAL

FLUVOXAMINE MALEATE

@	CARACO	25MG	A075900	001	Feb 23, 2006	Jun DISC
---	--------	------	---------	-----	--------------	----------

@		50MG	A075900	002	Feb 23, 2006	Jun DISC
---	--	------	---------	-----	--------------	----------

@		100MG	A075900	003	Feb 23, 2006	Jun DISC
---	--	-------	---------	-----	--------------	----------

FOLIC ACID

TABLET; ORAL

FOLIC ACID

AA	BICON PHARM	1MG	A091145	001	Jul 12, 2013	Jul NEWA
----	-------------	-----	---------	-----	--------------	----------

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS

EMEND

@	MERCK AND CO INC	EQ 115MG BASE/VIAL	N022023	001	Jan 25, 2008	Sep DISC
---	------------------	--------------------	---------	-----	--------------	----------

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

@	WATSON LABS	10MG	A076987	001	Dec 23, 2004	Mar DISC
---	-------------	------	---------	-----	--------------	----------

@		20MG	A076987	002	Dec 23, 2004	Mar DISC
---	--	------	---------	-----	--------------	----------

@		40MG	A076987	003	Dec 23, 2004	Mar DISC
---	--	------	---------	-----	--------------	----------

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

@	MYLAN	10MG;12.5MG	A077705	001	Aug 14, 2006	Aug DISC
---	-------	-------------	---------	-----	--------------	----------

@		20MG;12.5MG	A077705	002	Aug 14, 2006	Aug DISC
---	--	-------------	---------	-----	--------------	----------

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

AP	AMNEAL PHARMS	EQ 50MG PNEYTOIN NA/ML	A078476	001	Mar 18, 2008	May CAHN
----	---------------	------------------------	---------	-----	--------------	----------

@	APOTEX INC	EQ 50MG PHENYTOIN NA/ML	A078126	001	Aug 06, 2007	Apr DISC
---	------------	-------------------------	---------	-----	--------------	----------

@	TEVA PHARMS USA	EQ 50MG PHENYTOIN NA/ML	A076886	001	Aug 06, 2007	May CAHN
---	-----------------	-------------------------	---------	-----	--------------	----------

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE

@ INTL MEDICATION 10MG/ML

N018025 001

Jan DISC

TABLET; ORAL

FUROSEMIDE

@ DAVA PHARMS INC 20MG

N018415 001 Jul 27, 1982 Feb DISC

@ 40MG

N018415 002 Jul 27, 1982 Feb DISC

@ 80MG

N018415 003 Nov 26, 1984 Feb DISC

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

AB TARO 100MG

A077261 001 Aug 02, 2013 Jul NEWA

AB 300MG

A077261 002 Aug 02, 2013 Jul NEWA

AB 400MG

A077261 003 Aug 02, 2013 Jul NEWA

SOLUTION; ORAL

GABAPENTIN

AA TARO 250MG/5ML

A076672 001 Jul 03, 2013 Jun NEWA

TABLET; ORAL

GABAPENTIN

AB ALLIED PHARMA INC 600MG

A203244 002 Jul 12, 2013 Jul NEWA

AB 800MG

A203244 001 Jul 12, 2013 Jul NEWA

GABAPENTIN ENACARBIL

TABLET, EXTENDED RELEASE; ORAL
HORIZANT

XENOPORT INC 300MG

N022399 002 Dec 13, 2011 May CAHN

+ 600MG

N022399 001 Apr 06, 2011 May CAHN

GADOTERATE MEGLUMINE

SOLUTION; INTRAVENOUS
DOTAREM

+ GUERBET 3.769GM/10ML (376.9MG/ML)

N204781 002 Mar 20, 2013 Mar NEWA

+ 5.6535GM/15ML (376.9MG/ML)

N204781 003 Mar 20, 2013 Mar NEWA

+ 7.538GM/20ML (376.9MG/ML)

N204781 004 Mar 20, 2013 Mar NEWA

+ 37.69GM/100ML (376.9MG/ML)

N204781 001 Mar 20, 2013 Mar NEWA

GADOXETATE DISODIUM

SOLUTION; INTRAVENOUS
EOVIST

BAYER HLTHCARE 2.72145GM/15ML (181.43MG/ML)

N022090 002 Feb 04, 2013 Feb NEWA

GALLIUM NITRATE

INJECTABLE; INJECTION
GANITE

@ CHAPTER 7 TRUSTEE 25MG/ML

N019961 002 Jan 17, 1991 Jul CAHN

@ GENTA 25MG/ML

N019961 002 Jan 17, 1991 Jul DISC

GANCICLOVIR

IMPLANT; IMPLANTATION
VITRASERT

@ BAUSCH AND LOMB 4.5MG

N020569 001 Mar 04, 1996 May DISC

GANCICLOVIR SODIUM

INJECTABLE; INJECTION
GANCICLOVIR

AP LUITPOLD EQ 500MG BASE/VIAL

A202624 001 Sep 18, 2013 Oct CAHN

AP PHARMAFORCE EQ 500MG BASE/VIAL

A202624 001 Sep 18, 2013 Aug NEWA

GANIRELIX ACETATE

INJECTABLE; INJECTION
GANIRELIX ACETATE

+ ORGANON USA INC EQ 250MCG BASE/0.5ML

N021057 001 Jul 29, 1999 Aug CTNA

GATIFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

GATIFLOXACIN

	@ APOTEX INC	0.3%	A079084	001	Aug 19, 2011	Apr DISC
AT	LUPIN LTD	0.5%	A202653	001	Aug 28, 2013	Aug NEWA
	ZYMAXID					
AT	+ ALLERGAN	0.5%	N022548	001	May 18, 2010	Aug CFTG

GEMCITABINE HYDROCHLORIDE

INJECTABLE;INJECTION

GEMCITABINE HYDROCHLORIDE

AP	CIPLA LTD	EQ 1GM BASE/VIAL	A078759	002	Jul 25, 2011	Jul CAHN
AP		EQ 200MG BASE/VIAL	A078759	001	Jul 25, 2011	Jul CAHN
AP	DR REDDYS LABS LTD	EQ 2GM BASE/VIAL	A202997	001	May 07, 2013	Apr NEWA
AP	JIANGSU HANSON PHARM	EQ 1GM BASE/VIAL	A202485	002	May 07, 2013	Apr NEWA
AP		EQ 200MG BASE/VIAL	A202485	001	May 07, 2013	Apr NEWA
AP	LUITPOLD	EQ 1GM BASE/VIAL	A202031	002	May 07, 2013	Aug CAHN
AP		EQ 200MG BASE/VIAL	A202031	001	May 07, 2013	Aug CAHN
AP	PHARMAFORCE	EQ 1GM BASE/VIAL	A202031	002	May 07, 2013	Apr NEWA
AP		EQ 200MG BASE/VIAL	A202031	001	May 07, 2013	Apr NEWA
AP	SAGENT PHARMS	EQ 1GM BASE/VIAL	A091597	002	May 07, 2013	Apr NEWA
AP		EQ 200MG BASE/VIAL	A091597	001	May 07, 2013	Apr NEWA

GEMFIBROZIL

TABLET;ORAL

GEMFIBROZIL

AB	CARACO	600MG	A079239	001	Dec 29, 2008	Jun CAHN
----	--------	-------	---------	-----	--------------	----------

GEMIFLOXACIN MESYLATE

TABLET;ORAL

FACTIVE

>D>	+ CORNERSTONE THERAP	EQ 320MG BASE	N021158	001	Apr 04, 2003	Nov CAHN
>A>	+ LG LIFE SCIENCES	EQ 320MG BASE	N021158	001	Apr 04, 2003	Nov CAHN

GENTAMICIN SULFATE

INJECTABLE;INJECTION

GENTAMICIN SULFATE

	@ FRESENIUS KABI USA	EQ 10MG BASE/ML	A062356	001	Mar 04, 1982	Aug DISC
AP		EQ 10MG BASE/ML	A062366	002	Feb 06, 1986	Aug NEWA
	@	EQ 40MG BASE/ML	A062356	002	Mar 04, 1982	Aug DISC
AP	+	EQ 40MG BASE/ML	A062366	001	Aug 04, 1983	Aug CRLD

OINTMENT;OPHTHALMIC

GENTAMICIN SULFATE

AT	PERRIGO CO TENNESSEE	EQ 0.3% BASE	A065024	001	Jul 30, 2004	Jun CAHN
	SOLUTION/DROPS;OPHTHALMIC					
	GENTAMICIN SULFATE					
AT	PERRIGO CO TENNESSEE	EQ 0.3% BASE	A065121	001	Jan 30, 2004	Jun CAHN

GLATIRAMER ACETATE

FOR SOLUTION;SUBCUTANEOUS

COPAXONE

@ TEVA PHARMS USA

20MG/VIAL

N020622	001	Dec 20, 1996	Apr CAHN
---------	-----	--------------	----------

INJECTABLE;SUBCUTANEOUS

COPAXONE

+ TEVA PHARMS USA

20MG/ML

N020622	002	Feb 12, 2002	Apr CAHN
---------	-----	--------------	----------

GLIMEPIRIDE

TABLET;ORAL

GLIMEPIRIDE

@ COREPHARMA

1MG

A077274	001	Oct 06, 2005	Feb DISC
---------	-----	--------------	----------

@

2MG

A077274	002	Oct 06, 2005	Feb DISC
---------	-----	--------------	----------

@

4MG

A077274	003	Oct 06, 2005	Feb DISC
---------	-----	--------------	----------

AB	HIKMA PHARMS	1MG	A078952	001	Aug 01, 2013	Jul NEWA
AB		2MG	A078952	002	Aug 01, 2013	Jul NEWA
AB		4MG	A078952	003	Aug 01, 2013	Jul NEWA
AB	INDOCO REMEDIES	1MG	A202112	001	Apr 17, 2013	Apr NEWA
AB		2MG	A202112	002	Apr 17, 2013	Apr NEWA
AB		4MG	A202112	003	Apr 17, 2013	Apr NEWA
AB	MICRO LABS LTD INDIA	1MG	A091220	001	Jun 29, 2012	Jul CAHN
AB		2MG	A091220	002	Jun 29, 2012	Jul CAHN
		3MG	A091220	003	Jun 29, 2012	Jul CAHN

TABLET;ORAL
GLIMEPIRIDE

AB		4MG	A091220	004	Jun 29, 2012	Jul CAHN
		6MG	A091220	005	Jun 29, 2012	Jul CAHN
AB		8MG	A091220	006	Jun 29, 2012	Jul CAHN
	@ MYLAN	1MG	A077486	001	Feb 10, 2006	Aug DISC
	@	2MG	A077486	002	Feb 10, 2006	Aug DISC
	@	4MG	A077486	003	Feb 10, 2006	Aug DISC

GLIPIZIDE

TABLET;ORAL
GLIPIZIDE

AB	ACCORD HLTHCARE	5MG	A074550	001	Sep 11, 1997	Apr CAHN
AB		10MG	A074550	002	Sep 11, 1997	Apr CAHN
	@ BARR LABS INC	5MG	A074619	001	Apr 04, 1997	May CAHN
	@	10MG	A074619	002	Apr 04, 1997	May CAHN

TABLET, EXTENDED RELEASE;ORAL
GLIPIZIDE

AB	PAR PHARM	5MG	A076159	002	Sep 20, 2013	Sep NEWA
AB		10MG	A076159	001	Sep 20, 2013	Sep NEWA

GLYCEROL PHENYLBUTYRATE

LIQUID;ORAL
RAVICTI

+	HYPERION THERAP INC	1.1GM/ML	N203284	001	Feb 01, 2013	Feb NEWA
---	---------------------	----------	---------	-----	--------------	----------

GLYCOPYRROLATE

INJECTABLE;INJECTION
ROBINUL

AP	+ HIKMA MAPLE	0.2MG/ML	N017558	001		Apr CAHN
----	---------------	----------	---------	-----	--	----------

TABLET;ORAL
GLYCOPYRROLATE

AA	AUROLIFE PHARMA LLC	1MG	A202675	001	Apr 15, 2013	Apr NEWA
	@ COREPHARMA	1MG	A040568	001	Dec 22, 2004	Mar DISC
	@	2MG	A040568	002	Dec 22, 2004	Mar DISC
	@ WEST WARD	1MG	A040836	001	Mar 05, 2009	Jul DISC
	@	2MG	A040836	002	Mar 05, 2009	Jul DISC

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION
GRANISETRON HYDROCHLORIDE

	@ APOTEX INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078197	001	Dec 31, 2007	Apr DISC
	@	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198	001	Jun 30, 2008	Apr DISC
	@	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198	002	Jun 30, 2008	Apr DISC
>D> AP	DR REDDYS LABS INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078863	001	Jun 30, 2008	Nov CAHN
>D> AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880	001	Jun 30, 2008	Nov CAHN
>A> AP	DSM PHARMS INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078863	001	Jun 30, 2008	Nov CAHN
>A> AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880	001	Jun 30, 2008	Nov CAHN
	@ EBEWE PHARMA	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078808	001	Apr 29, 2008	Feb DISC
AP	+ TEVA PHARMS USA	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078392	001	Dec 31, 2007	May CAHN
AP	+	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077963	001	Jan 03, 2008	May CAHN
AP	+	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077297	001	Jun 30, 2008	May CAHN
	GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE					
>D> AP	DR REDDYS LABS INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008	Nov CAHN
>A> AP	DSM PHARMS INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008	Nov CAHN
	@ TEVA PHARMS USA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077165	001	Dec 31, 2007	May CAHN

GRISEOFULVIN, MICROSIZE

SUSPENSION;ORAL
GRIFULVIN V

AB	+ VALEANT LUXEMBOURG	125MG/5ML	A062483	001	Jan 26, 1984	Apr CAHN
----	----------------------	-----------	---------	-----	--------------	----------

TABLET;ORAL
GRISEOFULVIN

	SANDOZ	250MG	A091592	001	Aug 07, 2013	Jul NEWA
AB		500MG	A091592	002	Aug 07, 2013	Jul NEWA

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

@ EPIC PHARMA LLC	EQ 1MG BASE	A074673	001	Feb 28, 1997	Jun DISC
@	EQ 2MG BASE	A074673	002	Feb 28, 1997	Jun DISC

HALOBETASOL PROPIONATE

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

@ FOUGERA PHARMS	0.05%	A076903	001	Dec 16, 2004	Apr DISC
@ G AND W LABS INC	0.05%	A077109	001	Jun 14, 2005	Jun CAHN
@ TARO	0.05%	A076994	001	Dec 16, 2004	Mar DISC

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

@ AGILA SPECLTS	EQ 50MG BASE/ML	A075440	001	Feb 28, 2000	Aug CAHN
@	EQ 100MG BASE/ML	A075440	002	Feb 28, 2000	Aug CAHN
@ APOTEX INC	EQ 50MG BASE/ML	A075440	001	Feb 28, 2000	Apr DISC
@	EQ 100MG BASE/ML	A075440	002	Feb 28, 2000	Apr DISC
AO TEVA PHARMS USA	EQ 50MG BASE/ML	A075393	001	May 11, 1999	Jun CAHN
AO	EQ 100MG BASE/ML	A075393	002	May 11, 1999	Jun CAHN

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

>A> AP	AGILA SPECLTS	EQ 5MG BASE/ML	A078347	001	Sep 14, 2009	Nov CAHN
	@ APOTEX INC	EQ 5MG BASE/ML	A076791	001	Aug 25, 2004	Apr DISC
	@	EQ 5MG BASE/ML	A076828	001	Aug 25, 2004	Apr DISC
>D> AP	PFIZER	EQ 5MG BASE/ML	A078347	001	Sep 14, 2009	Nov CAHN
AP	TEVA PHARMS USA	EQ 5MG BASE/ML	A076035	001	Aug 29, 2001	Jun CAHN

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

AP +	HIKMA MAPLE	1,000 UNITS/ML	N017037	001		Aug CAHN
AP +		5,000 UNITS/ML	N017037	002		Aug CAHN
	@	5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986	Aug CAHN
AP +		10,000 UNITS/ML	N017037	003		Aug CAHN

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

AA	NOVEL LABS INC	1.5MG; 5MG	A091528	001	Apr 20, 2011	Sep CTEC
AA	+ TUSSIGON					
AA	+ KING PHARMS	1.5MG; 5MG	A088508	001	Jul 30, 1985	Sep CTEC

HYALURONIDASE

INJECTABLE; INJECTION

VITRASE

+ BAUSCH AND LOMB	200 UNITS/VIAL	N021640	002	Dec 02, 2004	May CAHN
@	6,200 UNITS/VIAL	N021640	001	May 05, 2004	May CAHN

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

AP	NAVINTA LLC	20MG/ML	A202938	001	Mar 28, 2013	Mar NEWA
----	-------------	---------	---------	-----	--------------	----------

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

AA	ACTAVIS GRP PTC	10MG	A091679	001	Mar 04, 2013	Apr CAHN
AA		25MG	A091679	002	Mar 04, 2013	Apr CAHN
AA		50MG	A091679	003	Mar 04, 2013	Apr CAHN
AA		100MG	A091679	004	Mar 04, 2013	Apr CAHN
AA	ACTAVIS PHARMA	10MG	A091679	001	Mar 04, 2013	Feb NEWA
AA		25MG	A091679	002	Mar 04, 2013	Feb NEWA
AA		50MG	A091679	003	Mar 04, 2013	Feb NEWA
AA		100MG	A091679	004	Mar 04, 2013	Feb NEWA
AA	ALKEM LABS LTD	10MG	A200737	001	Dec 07, 2012	Apr CTEC
AA		25MG	A200737	002	Dec 07, 2012	Apr CTEC
AA		50MG	A200737	003	Dec 07, 2012	Apr CTEC
AA		100MG	A200737	004	Dec 07, 2012	Apr CTEC

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

AA	HETERO LABS LTD III	10MG	A040901	001	Sep 12, 2008	Apr CAHN
AA		25MG	A040901	002	Sep 12, 2008	Apr CAHN
AA		50MG	A040901	003	Sep 12, 2008	Apr CAHN
AA		100MG	A040901	004	Sep 12, 2008	Apr CAHN
AA	STRIDES ARCOLAB LTD	25MG	A200770	001	May 03, 2013	Apr NEWA
AA		50MG	A200770	002	May 03, 2013	Apr NEWA
AA		100MG	A200770	003	May 03, 2013	Apr NEWA
	@ ZYDUS PHARMS USA	10MG	A040858	001	Feb 26, 2010	Jun DISC
	@	25MG	A040858	002	Feb 26, 2010	Jun DISC
	@	50MG	A040858	003	Feb 26, 2010	Jun DISC
	@	100MG	A040858	004	Feb 26, 2010	Jun DISC

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

@	WATSON LABS	25MG	A081189	001	Jan 24, 1992	Mar DISC
---	-------------	------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB	AUROBINDO PHARMA LTD	12.5MG;150MG	A203630	001	Feb 22, 2013	Feb NEWA
AB		12.5MG;300MG	A203630	002	Feb 22, 2013	Feb NEWA
AB	LUPIN LTD	12.5MG;150MG	A201524	001	Feb 27, 2013	Feb NEWA
AB		12.5MG;300MG	A201524	002	Feb 27, 2013	Feb NEWA

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

AB	HIKMA PHARMS LLC	12.5MG;10MG	A076265	001	Jul 08, 2002	Oct CAHN
AB		12.5MG;20MG	A076265	002	Jul 08, 2002	Oct CAHN
AB		25MG;20MG	A076265	003	Jul 08, 2002	Oct CAHN

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

HYZAAR

AB	MERCK SHARP DOHME	12.5MG;50MG	N020387	001	Apr 28, 1995	Oct CAHN
AB		12.5MG;100MG	N020387	003	Oct 20, 2005	Oct CAHN
AB	+	25MG;100MG	N020387	002	Nov 10, 1998	Oct CAHN

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB	IPCA LABS LTD	12.5MG;50MG	A201682	001	Mar 01, 2013	Feb NEWA
AB		12.5MG;100MG	A201682	002	Mar 01, 2013	Feb NEWA
AB		25MG;100MG	A201682	003	Mar 01, 2013	Feb NEWA

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC PHARMS LTD	25MG;50MG	A202870	001	Nov 06, 2013	Oct NEWA
AB		25MG;100MG	A202870	002	Nov 06, 2013	Oct NEWA
AB		50MG;100MG	A202870	003	Nov 06, 2013	Oct NEWA

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

INDERIDE-40/25

AB	+	WYETH PHARMS INC	25MG;40MG	N018031	001	Jul CAHN
----	---	------------------	-----------	---------	-----	----------

INDERIDE-80/25

@ WYETH PHARMS INC 25MG;80MG

N018031	002	Jul CAHN
---------	-----	----------

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ WATSON LABS 25MG;40MG

A070301	001	Apr 18, 1986	Sep DISC
---------	-----	--------------	----------

@ 25MG;80MG

A070305	001	Apr 18, 1986	Sep DISC
---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	APOTEX CORP	12.5MG;EQ 10MG BASE	A091524	001	Mar 12, 2013	Mar NEWA
AB		12.5MG;EQ 20MG BASE	A091524	002	Mar 12, 2013	Mar NEWA
AB		25MG;EQ 20MG BASE	A091524	003	Mar 12, 2013	Mar NEWA

HYDROCHLOROTHIAZIDE; TRIAMTERENE

TABLET; ORAL

MAXZIDE

AB	+	MYLAN PHARMS INC	50MG;75MG	N019129	001	Oct 22, 1984	May CAHN
		MAXZIDE-25					
AB		MYLAN PHARMS INC	25MG;37.5MG	N019129	003	May 13, 1988	May CAHN
		TRIAMTERENE AND HYDROCHLOROTHIAZIDE					
		@ WATSON LABS	50MG;75MG	A071969	001	Apr 17, 1988	Jan DISC

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC LTD	12.5MG;80MG	A201662	001	Mar 21, 2013	Mar NEWA
AB			12.5MG;160MG	A201662	002	Mar 21, 2013	Mar NEWA
AB			12.5MG;320MG	A201662	003	Mar 21, 2013	Mar NEWA
AB			25MG;160MG	A201662	004	Mar 21, 2013	Mar NEWA
AB			25MG;320MG	A201662	005	Mar 21, 2013	Mar NEWA
AB		APOTEX INC	12.5MG;80MG	A203026	001	Mar 21, 2013	Mar NEWA
AB			12.5MG;160MG	A203026	002	Mar 21, 2013	Mar NEWA
AB			12.5MG;320MG	A203026	003	Mar 21, 2013	Mar NEWA
AB			25MG;160MG	A203026	004	Mar 21, 2013	Mar NEWA
AB			25MG;320MG	A203026	005	Mar 21, 2013	Mar NEWA
AB		AUROBINDO PHARMA LTD	12.5MG;80MG	A202519	001	Mar 21, 2013	Mar NEWA
AB			12.5MG;160MG	A202519	002	Mar 21, 2013	Mar NEWA
AB			12.5MG;320MG	A202519	003	Mar 21, 2013	Mar NEWA
AB			25MG;160MG	A202519	004	Mar 21, 2013	Mar NEWA
AB			25MG;320MG	A202519	005	Mar 21, 2013	Mar NEWA
AB		LUPIN LTD	12.5MG;80MG	A078946	003	Mar 21, 2013	Mar NEWA
AB			12.5MG;160MG	A078946	004	Mar 21, 2013	Mar NEWA
AB			12.5MG;320MG	A078946	001	Mar 21, 2013	Mar NEWA
AB			25MG;160MG	A078946	005	Mar 21, 2013	Mar NEWA
AB			25MG;320MG	A078946	002	Mar 21, 2013	Mar NEWA
AB		MACLEODS PHARMS LTD	12.5MG;80MG	A203145	001	Apr 19, 2013	Apr NEWA
AB			12.5MG;160MG	A203145	002	Apr 19, 2013	Apr NEWA
AB			12.5MG;320MG	A203145	003	Apr 19, 2013	Apr NEWA
AB			25MG;160MG	A203145	004	Apr 19, 2013	Apr NEWA
AB			25MG;320MG	A203145	005	Apr 19, 2013	Apr NEWA
AB		WATSON LABS INC	12.5MG;80MG	A091519	001	Mar 21, 2013	Mar NEWA
AB			12.5MG;160MG	A091519	002	Mar 21, 2013	Mar NEWA
AB			12.5MG;320MG	A091519	003	Mar 21, 2013	Mar NEWA
AB			25MG;160MG	A091519	004	Mar 21, 2013	Mar NEWA
AB			25MG;320MG	A091519	005	Mar 21, 2013	Mar NEWA

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

ZOHYDRO ER

	+	ZOGENIX INC	10MG	N202880	001	Oct 25, 2013	Oct NEWA
			15MG	N202880	002	Oct 25, 2013	Oct NEWA
			20MG	N202880	003	Oct 25, 2013	Oct NEWA
			30MG	N202880	004	Oct 25, 2013	Oct NEWA
			40MG	N202880	005	Oct 25, 2013	Oct NEWA
			50MG	N202880	006	Oct 25, 2013	Oct NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

AB		SUN PHARM INDS INC	2.5MG;200MG	A091633	001	May 28, 2013	May NEWA
AB			5MG;200MG	A091633	002	May 28, 2013	May NEWA
AB			7.5MG;200MG	A091633	003	May 28, 2013	May NEWA
AB			10MG;200MG	A091633	004	May 28, 2013	May NEWA
		REPREXAIN					
AB		AMNEAL PHARMS NY	2.5MG;200MG	A076642	003	Oct 19, 2007	May CFTG
AB			10MG;200MG	A076642	004	Oct 19, 2007	May CFTG

HYDROCORTISONE

LOTION; TOPICAL

STIE-CORT

@ PERRIGO CO

1%

A089066 001 Nov 25, 1985 Feb DISC

OINTMENT; TOPICAL

HYDROCORTISONE

@ TARO

2.5%

A040310 001 Dec 29, 2000 Mar DISC

HYDROCORTISONE ACETATECREAM;TOPICAL
MICORT-HC

>D>	+	FERNDAL LABS	2%	A040398	001	Mar 29, 2002	Nov CAHN
>D>			2.5%	A040396	001	Feb 27, 2001	Nov CAHN
>A>	+	SEBELA IRELAND LTD	2%	A040398	001	Mar 29, 2002	Nov CAHN
>A>			2.5%	A040396	001	Feb 27, 2001	Nov CAHN

PASTE;TOPICAL
ORABASE HCA

@ COLGATE	0.5%	A083205	001			Mar DISC
-----------	------	---------	-----	--	--	----------

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDECREAM;TOPICAL
PRAMOSONE

>D>		FERNDAL LABS	0.5%;1%	A083778	001		Nov CAHN
>D>			1%;1%	A085368	001		Nov CAHN
>A>		SEBELA IRELAND LTD	0.5%;1%	A083778	001		Nov CAHN
>A>			1%;1%	A085368	001		Nov CAHN

LOTION;TOPICAL
PRAMOSONE

>D>		FERNDAL LABS	1%;1%	A085980	001		Nov CAHN
>D>			2.5%;1%	A085979	001		Nov CAHN
>A>		SEBELA IRELAND LTD	1%;1%	A085980	001		Nov CAHN
>A>			2.5%;1%	A085979	001		Nov CAHN

HYDROCORTISONE ACETATE; UREACREAM;TOPICAL
CARMOL HC

@ FOUGERA PHARMS	1%;10%	A080505	001			Aug DISC
------------------	--------	---------	-----	--	--	----------

U-CORT

TARO	1%;10%	A089472	001	Jun 13, 1988		Aug CTEC
------	--------	---------	-----	--------------	--	----------

HYDROCORTISONE BUTYRATECREAM;TOPICAL
HYDROCORTISONE BUTYRATE

AB		GLENMARK GENERICS	0.1%	A202145	001	Sep 27, 2013	Sep NEWA
		LOCOID LIPOCREAM					
AB	+	PRECISION DERMAT	0.1%	N020769	001	Sep 08, 1997	Sep CTEC

HYDROCORTISONE VALERATEOINTMENT;TOPICAL
HYDROCORTISONE VALERATE

@ FOUGERA PHARMS	0.2%	A075085	001	Jul 31, 2001		Feb DISC
+	TARO	0.2%	A075043	001	Aug 25, 1998	Feb CRLD
	WESTCORT					
@ RANBAXY	0.2%	N018726	001	Aug 08, 1983		Feb DISC

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATESUSPENSION/DROPS;OTIC
CORTISPORIN

>A>	AT	+	CITRON PHARMA LLC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A060613	001		Nov CAHN
>D>	AT	+	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A060613	001		Nov CAHN

HYDROMORPHONE HYDROCHLORIDETABLET, EXTENDED RELEASE;ORAL
EXALGO

MALLINCKRODT INC	16MG	N021217	003	Mar 01, 2010		Jan CRLD
+	32MG	N021217	004	Aug 24, 2012		Jan CRLD

HYDROXYUREACAPSULE;ORAL
HYDROXYUREA

@ BARR LABS INC	250MG	A075020	002	Jun 26, 2000		Jun CAHN
@	500MG	A075020	001	Jul 30, 1998		Jun CAHN

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

AA	SILARX PHARMS INC	10MG/5ML	A201674	001	Aug 21, 2013	Jul	NEWA
	TABLET; ORAL						
	HYDROXYZINE HYDROCHLORIDE						
AB	CARACO	10MG	A040899	001	Jun 10, 2008	Jun	CAHN
AB		25MG	A040899	002	Jun 10, 2008	Jun	CAHN
AB		50MG	A040899	003	Jun 10, 2008	Jun	CAHN
AB	HETERO LABS LTD III	10MG	A040805	001	May 29, 2008	Apr	CAHN
AB		25MG	A040805	002	May 29, 2008	Apr	CAHN
AB		50MG	A040805	003	May 29, 2008	Apr	CAHN

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

AB	EMCURE PHARMS USA	25MG	A201507	001	Jun 03, 2013	May	NEWA
AB		50MG	A201507	002	Jun 03, 2013	May	NEWA

>A> IBRUTINIB

>A> CAPSULE; ORAL

>A> IMBRUVICA

>A>	+	PHARMACYCLICS INC	140MG	N205552	001	Nov 13, 2013	Nov	NEWA
-----	---	-------------------	-------	---------	-----	--------------	-----	------

IBUPROFEN

SOLUTION; INTRAVENOUS

CALDOLOR

@ CUMBERLAND PHARMS

400MG/4ML (100MG/ML)

N022348	001	Jun 11, 2009	May	DISC
---------	-----	--------------	-----	------

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS

NEOPROFEN

+ RECORDATI RARE

EQ 20MG BASE/2ML (EQ 10MG BASE/ML)

N021903	001	Apr 13, 2006	May	CAHN
---------	-----	--------------	-----	------

ICOSAPENT ETHYL

CAPSULE; ORAL

VASCEPA

+ AMARIN PHARMS

1GM

N202057	001	Jul 26, 2012	Jun	NEWA
---------	-----	--------------	-----	------

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HYDROCHLORIDE PFS

AP TEVA PHARMS USA

1MG/ML

A065036	001	May 01, 2002	Apr	CAHN
---------	-----	--------------	-----	------

IFOSFAMIDE

INJECTABLE; INJECTION

IFOSFAMIDE

AP + TEVA PHARMS USA

1GM/20ML (50MG/ML)

A076657	001	Apr 04, 2007	May	CAHN
---------	-----	--------------	-----	------

AP +

3GM/60ML (50MG/ML)

A076657	002	Apr 04, 2007	May	CAHN
---------	-----	--------------	-----	------

IFOSFAMIDE; MESNA

INJECTABLE; INTRAVENOUS

IFOSFAMIDE/MESNA KIT

+ TEVA PHARMS USA

1GM/20ML; 1GM/10ML
(50MG/ML; 100MG/ML)

A075874	001	Feb 26, 2002	May	CAHN
---------	-----	--------------	-----	------

+

3GM/60ML; 1GM/10ML
(50MG/ML; 100MG/ML)

A075874	002	Feb 26, 2002	May	CAHN
---------	-----	--------------	-----	------

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

@ PROSAM LABS

10MG

A040753	001	Feb 28, 2008	Mar	DISC
---------	-----	--------------	-----	------

@

25MG

A040752	001	Feb 28, 2008	Mar	DISC
---------	-----	--------------	-----	------

@

50MG

A040751	001	Feb 28, 2008	Mar	DISC
---------	-----	--------------	-----	------

IMIPRAMINE PAMOATE

CAPSULE; ORAL

IMIPRAMINE PAMOATE

AB MYLAN PHARMS INC

EQ 75MG HCL

A202338	001	Jun 28, 2013	Jun	NEWA
---------	-----	--------------	-----	------

AB

EQ 100MG HCL

A202338	002	Jun 28, 2013	Jun	NEWA
---------	-----	--------------	-----	------

AB

EQ 125MG HCL

A202338	003	Jun 28, 2013	Jun	NEWA
---------	-----	--------------	-----	------

CAPSULE;ORAL							
IMIPRAMINE PAMOATE							
AB		EQ 150MG HCL	A202338	004	Jun 28, 2013	Jun	NEWA
<u>INDINAVIR SULFATE</u>							
CAPSULE;ORAL							
CRIXIVAN							
	@ MERCK SHARP DOHME	EQ 100MG BASE	N020685	006	Apr 19, 2000	Jun	DISC
<u>INDOMETHACIN</u>							
CAPSULE;ORAL							
INDOCIN							
	@ ICEUTICA OPERATIONS	25MG	N016059	001		Mar	CAHN
	@	50MG	N016059	002		Mar	CAHN
INDOMETHACIN							
AB	CARACO	25MG	A091401	001	Mar 28, 2013	Jun	CAHN
AB		50MG	A091401	002	Mar 28, 2013	Jun	CAHN
AB	HETERO LABS LTD III	25MG	A091240	001	Apr 12, 2011	Apr	CAHN
AB		50MG	A091240	002	Apr 12, 2011	Apr	CAHN
AB	SUN PHARM INDS INC	25MG	A091401	001	Mar 28, 2013	Mar	NEWA
AB		50MG	A091401	002	Mar 28, 2013	Mar	NEWA
CAPSULE, EXTENDED RELEASE;ORAL							
INDOMETHACIN							
>A> AB	WATSON LABS INC	75MG	A202572	001	Dec 09, 2013	Nov	NEWA
<u>INDOMETHACIN SODIUM</u>							
INJECTABLE;INJECTION							
INDOCIN							
AP	+ RECORDATI RARE	EQ 1MG BASE/VIAL	N018878	001	Jan 30, 1985	May	CAHN
<u>INSULIN GLARGINE RECOMBINANT</u>							
INJECTABLE;INJECTION							
LANTUS SOLOSTAR							
	+ SANOFI AVENTIS US	300 UNITS/3ML (100 UNITS/ML)	N021081	002	Apr 27, 2007	Aug	NEWA
<u>IPRATROPIUM BROMIDE</u>							
SOLUTION;INHALATION							
IPRATROPIUM BROMIDE							
	@ APOTEX INC	0.02%	A075441	001	Mar 28, 2001	Apr	DISC
	@ TEVA PHARMS USA	0.02%	A075313	001	Feb 07, 2000	Mar	DISC
SPRAY, METERED;NASAL							
IPRATROPIUM BROMIDE							
	@ APOTEX INC	0.021MG/SPRAY	A076156	001	Apr 18, 2003	Apr	DISC
	@	0.042MG/SPRAY	A076155	001	Apr 18, 2003	Apr	DISC
<u>IRINOTECAN HYDROCHLORIDE</u>							
INJECTABLE;INJECTION							
IRINOTECAN HYDROCHLORIDE							
AP	TEVA PHARMS USA	40MG/2ML (20MG/ML)	A090101	002	Feb 27, 2008	Sep	CAHN
AP		100MG/5ML (20MG/ML)	A090101	003	Feb 27, 2008	Sep	CAHN
AP		500MG/25ML (20MG/ML)	A090101	001	Nov 26, 2008	Sep	CAHN
<u>IRON SUCROSE</u>							
INJECTABLE;INTRAVENOUS							
VENOFER							
	@ LUITPOLD	EQ 65MG BASE/3.25ML (EQ 20MG BASE/ML)	N021135	005	Mar 29, 2013	Sep	DISC
		EQ 65MG BASE/3.25ML (EQ 20MG BASE/ML)	N021135	005	Mar 29, 2013	Mar	NEWA
<u>ISONIAZID</u>							
TABLET;ORAL							
ISONIAZID							
	@ MIKART	100MG	A040090	001	Jun 26, 1997	Aug	DISC
	@	300MG	A040090	002	Jun 26, 1997	Aug	DISC
	@ WATSON LABS	300MG	A080521	001		Jun	DISC
LANIAZID							
>D>	@ LANNETT	300MG	A089776	001	Jun 13, 1988	Nov	CMFD
>A> AA		300MG	A089776	001	Jun 13, 1988	Nov	CMFD

ISONIAZID; RIFAMPINCAPSULE; ORAL
RIFAMATE+ SANOFI AVENTIS US 150MG; 300MG
RIFAMPIN AND ISONIAZID
@ WEST WARD PHARM CORP 150MG; 300MGA061884 001 Apr CTEC
A065221 001 Jul 29, 2005 Apr DISCISOPROTERENOL HYDROCHLORIDEINJECTABLE; INJECTION
ISOPROTERENOL HYDROCHLORIDE
@ INTL MEDICATION 0.2MG/ML
ISUPREL

+ HOSPIRA 0.2MG/ML

A083724 001 Mar DISC
N010515 001 Mar CTECISOSORBIDE DINITRATECAPSULE, EXTENDED RELEASE; ORAL
DILATRATE-SR

+ ACTIENT PHARMS 40MG

N019790 001 Sep 02, 1988 May CAHN

TABLET; ORAL
ISORDILAB VALEANT BERMUDA 5MG
AB 10MG
AB 20MG
AB + 30MG
+ 40MG
AB VALEANT PHARM NORTH 5MG
AB 10MG
AB 20MG
AB + 30MG
+ 40MGN012093 007 Jul 29, 1988 Apr CAHN
N012093 002 Jul 29, 1988 Apr CAHN
N012093 006 Jul 29, 1988 Apr CAHN
N012093 005 Jul 29, 1988 Apr CAHN
N012093 001 Jul 29, 1988 Apr CAHN
N012093 007 Jul 29, 1988 Mar CAHN
N012093 002 Jul 29, 1988 Mar CAHN
N012093 006 Jul 29, 1988 Mar CAHN
N012093 005 Jul 29, 1988 Mar CAHN
N012093 001 Jul 29, 1988 Mar CAHN

ISOSORBIDE DINITRATE

AB PAR PHARM 5MG
@ 5MG
@ WATSON LABS 5MG
@ 10MGA086923 001 Mar 12, 1987 Apr CMFD
A086923 001 Mar 12, 1987 Feb DISC
A086034 001 Jan 06, 1988 Apr DISC
A086032 001 Jan 07, 1988 Apr DISC

TABLET; SUBLINGUAL

ISOSORBIDE DINITRATE

@ WATSON LABS 2.5MG
@ 5MG
@ WEST WARD 2.5MG
@ WEST WARD PHARM CORP 5MG
AB + 5MGA086033 001 Feb 26, 1988 Jun DISC
A086031 001 Sep 29, 1987 Jun DISC
A086054 001 Oct 29, 1987 Aug DISC
A086055 001 Nov 02, 1987 Aug DISC
A086055 001 Nov 02, 1987 Jun CRLDISOSORBIDE MONONITRATETABLET, EXTENDED RELEASE; ORAL
ISOSORBIDE MONONITRATEAB HIKMA PHARMS 30MG
AB 60MGA076813 002 Mar 30, 2006 Oct CAHN
A076813 001 Jan 07, 2005 Oct CAHNISOTRETINOINCAPSULE; ORAL
ABSORICABX RANBAXY 10MG
BX 20MG
BX 30MG
BX + 40MG
BX 40MGN021951 001 May 25, 2012 Feb CAHN
N021951 002 May 25, 2012 Feb CAHN
N021951 003 May 25, 2012 Feb CAHN
N021951 004 May 25, 2012 Aug CRLD
N021951 004 May 25, 2012 Feb CAHN

AMNESTEEM

AB MYLAN PHARMS INC 20MG
CLARAVIS

A075945 002 Nov 08, 2002 Apr CRLD

AB TEVA PHARMS USA 10MG
AB 30MG
AB + 40MGA076356 001 Apr 11, 2003 May CAHN
A076135 003 May 11, 2006 Apr CRLD
A076135 001 Apr 11, 2003 Apr CRLD

ZENATANE

AB DR REDDYS LABS LTD 10MG
AB 20MG
AB 40MGA202099 001 Mar 25, 2013 Mar NEWA
A202099 002 Mar 25, 2013 Mar NEWA
A202099 003 Mar 25, 2013 Mar NEWA

ISRADIPINE

TABLET, EXTENDED RELEASE;ORAL
DYNACIRC CR

@ GLAXOSMITHKLINE LLC	5MG	N020336	001	Jun 01, 1994	Jun DISC
@	10MG	N020336	002	Jun 01, 1994	Jun DISC

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION
KETOROLAC TROMETHAMINE

>A> AP	AGILA SPECLTS	15MG/ML	A078299	001	Jul 16, 2007	Nov CAHN
>A> AP		30MG/ML	A078299	002	Jul 16, 2007	Nov CAHN
	@ APOTEX INC	15MG/ML	A075631	002	Jun 29, 2001	Apr DISC
	@	30MG/ML	A075626	001	Jul 24, 2001	Apr DISC
	@	30MG/ML	A075631	001	Jun 29, 2001	Apr DISC
	@	30MG/ML	A077201	001	Oct 14, 2005	Apr DISC
	@ LUITPOLD	15MG/ML	A078145	001	Jan 14, 2008	Jun DISC
	@	30MG/ML	A078145	002	Jan 14, 2008	Jun DISC
>D> AP	PFIZER	15MG/ML	A078299	001	Jul 16, 2007	Nov CAHN
>D> AP		30MG/ML	A078299	002	Jul 16, 2007	Nov CAHN
>A> AP	SAGENT PHARMS	15MG/ML	A091065	001	Nov 27, 2013	Nov NEWA
>A> AP		30MG/ML	A091065	002	Nov 27, 2013	Nov NEWA

SOLUTION/DROPS;OPHTHALMIC
ACULAR PRESERVATIVE FREE

@ ALLERGAN	0.5%	N020811	001	Nov 03, 1997	May DISC
------------	------	---------	-----	--------------	----------

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION
LABETALOL HYDROCHLORIDE

AP	AKORN INC	5MG/ML	A075431	001	Nov 29, 1999	Jul CAHN
AP		5MG/ML	A075524	001	Nov 29, 1999	Jul CAHN
	@ APOTEX INC	5MG/ML	A076051	001	Jul 05, 2002	Apr DISC

TABLET;ORAL

LABETALOL HYDROCHLORIDE

AB	+ SANDOZ	200MG	A075113	002	Aug 04, 1998	Jan CRLD
	TRANDATE					
	@ PROMETHEUS LABS	100MG	N018716	001	May 24, 1985	Jan DISC
	@	200MG	N018716	002	Aug 01, 1984	Jan DISC

LACTULOSE

SOLUTION;ORAL

LACTULOSE

@ APOTEX INC	10GM/15ML	A075911	001	Feb 21, 2002	Apr DISC
--------------	-----------	---------	-----	--------------	----------

SOLUTION;ORAL, RECTAL

LACTULOSE

@ APOTEX INC	10GM/15ML	A076645	001	Jul 28, 2003	Apr DISC
--------------	-----------	---------	-----	--------------	----------

LAMOTRIGINE

TABLET;ORAL

LAMICTAL

AB	+ GLAXOSMITHKLINE LLC	25MG	N020241	005	Dec 27, 1994	Mar CAHN
	@	50MG	N020241	006	Dec 27, 1994	Mar CAHN
AB		100MG	N020241	001	Dec 27, 1994	Mar CAHN
AB		150MG	N020241	002	Dec 27, 1994	Mar CAHN
AB		200MG	N020241	003	Dec 27, 1994	Mar CAHN
	@	250MG	N020241	004	Dec 27, 1994	Mar CAHN

LAMOTRIGINE

AB	ALKEM LABS LTD	25MG	A200694	001	Jun 14, 2013	Jun NEWA
AB		100MG	A200694	002	Jun 14, 2013	Jun NEWA
AB		150MG	A200694	003	Jun 14, 2013	Jun NEWA
AB		200MG	A200694	004	Jun 14, 2013	Jun NEWA
AB	CIPLA LTD	25MG	A077783	001	Nov 01, 2010	Aug CAHN
AB		100MG	A077783	002	Nov 01, 2010	Aug CAHN
AB		150MG	A077783	003	Nov 01, 2010	Aug CAHN
AB		200MG	A077783	004	Nov 01, 2010	Aug CAHN

TABLET, CHEWABLE;ORAL

LAMICTAL CD

AB	GLAXOSMITHKLINE LLC	2MG	N020764	004	Sep 08, 2000	Mar CAHN
AB		5MG	N020764	001	Aug 24, 1998	Mar CAHN
AB	+	25MG	N020764	002	Aug 24, 1998	Mar CAHN
	@	100MG	N020764	003	Aug 24, 1998	Mar CAHN

TABLET, EXTENDED RELEASE;ORAL
LAMICTAL XR

AB	GLAXOSMITHKLINE LLC	25MG	N022115	001	May 29, 2009	Mar CAHN
AB	+	50MG	N022115	002	May 29, 2009	Mar CAHN
AB		100MG	N022115	003	May 29, 2009	Mar CAHN
AB		200MG	N022115	004	May 29, 2009	Mar CAHN
AB		250MG	N022115	006	Jun 21, 2011	Mar CAHN
AB		300MG	N022115	005	Apr 14, 2010	Mar CAHN
LAMOTRIGINE						
AB	ACTAVIS ELIZABETH	100MG	A200672	003	Oct 17, 2013	Sep NEWA
AB		200MG	A200672	004	Oct 17, 2013	Sep NEWA
AB		25MG	A200672	001	Oct 17, 2013	Sep NEWA
AB		50MG	A200672	002	Oct 17, 2013	Sep NEWA
AB		250MG	A203733	001	Nov 13, 2013	Oct NEWA
AB		300MG	A200672	005	Oct 17, 2013	Sep NEWA
AB	DR REDDYS LABS LTD	25MG	A202383	001	Jun 19, 2013	Jun NEWA
AB		50MG	A202383	002	Jun 19, 2013	Jun NEWA
AB		100MG	A202383	003	Jun 19, 2013	Jun NEWA
AB		200MG	A202383	004	Jun 19, 2013	Jun NEWA
AB		300MG	A202383	005	Jun 19, 2013	Jun NEWA
AB	PAR PHARM	25MG	A201791	001	Jan 18, 2013	Jan NEWA
AB		50MG	A201791	002	Jan 18, 2013	Jan NEWA
AB		100MG	A201791	003	Jan 18, 2013	Jan NEWA
AB		200MG	A201791	004	Jan 18, 2013	Jan NEWA
AB		250MG	A201791	005	Jan 18, 2013	Jan NEWA
AB		300MG	A201791	006	Jan 18, 2013	Jan NEWA
AB	WILSHIRE PHARMS INC	25MG	A202887	001	Jun 17, 2013	Jun NEWA
AB		50MG	A202887	002	Jun 17, 2013	Jun NEWA
AB		100MG	A202887	003	Jun 17, 2013	Jun NEWA
AB		200MG	A202887	004	Jun 17, 2013	Jun NEWA

TABLET, ORALLY DISINTEGRATING;ORAL
LAMICTAL ODT

AB	GLAXOSMITHKLINE LLC	25MG	N022251	001	May 08, 2009	Jul CFTG
		25MG	N022251	001	May 08, 2009	Mar CAHN
AB	+	50MG	N022251	002	May 08, 2009	Jul CFTG
	+	50MG	N022251	002	May 08, 2009	Mar CAHN
AB		100MG	N022251	003	May 08, 2009	Jul CFTG
		100MG	N022251	003	May 08, 2009	Mar CAHN
AB		200MG	N022251	004	May 08, 2009	Jul CFTG
		200MG	N022251	004	May 08, 2009	Mar CAHN
LAMOTRIGINE						
AB	WATSON LABS INC	25MG	A200828	001	Jul 15, 2013	Jul NEWA
AB		50MG	A200828	002	Jul 15, 2013	Jul NEWA
AB		100MG	A200828	003	Jul 15, 2013	Jul NEWA
AB		200MG	A200828	004	Jul 15, 2013	Jul NEWA

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL
LANSOPRAZOLE

AB	SUN PHARMA GLOBAL	15MG	A202637	001	Sep 13, 2013	Aug NEWA
AB		30MG	A091509	001	Sep 13, 2013	Aug NEWA
AB	ZYDUS HLTHCARE	15MG	A202366	001	Aug 19, 2013	Jul NEWA
AB		30MG	A202366	002	Aug 19, 2013	Jul NEWA
LANSOPRAZOLE						
AB	KRKA TOVARNA ZDRAVIL	15MG	A091212	001	Sep 16, 2013	Aug NEWA
AB		30MG	A091212	002	Sep 16, 2013	Aug NEWA

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC
LATANOPROST

AT	@ APOTEX INC	0.005%	A077697	001	Mar 22, 2011	Apr DISC
	DR REDDYS LABS LTD	0.005%	A202077	001	Feb 11, 2013	Jan NEWA

LENALIDOMIDE

CAPSULE;ORAL
REVLIMID

	CELGENE	20MG	N021880	006	Jun 05, 2013	Jun NEWA
--	---------	------	---------	-----	--------------	----------

LEPIRUDIN RECOMBINANTINJECTABLE; INJECTION
REFLUDAN

@ BAYER HLTHCARE	50MG/VIAL	N020807	001	Mar 06, 1998	Jun DISC
------------------	-----------	---------	-----	--------------	----------

LETROZOLETABLET; ORAL
LETROZOLE

AB	JIANGSU HENGRUI MED	2.5MG	A202716	001	May 16, 2013	Apr NEWA
----	---------------------	-------	---------	-----	--------------	----------

LEUCOVORIN CALCIUMINJECTABLE; INJECTION
LEUCOVORIN CALCIUM

AP	TEVA PHARMS USA	EQ 100MG BASE/VIAL	A081277	001	Sep 28, 1993	Mar CAHN
AP		EQ 350MG BASE/VIAL	A040174	001	Jun 12, 1997	Mar CAHN
	LEUCOVORIN CALCIUM PRESERVATIVE FREE					
	@ LUITPOLD	EQ 50MG BASE/VIAL	A040338	001	Jan 31, 2001	Jun DISC

LEUPROLIDE ACETATEINJECTABLE; INJECTION
LEUPROLIDE ACETATE

AP	TEVA PHARMS USA	1MG/0.2ML	A075471	001	Oct 25, 2000	Mar CAHN
	LUPRON					
	@ ABBVIE ENDOCRINE INC	1MG/0.2ML	N019010	001	Apr 09, 1985	Jul CAHN
	LUPRON DEPOT					
+	ABBVIE ENDOCRINE INC	3.75MG/VIAL	N020011	001	Oct 22, 1990	Apr CAHN
+		7.5MG/VIAL	N019732	001	Jan 26, 1989	Jul CAHN
+		11.25MG/VIAL	N020708	001	Mar 07, 1997	Jul CAHN
+		22.5MG/VIAL	N020517	001	Dec 22, 1995	Jul CAHN
+		30MG/VIAL	N020517	002	May 30, 1997	Jul CAHN
		45MG/VIAL	N020517	003	Jun 17, 2011	Jul CAHN
	LUPRON DEPOT-PED					
	@ ABBVIE ENDOCRINE INC	3.75MG/VIAL, 7.5MG/VIAL	N020263	003	Apr 16, 1993	Jul CAHN
	@	7.5MG/VIAL, 7.5MG/VIAL	N020263	004	Apr 16, 1993	Jul CAHN
+		7.5MG/VIAL	N020263	002	Apr 16, 1993	Jul CAHN
+		11.25MG/VIAL	N020263	005	Jan 21, 1994	Jul CAHN
+		11.25MG/VIAL	N020263	007	Aug 15, 2011	Jul CAHN
+		15MG/VIAL	N020263	006	Jan 21, 1994	Jul CAHN
+		30MG/VIAL	N020263	008	Aug 15, 2011	Jul CAHN

LEVALBUTEROL HYDROCHLORIDESOLUTION; INHALATION
LEVALBUTEROL HYDROCHLORIDE

AN	DEY	EQ 0.0103% BASE	A077800	001	Mar 15, 2013	Mar NEWA
AN		EQ 0.021% BASE	A077800	002	Mar 15, 2013	Mar NEWA
AN		EQ 0.042% BASE	A077800	003	Mar 15, 2013	Mar NEWA
AN	TEVA PHARMS USA	EQ 0.0103% BASE	A090297	001	Apr 26, 2013	Apr NEWA
AN		EQ 0.021% BASE	A090297	002	Apr 26, 2013	Apr NEWA
AN		EQ 0.042% BASE	A090297	003	Apr 26, 2013	Apr NEWA

LEVETIRACETAMINJECTABLE; IV (INFUSION)
LEVETIRACETAM

AP	SAGENT PHARMS	500MG/5ML (100MG/ML)	A091627	001	Jun 26, 2013	Jun NEWA
----	---------------	----------------------	---------	-----	--------------	----------

SOLUTION; ORAL
LEVETIRACETAM

	@ APOTEX INC	100MG/ML	A090187	001	Aug 05, 2011	Apr DISC
AA	BRECKENRIDGE PHARM	100MG/ML	A079120	001	Jan 16, 2009	Sep CAHN
AA	HETERO DRUGS LTD	100MG/ML	A203052	001	Feb 28, 2013	Feb NEWA
AA	HETERO LABS LTD III	100MG/ML	A203052	001	Feb 28, 2013	Apr CAHN
AA	ORIT LABS LLC	100MG/ML	A203067	001	May 09, 2013	Apr NEWA

TABLET; ORAL

LEVETIRACETAM

AB	HETERO LABS LTD III	1GM	A090515	004	Oct 08, 2010	Apr CAHN
AB		250MG	A090515	001	Oct 08, 2010	Apr CAHN
AB		500MG	A090515	002	Oct 08, 2010	Apr CAHN
AB		750MG	A090515	003	Oct 08, 2010	Apr CAHN
AB	PRINSTON INC	1GM	A078106	004	Feb 10, 2009	Apr CAHN
AB		250MG	A078106	001	Feb 10, 2009	Apr CAHN
AB		500MG	A078106	002	Feb 10, 2009	Apr CAHN
AB		750MG	A078106	003	Feb 10, 2009	Apr CAHN

TABLET, EXTENDED RELEASE;ORAL
LEVETIRACETAM

	@ SANDOZ	500MG	A091668	001	Nov 01, 2012	Mar	DISC
	@	750MG	A091668	002	Nov 01, 2012	Mar	DISC
AB	SUN PHARMA GLOBAL	500MG	A203059	001	Sep 09, 2013	Aug	NEWA
AB		750MG	A203059	002	Sep 09, 2013	Aug	NEWA
AB	VINTAGE PHARMS LLC	500MG	A202533	001	Jul 20, 2012	Jan	NEWA
AB		750MG	A202533	002	Jul 20, 2012	Jan	NEWA

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
LEVOBUNOLOL HYDROCHLORIDE

	@ APOTEX INC	0.25%	A075473	001	Aug 03, 2000	Apr	DISC
	@	0.5%	A075475	001	Aug 03, 2000	Apr	DISC

LEVOCARNITINE

INJECTABLE;INJECTION
LEVOCARNITINE

AP	TEVA PHARMS USA	200MG/ML	A075881	001	Mar 29, 2001	May	CAHN
----	-----------------	----------	---------	-----	--------------	-----	------

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL
LEVOCETIRIZINE DIHYDROCHLORIDE

AA	TARO PHARM INDS	2.5MG/5ML	A202673	001	Jul 26, 2013	Jul	NEWA
----	-----------------	-----------	---------	-----	--------------	-----	------

TABLET;ORAL

	LEVOCETIRIZINE DIHYDROCHLORIDE						
AB	MICRO LABS LTD INDIA	5MG	A202046	001	Sep 17, 2013	Aug	NEWA
AB	SANDOZ	5MG	A090486	001	Mar 26, 2013	Mar	NEWA
AB	SUN PHARMA GLOBAL	5MG	A090362	001	Jan 31, 2013	Jan	NEWA

LEVOFLOXACIN

INJECTABLE;INJECTION
LEVOFLOXACIN

AP	AUROBINDO PHARMA LTD	EQ 500MG/20ML (EQ 25MG/ML)	A202328	001	Jan 24, 2013	Jan	NEWA
AP		EQ 750MG/30ML (EQ 25MG/ML)	A202328	002	Jan 24, 2013	Jan	NEWA
AP	CLARIS LIFESCIENCES	EQ 500MG/20ML (EQ 25MG/ML)	A091436	001	Jun 05, 2013	May	NEWA
AP	EMCURE PHARMS LTD	EQ 500MG/20ML (EQ 25MG/ML)	A202590	001	Jan 24, 2013	Jan	NEWA
AP		EQ 750MG/30ML (EQ 25MG/ML)	A202590	002	Jan 24, 2013	Jan	NEWA
	LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	CLARIS LIFESCIENCES	EQ 250MG/50ML (EQ 5MG/ML)	A091397	001	Aug 08, 2013	Jul	NEWA
AP		EQ 500MG/100ML (EQ 5MG/ML)	A091397	002	Aug 08, 2013	Jul	NEWA
AP		EQ 750MG/150ML (EQ 5MG/ML)	A091397	003	Aug 08, 2013	Jul	NEWA
AP	FRESENIUS KABI USA	EQ 250MG/50ML (EQ 5MG/ML)	A200674	001	Jun 19, 2013	Jun	NEWA
AP		EQ 500MG/100ML (EQ 5MG/ML)	A200674	002	Jun 19, 2013	Jun	NEWA
AP		EQ 750MG/150ML (EQ 5MG/ML)	A200674	003	Jun 19, 2013	Jun	NEWA

SOLUTION/DROPS;OPHTHALMIC
LEVOFLOXACIN

	@ APOTEX INC	0.5%	A078282	001	Dec 20, 2010	Apr	DISC
--	--------------	------	---------	-----	--------------	-----	------

TABLET;ORAL

LEVOFLOXACIN

>A>	AB	WATSON LABS INC	250MG	A201484	001	Nov 22, 2013	Nov	NEWA
>A>	AB		500MG	A201484	002	Nov 22, 2013	Nov	NEWA
>A>	AB		750MG	A201484	003	Nov 22, 2013	Nov	NEWA

LEVOMILNACIPRAN HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
FETZIMA

	FOREST LABS INC	EQ 20MG BASE	N204168	001	Jul 25, 2013	Jul	NEWA
		EQ 40MG BASE	N204168	002	Jul 25, 2013	Jul	NEWA
		EQ 80MG BASE	N204168	003	Jul 25, 2013	Jul	NEWA
+		EQ 120MG BASE	N204168	004	Jul 25, 2013	Jul	NEWA

LEVONORDEFIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

ISOCAINE HYDROCHLORIDE W/ LEVONORDEFIN

	@ NOVOCOL	0.05MG/ML;2%	A084697	001		Jun	DISC
	SCANDONEST L						

+	DEPROCO	0.05MG/ML;2%	A088388	001	Oct 10, 1984	Jun	CRLD
---	---------	--------------	---------	-----	--------------	-----	------

LEVONORGESTREL

INTRAUTERINE DEVICE; INTRAUTERINE
SKYLA

	+	BAYER HLTHCARE	13.5MG	N203159	001	Jan 09, 2013	Jan NEWA
		TABLET; ORAL					
		LEVONORGESTREL					
AB		LUPIN LTD	0.75MG	A091328	001	Jan 23, 2013	Jan NEWA
AB		NOVEL LABS INC	1.5MG	A202508	001	Feb 22, 2013	Feb NEWA

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET; ORAL

LEVOTHYROXINE SODIUM

	@	MERCK KGAA	0.025MG	A076752	001	Jun 16, 2005	Jul DISC
	@		0.05MG	A076752	002	Jun 16, 2005	Jul DISC
	@		0.075MG	A076752	003	Jun 16, 2005	Jul DISC
	@		0.088MG	A076752	004	Jun 16, 2005	Jul DISC
	@		0.1MG	A076752	005	Jun 16, 2005	Jul DISC
	@		0.112MG	A076752	006	Jun 16, 2005	Jul DISC
	@		0.125MG	A076752	007	Jun 16, 2005	Jul DISC
	@		0.15MG	A076752	008	Jun 16, 2005	Jul DISC
	@		0.175MG	A076752	009	Jun 16, 2005	Jul DISC
	@		0.2MG	A076752	010	Jun 16, 2005	Jul DISC
	@		0.3MG	A076752	011	Jun 16, 2005	Jul DISC
		LEVOXYL					
AB1,		KING PHARMS R AND D	0.025MG	N021301	001	May 25, 2001	Mar CAHN
AB3							
AB1,			0.05MG	N021301	002	May 25, 2001	Mar CAHN
AB3							
AB1,			0.075MG	N021301	003	May 25, 2001	Mar CAHN
AB3							
AB1,			0.088MG	N021301	004	May 25, 2001	Mar CAHN
AB3							
AB1,			0.1MG	N021301	005	May 25, 2001	Mar CAHN
AB3							
AB1,			0.112MG	N021301	006	May 25, 2001	Mar CAHN
AB3							
AB1,			0.125MG	N021301	007	May 25, 2001	Mar CAHN
AB3							
AB1,			0.137MG	N021301	008	May 25, 2001	Mar CAHN
AB3							
AB1,			0.15MG	N021301	009	May 25, 2001	Mar CAHN
AB3							
AB1,			0.175MG	N021301	010	May 25, 2001	Mar CAHN
AB3							
AB1, +			0.2MG	N021301	011	May 25, 2001	Mar CAHN
AB3							
	@		0.3MG	N021301	012	May 25, 2001	Mar CAHN

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

>A>	AP	AGILA SPECLTS	0.5%	A091056	001	Dec 08, 2010	Nov CAHN
>A>	AP		0.5%	A091058	001	Sep 30, 2010	Nov CAHN
>A>	AP		1%	A091056	002	Dec 08, 2010	Nov CAHN
>A>	AP		1%	A091058	002	Sep 30, 2010	Nov CAHN
	AP	INTL MEDICATION	1%	A083173	001		Sep CMFD
	AP		2%	A083173	002		Sep CMFD
	@	LUITPOLD	2%	A083198	001		Mar DISC
>D>	AP	PFIZER	0.5%	A091056	001	Dec 08, 2010	Nov CAHN
>D>	AP		0.5%	A091058	001	Sep 30, 2010	Nov CAHN
>D>	AP		1%	A091056	002	Dec 08, 2010	Nov CAHN
>D>	AP		1%	A091058	002	Sep 30, 2010	Nov CAHN
		LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE					
>A>	AP	AGILA SPECLTS	2%	A090665	001	Sep 27, 2010	Nov CAHN
	AP	AUROBINDO PHARMA LTD	1%	A203040	001	Mar 14, 2013	Mar NEWA
	AP		1%	A203082	001	Mar 14, 2013	Mar NEWA
	AP		2%	A203040	002	Mar 14, 2013	Mar NEWA
	AP		2%	A203082	002	Mar 14, 2013	Mar NEWA
>D>	AP	PFIZER	2%	A090665	001	Sep 27, 2010	Nov CAHN

JELLY; TOPICAL

ANESTACON

	@	POLYMEDICA	2%	A080429	001		May DISC
--	---	------------	----	---------	-----	--	----------

JELLY; TOPICAL						
LIDOCAINE HYDROCHLORIDE						
@ TEVA PHARMS USA	2%		A081318	001	Apr 29, 1993	Jun DISC
<u>LIDOCAINE; TETRACAINE</u>						
PATCH; TOPICAL						
SYNERA						
+ GALEN SPECIALTY	70MG; 70MG		N021623	001	Jun 23, 2005	Aug CAHN
<u>LIOTHYRONINE SODIUM</u>						
TABLET; ORAL						
CYTOMEL						
AB KING PHARMS R AND D	EQ 0.005MG BASE		N010379	001		Mar CAHN
AB	EQ 0.025MG BASE		N010379	002		Mar CAHN
AB +	EQ 0.05MG BASE		N010379	003		Mar CAHN
<u>LISINOPRIL</u>						
TABLET; ORAL						
LISINOPRIL						
AB ACCORD HLTHCARE	2.5MG		A202554	001	Jul 30, 2013	Jul NEWA
AB	5MG		A202554	002	Jul 30, 2013	Jul NEWA
AB	10MG		A202554	003	Jul 30, 2013	Jul NEWA
AB	20MG		A202554	004	Jul 30, 2013	Jul NEWA
AB	30MG		A202554	005	Jul 30, 2013	Jul NEWA
AB	40MG		A202554	006	Jul 30, 2013	Jul NEWA
AB HIKMA PHARMS	2.5MG		A076063	001	Jul 01, 2002	Oct CAHN
AB	5MG		A076063	002	Jul 01, 2002	Oct CAHN
AB	10MG		A076063	003	Jul 01, 2002	Oct CAHN
AB	20MG		A076063	004	Jul 01, 2002	Oct CAHN
AB	30MG		A076063	006	Jun 27, 2003	Oct CAHN
AB	40MG		A076063	005	Jul 01, 2002	Oct CAHN
AB INVAGEN PHARMS	2.5MG		A203508	001	Oct 29, 2013	Oct NEWA
AB	5MG		A203508	002	Oct 29, 2013	Oct NEWA
AB	10MG		A203508	003	Oct 29, 2013	Oct NEWA
AB	20MG		A203508	004	Oct 29, 2013	Oct NEWA
AB	30MG		A203508	005	Oct 29, 2013	Oct NEWA
AB	40MG		A203508	006	Oct 29, 2013	Oct NEWA
@ SANDOZ	2.5MG		A075903	001	Jul 01, 2002	Aug DISC
@	2.5MG		A075999	001	Jul 01, 2002	Jan CAHN
@	5MG		A075903	002	Jul 01, 2002	Aug DISC
@	5MG		A075999	002	Jul 01, 2002	Jan CAHN
@	10MG		A075903	003	Jul 01, 2002	Aug DISC
@	10MG		A075999	003	Jul 01, 2002	Jan CAHN
@	20MG		A075903	004	Jul 01, 2002	Aug DISC
@	20MG		A075999	004	Jul 01, 2002	Jan CAHN
@	30MG		A075903	005	Jul 01, 2002	Aug DISC
@	30MG		A075999	005	Jul 01, 2002	Jan CAHN
@	40MG		A075903	006	Jul 01, 2002	Aug DISC
@	40MG		A075999	006	Jul 01, 2002	Jan CAHN
<u>LITHIUM CARBONATE</u>						
CAPSULE; ORAL						
LITHIUM CARBONATE						
@ APOTEX INC	300MG		A076795	001	Nov 22, 2004	Feb DISC
AB HETERO LABS LTD III	150MG		A090702	001	Sep 25, 2009	Apr CAHN
AB	300MG		A090702	002	Sep 25, 2009	Apr CAHN
AB	600MG		A090702	003	Sep 25, 2009	Apr CAHN
TABLET; ORAL						
LITHIUM CARBONATE						
@ WEST WARD	300MG		A078715	001	Dec 28, 2010	Aug DISC
<u>LOMUSTINE</u>						
CAPSULE; ORAL						
CEENU						
CORDEN PHARMA	10MG		N017588	001		Apr CAHN
	40MG		N017588	002		Apr CAHN
+	100MG		N017588	003		Apr CAHN

LORAZEPAMCONCENTRATE; ORAL
LORAZEPAM

AA	LUPIN LTD	2MG/ML	A091407	001	Feb 19, 2013	Feb NEWA
	INJECTABLE; INJECTION					
	LORAZEPAM					
AP	AKORN	2MG/ML	A075025	001	Jul 23, 1998	Jul CAHN
	@ WATSON LABS	2MG/ML	A074276	001	Apr 15, 1994	Sep DISC
	@	4MG/ML	A074276	002	Apr 15, 1994	Sep DISC
	TABLET; ORAL					
	LORAZEPAM					
	@ SANDOZ	0.5MG	A071193	001	Apr 15, 1988	Apr DISC
	@	1MG	A071194	001	Apr 15, 1988	Apr DISC
	@	2MG	A071195	001	Apr 15, 1988	Apr DISC

LOSARTAN POTASSIUMTABLET; ORAL
COZAAR

AB	MERCK SHARP DOHME	25MG	N020386	001	Apr 14, 1995	Oct CAHN
AB		50MG	N020386	002	Apr 14, 1995	Oct CAHN
AB	+	100MG	N020386	003	Oct 13, 1998	Oct CAHN
	LOSARTAN POTASSIUM					
AB	ACTAVIS GRP PTC	25MG	A090382	001	Oct 06, 2010	Mar CAHN
AB		50MG	A090382	002	Oct 06, 2010	Mar CAHN
AB		100MG	A090382	003	Oct 06, 2010	Mar CAHN
AB	IPCA LABS LTD	25MG	A200290	001	Aug 30, 2013	Aug NEWA
AB		50MG	A200290	002	Aug 30, 2013	Aug NEWA
AB		100MG	A200290	003	Aug 30, 2013	Aug NEWA

LOVASTATINTABLET; ORAL
LOVASTATIN

AB	+ CARLSBAD	40MG	A075991	003	Jun 05, 2002	Feb CRLD
	MEVACOR					
	@ MERCK	20MG	N019643	003	Aug 31, 1987	Feb DISC
	@	40MG	N019643	004	Dec 14, 1988	Feb DISC

LOXAPINEPOWDER; INHALATION
ADASUVE

	+ TEVA PHARMS USA INC	10MG	N022549	001	Dec 21, 2012	Jul CAHN
--	-----------------------	------	---------	-----	--------------	----------

LOXAPINE SUCCINATECAPSULE; ORAL
LOXAPINE SUCCINATE

AB	MIKAH PHARMA	EQ 5MG BASE	A076868	001	Aug 04, 2005	May CMFD
AB		EQ 10MG BASE	A076868	002	Aug 04, 2005	May CMFD
AB		EQ 25MG BASE	A076868	003	Aug 04, 2005	May CMFD
AB		EQ 50MG BASE	A076868	004	Aug 04, 2005	May CMFD

>A> LULICONAZOLE

>A> CREAM; TOPICAL

>A> LUZU

>A>	MEDICIS	1%	N204153	001	Nov 14, 2013	Nov NEWA
-----	---------	----	---------	-----	--------------	----------

LURASIDONE HYDROCHLORIDETABLET; ORAL
LATUDA

	SUNOVION PHARMS INC	60MG	N200603	005	Jul 12, 2013	Jul NEWA
--	---------------------	------	---------	-----	--------------	----------

MACITENTANTABLET; ORAL
OPSUMIT

	+ ACTELION PHARMS LTD	10MG	N204410	001	Oct 18, 2013	Oct NEWA
--	-----------------------	------	---------	-----	--------------	----------

MAFENIDE ACETATE

		CREAM;TOPICAL SULFAMYLON						
		+ MYLAN INSTITUTIONAL	EQ 85MG BASE/GM	N016763	001			May CAHN
		FOR SOLUTION;TOPICAL MAFENIDE ACETATE						
AB		PAR FORM	5%	A201511	001	Feb 12, 2013		Jan NEWA
		SULFAMYLON						
AB		+ MYLAN INSTITUTIONAL	5%	N019832	003	Jun 05, 1998		May CAHN
AB		+ MYLAN LLC	5%	N019832	003	Jun 05, 1998		Jan CFTG

MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SOLUTION;ORAL
SUCLEAR

		+ BRAINTREE LABS	1.6GM/BOT,3.13GM/BOT,17.5GM/BOT,N/A,N/A,N/A,N/A;N/A,N/A,N/A,210GM,0.74GM,2.86GM,5.6GM	N203595	001	Jan 18, 2013		Jan NEWA
--	--	------------------	---	---------	-----	--------------	--	----------

MANNITOL

INJECTABLE;INJECTION
MANNITOL 20%

		@ B BRAUN	20GM/100ML	N014738	001			Jan DISC
--	--	-----------	------------	---------	-----	--	--	----------

MECAMYLAMINE HYDROCHLORIDE

TABLET;ORAL
MECAMYLAMINE HYDROCHLORIDE
NEXGEN PHARMA

2.5MG

A204054 001 Mar 19, 2013 Mar NEWA

MECHLORETHAMINE HYDROCHLORIDE

GEL;TOPICAL
VALCHLOR

		+ ACTELION PHARMS LTD	0.02%	N202317	001	Aug 23, 2013		Sep CAHN
		+ CEPTARIS THERAP	0.02%	N202317	001	Aug 23, 2013		Aug NEWA

INJECTABLE;INJECTION
MUSTARGEN

		+ RECORDATI RARE	10MG/VIAL	N006695	001			May CAHN
--	--	------------------	-----------	---------	-----	--	--	----------

MECLIZINE HYDROCHLORIDE

TABLET;ORAL
ANTIVERT

>A>	AA	+ CITRON PHARMA LLC	12.5MG	N010721	006			Nov CAHN
>A>	AA	+	25MG	N010721	004			Nov CAHN
>A>	AA	+	50MG	N010721	001	Jan 20, 1982		Nov CAHN
>D>	AA	+ PFIZER	12.5MG	N010721	006			Nov CAHN
>D>	AA	+	25MG	N010721	004			Nov CAHN
>D>	AA	+	50MG	N010721	001	Jan 20, 1982		Nov CAHN

TABLET, CHEWABLE;ORAL
ANTIVERT

>A>		@ CITRON PHARMA LLC	25MG	N010721	005			Nov CAHN
>D>		@ PFIZER	25MG	N010721	005			Nov CAHN

MECLOFENAMATE SODIUM

CAPSULE;ORAL
MECLOFENAMATE SODIUM

		MYLAN	EQ 50MG BASE	A071081	002	Sep 03, 1986		Sep CTEC
		+	EQ 100MG BASE	A071081	001	Sep 03, 1986		Sep CTEC
		@ WATSON LABS	EQ 50MG BASE	A071468	001	Apr 15, 1987		Sep DISC
		@	EQ 100MG BASE	A071469	001	Apr 15, 1987		Sep DISC

MEDROXYPROGESTERONE ACETATE

INJECTABLE;INJECTION
MEDROXYPROGESTERONE ACETATE

		@ TEVA PHARMS USA	150MG/ML	A076552	001	Oct 27, 2004		May CAHN
AB			150MG/ML	A076553	001	Jul 28, 2004		May CAHN

MEFENAMIC ACID

CAPSULE; ORAL

MEFENAMIC ACID

AB	BRECKENRIDGE PHARM	250MG	A090359	001	Feb 05, 2013	Sep CAHN
AB	CYPRESS PHARM	250MG	A090359	001	Feb 05, 2013	Jan NEWA

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

MEFLOQUINE HYDROCHLORIDE

@ WEST WARD PHARM CORP 250MG

A077699 001 Apr 21, 2010 Jun DISC

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGESTROL ACETATE

@ APOTEX INC 40MG/ML

A077404 001 Feb 16, 2006 Apr DISC

MELOXICAM

TABLET; ORAL

MELOXICAM

AB	CIPLA LTD	7.5MG	A077929	001	Jul 19, 2006	Aug CAHN
AB		15MG	A077929	002	Jul 19, 2006	Aug CAHN
	@ COREPHARMA	7.5MG	A077930	001	Jul 19, 2006	Feb DISC
	@	15MG	A077930	002	Jul 19, 2006	Feb DISC
	@ CR DOUBLE CRANE	7.5MG	A078039	001	Dec 14, 2006	Apr DISC
AB		7.5MG	A078039	001	Dec 14, 2006	Mar CAHN
	@	15MG	A078039	002	Dec 14, 2006	Apr DISC
AB		15MG	A078039	002	Dec 14, 2006	Mar CAHN
	@ MYLAN	7.5MG	A077934	001	Jul 20, 2006	Aug DISC
	@	15MG	A077934	002	Jul 20, 2006	Aug DISC

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

MELPHALAN HYDROCHLORIDE

>D>	AP	MYLAN INSTITUTIONAL	EQ 50MG BASE/VIAL	A090299	001	Oct 27, 2009	Nov DISC
>A>		@	EQ 50MG BASE/VIAL	A090299	001	Oct 27, 2009	Nov DISC

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

@	TARO	200MG
@		400MG

A200998	001	May 23, 2011	Jan DISC
A200998	002	May 23, 2011	Jan DISC

MESALAMINE

CAPSULE, DELAYED RELEASE; ORAL

DELZICOL

+ WARNER CHILCOTT LLC 400MG

N204412 001 Feb 01, 2013 Feb NEWA

SUPPOSITORY; RECTAL

CANASA

+ APTALIS PHARMA US 1GM

N021252 002 Nov 05, 2004 Feb CRLD

MESNA

INJECTABLE; INTRAVENOUS

MESNA

AP	TEVA PHARMS USA	100MG/ML	A075764	001	Apr 27, 2001	May CAHN
----	-----------------	----------	---------	-----	--------------	----------

METAPROTERENOL SULFATE

SOLUTION; INHALATION

METAPROTERENOL SULFATE

@	APOTEX INC	0.4%
@		0.6%

A075402	001	Feb 28, 2001	Apr DISC
A075403	001	Feb 28, 2001	Apr DISC

SYRUP; ORAL

METAPROTERENOL SULFATE

@	APOTEX INC	10MG/5ML
@	NOVEX	10MG/5ML
+	SILARX	10MG/5ML

A075235	001	Jan 27, 2000	Apr DISC
A075235	001	Jan 27, 2000	Feb DISC
A073632	001	Jul 22, 1992	Feb CTEC

TABLET; ORAL

METAPROTERENOL SULFATE

	PAR PHARM	10MG
+		20MG
@	WATSON LABS	10MG
@		20MG

A072024	001	Jun 28, 1988	Mar CTEC
A072025	001	Jun 28, 1988	Mar CTEC
A073013	001	Jan 31, 1991	Mar DISC
A072795	001	Jan 31, 1991	Mar DISC

METAXALONETABLET; ORAL
METAXALONE

AB	AMNEAL PHARMS	800MG	A203399	001	Jun 21, 2013	Jun	NEWA
----	---------------	-------	---------	-----	--------------	-----	------

METFORMIN HYDROCHLORIDETABLET; ORAL
METFORMIN HYDROCHLORIDE

AB	CHARTWELL LIFE SCI	1GM	A075972	003	Jan 24, 2002	Aug	CAHN
AB		500MG	A075972	001	Jan 24, 2002	Aug	CAHN
		625MG	A075972	005	Jan 24, 2002	Aug	CAHN
		750MG	A075972	004	Jan 24, 2002	Aug	CAHN
AB		850MG	A075972	002	Jan 24, 2002	Aug	CAHN
AB	SANDOZ	1GM	A075965	003	Jan 25, 2002	May	CMFD
	@	1GM	A075965	003	Jan 25, 2002	Mar	DISC
AB		500MG	A075965	001	Jan 25, 2002	May	CMFD
	@	500MG	A075965	001	Jan 25, 2002	Mar	DISC
AB		850MG	A075965	002	Jan 25, 2002	May	CMFD
	@	850MG	A075965	002	Jan 25, 2002	Mar	DISC
AB	SCIEGEN PHARMS INC	500MG	A203769	001	Sep 11, 2013	Aug	NEWA
AB		850MG	A203769	002	Sep 11, 2013	Aug	NEWA
AB		1GM	A203769	003	Sep 11, 2013	Aug	NEWA

TABLET, EXTENDED RELEASE; ORAL
FORTAMET

AB2	+ ANDRX LABS LLC	1GM	N021574	002	Apr 27, 2004	Jul	CTEC
	GLUMETZA						
AB3	+ SANTARUS	1GM	N021748	002	Jun 03, 2005	Jul	CTEC
AB3		500MG	N021748	001	Jun 03, 2005	Jul	CTEC
	METFORMIN HYDROCHLORIDE						
AB1	CSPC OUYI PHARM CO	500MG	A078321	001	Apr 17, 2008	Sep	CAHN
AB		750MG	A078321	002	Apr 17, 2008	Sep	CAHN
AB2	LUPIN LTD	1GM	A090692	002	Jun 29, 2011	Jul	CTEC
AB3		1GM	A091664	002	Jul 19, 2013	Jul	NEWA
AB3		500MG	A091664	001	Jul 19, 2013	Jul	NEWA
AB2	MYLAN PHARMS INC	1GM	A200690	002	Aug 01, 2012	Jul	CTEC
	@ TORRENT PHARMS LTD	750MG	A079226	001	Feb 18, 2010	Jun	DISC
	@ WATSON LABS INC	500MG	A076818	001	Dec 14, 2004	Mar	DISC

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDETABLET; ORAL
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	500MG;EQ 15MG BASE	A200823	001	Feb 13, 2013	Jan	NEWA
AB		850MG;EQ 15MG BASE	A200823	002	Feb 13, 2013	Jan	NEWA
AB	SANDOZ	500MG;EQ 15MG BASE	A091273	001	Apr 16, 2013	Apr	NEWA
AB		850MG;EQ 15MG BASE	A091273	002	Apr 16, 2013	Apr	NEWA
AB	TORRENT PHARMS LTD	500MG;EQ 15MG BASE	A202001	001	Feb 13, 2013	Jan	NEWA
AB		850MG;EQ 15MG BASE	A202001	002	Feb 13, 2013	Jan	NEWA

METHADONE HYDROCHLORIDETABLET, FOR SUSPENSION; ORAL
METHADONE HYDROCHLORIDE

AA	MALLINCKRODT INC	40MG	A077142	001	Jul 12, 2005	Mar	CDFR
AA	+ ROXANE	40MG	N017058	001		Mar	CDFR
AA	SANDOZ	40MG	A075082	001	Mar 25, 1998	Mar	CDFR
	METHADOSE						
AA	MALLINCKRODT	40MG	A074184	001	Apr 29, 1993	Mar	CDFR

METHAMPHETAMINE HYDROCHLORIDETABLET; ORAL
DESOXYN

AA	+ RECORDATI RARE	5MG	N005378	002		May	CAHN
----	------------------	-----	---------	-----	--	-----	------

METHOCARBAMOLINJECTABLE; INJECTION
METHOCARBAMOL

	@ WATSON LABS	100MG/ML	A086459	001		Jul	DISC
	ROBAXIN						
+	BAXTER HLTHCARE CORP	100MG/ML	N011790	001		Jul	CTEC
+	HIKMA MAPLE	100MG/ML	N011790	001		Sep	CAHN

TABLET;ORAL									
METHOCARBAMOL									
AA	AUSTARPHARMA LLC	500MG	A200958	001	Oct 21, 2011	May	CMFD		
	@	500MG	A200958	001	Oct 21, 2011	Jan	DISC		
AA		750MG	A200958	002	Oct 21, 2011	May	CMFD		
AA	HETERO LABS LTD III	500MG	A090200	001	Nov 06, 2009	Apr	CAHN		
AA		750MG	A090200	002	Nov 06, 2009	Apr	CAHN		
AA	HIKMA PHARMS	750MG	A085123	001		Oct	CAHN		
AA	PRINSTON INC	500MG	A086989	001		Feb	CMFD		
AA		750MG	A086988	001		Feb	CAHN		
	@ SOLCO HLTHCARE	500MG	A086989	001		Jan	DISC		
<u>METHOTREXATE</u>									
SOLUTION;SUBCUTANEOUS									
OTREXUP									
	ANTARES PHARMA INC	10MG/0.4ML	N204824	001	Oct 11, 2013	Oct	NEWA		
		15MG/0.4ML	N204824	002	Oct 11, 2013	Oct	NEWA		
		20MG/0.4ML	N204824	003	Oct 11, 2013	Oct	NEWA		
+		25MG/0.4ML	N204824	004	Oct 11, 2013	Oct	NEWA		
<u>METHOXSALEN</u>									
CAPSULE;ORAL									
OXSORALEN-ULTRA									
+	DOW PHARM	10MG	N019600	001	Oct 30, 1986	Apr	CAHN		
<u>METHYLCLOTHIAZIDE</u>									
TABLET;ORAL									
METHYLCLOTHIAZIDE									
+	MYLAN PHARMS INC	5MG	A087672	001	Aug 17, 1982	Jan	CTEC		
	@ WATSON LABS	5MG	A088724	001	Sep 06, 1984	Jan	DISC		
<u>METHYL AMINOLEVULINATE HYDROCHLORIDE</u>									
CREAM;TOPICAL									
METVIXIA									
	@ GALDERMA LABS LP	EQ 16.8% BASE	N021415	001	Jul 27, 2004	Jun	DISC		
<u>METHYLDOPA</u>									
TABLET;ORAL									
METHYLDOPA									
	@ ACCORD HLTHCARE	125MG	A070070	003	Oct 15, 1985	Apr	CAHN		
AB		250MG	A070084	001	Oct 15, 1985	Apr	CAHN		
AB		500MG	A070085	001	Oct 15, 1985	Apr	CAHN		
<u>METHYLPHENIDATE HYDROCHLORIDE</u>									
CAPSULE, EXTENDED RELEASE;ORAL									
METADATE CD									
AB2	UCB INC	10MG	N021259	003	May 27, 2003	Sep	CTEC		
AB2		50MG	N021259	005	Feb 19, 2006	Sep	CTEC		
AB2	+	60MG	N021259	006	Feb 19, 2006	Sep	CTEC		
METHYLPHENIDATE HYDROCHLORIDE									
AB2	TEVA PHARMS	10MG	A077707	001	Jul 19, 2012	Sep	CTEC		
AB2		50MG	A078873	002	Jul 19, 2012	Sep	CTEC		
AB2		60MG	A078873	003	Jul 19, 2012	Sep	CTEC		
AB1	WATSON LABS INC	20MG	A078458	001	Dec 01, 2011	Apr	CAHN		
AB1		30MG	A078458	002	Dec 01, 2011	Apr	CAHN		
AB1		40MG	A078458	003	Dec 01, 2011	Apr	CAHN		
SOLUTION;ORAL									
METHYLPHENIDATE HYDROCHLORIDE									
AA	CARACO	5MG/5ML	A201466	001	Nov 12, 2013	Oct	NEWA		
AA		10MG/5ML	A201466	002	Nov 12, 2013	Oct	NEWA		
TABLET;ORAL									
METHYLPHENIDATE HYDROCHLORIDE									
AB	CARACO	5MG	A090710	001	Mar 15, 2012	May	CAHN		
AB		10MG	A090710	002	Mar 15, 2012	May	CAHN		
AB		20MG	A090710	003	Mar 15, 2012	May	CAHN		
TABLET, EXTENDED RELEASE;ORAL									
CONCERTA									
AB	JANSSEN PHARMS	18MG	N021121	001	Aug 01, 2000	Jun	CTEC		
METHYLIN ER									
	MALLINCKRODT INC	10MG	A075629	001	May 09, 2000	Feb	CTEC		

TABLET, EXTENDED RELEASE;ORAL									
METHYLPHENIDATE HYDROCHLORIDE									
AB	KUDCO IRELAND	18MG	A091695	001	Jul 09, 2013	Jun	NEWA		
AB		27MG	A091695	002	Jul 09, 2013	Jun	NEWA		
AB		36MG	A091695	003	Sep 23, 2013	Sep	NEWA		
AB		54MG	A091695	004	Sep 23, 2013	Sep	NEWA		
<u>METHYLPREDNISOLONE</u>									
TABLET;ORAL									
MEDROL									
AB	PHARMACIA AND UPJOHN	2MG	N011153	002		Oct	CMFD		
<u>METHYLPREDNISOLONE ACETATE</u>									
INJECTABLE;INJECTION									
METHYLPREDNISOLONE ACETATE									
AB	TEVA PHARMS USA	40MG/ML	A040557	001	Feb 23, 2005	May	CAHN		
AB		40MG/ML	A040620	001	Oct 27, 2006	May	CAHN		
AB		80MG/ML	A040557	002	Feb 23, 2005	May	CAHN		
AB		80MG/ML	A040620	002	Oct 27, 2006	May	CAHN		
<u>METOCLOPRAMIDE HYDROCHLORIDE</u>									
INJECTABLE;INJECTION									
METOCLOPRAMIDE HYDROCHLORIDE									
AP	BD RX	EQ 5MG BASE/ML	A091392	001	Apr 19, 2013	Apr	NEWA		
	@ TEVA PARENTERAL	EQ 5MG BASE/ML	A073135	001	Nov 27, 1991	Feb	DISC		
	@ TEVA PHARMS USA	EQ 5MG BASE/ML	A073135	001	Nov 27, 1991	May	CAHN		
TABLET, ORALLY DISINTEGRATING;ORAL									
METOZOLV ODT									
+	SALIX PHARMS	EQ 5MG BASE	N022246	001	Sep 04, 2009	Jul	CRLD		
	@	EQ 10MG BASE	N022246	002	Sep 04, 2009	Jul	DISC		
<u>METOLAZONE</u>									
TABLET;ORAL									
METOLAZONE									
	@ TEVA	2.5MG	A076600	001	Jan 06, 2004	Mar	DISC		
	@	5MG	A076833	001	Mar 01, 2004	Jun	DISC		
	@	10MG	A075543	003	Dec 24, 2003	May	DISC		
<u>METOPROLOL SUCCINATE</u>									
TABLET, EXTENDED RELEASE;ORAL									
METOPROLOL SUCCINATE									
	@ NESHER PHARMS	EQ 25MG TARTRATE	A077779	001	Mar 20, 2008	Feb	DISC		
	@	EQ 50MG TARTRATE	A077176	001	May 14, 2008	May	DISC		
<u>METOPROLOL TARTRATE</u>									
INJECTABLE;INJECTION									
METOPROLOL TARTRATE									
AP	CLARIS LIFESCIENCES	1MG/ML	A078950	001	Apr 29, 2013	Apr	NEWA		
	@ WATSON LABS	1MG/ML	A074032	001	Dec 21, 1993	Mar	DISC		
TABLET;ORAL									
METOPROLOL TARTRATE									
AB	ALEMBIC PHARMS LTD	25MG	A202871	001	May 28, 2013	May	NEWA		
AB		50MG	A202871	002	May 28, 2013	May	NEWA		
AB		100MG	A202871	003	May 28, 2013	May	NEWA		
	@ PRINSTON INC	50MG	A074453	001	Apr 27, 1995	Mar	CAHN		
	@	100MG	A074453	002	Apr 27, 1995	Mar	CAHN		
<u>METRONIDAZOLE</u>									
TABLET;ORAL									
METRONIDAZOLE									
AB	TEVA PHARMS USA	250MG	A070027	001	Nov 06, 1984	Mar	CAHN		
<u>METYROSINE</u>									
CAPSULE;ORAL									
DEMSEER									
+	ATON PHARMA VPNA	250MG	N017871	001		Jun	CAHN		

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

	TEVA	150MG	A074377	001	May 16, 1995	Sep CTEC
		200MG	A074377	002	May 16, 1995	Sep CTEC
+		250MG	A074377	003	May 16, 1995	Sep CTEC
@	WATSON LABS	150MG	A074711	001	Feb 26, 1997	Sep DISC
@		150MG	A074865	001	Apr 13, 1998	Sep DISC
@		200MG	A074711	002	Feb 26, 1997	Sep DISC
@		200MG	A074865	002	Apr 13, 1998	Sep DISC
@		250MG	A074711	003	Feb 26, 1997	Sep DISC
@		250MG	A074865	003	Apr 13, 1998	Sep DISC

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

AP	AKORN INC	EQ 1MG BASE/ML	A075494	001	Jun 30, 2000	Jul CAHN
AP		EQ 5MG BASE/ML	A075481	001	Jun 30, 2000	Jul CAHN
AP		EQ 5MG BASE/ML	A075494	002	Jun 30, 2000	Jul CAHN
@	APOTEX INC	EQ 1MG BASE/ML	A075637	001	Oct 31, 2000	Apr DISC
@		EQ 5MG BASE/ML	A075637	002	Oct 31, 2000	Apr DISC
@	CLARIS LIFESCIENCES	EQ 1MG BASE/ML	A075637	001	Oct 31, 2000	Jan DISC
@		EQ 5MG BASE/ML	A075637	002	Oct 31, 2000	Jan DISC
@	INTL MEDICATED	EQ 1MG BASE/ML	A076144	001	Jan 26, 2005	Jun DISC
@		EQ 5MG BASE/ML	A076144	002	Jan 26, 2005	Jun DISC
@	INTL MEDICATION	EQ 1MG BASE/ML	A076020	001	Jul 16, 2004	May DISC
@		EQ 5MG BASE/ML	A076020	002	Jul 16, 2004	May DISC
SYRUP; ORAL						
MIDAZOLAM HYDROCHLORIDE						
@	APOTEX INC	EQ 2MG BASE/ML	A077115	001	Sep 09, 2005	Apr DISC

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

@	APOTEX INC	EQ 1MG BASE/ML	A076427	001	Sep 21, 2004	Apr DISC
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER						
@	APOTEX INC	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151	001	Jul 20, 2005	Apr DISC

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

MINOCYCLINE HYDROCHLORIDE

AB	CARACO	EQ 50MG BASE	A090867	001	May 13, 2013	Apr NEWA
AB		EQ 75MG BASE	A090867	002	May 13, 2013	Apr NEWA
AB		EQ 100MG BASE	A090867	003	May 13, 2013	Apr NEWA
CAPSULE, EXTENDED RELEASE; ORAL						
XIMINO						
@	RANBAXY LABS LTD	EQ 45MG BASE	N201922	001	Jul 11, 2012	May DISC
@		EQ 67.5MG BASE	N201922	002	Jul 11, 2012	May DISC
@		EQ 90MG BASE	N201922	003	Jul 11, 2012	May DISC
@		EQ 112.5MG BASE	N201922	004	Jul 11, 2012	May DISC
@		EQ 135MG BASE	N201922	005	Jul 11, 2012	May DISC
TABLET, EXTENDED RELEASE; ORAL						
SOLODYN						
@	MEDICIS	EQ 45MG BASE	N050808	001	May 08, 2006	Apr DISC
+		EQ 55MG BASE	N050808	008	Aug 27, 2010	Apr CRLD
+		EQ 80MG BASE	N050808	007	Aug 27, 2010	Apr CRLD
@		EQ 135MG BASE	N050808	003	May 08, 2006	Apr DISC

MIPOMERSEN SODIUM

SOLUTION; SUBCUTANEOUS

KYNAMRO

+	GENZYME CORP	200MG/ML (200MG/ML)	N203568	001	Jan 29, 2013	Jan NEWA
---	--------------	---------------------	---------	-----	--------------	----------

MIRTAZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

@	ACTAVIS ELIZABETH	15MG	A077959	001	Feb 14, 2011	Jun DISC
@		30MG	A077959	002	Feb 14, 2011	Jun DISC
@		45MG	A077959	003	Feb 14, 2011	Jun DISC

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

AP	ONCO THERAPIES LTD	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A201014	001	Dec 11, 2012	Mar	CAIN
AP	TEVA PHARMS USA	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A077356	001	Apr 11, 2006	May	CAHN
AP		EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A077356	002	Apr 11, 2006	May	CAHN
AP		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A077356	003	Apr 11, 2006	May	CAHN

MOMETASONE FUROATE

CREAM; TOPICAL

ELOCON

AB	MERCK SHARP DOHME	0.1%	N019625	002	Apr 19, 2013	Apr	NEWA
	OINTMENT; TOPICAL						
	MOMETASONE FUROATE						
	@ TARO	0.1%	A076624	001	Dec 03, 2004	May	DISC

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

KADIAN

AB1	+	WATSON LABS INC	10MG	N020616	008	Apr 20, 2007	May	CTEC
	+		10MG	N020616	008	Apr 20, 2007	Apr	CAHN
AB1			20MG	N020616	001	Jul 03, 1996	Apr	CAHN
AB1			30MG	N020616	004	Mar 09, 2001	Apr	CAHN
			40MG	N020616	009	Jul 09, 2012	Apr	CAHN
AB1			50MG	N020616	002	Jul 03, 1996	Apr	CAHN
AB1			60MG	N020616	005	Mar 09, 2001	Apr	CAHN
			70MG	N020616	010	Jul 09, 2012	Apr	CAHN
AB1			80MG	N020616	006	Oct 27, 2006	Apr	CAHN
AB1	+		100MG	N020616	003	Jul 03, 1996	Apr	CAHN
			130MG	N020616	011	Jul 09, 2012	Apr	CAHN
			150MG	N020616	012	Jul 09, 2012	Apr	CAHN
AB1	+		200MG	N020616	007	Feb 27, 2007	May	CTEC
	+		200MG	N020616	007	Feb 27, 2007	Apr	CAHN

MORPHINE SULFATE

AB1		PAR PHARM INC	20MG	A200812	001	Nov 10, 2011	Apr	CTEC
AB1			30MG	A200812	002	Nov 10, 2011	Apr	CTEC
AB1			50MG	A200812	003	Nov 10, 2011	Apr	CTEC
AB1			60MG	A200812	004	Nov 10, 2011	Apr	CTEC
AB1			80MG	A200812	005	Nov 10, 2011	Apr	CTEC
AB1			100MG	A200812	006	Nov 10, 2011	Apr	CTEC
AB1		UPSHER SMITH	10MG	A202104	001	Jun 03, 2013	May	NEWA
AB1			20MG	A202104	002	Jun 03, 2013	May	NEWA
AB1			30MG	A202104	003	Jun 03, 2013	May	NEWA
AB1			50MG	A202104	004	Jun 03, 2013	May	NEWA
AB1			60MG	A202104	005	Jun 03, 2013	May	NEWA
AB1			80MG	A202104	006	Jun 03, 2013	May	NEWA
AB1			100MG	A202104	007	Jun 03, 2013	May	NEWA

SOLUTION; IM-IV

MORPHINE SULFATE

+	BD RX	2MG/ML (2MG/ML)	N204223	001	Oct 30, 2013	Oct	NEWA
+		4MG/ML (4MG/ML)	N204223	002	Oct 30, 2013	Oct	NEWA
+		5MG/ML (5MG/ML)	N204223	003	Oct 30, 2013	Oct	NEWA
+		8MG/ML (8MG/ML)	N204223	004	Oct 30, 2013	Oct	NEWA
+		10MG/ML (10MG/ML)	N204223	005	Oct 30, 2013	Oct	NEWA

SOLUTION; ORAL

MORPHINE SULFATE

	LANNETT HOLDINGS INC	100MG/5ML	N201517	001	Jun 23, 2011	Jul	CPOT
--	----------------------	-----------	---------	-----	--------------	-----	------

MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EMBEDA

+	ALPHARMA KING	60MG; 2.4MG	N022321	004	Aug 13, 2009	Jul	CRLD
		100MG; 4MG	N022321	006	Aug 13, 2009	Jul	CRLD

MUPIROCIN CALCIUM

CREAM; TOPICAL

BACTROBAN

AB	+	GLAXOSMITHKLINE	EQ 2% BASE	N050746	001	Dec 11, 1997	Jan	CFTG
		MUPIROCIN						
AB		GLENMARK GENERICS	EQ 2% BASE	A201587	001	Jan 24, 2013	Jan	NEWA

MYCOPHENOLATE MOFETIL

CAPSULE;ORAL

MYCOPHENOLATE MOFETIL

AB	ACCORD HLTHCARE	250MG	A090253	001	May 04, 2009	Apr CAHN
AB	ALKEM LABS LTD	250MG	A200197	001	Jun 13, 2013	Jun NEWA

NABUMETONE

TABLET;ORAL

NABUMETONE

@ DR REDDYS LABS LTD

500MG

A078420 001 Sep 24, 2008 Apr DISC

@

750MG

A078420 002 Sep 24, 2008 Apr DISC

@ PROSAM LABS

500MG

A079093 001 Feb 27, 2009 Mar DISC

@

750MG

A079093 002 Feb 27, 2009 Mar DISC

NAFTIFINE HYDROCHLORIDE

GEL;TOPICAL

NAFTIN

+ MERZ PHARMS 2%

N204286 001 Jun 27, 2013 Jun NEWA

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET;ORAL

NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE

AB	GAVIS PHARMS	EQ 0.5MG BASE;EQ 50MG BASE	A075735	001	Jul 11, 2001	Aug CTNA
AB	RANBAXY	EQ 0.5MG BASE;EQ 50MG BASE	A075523	001	Mar 17, 2000	Aug CTNA
AB	+ WATSON LABS	EQ 0.5MG BASE;EQ 50MG BASE	A074736	001	Jan 21, 1997	Aug CTNA

NALTREXONE HYDROCHLORIDE

TABLET;ORAL

NALTREXONE HYDROCHLORIDE

@ SANDOZ

50MG

A075434 001 Mar 08, 2000 Apr DISC

REVIA

AB + TEVA WOMENS 50MG

N018932 001 Nov 20, 1984 Jul CAHN

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

NAPHAZOLINE HYDROCHLORIDE

AT	AKORN INC	0.1%	A083590	001		Jul CAHN
----	-----------	------	---------	-----	--	----------

NAPROXEN

TABLET;ORAL

NAPROXEN

AB	WEST WARD PHARM CORP	250MG	A076494	001	Jan 14, 2004	Apr CAHN
AB		375MG	A076494	002	Jan 14, 2004	Apr CAHN
AB		500MG	A076494	003	Jan 14, 2004	Apr CAHN

NAPROXEN SODIUM

TABLET, EXTENDED RELEASE;ORAL

NAPRELAN

>A>	ALMATICA PHARMA INC	EQ 375MG BASE	N020353	001	Jan 05, 1996	Nov CAHN
>A>		EQ 500MG BASE	N020353	002	Jan 05, 1996	Nov CAHN
>A>	+	EQ 750MG BASE	N020353	003	Jan 05, 1996	Nov CAHN
>D>	STAT TRADE	EQ 375MG BASE	N020353	001	Jan 05, 1996	Nov CAHN
>D>		EQ 500MG BASE	N020353	002	Jan 05, 1996	Nov CAHN
>D>	+	EQ 750MG BASE	N020353	003	Jan 05, 1996	Nov CAHN

NARATRIPTAN HYDROCHLORIDE

TABLET;ORAL

AMERGE

AB	GLAXOSMITHKLINE LLC	EQ 1MG BASE	N020763	002	Feb 10, 1998	Mar CAHN
AB	+	EQ 2.5MG BASE	N020763	001	Feb 10, 1998	Mar CAHN

NELFINAVIR MESYLATE

POWDER;ORAL

VIRACEPT

@ AGOURON

EQ 50MG BASE/SCOOPFUL

N020778 001 Mar 14, 1997 Jun DISC

NEOMYCIN SULFATEPOWDER;FOR RX COMPOUNDING
NEO-RX

@ X GEN PHARMS	100%	A061579	001		Mar	DISC
----------------	------	---------	-----	--	-----	------

NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATESUSPENSION/DROPS;OPHTHALMIC
POLY-PRED

@ ALLERGAN	EQ 0.35% BASE;10,000 UNITS/ML;0.5%	N050081	002		May	DISC
------------	------------------------------------	---------	-----	--	-----	------

NEOSTIGMINE METHYLSULFATESOLUTION;INTRAVENOUS
BLOXIVERZ

+	ECLAT PHARMS LLC	5MG/10ML (0.5MG/ML)	N204078	001	May 31, 2013	May NEWA
+		10MG/10ML (1MG/ML)	N204078	002	May 31, 2013	May NEWA

NEPAFENACSUSPENSION/DROPS;OPHTHALMIC
ILEVRO

+	ALCON RES LTD	0.3%	N203491	001	Oct 16, 2012	Aug CTNA
---	---------------	------	---------	-----	--------------	----------

NESIRITIDE RECOMBINANTFOR SOLUTION;INTRAVENOUS
NATRECOR

>D>	+	SCIOS	1.5MG/VIAL	N020920	001	Aug 10, 2001	Nov CAHN
>A>	+	SCIOS LLC	1.5MG/VIAL	N020920	001	Aug 10, 2001	Nov CAHN

NIACINTABLET, EXTENDED RELEASE;ORAL
NIACIN

AB		BARR	1GM	A076250	001	Apr 14, 2005	Aug CMFD
AB			500MG	A076378	001	Apr 26, 2005	Aug CMFD
AB			750MG	A076378	002	Apr 26, 2005	Aug CMFD
		NIASPAN					
AB	+	ABBVIE	1GM	N020381	004	Jul 28, 1997	Oct CTEC
AB			500MG	N020381	002	Jul 28, 1997	Oct CTEC
AB	+		750MG	N020381	003	Jul 28, 1997	Oct CTEC

NIFEDIPINECAPSULE;ORAL
NIFEDIPINE

AB		ACTAVIS ELIZABETH	20MG	A072556	001	Sep 20, 1990	Apr CTEC
		@ CATALENT	10MG	A073250	001	Oct 08, 1991	Apr DISC
AB		EMCURE PHARMS USA	10MG	A202644	001	Apr 25, 2013	Apr NEWA
AB			20MG	A202644	002	Apr 25, 2013	Apr NEWA

NILUTAMIDETABLET;ORAL
NILANDRON

@ COVIS PHARMA SARL	50MG	N020169	001	Sep 19, 1996	Apr CAHN
+	150MG	N020169	002	Apr 30, 1999	Apr CAHN

NIMODIPINECAPSULE;ORAL
NIMODIPINE

AB	+	BANNER PHARMACAPS	30MG	A076740	001	Jan 17, 2008	Jul CRLD
AB		SUN PHARM INDS INC	30MG	A077067	001	Apr 17, 2007	Jul CRLD
		SOLUTION;ORAL					
		NYMALIZE					
+	ARBOR PHARMS INC	60MG/20ML	N203340	001	May 10, 2013	May NEWA	

NISOLDIPINETABLET, EXTENDED RELEASE;ORAL
NISOLDIPINE

MYLAN	20MG	A079051	001	Jul 25, 2008	Jul CRLD
	25.5MG	A091001	003	Jan 26, 2011	Oct CTEC
SULAR					
@ SHIONOGI INC	25.5MG	N020356	006	Jan 02, 2008	Oct DISC

NITISINONECAPSULE;ORAL
ORFADIN

SWEDISH ORPHAN

2MG

N021232 001 Jan 18, 2002 May CAHN

5MG

N021232 002 Jan 18, 2002 May CAHN

+

10MG

N021232 003 Jan 18, 2002 May CAHN

NITROFURANTOINSUSPENSION;ORAL
NITROFURANTOIN

AB

CARACO

25MG/5ML

A201355 001 Aug 14, 2013 Jul NEWA

NITROFURANTOIN, MACROCRYSTALLINECAPSULE;ORAL
MACRODANTIN

ALVOGEN INC

25MG

N016620 003 Mar CTEC

AB

25MG

N016620 003 Feb CAHN

AB

50MG

N016620 001 Feb CAHN

AB

+

100MG

N016620 002 Feb CAHN

NITROFURANTOIN

@ WATSON LABS

25MG

A073696 001 Dec 31, 1992 Mar DISC

@

50MG

A073696 002 Dec 31, 1992 Mar DISC

@

100MG

A073696 003 Dec 31, 1992 Mar DISC

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINECAPSULE;ORAL
MACROBID

AB

+

ALVOGEN INC

75MG;25MG

N020064 001 Dec 24, 1991 Mar CAHN

NITROGLYCERINFILM, EXTENDED RELEASE;TRANSDERMAL
NITRO-DUR

AB1

+

MERCK SHARP DOHME

0.1MG/HR

N020145 001 Apr 04, 1995 Mar CAHN

AB1

+

0.2MG/HR

N020145 002 Apr 04, 1995 Mar CAHN

+

0.3MG/HR

N020145 003 Apr 04, 1995 Mar CAHN

AB1

+

0.4MG/HR

N020145 004 Apr 04, 1995 Mar CAHN

AB1

+

0.6MG/HR

N020145 005 Apr 04, 1995 Mar CAHN

+

0.8MG/HR

N020145 006 Apr 04, 1995 Mar CAHN

INJECTABLE;INJECTION
NITROGLYCERIN

@ HOSPIRA

5MG/ML

N018531 001 Jul DISC

+ LUITPOLD

5MG/ML

A072034 001 May 24, 1988 Jul CTEC

SPRAY, METERED;SUBLINGUAL
NITROGLYCERIN

AB

PERRIGO ISRAEL

0.4MG/SPRAY

A091496 001 Sep 20, 2013 Sep NEWA

NITROLINGUAL PUMPSPRAY

AB

+

POHL BOSKAMP

0.4MG/SPRAY

N018705 002 Jan 10, 1997 Sep CFTG

NIZATIDINECAPSULE;ORAL
NIZATIDINE

@ APOTEX INC

150MG

A076383 001 Jan 23, 2003 Feb DISC

@

300MG

A076383 002 Jan 23, 2003 Feb DISC

NOREPINEPHRINE BITARTRATEINJECTABLE;INJECTION
NOREPINEPHRINE BITARTRATE

AP

TEVA PHARMS USA

EQ 1MG BASE/ML

A040455 001 Mar 03, 2003 May CAHN

NORETHINDRONETABLET;ORAL
NORETHINDRONE

AB1

HAUPT PHARMA

0.35MG

A202260 001 Aug 01, 2013 Jul NEWA

TABLET;ORAL-28

JENCYCLA

AB2

LUPIN LTD

0.35MG

A091323 001 Mar 28, 2013 Apr CTEC

AB

0.35MG

A091323 001 Mar 28, 2013 Mar NEWA

NORETHINDRONE

AB2

FAMY CARE LTD

0.35MG

A200980 001 Jun 12, 2013 May NEWA

AB1

0.35MG

A201483 001 Jun 24, 2013 Jun NEWA

AB1

HAUPT PHARMA

0.35MG

A202260 001 Aug 01, 2013 Aug CDFR

TABLET;ORAL-28

NORETHINDRONE

AB2	NOVAST LABS	0.35MG	A200961	001	Sep 13, 2013	Aug NEWA
AB1	NOVAST LABS LTD	0.35MG	A202014	001	Sep 13, 2013	Aug NEWA

NORETHINDRONE ACETATE

TABLET;ORAL

NORETHINDRONE ACETATE

AB	AMNEAL PHARMS	5MG	A200275	001	Jul 30, 2012	Sep CTNA
----	---------------	-----	---------	-----	--------------	----------

NYSTATIN

SUSPENSION;ORAL

NILSTAT

@	GLENMARK GENERICS	100,000 UNITS/ML	N050299	001		Feb DISC
---	-------------------	------------------	---------	-----	--	----------

OCTREOTIDE ACETATE

INJECTABLE;INJECTION

OCTREOTIDE ACETATE

AP	SAGENT PHARMS	EQ 0.2MG BASE/ML	A091041	001	Nov 12, 2013	Oct NEWA
AP		EQ 1MG BASE/ML	A091041	002	Nov 12, 2013	Oct NEWA
AP	TEVA PHARMS USA	EQ 0.05MG BASE/ML	A075957	001	Oct 03, 2005	May CAHN
AP		EQ 0.1MG BASE/ML	A075957	002	Oct 03, 2005	May CAHN
AP		EQ 0.2MG BASE/ML	A075959	001	Nov 21, 2005	May CAHN
AP		EQ 0.5MG BASE/ML	A075957	003	Oct 03, 2005	May CAHN
AP		EQ 1MG BASE/ML	A075959	002	Nov 21, 2005	May CAHN
	OCTREOTIDE ACETATE (PRESERVATIVE FREE)					
AP	SAGENT PHARMS	EQ 0.05MG BASE/ML	A090834	001	Nov 12, 2013	Oct NEWA
AP		EQ 0.1MG BASE/ML	A090834	002	Nov 12, 2013	Oct NEWA
AP		EQ 0.5MG BASE/ML	A090834	003	Nov 12, 2013	Oct NEWA

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

OFLOXACIN

AT	ALTAIRE PHARMS INC	0.3%	A202692	001	Apr 29, 2013	Apr NEWA
	@ APOTEX INC	0.3%	A076513	001	May 14, 2004	Apr DISC

OLIVE OIL; SOYBEAN OIL

INJECTABLE;INJECTION

CLINOLIPID 20%

+	BAXTER HLTHCARE	16% (160GM/1000ML); 4% (40GM/1000ML)	N204508	001	Oct 03, 2013	Oct NEWA
---	-----------------	--------------------------------------	---------	-----	--------------	----------

OMEPRAZOLE; SODIUM BICARBONATE

FOR SUSPENSION;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AB	PAR PHARM	20MG/PACKET;1.68GM/PACKET	A079182	001	Apr 19, 2013	Apr NEWA
AB		40MG/PACKET;1.68GM/PACKET	A079182	002	Apr 19, 2013	Apr NEWA
	ZEGERID					
AB	SANTARUS	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Apr CFTG
AB	+	40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Apr CFTG

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE

>A>	AP	AGILA SPECLTS	EQ 2MG BASE/ML	A078257	001	Apr 23, 2008	Nov CAHN
		@ APOTEX INC	EQ 2MG BASE/ML	A077368	001	Dec 26, 2006	Apr DISC
	AP	CLARIS LIFESCIENCES	EQ 2MG BASE/ML	A078288	001	Feb 22, 2013	Jul CPOT
	AP		2MG/ML	A078288	001	Feb 22, 2013	Feb NEWA
		@ LUITPOLD	EQ 2MG BASE/ML	A077582	001	Dec 26, 2006	Mar DISC
>D>	AP	PFIZER	EQ 2MG BASE/ML	A078257	001	Apr 23, 2008	Nov CAHN
		@ PLIVA HRVATSKA DOO	EQ 2MG BASE/ML	A077544	001	Dec 26, 2006	Feb DISC
	ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER						
		@ CLARIS LIFESCIENCES	EQ 0.64MG BASE/ML	A078308	001	Mar 17, 2008	Jan DISC
		@ HOSPIRA	EQ 0.64MG BASE/ML	A077348	001	Feb 01, 2007	Jan DISC
	ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE						
>A>	AP	AGILA SPECLTS	EQ 2MG BASE/ML	A078244	001	Apr 23, 2008	Nov CAHN
		@ APOTEX INC	EQ 2MG BASE/ML	A077343	001	Dec 26, 2006	Apr DISC
	AP	BD RX	EQ 2MG BASE/ML	A202253	001	Jul 19, 2013	Jul NEWA
	AP	CLARIS LIFESCIENCES	EQ 2MG BASE/ML	A078287	001	Feb 22, 2013	Jul CPOT
	AP		2MG/ML	A078287	001	Feb 22, 2013	Feb NEWA
		@ LUITPOLD	EQ 2MG BASE/ML	A077387	001	Dec 26, 2006	Mar DISC
>D>	AP	PFIZER	EQ 2MG BASE/ML	A078244	001	Apr 23, 2008	Nov CAHN

TABLET;ORAL									
ONDANSETRON HYDROCHLORIDE									
	@ TARO	EQ 4MG BASE	A077729	001	Mar 28, 2011	Sep	DISC		
	@	EQ 8MG BASE	A077729	002	Mar 28, 2011	Sep	DISC		
	@	EQ 24MG BASE	A077729	003	Mar 28, 2011	Sep	DISC		
<u>ORPHENADRINE CITRATE</u>									
TABLET, EXTENDED RELEASE;ORAL									
ORPHENADRINE CITRATE									
AB	TEDOR PHARMA INC	100MG	A040249	001	Jan 29, 1999	Oct	CAHN		
<u>OSPEMIFENE</u>									
TABLET;ORAL									
OSPHERA									
+	SHIONOGI INC	60MG	N203505	001	Feb 26, 2013	Feb	NEWA		
<u>OXACILLIN SODIUM</u>									
INJECTABLE;INJECTION									
OXACILLIN SODIUM									
AP	AUROBINDO PHARMA LTD	EQ 1GM BASE/VIAL	A201539	001	Jan 18, 2013	Jan	NEWA		
AP		EQ 2GM BASE/VIAL	A201539	002	Jan 18, 2013	Jan	NEWA		
AP		EQ 10GM BASE/VIAL	A201538	001	Jan 18, 2013	Jan	NEWA		
<u>OXAPROZIN</u>									
TABLET;ORAL									
OXAPROZIN									
>D>	@ CARACO	600MG	A075844	001	Jan 03, 2002	Nov	CMFD		
>A>	AB	600MG	A075844	001	Jan 03, 2002	Nov	CMFD		
	@	600MG	A075844	001	Jan 03, 2002	Jan	DISC		
<u>OXAZEPAM</u>									
CAPSULE;ORAL									
OXAZEPAM									
AB	+ ACTAVIS ELIZABETH	30MG	A072253	001	Apr 14, 1988	Jul	CRLD		
AB	IVAX SUB TEVA PHARMS	30MG	A070945	001	Aug 03, 1987	Jul	CRLD		
<u>OXCARBAZEPINE</u>									
TABLET;ORAL									
OXCARBAZEPINE									
	@ TEVA PHARMS USA	150MG	A078005	001	Dec 11, 2007	Mar	DISC		
	@	300MG	A078005	002	Dec 11, 2007	Mar	DISC		
	@	600MG	A078005	003	Dec 11, 2007	Mar	DISC		
<u>OXYBUTYNIN</u>									
GEL, METERED;TRANSDERMAL									
GELNIQUE 3%									
+	WATSON LABS INC	3%	N202513	001	Dec 07, 2011	Jun	CTNA		
<u>OXYBUTYNIN CHLORIDE</u>									
SYRUP;ORAL									
OXYBUTYNIN CHLORIDE									
	@ APOTEX INC	5MG/5ML	A074997	001	Oct 15, 1997	Apr	DISC		
	@ MIKART	5MG/5ML	A075039	001	Jan 29, 1999	Jun	DISC		
TABLET;ORAL									
OXYBUTYNIN CHLORIDE									
AB	TEVA PHARMS USA	5MG	A071655	001	Nov 14, 1988	Mar	CAHN		
<u>OXYCODONE HYDROCHLORIDE</u>									
SOLUTION;ORAL									
OXYCODONE HYDROCHLORIDE									
AA	ROXANE	5MG/5ML	A204037	001	Jul 15, 2013	Jul	NEWA		
AA		100MG/5ML	A203208	001	Jul 12, 2013	Jul	NEWA		
AA	+ VISTAPHARM	5MG/5ML	N201194	001	Jan 12, 2012	Jul	CTEC		
TABLET;ORAL									
OXYCODONE HYDROCHLORIDE									
AB	NESHER PHARMS	5MG	A077290	001	Dec 08, 2005	Jun	CMFD		
	@	5MG	A077290	001	Dec 08, 2005	Mar	DISC		
AB		10MG	A077290	002	Dec 08, 2005	Jun	CMFD		
	@	10MG	A077290	002	Dec 08, 2005	Mar	DISC		
AB		15MG	A077290	003	Dec 08, 2005	Jun	CMFD		
	@	15MG	A077290	003	Dec 08, 2005	Mar	DISC		
AB		20MG	A077290	004	Dec 08, 2005	Jun	CMFD		

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

	@	20MG	A077290	004	Dec 08, 2005	Mar DISC
AB		30MG	A077290	005	Dec 08, 2005	Jun CMFD
	@	30MG	A077290	005	Dec 08, 2005	Mar DISC

OXYMORPHONE HYDROCHLORIDE

TABLET;ORAL

OXYMORPHONE HYDROCHLORIDE

AB	AVANTHI INC	5MG	A203601	001	Jan 30, 2013	Jan NEWA
AB		10MG	A203601	002	Jan 30, 2013	Jan NEWA
AB	MALLINCKRODT INC	5MG	A202321	001	Apr 25, 2013	Apr NEWA
AB		10MG	A202321	002	Apr 25, 2013	Apr NEWA

TABLET, EXTENDED RELEASE;ORAL

OXYMORPHONE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	5MG	A079046	003	Jul 11, 2013	Jul NEWA
AB		7.5MG	A079046	001	Dec 13, 2010	Apr CAHN
AB		10MG	A079046	004	Jul 11, 2013	Jul NEWA
AB		15MG	A079046	002	Dec 13, 2010	Apr CAHN
AB		20MG	A079046	005	Jul 11, 2013	Jul NEWA
AB		30MG	A079046	006	Jul 11, 2013	Jul NEWA
AB		40MG	A079046	007	Jul 11, 2013	Jul NEWA
AB	IMPAX LABS	5MG	A079087	001	Jun 14, 2010	Jul CTEC
AB		10MG	A079087	003	Jun 14, 2010	Jul CTEC
AB		20MG	A079087	005	Jun 14, 2010	Jul CTEC
AB		30MG	A079087	006	Jul 22, 2010	Jul CTEC
AB		40MG	A079087	007	Jun 14, 2010	Jul CTEC
AB	ROXANE	5MG	A200822	002	Jul 15, 2013	Jul NEWA
AB		7.5MG	A200822	003	Jul 15, 2013	Jul NEWA
AB		10MG	A200822	004	Jul 15, 2013	Jul NEWA
AB		15MG	A200822	005	Jul 15, 2013	Jul NEWA
AB		20MG	A200822	006	Jul 15, 2013	Jul NEWA
AB		30MG	A200822	007	Jul 15, 2013	Jul NEWA
AB		40MG	A200822	001	Jul 15, 2013	Jul NEWA

OXYTOCIN

INJECTABLE;INJECTION

OXYTOCIN

AP	HIKMA FARMACEUTICA	10USP UNITS/ML (10USP UNITS/ML)	A200219	001	Feb 13, 2013	Jan NEWA
	@ TEVA PHARMS USA	10USP UNITS/ML (10USP UNITS/ML)	A077453	001	Jan 24, 2008	May CAHN
	@	100USP UNITS/10ML (10USP UNITS/ML)	A077453	002	Jan 24, 2008	May CAHN

PACLITAXEL

INJECTABLE;INJECTION

PACLITAXEL

	@ ACCORD HLTHCARE	6MG/ML	A075436	001	Nov 12, 2004	Apr DISC
	@ TEVA PHARMS USA	6MG/ML	A075297	001	Jan 25, 2002	May CAHN
	TAXOL					
AP	HQ SPCLT PHARMA	6MG/ML	N020262	001	Dec 29, 1992	Apr CMFD
	@	6MG/ML	N020262	001	Dec 29, 1992	Jan CAHN

PAMIDRONATE DISODIUM

INJECTABLE;INJECTION

PAMIDRONATE DISODIUM

>A>	AP	AGILA SPECLTS	30MG/10ML (3MG/ML)	A078520	001	Oct 31, 2008	Nov CAHN
>A>	AP		90MG/10ML (9MG/ML)	A078520	002	Oct 31, 2008	Nov CAHN
>D>	AP	PFIZER	30MG/10ML (3MG/ML)	A078520	001	Oct 31, 2008	Nov CAHN
>D>	AP		90MG/10ML (9MG/ML)	A078520	002	Oct 31, 2008	Nov CAHN
	AP	TEVA PHARMS USA	30MG/10ML (3MG/ML)	A076153	001	Mar 27, 2002	Mar CAHN
	AP		90MG/10ML (9MG/ML)	A076153	002	Mar 27, 2002	Mar CAHN

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE;ORAL

CREON

	ABBVIE	180,000USP UNITS;36,000USP UNITS;114,000USP UNITS	N020725	005	Mar 14, 2013	Mar NEWA
--	--------	---	---------	-----	--------------	----------

PANCURONIUM BROMIDE

INJECTABLE; INJECTION
PANCURONIUM BROMIDE

AP	+	TEVA PHARMS USA	1MG/ML	A072759	001	Jul 31, 1990	May CAHN
AP	+		2MG/ML	A072760	001	Jul 31, 1990	Mar CAHN

PARICALCITOL

CAPSULE; ORAL
PARICALCITOL

AB		TEVA PHARMS USA	1MCG	A090829	001	Sep 27, 2013	Sep NEWA
AB			2MCG	A090829	002	Sep 27, 2013	Sep NEWA
AB			4MCG	A090829	003	Sep 27, 2013	Sep NEWA
		ZEMPLAR					
AB		ABBVIE	1MCG	N021606	001	May 26, 2005	Sep CFTG
AB			2MCG	N021606	002	May 26, 2005	Sep CFTG
AB	+		4MCG	N021606	003	May 26, 2005	Sep CFTG

PAROXETINE HYDROCHLORIDE

SUSPENSION; ORAL
PAROXETINE HYDROCHLORIDE

@	APOTEX INC	EQ 10MG BASE/5ML	A077395	001	Dec 05, 2006	Apr DISC
---	------------	------------------	---------	-----	--------------	----------

PAROXETINE MESYLATE

CAPSULE; ORAL
BRISDELLE

+	NOVEN THERAP	EQ 7.5MG BASE	N204516	001	Jun 28, 2013	Jun NEWA
---	--------------	---------------	---------	-----	--------------	----------

PEGINESATIDE ACETATE

SOLUTION; INTRAVENOUS, SUBCUTANEOUS
OMONTYS

@	TAKEDA PHARMS USA	EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799	007	Mar 27, 2012	May DISC
+		EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799	007	Mar 27, 2012	Apr CAHN
@		EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799	008	Mar 27, 2012	May DISC
+		EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799	008	Mar 27, 2012	Apr CAHN
	OMONTYS PRESERVATIVE FREE					
@	TAKEDA PHARMS USA	EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799	001	Mar 27, 2012	May DISC
+		EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799	001	Mar 27, 2012	Apr CAHN
@		EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799	002	Mar 27, 2012	May DISC
+		EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799	002	Mar 27, 2012	Apr CAHN
@		EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N202799	003	Mar 27, 2012	May DISC
+		EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N202799	003	Mar 27, 2012	Apr CAHN
@		EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	N202799	004	Mar 27, 2012	May DISC
+		EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	N202799	004	Mar 27, 2012	Apr CAHN
@		EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	N202799	005	Mar 27, 2012	May DISC
+		EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	N202799	005	Mar 27, 2012	Apr CAHN
@		EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	N202799	006	Mar 27, 2012	May DISC
+		EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	N202799	006	Mar 27, 2012	Apr CAHN

PENICILLIN V POTASSIUM

TABLET; ORAL
PENICILLIN V POTASSIUM

AB		HIKMA PHARMS	EQ 250MG BASE	A090549	001	Oct 11, 2013	Sep NEWA
AB			EQ 500MG BASE	A090549	002	Oct 11, 2013	Sep NEWA

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
PHENYLEPHRINE HYDROCHLORIDE

	PARAGON BIOTECK	2.5%	N203510	001	Mar 21, 2013	Mar NEWA
+		10%	N203510	002	Mar 21, 2013	Mar NEWA

PHENYTOIN SODIUM

INJECTABLE; INJECTION

PHENYTOIN SODIUM

@ HOSPIRA

50MG/ML

A089744 001 Dec 18, 1987 Mar DISC

PHYTONADIONE

TABLET; ORAL

MEPHYTON

+ VALEANT PHARMS

5MG

N010104 003 Jun CAHN

PINDOLOL

TABLET; ORAL

PINDOLOL

MYLAN PHARMS INC

5MG

A074019 001 Sep 03, 1992 Jun CTEC

+

10MG

A074019 002 Sep 03, 1992 Jun CTEC

@ WATSON LABS

5MG

A074437 001 Feb 27, 1995 Jun DISC

@

10MG

A074437 002 Feb 27, 1995 Jun DISC

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE

AB ACCORD HLTHCARE EQ 15MG BASE A200044 001 Feb 13, 2013 Jan NEWA

AB EQ 30MG BASE A200044 002 Feb 13, 2013 Jan NEWA

AB EQ 45MG BASE A200044 003 Feb 13, 2013 Jan NEWA

AB AUROBINDO PHARMA LTD EQ 15MG BASE A200268 001 Feb 13, 2013 Jan NEWA

AB EQ 30MG BASE A200268 002 Feb 13, 2013 Jan NEWA

AB EQ 45MG BASE A200268 003 Feb 13, 2013 Jan NEWA

AB DR REDDYS LABS LTD EQ 15MG BASE A078383 001 Mar 12, 2013 Mar NEWA

AB EQ 30MG BASE A078383 002 Mar 12, 2013 Mar NEWA

AB EQ 45MG BASE A078383 003 Mar 12, 2013 Mar NEWA

AB MACLEODS PHARMS LTD EQ 15MG BASE A202467 001 Feb 06, 2013 Jan NEWA

AB EQ 30MG BASE A202467 002 Feb 06, 2013 Jan NEWA

AB EQ 45MG BASE A202467 003 Feb 06, 2013 Jan NEWA

AB SANDOZ EQ 15MG BASE A078670 001 Feb 13, 2013 Jan NEWA

AB EQ 30MG BASE A078670 002 Feb 13, 2013 Jan NEWA

AB EQ 45MG BASE A078670 003 Feb 13, 2013 Jan NEWA

AB SYNTHON PHARMS EQ 15MG BASE A078472 001 Feb 13, 2013 Jan NEWA

AB EQ 30MG BASE A078472 002 Feb 13, 2013 Jan NEWA

AB EQ 45MG BASE A078472 003 Feb 13, 2013 Jan NEWA

AB TORRENT PHARMS LTD EQ 15MG BASE A091298 001 Feb 13, 2013 Jan NEWA

AB EQ 30MG BASE A091298 002 Feb 13, 2013 Jan NEWA

AB EQ 45MG BASE A091298 003 Feb 13, 2013 Jan NEWA

AB ZYDUS PHARMS USA INC EQ 15MG BASE A202456 001 Feb 13, 2013 Jan NEWA

AB EQ 30MG BASE A202456 002 Feb 13, 2013 Jan NEWA

AB EQ 45MG BASE A202456 003 Feb 13, 2013 Jan NEWA

POLIDOCANOL

SOLUTION; INTRAVENOUS

VARITHENA

>A>

+ PROVENSIS

180MG/18ML (10MG/ML)

N205098 001 Nov 25, 2013 Nov NEWA

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

COLYTE

MEDA PHARMS

227.1GM/BOT; 2.82GM/BOT; 6.36GM/BOT; N018983 010 Jan 31, 1989 Jul CTEC

5.53GM/BOT; 21.5GM/BOT

@ 240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5. N018983 007 Jun 12, 1987 Jul DISC

84GM/BOT; 22.72GM/BOT

COLYTE WITH FLAVOR PACKS

MEDA PHARMS

240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5. N018983 012 Oct 08, 1998 Jul CTEC

84GM/BOT; 22.72GM/BOT

COLYTE-FLAVORED

@ MEDA PHARMS

227.1GM/BOT; 2.82GM/BOT; 6.36GM/BOT; N018983 008 Nov 14, 1991 Jul DISC

5.53GM/BOT; 21.5GM/BOT

@ 240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5. N018983 009 Nov 14, 1991 Jul DISC

84GM/BOT; 22.72GM/BOT

POLYMYXIN B SULFATEPOWDER;FOR RX COMPOUNDING
POLY-RX

@ X GEN PHARMS	100,000,000 UNITS/BOT	A061578	001		Mar	DISC
----------------	-----------------------	---------	-----	--	-----	------

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATESOLUTION/DROPS;OPHTHALMIC
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT	AKORN INC	10,000 UNITS/ML;EQ 1MG BASE/ML	A065006	001	Dec 17, 1998	Jul CAHN
----	-----------	--------------------------------	---------	-----	--------------	----------

POMALIDOMIDECAPSULE;ORAL
POMALYST

	CELGENE	1MG	N204026	001	Feb 08, 2013	Feb NEWA
		2MG	N204026	002	Feb 08, 2013	Feb NEWA
		3MG	N204026	003	Feb 08, 2013	Feb NEWA
+		4MG	N204026	004	Feb 08, 2013	Feb NEWA

POSACONAZOLE>A> TABLET, DELAYED RELEASE;ORAL
>A> NOXAFIL

>A>	+	MERCK SHARP DOHME	100MG	N205053	001	Nov 25, 2013	Nov NEWA
-----	---	-------------------	-------	---------	-----	--------------	----------

POTASSIUM CHLORIDECAPSULE, EXTENDED RELEASE;ORAL
POTASSIUM CHLORIDE

AB	AMNEAL PHARMS	10MEQ	A202128	001	Feb 22, 2013	Feb NEWA
----	---------------	-------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL
K-TAB

>A> BC	ABBVIE	20MEQ	N018279	003	Nov 25, 2013	Nov NEWA
--------	--------	-------	---------	-----	--------------	----------

KLOR-CON

>D> BC	UPSHER-SMITH LABS	8MEQ	N019123	001	Apr 17, 1986	Nov CTEC
--------	-------------------	------	---------	-----	--------------	----------

>A>		8MEQ	N019123	001	Apr 17, 1986	Nov CTEC
-----	--	------	---------	-----	--------------	----------

POTASSIUM CHLORIDE

>D> BC	ABBVIE	8MEQ	N018279	002	Aug 01, 1988	Nov DISC
--------	--------	------	---------	-----	--------------	----------

>A>	@	8MEQ	N018279	002	Aug 01, 1988	Nov DISC
-----	---	------	---------	-----	--------------	----------

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB	ACTAVIS GRP PTC	0.125MG	A091254	001	Nov 30, 2010	Mar CAHN
AB		0.25MG	A091254	002	Nov 30, 2010	Mar CAHN
AB		0.5MG	A091254	003	Nov 30, 2010	Mar CAHN
AB		0.75MG	A091254	004	Nov 30, 2010	Mar CAHN
AB		1MG	A091254	005	Nov 30, 2010	Mar CAHN
AB		1.5MG	A091254	006	Nov 30, 2010	Mar CAHN
AB	SUN PHARM INDS INC	0.125MG	A091683	001	Mar 27, 2013	Mar NEWA
AB		0.25MG	A091683	002	Mar 27, 2013	Mar NEWA
AB		0.5MG	A091683	003	Mar 27, 2013	Mar NEWA
AB		0.75MG	A091683	004	Mar 27, 2013	Mar NEWA
AB		1MG	A091683	005	Mar 27, 2013	Mar NEWA
AB		1.5MG	A091683	006	Mar 27, 2013	Mar NEWA

PRAMLINTIDE ACETATEINJECTABLE;SUBCUTANEOUS
SYMLINAMYLIN PHARMS EQ 2.7MG BASE/2.7ML (EQ 1MG
BASE/ML)

N021332	003	Sep 25, 2007	Jan CAHN
---------	-----	--------------	----------

+ EQ 3MG BASE/5ML (EQ 600MCG
BASE/ML)

N021332	001	Mar 16, 2005	Jan CAHN
---------	-----	--------------	----------

+ AMYLIN PHARMS LLC EQ 2.7MG BASE/2.7ML (EQ 1MG
BASE/ML)

N021332	003	Sep 25, 2007	Jun CRLD
---------	-----	--------------	----------

@ EQ 3MG BASE/5ML (EQ 600MCG
BASE/ML)

N021332	001	Mar 16, 2005	Jun DISC
---------	-----	--------------	----------

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVASTATIN SODIUM

AB	CIPLA LTD	10MG	A077904	001	Oct 23, 2006	Aug CAHN
AB		20MG	A077904	002	Oct 23, 2006	Aug CAHN
AB		40MG	A077904	003	Oct 23, 2006	Aug CAHN

PRAZIQUANTELTABLET; ORAL
BILTRICIDE

+	BAYER HLTHCARE	600MG	N018714	001	Dec 29, 1982	Jun CAHN
---	----------------	-------	---------	-----	--------------	----------

PREDNISOLONESYRUP; ORAL
PREDNISOLONE

@	APOTEX INC	5MG/5ML	A040570	001	Aug 25, 2005	Apr DISC
@		15MG/5ML	A040571	001	Aug 25, 2005	Apr DISC

PREDNISOLONE SODIUM PHOSPHATESOLUTION; ORAL
ORAPRED

AA	+	CONCORDIA PHARMS INC	EQ 15MG BASE/5ML	A075117	001	Dec 14, 2000	May CAHN
		PREDNISOLONE SODIUM PHOSPHATE					
		@ NESHER PHARMS	EQ 15MG BASE/5ML	A076988	001	May 24, 2005	May DISC
		@ PHARM ASSOC	EQ 5MG BASE/5ML	A076123	001	Dec 23, 2002	Mar DISC
		@ WE PHARMS	EQ 15MG BASE/5ML	A075250	001	Jul 12, 2002	Mar DISC

TABLET, ORALLY DISINTEGRATING; ORAL
ORAPRED ODT

AB		CONCORDIA PHARMS INC	EQ 10MG BASE	N021959	001	Jun 01, 2006	May CAHN
AB			EQ 15MG BASE	N021959	002	Jun 01, 2006	May CAHN
AB	+		EQ 30MG BASE	N021959	003	Jun 01, 2006	May CAHN
AB		SHIONOGI INC	EQ 10MG BASE	N021959	001	Jun 01, 2006	Mar CFTG
AB			EQ 15MG BASE	N021959	002	Jun 01, 2006	Mar CFTG
AB	+		EQ 30MG BASE	N021959	003	Jun 01, 2006	Mar CFTG
		PREDNISOLONE SODIUM PHOSPHATE					
AB		MYLAN PHARMS INC	EQ 10MG BASE	A202179	001	Apr 10, 2013	Mar NEWA
AB			EQ 15MG BASE	A202179	002	Apr 10, 2013	Mar NEWA
AB			EQ 30MG BASE	A202179	003	Apr 10, 2013	Mar NEWA

PREDNISONETABLET; ORAL
PREDNISONE

AB		HIKMA PHARMS	1MG	A040890	001	Nov 01, 2010	May CAHN
AB			2.5MG	A040538	001	Jan 08, 2004	May CAHN
AB			5MG	A080292	001		May CAHN
AB			10MG	A088832	001	Dec 04, 1985	May CAHN
AB			20MG	A083677	001		May CAHN
AB			50MG	A088465	001	Jun 01, 1984	May CAHN

PRIMIDONETABLET; ORAL
PRIMIDONE

@	DR REDDYS LABS LTD	50MG	A040862	001	Oct 03, 2008	Apr DISC
@		250MG	A040862	002	Oct 03, 2008	Apr DISC
@	WEST WARD	50MG	A040667	001	Jul 27, 2006	Jul DISC

PROBENECIDTABLET; ORAL
PROBENECID

@	IVAX SUB TEVA PHARMS	500MG	A083740	001	May 09, 1984	May DISC
---	----------------------	-------	---------	-----	--------------	----------

PROCHLORPERAZINE EDISYLATEINJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE

AP		EMCURE PHARMS LTD	EQ 5MG BASE/ML	A204147	001	Oct 15, 2013	Sep NEWA
----	--	-------------------	----------------	---------	-----	--------------	----------

PROGESTERONECAPSULE; ORAL
PROGESTERONE

AB		BANNER PHARMACAPS	100MG	A200900	001	Aug 16, 2013	Jul NEWA
AB			200MG	A200900	002	Aug 16, 2013	Jul NEWA
		PROMETRIUM					
AB		ABBVIE INC	100MG	N019781	001	May 14, 1998	May CAHN
AB	+		200MG	N019781	002	Oct 15, 1999	May CAHN
	@		300MG	N019781	003	Oct 15, 1999	May CAHN

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HYDROCHLORIDE

AP	+	TEVA PHARMS USA	25MG/ML	A040454	001	Aug 22, 2002	Mar CAHN
AP	+		50MG/ML	A040454	002	Aug 22, 2002	Mar CAHN

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

AA		CARACO	6.25MG/5ML	A040891	001	Mar 13, 2009	May CAHN
----	--	--------	------------	---------	-----	--------------	----------

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

AB		CARACO	12.5MG	A040863	001	Dec 30, 2008	May CAHN
AB			25MG	A040863	002	Dec 30, 2008	May CAHN
AB			50MG	A040863	003	Dec 30, 2008	May CAHN

PROPACARINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

PROPACARINE HYDROCHLORIDE

AT		AKORN INC	0.5%	A040277	001	Mar 16, 2000	Jul CAHN
----	--	-----------	------	---------	-----	--------------	----------

PROPIOMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

LARGON

>D>		@ BAXTER HLTHCARE CORP	20MG/ML	N012382	002		Nov CAHN
>A>		@ HIKMA MAPLE	20MG/ML	N012382	002		Nov CAHN

PROPOFOL

INJECTABLE; INJECTION

PROPOFOL

AB		TEVA PHARMS USA	10MG/ML	A075102	001	Jan 04, 1999	Mar CAHN
----	--	-----------------	---------	---------	-----	--------------	----------

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HYDROCHLORIDE

AB		GLATT AIR	60MG	A078065	001	Jan 26, 2007	Feb CAHN
AB			80MG	A078065	002	Jan 26, 2007	Feb CAHN
AB			120MG	A078065	003	Jan 26, 2007	Feb CAHN
AB			160MG	A078065	004	Jan 26, 2007	Feb CAHN

TABLET; ORAL

INDERAL

		@ WYETH PHARMS INC	10MG	N016418	001		Jul CAHN
		@	20MG	N016418	003		Jul CAHN
AB			40MG	N016418	002		Jul CAHN
AB			60MG	N016418	009	Oct 18, 1982	Jul CAHN
AB	+		80MG	N016418	004		Jul CAHN
		@	90MG	N016418	010	Oct 18, 1982	Jul CAHN

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

VIVACTIL

		@ TEVA WOMENS	5MG	N016012	001		Mar CAHN
		@	10MG	N016012	002		Mar CAHN

PYRIDOSTIGMINE BROMIDE

TABLET; ORAL

PYRIDOSTIGMINE BROMIDE

>D>	AB	COREPHARMA	60MG	A040457	001	Dec 26, 2002	Nov DISC
>A>		@	60MG	A040457	001	Dec 26, 2002	Nov DISC

PRIMETHAMINE

TABLET; ORAL

DARAPRIM

	+	AMEDRA PHARMS	25MG	N008578	001		Apr CAHN
--	---	---------------	------	---------	-----	--	----------

QUAZEPAM

TABLET; ORAL

DORAL

		@ SCIECURE PHARMA INC	7.5MG	N018708	003	Feb 26, 1987	Jun CAHN
	+		15MG	N018708	001	Dec 27, 1985	Jun CAHN

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

AB	ACCORD HLTHCARE	EQ 25MG BASE	A202152	001	Mar 27, 2012	Apr CAHN
AB		EQ 50MG BASE	A202152	002	Mar 27, 2012	Apr CAHN
AB		EQ 100MG BASE	A202152	003	Mar 27, 2012	Apr CAHN
AB		EQ 200MG BASE	A202152	004	Mar 27, 2012	Apr CAHN
AB		EQ 300MG BASE	A202152	005	Mar 27, 2012	Apr CAHN
AB		EQ 400MG BASE	A202152	006	Mar 27, 2012	Apr CAHN
AB	ACTAVIS GRP PTC	EQ 25MG BASE	A201762	001	Feb 27, 2013	May CAHN
AB		EQ 50MG BASE	A201762	002	Feb 27, 2013	May CAHN
AB		EQ 100MG BASE	A201762	003	Feb 27, 2013	May CAHN
AB		EQ 150MG BASE	A201762	004	Feb 27, 2013	May CAHN
AB		EQ 200MG BASE	A201762	005	Feb 27, 2013	May CAHN
AB		EQ 300MG BASE	A201762	006	Feb 27, 2013	May CAHN
AB		EQ 400MG BASE	A201762	007	Feb 27, 2013	May CAHN
AB	ACTAVIS PHARMA	EQ 25MG BASE	A201762	001	Feb 27, 2013	Feb NEWA
AB		EQ 50MG BASE	A201762	002	Feb 27, 2013	Feb NEWA
AB		EQ 100MG BASE	A201762	003	Feb 27, 2013	Feb NEWA
AB		EQ 150MG BASE	A201762	004	Feb 27, 2013	Feb NEWA
AB		EQ 200MG BASE	A201762	005	Feb 27, 2013	Feb NEWA
AB		EQ 300MG BASE	A201762	006	Feb 27, 2013	Feb NEWA
AB		EQ 400MG BASE	A201762	007	Feb 27, 2013	Feb NEWA
AB	ALKEM LABS LTD	EQ 25MG BASE	A201504	001	Feb 12, 2013	Jan NEWA
AB		EQ 50MG BASE	A201504	002	Feb 12, 2013	Jan NEWA
AB		EQ 100MG BASE	A201504	003	Feb 12, 2013	Jan NEWA
AB		EQ 150MG BASE	A201504	004	Feb 12, 2013	Jan NEWA
AB		EQ 200MG BASE	A201504	005	Feb 12, 2013	Jan NEWA
AB		EQ 300MG BASE	A201504	006	Feb 12, 2013	Jan NEWA
AB		EQ 400MG BASE	A201504	007	Feb 12, 2013	Jan NEWA
>A> AB	JUBILANT LIFE	EQ 25MG BASE	A203150	001	Nov 26, 2013	Nov NEWA

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

	@ APOTEX INC	EQ 5MG BASE	A076240	001	Jan 26, 2006	Mar DISC
	@	EQ 10MG BASE	A076240	002	Jan 26, 2006	Mar DISC
	@	EQ 20MG BASE	A076240	003	Jan 26, 2006	Mar DISC
	@	EQ 40MG BASE	A076240	004	Jan 26, 2006	Mar DISC
AB	AUROBINDO PHARMA LTD	EQ 5MG BASE	A202725	001	Apr 29, 2013	Apr NEWA
AB		EQ 10MG BASE	A202725	002	Apr 29, 2013	Apr NEWA
AB		EQ 20MG BASE	A202725	003	Apr 29, 2013	Apr NEWA
AB		EQ 40MG BASE	A202725	004	Apr 29, 2013	Apr NEWA
	@ MYLAN	EQ 5MG BASE	A076036	001	Jan 28, 2005	Aug DISC
	@	EQ 10MG BASE	A076036	002	Jan 28, 2005	Aug DISC
	@	EQ 20MG BASE	A076036	003	Jan 28, 2005	Aug DISC
	@	EQ 40MG BASE	A076036	004	Jan 28, 2005	Aug DISC

RABEPRAZOLE SODIUM

CAPSULE, DELAYED RELEASE; ORAL

ACIPHEX SPRINKLE

	EISAI INC	5MG	N204736	001	Mar 26, 2013	Mar NEWA
+		10MG	N204736	002	Mar 26, 2013	Mar NEWA

TABLET, DELAYED RELEASE; ORAL

ACIPHEX

AB	+ EISAI INC	20MG	N020973	002	Aug 19, 1999	Oct CFTG
	RABEPRAZOLE SODIUM					
AB	DR REDDYS LABS LTD	20MG	A076824	001	Nov 08, 2013	Oct NEWA
AB	KREMERS URBAN DEV	20MG	A090678	001	Nov 08, 2013	Oct NEWA
AB	LUPIN LTD	20MG	A078964	001	Nov 08, 2013	Oct NEWA
AB	MYLAN PHARMS INC	20MG	A076885	001	Nov 08, 2013	Oct NEWA
AB	TEVA PHARMS USA	20MG	A076822	001	Nov 08, 2013	Oct NEWA
AB	TORRENT PHARMS LTD	20MG	A202376	001	Nov 08, 2013	Oct NEWA

RADIUM RA-223 DICHLORIDE

SOLUTION; INTRAVENOUS

XOFIGO

+	BAYER HLTHCARE	162MCI/6ML (27MCI/ML)	N203971	001	May 15, 2013	May NEWA
---	----------------	-----------------------	---------	-----	--------------	----------

RAMELTEON

TABLET; ORAL							
RAMELTEON							
AB	TEVA PHARMS USA	8MG	A091693	001	Jul 26, 2013	Jul	NEWA
ROZEREM							
AB	+ TAKEDA PHARMS USA	8MG	N021782	001	Jul 22, 2005	Jul	CFTG

RAMIPRIL

CAPSULE; ORAL							
RAMIPRIL							
	@ CIPLA	1.25MG	A077004	001	Aug 07, 2008	Jul	DISC
	@	2.5MG	A077004	002	Aug 07, 2008	Jul	DISC
	@	5MG	A077004	003	Aug 07, 2008	Jul	DISC
	@	10MG	A077004	004	Aug 07, 2008	Jul	DISC

RANITIDINE HYDROCHLORIDE

GRANULE, EFFERVESCENT; ORAL							
ZANTAC 150							
	@ GLAXO GRP LTD	EQ 150MG BASE/PACKET	N020251	002	Mar 31, 1994	Jun	CAHN
INJECTABLE; INJECTION							
RANITIDINE HYDROCHLORIDE							
AP	ZYDUS PHARMS USA INC	25MG/ML	A091534	001	Feb 22, 2013	Feb	NEWA
ZANTAC IN PLASTIC CONTAINER							
	@ COVIS PHARMA SARL	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991	Jun	DISC
SYRUP; ORAL							
RANITIDINE HYDROCHLORIDE							
	@ APOTEX INC	EQ 15MG BASE/ML	A077602	001	Sep 17, 2007	Apr	DISC
AA	BIO PHARM INC	EQ 15MG BASE/ML	A090102	001	May 26, 2009	Apr	CAHN
AA	BRECKENRIDGE PHARM	EQ 15MG BASE/ML	A078684	001	Aug 27, 2009	Sep	CAHN
AA	CARACO	EQ 15MG BASE/ML	A091091	001	Sep 20, 2011	Apr	CAHN
ZANTAC							
AA	+ GLAXO GRP LTD	EQ 15MG BASE/ML	N019675	001	Dec 30, 1988	Jun	CAHN
TABLET; ORAL							
RANITIDINE HYDROCHLORIDE							
	@ WATSON LABS	EQ 150MG BASE	A074864	001	Oct 20, 1997	Jan	DISC
	@	EQ 300MG BASE	A074864	002	Oct 20, 1997	Jan	DISC
	@ WATSON LABS INC	EQ 150MG BASE	A077426	001	Dec 19, 2005	Mar	DISC
	@	EQ 300MG BASE	A077426	002	Dec 19, 2005	Mar	DISC
ZANTAC 150							
AB	GLAXO GRP LTD	EQ 150MG BASE	N018703	001	Jun 09, 1983	Jun	CAHN
ZANTAC 300							
AB	+ GLAXO GRP LTD	EQ 300MG BASE	N018703	002	Dec 09, 1985	Jun	CAHN
TABLET, EFFERVESCENT; ORAL							
ZANTAC 150							
	@ GLAXO GRP LTD	EQ 150MG BASE	N020251	001	Mar 31, 1994	Jun	CAHN

RANOLAZINE

TABLET, EXTENDED RELEASE; ORAL							
RANEXA							
AB	+ GILEAD	1GM	N021526	001	Feb 12, 2007	Jul	CFTG
AB		500MG	N021526	002	Jan 27, 2006	Jul	CFTG
RANOLAZINE							
AB	LUPIN LTD	500MG	A201046	001	Jul 29, 2013	Jul	NEWA
AB		1GM	A201046	002	Jul 29, 2013	Jul	NEWA

RASAGILINE MESYLATE

TABLET; ORAL							
AZILECT							
AB	TEVA	EQ 0.5MG BASE	N021641	001	May 16, 2006	Jun	CFTG
AB	+ RASAGILINE MESYLATE	EQ 1MG BASE	N021641	002	May 16, 2006	Jun	CFTG
AB	APOTEX INC	EQ 0.5MG BASE	A201950	001	Sep 12, 2013	Aug	NEWA
AB		EQ 1MG BASE	A201950	002	Sep 12, 2013	Aug	NEWA
AB	WATSON LABS INC	EQ 0.5MG BASE	A201823	001	Jul 01, 2013	Jun	NEWA
AB		EQ 1MG BASE	A201823	002	Jul 01, 2013	Jun	NEWA

REPAGLINIDETABLET; ORAL
PRANDIN

AB	NOVO NORDISK INC	0.5MG	N020741	001	Dec 22, 1997	Jul CTEC
AB		1MG	N020741	002	Dec 22, 1997	Jul CFTG
AB	+	2MG	N020741	003	Dec 22, 1997	Jul CFTG
	REPAGLINIDE					
AB	CARACO	1MG	A077571	002	Jul 11, 2013	Jul NEWA
AB		2MG	A077571	003	Jul 11, 2013	Jul NEWA
AB	MYLAN PHARMS INC	0.5MG	A090252	001	Aug 23, 2013	Aug NEWA
AB	PADDOCK LLC	0.5MG	A201189	001	Jul 17, 2013	Jul NEWA
>A> AB	SANDOZ	0.5MG	A078555	001	Nov 22, 2013	Nov NEWA

RESERPINETABLET; ORAL
SERPALAN

@ LANNETT	0.1MG	N010124	001		May DISC
@	0.25MG	N010124	002		May DISC

RIFAMPINCAPSULE; ORAL
RIFAMPIN

AB	LUPIN PHARMS	150MG	A090034	001	Aug 21, 2013	Jul NEWA
AB		300MG	A090034	002	Aug 21, 2013	Jul NEWA
	INJECTABLE; INJECTION					
	RIFAMPIN					
>A> AP	AGILA SPECLTS	600MG/VIAL	A065421	001	May 22, 2008	Nov CAHN
>D> AP	PFIZER	600MG/VIAL	A065421	001	May 22, 2008	Nov CAHN

RILUZOLETABLET; ORAL
RILUTEK

AB	+ COVIS PHARMA SARL	50MG	N020599	001	Dec 12, 1995	Apr CAHN
	RILUZOLE					
AB	APOTEX CORP	50MG	A091300	001	Jun 18, 2013	Jun NEWA
AB	GLENMARK GENERICS	50MG	A091394	001	Jun 18, 2013	Jun NEWA
AB	MYLAN PHARMS INC	50MG	A203042	001	Jul 01, 2013	Jun NEWA
AB	SUN PHARM INDS LTD	50MG	A091417	001	Jun 18, 2013	Jun NEWA

RIMANTADINE HYDROCHLORIDETABLET; ORAL
RIMANTADINE HYDROCHLORIDE

@ COREPHARMA	100MG	A075916	001	Nov 02, 2001	Feb DISC
--------------	-------	---------	-----	--------------	----------

RIOCIGUATTABLET; ORAL
ADEMPAS

BAYER HLTHCARE	0.5MG	N204819	001	Oct 08, 2013	Oct NEWA
	1MG	N204819	002	Oct 08, 2013	Oct NEWA
	1.5MG	N204819	003	Oct 08, 2013	Oct NEWA
	2MG	N204819	004	Oct 08, 2013	Oct NEWA
+	2.5MG	N204819	005	Oct 08, 2013	Oct NEWA

RISPERIDONESOLUTION; ORAL
RISPERIDONE

AA	BIO PHARM INC	1MG/ML	A078909	001	Jul 29, 2009	May CAHN
----	---------------	--------	---------	-----	--------------	----------

TABLET, ORALLY DISINTEGRATING; ORAL
RISPERIDONE

AB	MYLAN PHARMS INC	0.25MG	A091537	006	Feb 12, 2013	Feb NEWA
AB	PAR PHARM	0.25MG	A077494	001	Apr 30, 2009	Feb CTEC
AB	SUN PHARM INDS LTD	0.5MG	A078464	001	Apr 08, 2013	Mar NEWA
AB		1MG	A078464	002	Apr 08, 2013	Mar NEWA
AB		2MG	A078464	003	Apr 08, 2013	Mar NEWA
AB		3MG	A078464	004	Apr 08, 2013	Mar NEWA
AB		4MG	A078464	005	Apr 08, 2013	Mar NEWA

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

RIVASTIGMINE TARTRATE

AB	APOTEX INC	EQ 1.5MG BASE	A091072	001	May 16, 2013	Apr	NEWA
AB		EQ 3MG BASE	A091072	002	May 16, 2013	Apr	NEWA
AB		EQ 4.5MG BASE	A091072	003	May 16, 2013	Apr	NEWA
AB		EQ 6MG BASE	A091072	004	May 16, 2013	Apr	NEWA

RIZATRIPTAN BENZOATE

TABLET;ORAL

RIZATRIPTAN BENZOATE

AB	CIPLA LTD	EQ 5MG BASE	A077526	001	Mar 26, 2013	Mar	NEWA
AB		EQ 10MG BASE	A077526	002	Mar 26, 2013	Mar	NEWA
>A> AB	EMCURE PHARMS LTD	EQ 5MG BASE	A204090	001	Nov 26, 2013	Nov	NEWA
>A> AB		EQ 10MG BASE	A204090	002	Nov 26, 2013	Nov	NEWA
AB	INVAGEN PHARMS	EQ 5MG BASE	A204339	001	Jul 01, 2013	Jun	NEWA
AB		EQ 10MG BASE	A204339	002	Jul 01, 2013	Jun	NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

RIZATRIPTAN BENZOATE

AB	APOTEX INC	EQ 5MG BASE	A202477	001	Jul 01, 2013	Jun	NEWA
AB		EQ 10MG BASE	A202477	002	Jul 01, 2013	Jun	NEWA
AB	AUROBINDO PHARMA LTD	EQ 5MG BASE	A203062	001	Jul 01, 2013	Jun	NEWA
AB		EQ 10MG BASE	A203062	002	Jul 01, 2013	Jun	NEWA
AB	GLENMARK GENERICS	EQ 5MG BASE	A201914	001	Jul 01, 2013	Jun	NEWA
AB		EQ 10MG BASE	A201914	002	Jul 01, 2013	Jun	NEWA
AB	NATCO PHARMA LTD	EQ 5MG BASE	A203478	001	Jul 01, 2013	Jun	NEWA
AB		EQ 10MG BASE	A203478	002	Jul 01, 2013	Jun	NEWA
AB	SANDOZ	EQ 5MG BASE	A078739	001	Jul 01, 2013	Jun	NEWA
AB		EQ 10MG BASE	A078739	002	Jul 01, 2013	Jun	NEWA

ROCURONIUM BROMIDE

INJECTABLE;INJECTION

ZEMURON

AP	+ ORGANON USA INC	50MG/5ML (10MG/ML)	N020214	001	Mar 17, 1994	Jan	CAHN
	@	10MG/ML (10MG/ML)	N020214	002	Mar 17, 1994	Jan	CAHN
AP	+	100MG/10ML (10MG/ML)	N020214	003	Mar 17, 1994	Jan	CAHN

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

REQUIP

AB	+ GLAXOSMITHKLINE LLC	EQ 0.25MG BASE	N020658	001	Sep 19, 1997	Mar	CAHN
AB		EQ 0.5MG BASE	N020658	002	Sep 19, 1997	Mar	CAHN
AB		EQ 1MG BASE	N020658	003	Sep 19, 1997	Mar	CAHN
AB		EQ 2MG BASE	N020658	004	Sep 19, 1997	Mar	CAHN
AB		EQ 3MG BASE	N020658	006	Jan 27, 1999	Mar	CAHN
AB		EQ 4MG BASE	N020658	007	Jan 27, 1999	Mar	CAHN
AB		EQ 5MG BASE	N020658	005	Sep 19, 1997	Mar	CAHN

ROPINIROLE HYDROCHLORIDE

@ COREPHARMA

@

@

@

@

@

@

@

		EQ 0.25MG BASE	A078230	001	May 20, 2008	Jul	DISC
		EQ 0.5MG BASE	A078230	002	May 20, 2008	Jul	DISC
		EQ 1MG BASE	A078230	003	May 20, 2008	Jul	DISC
		EQ 2MG BASE	A078230	004	May 20, 2008	Jul	DISC
		EQ 3MG BASE	A078230	005	May 20, 2008	Jul	DISC
		EQ 4MG BASE	A078230	006	May 20, 2008	Jul	DISC
		EQ 5MG BASE	A078230	007	May 20, 2008	Jul	DISC

TABLET, EXTENDED RELEASE;ORAL

REQUIP XL

AB	+ GLAXOSMITHKLINE LLC	EQ 2MG BASE	N022008	001	Jun 13, 2008	Mar	CAHN
	@	EQ 3MG BASE	N022008	002	Jun 13, 2008	Mar	CAHN
AB		EQ 4MG BASE	N022008	003	Jun 13, 2008	Mar	CAHN
AB		EQ 6MG BASE	N022008	006	Apr 10, 2009	Mar	CAHN
AB		EQ 8MG BASE	N022008	004	Jun 13, 2008	Mar	CAHN
AB		EQ 12MG BASE	N022008	005	Oct 31, 2008	Mar	CAHN

ROPINIROLE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	EQ 2MG BASE	A090869	001	May 17, 2012	Apr	CAHN
AB		EQ 4MG BASE	A090869	002	May 17, 2012	Apr	CAHN
AB		EQ 6MG BASE	A090869	003	May 17, 2012	Apr	CAHN
AB		EQ 8MG BASE	A090869	004	May 17, 2012	Apr	CAHN
AB		EQ 12MG BASE	A090869	005	May 17, 2012	Apr	CAHN
AB	ALEMBIC LTD	EQ 2MG BASE	A202786	001	Apr 22, 2013	Apr	NEWA
AB		EQ 4MG BASE	A202786	002	Apr 22, 2013	Apr	NEWA
AB		EQ 6MG BASE	A202786	003	Apr 22, 2013	Apr	NEWA

TABLET, EXTENDED RELEASE;ORAL
ROPINIROLE HYDROCHLORIDE

AB		EQ 8MG BASE	A202786	004	Apr 22, 2013	Apr NEWA
AB		EQ 12MG BASE	A202786	005	Apr 22, 2013	Apr NEWA

ROSIGLITAZONE MALEATE

TABLET;ORAL

AVANDIA

AB	SB PHARMC	EQ 2MG BASE	N021071	002	May 25, 1999	Jan CFTG
AB		EQ 4MG BASE	N021071	003	May 25, 1999	Jan CFTG
AB	+	EQ 8MG BASE	N021071	004	May 25, 1999	Jan CFTG
ROSIGLITAZONE MALEATE						
AB	TEVA	EQ 2MG BASE	A076747	001	Jan 25, 2013	Jan NEWA
AB		EQ 4MG BASE	A076747	002	Jan 25, 2013	Jan NEWA
AB		EQ 8MG BASE	A076747	003	Jan 25, 2013	Jan NEWA

ROTIGOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL
NEUPRO

+	UCB INC	2MG/24HR	N021829	001	May 09, 2007	May CRLD
		8MG/24HR	N021829	006	Apr 02, 2012	May CRLD

SAQUINAVIR MESYLATE

TABLET;ORAL

INVIRASE

+	HOFFMAN LA ROCHE	EQ 500MG BASE	N021785	001	Dec 17, 2004	Feb CAHN
---	------------------	---------------	---------	-----	--------------	----------

SELEGILINE HYDROCHLORIDE

TABLET;ORAL

SELEGILINE HYDROCHLORIDE

@	DAVA PHARMS INC	5MG	A074641	001	Aug 02, 1996	Jan DISC
---	-----------------	-----	---------	-----	--------------	----------

SERTACONAZOLE NITRATE

CREAM;TOPICAL

ERTACZO

+	VALEANT LUXEMBOURG	2%	N021385	001	Dec 10, 2003	Jun CAHN
---	--------------------	----	---------	-----	--------------	----------

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

@	CIPLA LTD	EQ 25MG BASE	A077162	001	Feb 06, 2007	Aug CAHN
@		EQ 50MG BASE	A077162	002	Feb 06, 2007	Aug CAHN
@		EQ 100MG BASE	A077162	003	Feb 06, 2007	Aug CAHN
@	DR REDDYS LABS LTD	EQ 25MG BASE	A076442	001	Apr 30, 2007	Apr DISC
@		EQ 50MG BASE	A076442	002	Apr 30, 2007	Apr DISC
@		EQ 100MG BASE	A076442	003	Apr 30, 2007	Apr DISC

SILDENAFIL CITRATE

TABLET;ORAL

SILDENAFIL CITRATE

AB	ACTAVIS GRP PTC	EQ 20MG BASE	A200149	001	Feb 25, 2013	Apr CAHN
AB	ACTAVIS PHARMA	EQ 20MG BASE	A200149	001	Feb 25, 2013	Feb NEWA
AB	AMNEAL PHARMS	EQ 20MG BASE	A202025	001	Feb 28, 2013	Feb NEWA

>A> SIMEPREVIR

>A> CAPSULE;ORAL

>A> OLYSIO

>A>	+	JANSSEN RES AND DEV	150MG	N205123	001	Nov 22, 2013	Nov NEWA
-----	---	---------------------	-------	---------	-----	--------------	----------

SIMVASTATIN; SITAGLIPTIN PHOSPHATE

TABLET;ORAL

JUVISYNC

@	MERCK SHARP DOHME	10MG;EQ 50MG BASE	N202343	004	Sep 18, 2012	Sep DISC
@		10MG;EQ 100MG BASE	N202343	001	Oct 07, 2011	Sep DISC
@		20MG;EQ 50MG BASE	N202343	005	Sep 18, 2012	Sep DISC
@		20MG;EQ 100MG BASE	N202343	002	Oct 07, 2011	Sep DISC
@		40MG;EQ 50MG BASE	N202343	006	Sep 18, 2012	Sep DISC
@		40MG;EQ 100MG BASE	N202343	003	Oct 07, 2011	Sep DISC

SIROLIMUSSOLUTION;ORAL
RAPAMUNE

+ PF PRISM CV 1MG/ML N021083 001 Sep 15, 1999 Sep CAHN

TABLET;ORAL
RAPAMUNE

PF PRISM CV 0.5MG N021110 004 Jan 25, 2010 Sep CAHN

1MG N021110 001 Aug 25, 2000 Sep CAHN

+ 2MG N021110 002 Aug 22, 2002 Sep CAHN

@ 5MG N021110 003 Feb 23, 2004 Sep CAHN

SODIUM CHLORIDE

INJECTABLE;INJECTION

SODIUM CHLORIDE 0.9%

MEDEFIL INC 18MG/2ML (9MG/ML) N202832 002 Jan 06, 2012 Mar NEWA

22.5MG/2.5ML (9MG/ML) N202832 003 Jan 06, 2012 Mar NEWA

27MG/3ML (9MG/ML) N202832 004 Jan 06, 2012 Mar NEWA

45MG/5ML (9MG/ML) N202832 005 Jan 06, 2012 Mar NEWA

90MG/10ML (9MG/ML) N202832 006 Jan 06, 2012 Mar NEWA

SODIUM CHLORIDE 0.9%

HIKMA MAPLE 9MG/ML A201833 001 Sep 24, 2013 Sep NEWA

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

MEDEFIL INC 9MG/ML (9MG/ML) N202832 001 Jan 06, 2012 Mar CPOT

SOLUTION;IRRIGATION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE 450MG/100ML N017864 001 Jan DISC

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS

SODIUM FLUORIDE F-18

+ MCPRF 10-91.5MCI/ML A203605 001 Jun 28, 2013 Jun NEWA

SODIUM IODIDE I-123

CAPSULE;ORAL

SODIUM IODIDE I 123

@ CARDINAL HLTH 414 400uCi N018671 003 May 27, 1982 Sep DISC

SODIUM PHENYLBUTYRATE

POWDER;ORAL

BUPHENYL

AB + MEDICIS 3GM/TEASPOONFUL N020573 001 Apr 30, 1996 Mar CFTG

SODIUM PHENYLBUTYRATE

AB SIGMAPHARM LABS LLC 3GM/TEASPOONFUL A202819 001 Mar 22, 2013 Mar NEWA

SODIUM PHOSPHATE, DIBASIC ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET;ORAL

VISICOL

@ SALIX PHARMS 0.398GM;1.102GM N021097 001 Sep 21, 2000 Jul DISC

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET;ORAL

MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE

@ NOVEL LABS INC 0.398GM;1.102GM A079247 001 Dec 30, 2011 Aug DISC

OSMOPREP

+ SALIX PHARMS 0.398GM;1.102GM N021892 001 Mar 16, 2006 Aug CTEC

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE;INJECTION

SODIUM PHOSPHATES IN PLASTIC CONTAINER

+ HOSPIRA 142MG/ML;276MG/ML N018892 001 May 10, 1983 Jun CRLD

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL

KAYEXALATE

AA + COVIS PHARMA SARL 453.6GM/BOT N011287 001 Apr CAHN

SUSPENSION;ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

AA ROXANE 15GM/60ML A089049 001 Nov 17, 1986 Oct CMFD

@ 15GM/60ML A089049 001 Nov 17, 1986 Mar DISC

STAVUDINECAPSULE;ORAL
STAVUDINE

AB	HETERO LABS LTD III	15MG	A078957	001	Dec 29, 2008	Apr CAHN
AB		20MG	A078957	002	Dec 29, 2008	Apr CAHN
AB		30MG	A078957	003	Dec 29, 2008	Apr CAHN
AB		40MG	A078957	004	Dec 29, 2008	Apr CAHN

STREPTOZOCININJECTABLE;INJECTION
ZANOSAR

+	TEVA PHARMS USA	1GM/VIAL	N050577	001	May 07, 1982	Apr CAHN
---	-----------------	----------	---------	-----	--------------	----------

SUCCIMERCAPSULE;ORAL
CHEMET

+	RECORDATI RARE	100MG	N019998	002	Jan 30, 1991	May CAHN
---	----------------	-------	---------	-----	--------------	----------

>A> SUCROFERRIC OXYHYDROXIDE>A> TABLET, CHEWABLE;ORAL
>A> VELPHORO

>A>	+	VIFOR FRESENIUS	500MG	N205109	001	Nov 27, 2013	Nov NEWA
-----	---	-----------------	-------	---------	-----	--------------	----------

SULFACETAMIDE SODIUMLOTION;TOPICAL
KLARON

AB	+	VALEANT BERMUDA	10%	N019931	001	Dec 23, 1996	Feb CAHN
----	---	-----------------	-----	---------	-----	--------------	----------

OINTMENT;OPHTHALMIC
SULFACETAMIDE SODIUM

AT		PERRIGO CO TENNESSEE	10%	A080029	001		Jun CAHN
----	--	----------------------	-----	---------	-----	--	----------

SULFAMETHOXAZOLE; TRIMETHOPRIMINJECTABLE;INJECTION
SULFAMETHOXAZOLE AND TRIMETHOPRIM

+	TEVA PHARMS USA	80MG/ML;16MG/ML	A073303	001	Oct 31, 1991	Mar CAHN
---	-----------------	-----------------	---------	-----	--------------	----------

TABLET;ORAL

SULFAMETHOPRIM

@	NOVEL LABS INC	400MG;80MG	A070022	001	Feb 15, 1985	Mar DISC
---	----------------	------------	---------	-----	--------------	----------

SULFAMETHOPRIM-DS

@	NOVEL LABS INC	800MG;160MG	A070032	001	Feb 15, 1985	Mar DISC
---	----------------	-------------	---------	-----	--------------	----------

SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH

@	SANDOZ	800MG;160MG	N018598	004	May 19, 1982	Jun DISC
---	--------	-------------	---------	-----	--------------	----------

SULINDACTABLET;ORAL
SULINDAC

AB	HERITAGE PHARMS INC	150MG	A073262	002	Sep 06, 1991	Apr CMFD
AB		200MG	A073262	001	Sep 06, 1991	Apr CMFD

SUMATRIPTAN SUCCINATEINJECTABLE;SUBCUTANEOUS
SUMATRIPTAN SUCCINATE

AP	AUROBINDO PHARMA LTD	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A202758	001	Apr 23, 2013	Apr NEWA
AP	HIKMA FARMACEUTICA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A200183	001	Sep 16, 2013	Aug NEWA
AP	SAGENT AGILA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090641	001	Jul 28, 2010	Feb CAHN
AP	TEVA PHARMS USA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077907	001	Feb 06, 2009	Mar CAHN

SYSTEM;IONTOPHORESIS
ZECUITY

+	NUPATHE	EQ 6.5MG BASE/4HR	N202278	001	Jan 17, 2013	Jan NEWA
---	---------	-------------------	---------	-----	--------------	----------

TABLET;ORAL

SUMATRIPTAN SUCCINATE

AB	HIKMA PHARMS	EQ 25MG BASE	A078298	001	May 21, 2013	May NEWA
AB		EQ 50MG BASE	A078298	002	May 21, 2013	May NEWA
AB		EQ 100MG BASE	A078298	003	May 21, 2013	May NEWA
	@ MYLAN	EQ 25MG BASE	A077163	001	Nov 02, 2009	Aug DISC
	@	EQ 50MG BASE	A077163	002	Nov 02, 2009	Aug DISC
	@	EQ 100MG BASE	A077163	003	Nov 02, 2009	Aug DISC

TABLET;ORAL

SUMATRIPTAN SUCCINATE

>D>	AB	TEVA	EQ 25MG BASE	A076840	001	Feb 09, 2009	Nov DISC
>A>	@		EQ 25MG BASE	A076840	001	Feb 09, 2009	Nov DISC
>D>	AB		EQ 50MG BASE	A076840	002	Feb 09, 2009	Nov DISC
>A>	@		EQ 50MG BASE	A076840	002	Feb 09, 2009	Nov DISC
>D>	AB		EQ 100MG BASE	A076840	003	Feb 09, 2009	Nov DISC
>A>	@		EQ 100MG BASE	A076840	003	Feb 09, 2009	Nov DISC

TACROLIMUS

CAPSULE, EXTENDED RELEASE;ORAL

ASTAGRAF XL

	ASTELLAS	EQ 0.5MG BASE	N204096	001	Jul 19, 2013	Jul NEWA
		EQ 1MG BASE	N204096	002	Jul 19, 2013	Jul NEWA
+		EQ 5MG BASE	N204096	003	Jul 19, 2013	Jul NEWA
	OINTMENT;TOPICAL					
	PROTOPIC					
+	ASTELLAS	0.03%	N050777	001	Dec 08, 2000	Jun CRLD

TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

TAMSULOSIN HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	0.4MG	A202433	001	Apr 30, 2013	Apr NEWA
----	--	----------------------	-------	---------	-----	--------------	----------

TECHNETIUM TC-99M TILMANOCEPT

INJECTABLE;INJECTION

LYMPHOSEEK KIT

	+	NAVIDEA BIOPHARMS	N/A	N202207	001	Mar 13, 2013	Mar NEWA
--	---	-------------------	-----	---------	-----	--------------	----------

TENIPOSIDE

INJECTABLE;INJECTION

VUMON

	+	CORDEN PHARMA	10MG/ML	N020119	001	Jul 14, 1992	Apr CAHN
	+	HQ SPECILT PHARMA	10MG/ML	N020119	001	Jul 14, 1992	Jul CAHN

TERBINAFINE HYDROCHLORIDE

TABLET;ORAL

TERBINAFINE HYDROCHLORIDE

AB		CIPLA LTD	EQ 250MG BASE	A077137	001	Jul 02, 2007	Jul CAHN
	@	MYLAN	EQ 250MG BASE	A077136	001	Jul 02, 2007	Aug DISC

TERBUTALINE SULFATE

INJECTABLE;INJECTION

TERBUTALINE SULFATE

	@	TEVA PHARMS USA	1MG/ML	A076853	001	Jul 20, 2004	Mar CAHN
AP		UNITED BIOMEDCL	1MG/ML	A200122	001	Nov 08, 2013	Oct NEWA

TESTOSTERONE

GEL;TRANSDERMAL

TESTOSTERONE

		PERRIGO ISRAEL	25MG/2.5GM PACKET	N203098	002	Jan 31, 2013	Jan NEWA
			50MG/5GM PACKET	N203098	003	Jan 31, 2013	Jan NEWA

GEL, METERED;TRANSDERMAL

TESTOSTERONE

		PERRIGO ISRAEL	12.5MG/1.25GM ACTUATION	N203098	001	Jan 31, 2013	Jan NEWA
--	--	----------------	-------------------------	---------	-----	--------------	----------

TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION

TESTOSTERONE CYPIONATE

AO		SUN PHARM INDS LTD	100MG/ML	A201720	001	Jun 03, 2013	May NEWA
AO			200MG/ML	A201720	002	Jun 03, 2013	May NEWA

TESTOSTERONE ENANTHATE

INJECTABLE;INJECTION

DELATESTRYL

	@	ENDO PHARMS	200MG/ML	N009165	001		Jan CAHN
AO	+		200MG/ML	N009165	003		Jan CAHN

THALLOUS CHLORIDE TL-201

INJECTABLE;INTRAVENOUS
THALLOUS CHLORIDE TL 201
@ MALLINCKRODT 2mCi/ML

A077698 001 Nov 09, 2006 Aug DISC

THEOPHYLLINE

TABLET, EXTENDED RELEASE;ORAL
THEOPHYLLINE
AB + TEVA PHARMS 450MG

A081236 001 Nov 09, 1992 Mar CAHN

THIABENDAZOLE

SUSPENSION;ORAL
MINTEZOL
@ MERCK SHARP DOHME 500MG/5ML

N016097 001 May CAHN

TABLET, CHEWABLE;ORAL
MINTEZOL
@ MERCK SHARP DOHME 500MG

N016096 001 May CAHN

THIOGUANINE

TABLET;ORAL
THIOGUANINE
+ ASPEN GLOBAL INC 40MG

N012429 001 Mar CAHN

TICLOPIDINE HYDROCHLORIDE

TABLET;ORAL
TICLOPIDINE HYDROCHLORIDE
@ MYLAN 250MG

A075161 001 Sep 13, 1999 Aug DISC

TIGECYCLINE

INJECTABLE;IV (INFUSION)
TYGACIL
+ PF PRISM CV 50MG/VIAL

N021821 001 Jun 15, 2005 Aug CAHN

TILUDRONATE DISODIUM

TABLET;ORAL
SKELID
@ SANOFI AVENTIS US EQ 200MG BASE

N020707 001 Mar 07, 1997 Jun DISC

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS;OPHTHALMIC
TIMOPTIC-XE
AB + VALEANT PHARMS LLC EQ 0.25% BASE
AB + EQ 0.5% BASE
SOLUTION/DROPS;OPHTHALMIC
ISTALOL
BT + BAUSCH AND LOMB EQ 0.5% BASE
TIMOLOL MALEATE
@ AKORN EQ 0.25% BASE
@ APOTEX INC EQ 0.25% BASE
@ EQ 0.5% BASE

N020330 001 Nov 04, 1993 Jan CAHN

N020330 002 Nov 04, 1993 Jan CAHN

N021516 001 Jun 04, 2004 May CAHN

A074515 001 Mar 25, 1997 Jun DISC

A075411 001 Sep 08, 2000 Apr DISC

A075412 001 Sep 08, 2000 Apr DISC

TINIDAZOLE

TABLET;ORAL
TINIDAZOLE
AB UNIQUE PHARM LABS 250MG
AB 500MG

A202489 001 Oct 09, 2013 Sep NEWA

A202489 002 Oct 09, 2013 Sep NEWA

TIOPRONIN

TABLET;ORAL
THIOLA
+ MISSION PHARMA 100MG

N019569 001 Aug 11, 1988 Aug CTNA

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL
TIZANIDINE HYDROCHLORIDE
AB MYLAN PHARMS INC EQ 2MG BASE
AB EQ 4MG BASE
AB EQ 6MG BASE

A091502 001 Nov 09, 2012 May CAHN

A091502 002 Nov 09, 2012 May CAHN

A091502 003 Nov 09, 2012 May CAHN

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

@ MYLAN PHARMS INC EQ 2MG BASE
@ EQ 4MG BASE

A076282 001 Dec 16, 2003 Feb DISC
A076282 002 Dec 16, 2003 Feb DISC

TOBRAMYCIN

POWDER;INHALATION

TOBI PODHALER

+ NOVARTIS 28MG

N201688 001 Mar 22, 2013 Mar NEWA

SOLUTION;INHALATION

TOBI

AN + NOVARTIS PHARMS 300MG/5ML
TOBRAMYCIN

N050753 001 Dec 22, 1997 Sep CFTG

AN TEVA PHARMS USA 300MG/5ML

A091589 001 Oct 10, 2013 Sep NEWA

SOLUTION/DROPS;OPHTHALMIC

TOBRAMYCIN

@ APOTEX INC 0.3%

A065087 001 Feb 25, 2002 Apr DISC

TOBRAMYCIN SULFATE

INJECTABLE;INJECTION

TOBRAMYCIN SULFATE

>A> AP AGILA SPECLTS EQ 40MG BASE/ML
>D> AP PFIZER EQ 40MG BASE/ML
AP TEVA PHARMS USA EQ 40MG BASE/ML

A065407 001 Mar 11, 2008 Nov CAHN
A065407 001 Mar 11, 2008 Nov CAHN
A063100 001 Jan 30, 1992 Sep CAHN

TOFACITINIB CITRATE

TABLET;ORAL

XELJANZ

+ PF PRISM CV EQ 5MG BASE

N203214 001 Nov 06, 2012 Sep CAHN

TOLAZAMIDE

TABLET;ORAL

TOLAZAMIDE

MYLAN PHARMS INC 250MG
+ 500MG
@ WATSON LABS 250MG
@ 500MG

A070259 001 Jan 02, 1986 Mar CTEC
A070259 003 Mar 17, 1986 Mar CTEC
A070514 001 Jan 09, 1986 Mar DISC
A070515 001 Jan 09, 1986 Mar DISC

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

DETROL LA

AB PHARMACIA AND UPJOHN 2MG
AB + 4MG

N021228 001 Dec 22, 2000 Oct CFTG
N021228 002 Dec 22, 2000 Oct CFTG

TOLTERODINE TARTRATE

AB MYLAN PHARMS INC 2MG
AB 4MG

A201486 001 Oct 31, 2013 Oct NEWA
A201486 002 Oct 31, 2013 Oct NEWA

TOPIRAMATE

CAPSULE, EXTENDED RELEASE;ORAL

TROKENDI XR

SUPERNUS PHARMS 25MG
50MG
100MG
+ 200MG

N201635 001 Aug 16, 2013 Aug NEWA
N201635 002 Aug 16, 2013 Aug NEWA
N201635 003 Aug 16, 2013 Aug NEWA
N201635 004 Aug 16, 2013 Aug NEWA

TABLET;ORAL

TOPAMAX

AB JANSSEN PHARMS 25MG
AB + 100MG

N020505 004 Dec 24, 1996 Apr CRLD
N020505 001 Dec 24, 1996 Apr CRLD

TOPIRAMATE

AB ACTIVIS TOTOWA LLC 25MG
AB 50MG
AB 100MG
AB 200MG

A078637 001 Feb 27, 2013 Feb NEWA
A078637 002 Feb 27, 2013 Feb NEWA
A078637 003 Feb 27, 2013 Feb NEWA
A078637 004 Feb 27, 2013 Feb NEWA

AB LUPIN 25MG
AB 50MG

A078410 001 Sep 11, 2013 Aug NEWA
A078410 002 Sep 11, 2013 Aug NEWA

AB 100MG
AB 200MG

A078410 003 Sep 11, 2013 Aug NEWA
A078410 004 Sep 11, 2013 Aug NEWA

AB UNICHEM LABS LTD 200MG
@ UPSHER SMITH 25MG

A090162 004 Feb 19, 2013 Feb NEWA
A078499 001 Jan 07, 2010 Jun DISC

@ 50MG

A078499 002 Jan 07, 2010 Jun DISC

@ 100MG

A078499 003 Jan 07, 2010 Jun DISC

@ 200MG

A078499 004 Jan 07, 2010 Jun DISC

TABLET;ORAL
TOPIRAMATE

>A>	AB	HIKMA PHARMS	25MG	A091185	001	Nov 25, 2013	Nov NEWA
>A>	AB		50MG	A091185	002	Nov 25, 2013	Nov NEWA
>A>	AB		100MG	A091185	003	Nov 25, 2013	Nov NEWA
>A>	AB		200MG	A091185	004	Nov 25, 2013	Nov NEWA

TOPOTECAN HYDROCHLORIDE

CAPSULE;ORAL
HYCANTIN

GLAXO WELLCOME EQ 0.25MG BASE
+ EQ 1MG BASE

N020981 001 Oct 11, 2007 Sep CAHN
N020981 002 Oct 11, 2007 Sep CAHN

INJECTABLE;INJECTION

TOPOTECAN HYDROCHLORIDE

AP ACCORD HLTHCARE EQ 4MG BASE/VIAL
AP SUN PHARM INDS LTD EQ 4MG BASE/VIAL

A202351 001 Jun 26, 2013 Jun NEWA
A202203 001 Aug 29, 2013 Aug NEWA

TOREMIFENE CITRATE

TABLET;ORAL
FARESTON

+ PROSTRAKAN INC EQ 60MG BASE

N020497 001 May 29, 1997 May CAHN

TORSEMIDE

TABLET;ORAL
TORSEMIDE

AB HETERO LABS LTD III 5MG
AB 10MG
AB 20MG
AB 100MG

A079234 001 Jan 27, 2009 Apr CAHN
A079234 002 Jan 27, 2009 Apr CAHN
A079234 003 Jan 27, 2009 Apr CAHN
A079234 004 Jan 27, 2009 Apr CAHN

TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE

AB ACCORD HLTHCARE INC 50MG
AB CSPC OUYI PHARM CO 50MG

A202390 001 May 16, 2013 Apr NEWA
A091498 001 Mar 29, 2013 Mar NEWA

TABLET, EXTENDED RELEASE;ORAL

RYZOLT

@ PURDUE PHARMA 100MG
@ 200MG
@ 300MG

N021745 001 Dec 30, 2008 Jan DISC
N021745 002 Dec 30, 2008 Jan DISC
N021745 003 Dec 30, 2008 Jan DISC

TRAMADOL HYDROCHLORIDE

AB2 ACTAVIS ELIZABETH 100MG
AB2 200MG
AB2 300MG
AB1 PAR PHARM INC 100MG
AB2 + SUN PHARMA GLOBAL 100MG

A091609 001 Jun 27, 2012 Apr CAHN
A091609 002 Jun 27, 2012 Apr CAHN
A091609 003 Jun 27, 2012 Apr CAHN
A078783 001 Nov 13, 2009 Feb CRLD
A091607 001 Dec 30, 2011 Feb CRLD

TABLET, ORALLY DISINTEGRATING;ORAL

RYBIX ODT

@ SHIONOGI INC 50MG

N021693 001 May 05, 2005 Aug DISC

TRAMETINIB DIMETHYL SULFOXIDE

TABLET;ORAL
MEKINIST

GLAXOSMITHKLINE LLC EQ 0.5MG NON-SOLVATED PARENT
EQ 1MG NON-SOLVATED PARENT
+ EQ 2MG NON-SOLVATED PARENT

N204114 001 May 29, 2013 May NEWA
N204114 002 May 29, 2013 May NEWA
N204114 003 May 29, 2013 May NEWA

TRANDOLAPRIL

TABLET;ORAL

TRANDOLAPRIL

@ CIPLA 1MG
@ 2MG
@ 4MG
@ DR REDDYS LABS LTD 1MG
@ 2MG
@ 4MG

A077307 002 Jun 12, 2007 Jul DISC
A077307 001 Jun 12, 2007 Jul DISC
A077307 003 Jun 12, 2007 Jul DISC
A078493 001 Aug 25, 2008 Apr DISC
A078493 002 Aug 25, 2008 Apr DISC
A078493 003 Aug 25, 2008 Apr DISC

TRANEXAMIC ACID

INJECTABLE; INJECTION
TRANEXAMIC ACID

AP	CUSTOPHARM INC	100MG/ML	A201580	001	Jun 14, 2013	Jun NEWA
AP	X-GEN PHARMS INC	100MG/ML	A201580	001	Jun 14, 2013	Oct CAHN

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC
TRAVOPROST

PAR PHARM	0.004%	A091340	001	Mar 01, 2013	Feb NEWA
-----------	--------	---------	-----	--------------	----------

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

AB	TEVA PHARMS USA	50MG	A071523	001	Dec 11, 1987	Mar CAHN
AB		100MG	A071524	001	Dec 11, 1987	Mar CAHN
>A> AB	TORRENT PHARMS LTD	50MG	A202180	001	Nov 27, 2013	Nov NEWA
>A> AB		100MG	A202180	002	Nov 27, 2013	Nov NEWA
>A> AB		150MG	A202180	003	Nov 27, 2013	Nov NEWA
>A> AB		300MG	A202180	004	Nov 27, 2013	Nov NEWA

TABLET, EXTENDED RELEASE; ORAL

OLEPTRO

@ ANGELINI LLC	150MG	N022411	001	Feb 02, 2010	May DISC
@	300MG	N022411	002	Feb 02, 2010	May DISC
+ ANGELINI PHARMA	150MG	N022411	001	Feb 02, 2010	Jun CMFD
	300MG	N022411	002	Feb 02, 2010	Jun CMFD

TREPROSTINIL

INJECTABLE; IV (INFUSION) - SC
REMOTULIN

UNITED THERAP	1MG/ML	N021272	001	May 21, 2002	May CAIN
	2.5MG/ML	N021272	002	May 21, 2002	May CAIN
	5MG/ML	N021272	003	May 21, 2002	May CAIN
+	10MG/ML	N021272	004	May 21, 2002	Jun CAIN

SOLUTION; INHALATION

TYVASO

+ UNITED THERAP	EQ 0.6MG BASE/ML	N022387	001	Jul 30, 2009	May CAIN
-----------------	------------------	---------	-----	--------------	----------

TRETINOIN

CREAM; TOPICAL

RETIN-A

AB + VALEANT BERMUDA	0.025%	N019049	001	Sep 16, 1988	Jun CAHN
AB1 +	0.05%	N017522	001		Jun CAHN
AB +	0.1%	N017340	001		Jun CAHN

GEL; TOPICAL

ATRALIN

+ DOW PHARM	0.05%	N022070	001	Jul 26, 2007	Apr CAHN
-------------	-------	---------	-----	--------------	----------

RETIN-A MICRO

AB + VALEANT INTL	0.04%	N020475	002	May 10, 2002	Jul CTEC
AB +	0.1%	N020475	001	Feb 07, 1997	Jul CTEC

TRETINOIN

AB SPEAR PHARMS INC	0.04%	A202567	001	Jul 17, 2013	Jul NEWA
AB	0.1%	A202026	001	Jul 17, 2013	Jul NEWA

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

KENALOG

@ APOTHECON	0.025%	N011601	003		Apr DISC
@	0.1%	N011601	006		Apr DISC

TRIACET

@ TEVA	0.025%	A084908	001		Apr DISC
@	0.5%	A084908	003		Apr DISC

TRIAMCINOLONE ACETONIDE

AT + FOUGERA PHARMS	0.025%	A085692	001		Apr CRLD
AT +	0.1%	A085692	003		Apr CRLD
@ G AND W LABS	0.025%	A089797	001	May 31, 1991	May DISC
@ TARO	0.025%	A086277	001		Apr DISC
@	0.1%	A086276	001		Apr DISC
@	0.5%	A086275	001		Apr DISC

INJECTABLE; INTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREAL								
TRIVARIS								
	@ ALLERGAN	8MG/0.1ML (8MG/0.1ML)	N022220	001	Jun 16, 2008	May	DISC	
LOTION; TOPICAL								
TRIAMCINOLONE ACETONIDE								
AT	VERSAPHARM INC	0.025%	A202374	001	May 08, 2013	Apr	NEWA	
AT		0.1%	A202374	002	May 08, 2013	Apr	NEWA	
AT	+ WOCKHARDT EU OPERATN	0.025%	A088450	001	Apr 01, 1985	Apr	CAHN	
OINTMENT; TOPICAL								
KENALOG								
	@ APOTHECON	0.025%	N011600	003		Apr	DISC	
	@	0.1%	N011600	001		Apr	DISC	
TRIAMCINOLONE ACETONIDE								
	@ TARO	0.025%	A040040	001	Sep 30, 1994	May	DISC	
	@	0.025%	A040374	001	Jun 05, 2001	May	DISC	
	@	0.1%	A087902	001	Dec 27, 1982	May	DISC	
	@	0.5%	A040386	001	Jun 05, 2001	May	DISC	
SPRAY, METERED; NASAL								
TRIAMCINOLONE ACETONIDE								
	TEVA PHARMS	0.055MG/SPRAY	A078104	001	Jul 30, 2009	Oct	CTEC	
<u>TRIHEXYPHENIDYL HYDROCHLORIDE</u>								
TABLET; ORAL								
TRIHEXYPHENIDYL HYDROCHLORIDE								
	@ WEST WARD	2MG	A040337	002	Feb 16, 2000	Jul	DISC	
	@	5MG	A040337	001	Feb 16, 2000	Jul	DISC	
<u>TRIMETHOPRIM</u>								
TABLET; ORAL								
TRIMETHOPRIM								
AB	+ TEVA	100MG	N018679	001	Jul 30, 1982	Jul	CRLD	
	@	200MG	A071259	001	Jun 18, 1987	Jun	DISC	
<u>TROSPIMUM CHLORIDE</u>								
CAPSULE, EXTENDED RELEASE; ORAL								
TROSPIMUM CHLORIDE								
AB	PADDOCK LLC	60MG	A201291	001	May 24, 2013	May	NEWA	
<u>URSODIOL</u>								
TABLET; ORAL								
URSODIOL								
AB	PAR PHARM	250MG	A202540	001	Feb 14, 2013	Feb	NEWA	
AB		500MG	A202540	002	Feb 14, 2013	Feb	NEWA	
	@ TEVA PHARMS USA	250MG	A079184	001	May 13, 2009	Apr	DISC	
	@	500MG	A079184	002	May 13, 2009	Apr	DISC	
<u>VALACYCLOVIR HYDROCHLORIDE</u>								
TABLET; ORAL								
VALACYCLOVIR HYDROCHLORIDE								
AB	ACTAVIS GRP PTC	EQ 1GM BASE	A090370	002	Mar 16, 2011	Mar	CAHN	
AB		EQ 500MG BASE	A090370	001	Mar 16, 2011	Mar	CAHN	
<u>VALPROIC ACID</u>								
CAPSULE; ORAL								
VALPROIC ACID								
AB	SUN PHARM INDS LTD	250MG	A091037	001	Feb 22, 2013	Feb	NEWA	
CAPSULE, DELAYED RELEASE; ORAL								
STAVZOR								
	@ BANNER PHARMACAPS	125MG	N022152	001	Jul 29, 2008	Jun	DISC	
	@	250MG	N022152	002	Jul 29, 2008	Jun	DISC	
	@	500MG	N022152	003	Jul 29, 2008	Jun	DISC	
<u>VANCOMYCIN HYDROCHLORIDE</u>								
INJECTABLE; INJECTION								
VANCOMYCIN HYDROCHLORIDE								
AP	AGILA SPECLTS	EQ 1GM BASE/VIAL	A065397	002	Dec 30, 2008	Sep	CAHN	
AP		EQ 5GM BASE/VIAL	A065432	001	Dec 30, 2008	Sep	CAHN	
AP		EQ 10GM BASE/VIAL	A091469	001	Jul 01, 2011	Sep	CAHN	
AP		EQ 500MG BASE/VIAL	A065397	001	Dec 30, 2008	Sep	CAHN	
AP	EMCURE PHARMS LTD	EQ 1GM BASE/VIAL	A202275	002	Oct 31, 2013	Oct	NEWA	
AP		EQ 10GM BASE/VIAL	A202464	001	Oct 09, 2013	Sep	NEWA	
AP		EQ 5GM BASE/VIAL	A202274	001	Oct 31, 2013	Oct	NEWA	

INJECTABLE;INJECTION
VANCOMYCIN HYDROCHLORIDE

AP EQ 500MG BASE/VIAL A202275 001 Oct 31, 2013 Oct NEWA

VECURONIUM BROMIDE

INJECTABLE;INJECTION
VECURONIUM BROMIDE

>A> AP AGILA SPECLTS 10MG/VIAL A090243 001 May 11, 2010 Nov CAHN
>A> AP 20MG/VIAL A090243 002 May 11, 2010 Nov CAHN
>D> AP PFIZER 10MG/VIAL A090243 001 May 11, 2010 Nov CAHN
>D> AP 20MG/VIAL A090243 002 May 11, 2010 Nov CAHN
AP TEVA PHARMS USA 10MG/VIAL A074688 001 Aug 25, 1999 Apr CAHN
AP 20MG/VIAL A074688 002 Aug 25, 1999 Apr CAHN

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
VENLAFAXINE HYDROCHLORIDE

AB VALEANT BERMUDA EQ 37.5MG BASE A090071 001 Apr 15, 2011 Jul CAHN
AB EQ 75MG BASE A090071 002 Apr 15, 2011 Jul CAHN
AB EQ 150MG BASE A090071 003 Apr 15, 2011 Jul CAHN

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
VERELAN PM

AB ALKERMES GAINESVILLE 100MG N020943 001 Nov 25, 1998 Sep CAHN
AB 200MG N020943 002 Nov 25, 1998 Sep CAHN
AB + 300MG N020943 003 Nov 25, 1998 Sep CAHN

INJECTABLE;INJECTION
VERAPAMIL HYDROCHLORIDE

@ INTL MEDICATION 2.5MG/ML

A070451 001 Dec 16, 1985 Mar DISC

TABLET;ORAL

VERAPAMIL HYDROCHLORIDE

AB HERITAGE PHARMS INC 80MG A071880 001 Apr 05, 1988 Aug CMFD
AB 120MG A071881 001 Apr 05, 1988 Aug CMFD

TABLET, EXTENDED RELEASE;ORAL
VERAPAMIL HYDROCHLORIDE

AB CARACO 120MG A090529 001 Dec 30, 2011 May CAHN
AB 180MG A090529 002 Dec 30, 2011 May CAHN
AB 240MG A090529 003 Dec 30, 2011 May CAHN

VERTEPORFIN

INJECTABLE;INJECTION
VISUDYNE

+ VALEANT PHARMS INC 15MG/VIAL

N021119 001 Apr 12, 2000 Jan CAHN

VINCRISTINE SULFATE

INJECTABLE;INJECTION
VINCRISTINE SULFATE PFS

AP TEVA PHARMS USA 1MG/ML A075493 001 Sep 01, 1999 Apr CAHN

VINORELBINE TARTRATE

INJECTABLE;INJECTION
VINORELBINE TARTRATE

AP DR REDDYS LABS LTD EQ 10MG BASE/ML A202017 001 Sep 12, 2013 Aug NEWA
AP TEVA PHARMS USA EQ 10MG BASE/ML A076028 001 Feb 03, 2003 Apr CAHN

VORICONAZOLE

FOR SUSPENSION;ORAL
VFEND

AB + PFIZER 200MG/5ML N021630 001 Dec 19, 2003 May CFTG

VORICONAZOLE

AB MYLAN PHARMS INC 200MG/5ML A202361 001 May 28, 2013 May NEWA

VORTIOXETINE HYDROBROMIDE

TABLET;ORAL

BRINTELLIX

TAKEDA PHARMS USA EQ 5MG BASE
EQ 10MG BASE
EQ 15MG BASE
+ EQ 20MG BASE

N204447 001 Sep 30, 2013 Sep NEWA
N204447 002 Sep 30, 2013 Sep NEWA
N204447 003 Sep 30, 2013 Sep NEWA
N204447 004 Sep 30, 2013 Sep NEWA

INJECTABLE;IV (INFUSION)							
ZOLEDRONIC ACID							
AP	PHARMS	EQ 4MG BASE/5ML	A202571	001	May 07, 2013	Apr	NEWA
+	SUN PHARMA GLOBAL	EQ 4MG BASE/VIAL	A090018	001	Mar 04, 2013	Feb	NEWA
AP		EQ 4MG BASE/5ML	A202746	001	Mar 04, 2013	Feb	NEWA
ZOMETA							
AP	NOVARTIS	EQ 4MG BASE/5ML	N021223	002	Mar 07, 2003	Feb	CFTG
AP	+	EQ 4MG BASE/100ML	N021223	003	Jun 17, 2011	Aug	CTEC
<u>ZOLMITRIPTAN</u>							
SPRAY;NASAL							
ZOMIG							
	ASTRAZENECA	2.5MG/SPRAY	N021450	003	Sep 16, 2013	Sep	NEWA
TABLET;ORAL							
ZOLMITRIPTAN							
AB	APOTEX INC	2.5MG	A202078	001	May 14, 2013	Apr	NEWA
AB		5MG	A202078	002	May 14, 2013	Apr	NEWA
AB	GLENMARK GENERICS	2.5MG	A201779	001	May 14, 2013	Apr	NEWA
AB		5MG	A201779	002	May 14, 2013	Apr	NEWA
AB	MYLAN PHARMS INC	2.5MG	A203186	001	May 14, 2013	Apr	NEWA
AB		5MG	A203186	002	May 14, 2013	Apr	NEWA
ZOMIG							
AB	IPR	2.5MG	N020768	001	Nov 25, 1997	Apr	CFTG
AB	+	5MG	N020768	002	Nov 25, 1997	Apr	CFTG
TABLET, ORALLY DISINTEGRATING;ORAL							
ZOLMITRIPTAN							
AB	APOTEX INC	2.5MG	A202476	001	May 14, 2013	Apr	NEWA
AB		5MG	A202476	002	May 14, 2013	Apr	NEWA
AB	GLENMARK GENERICS	2.5MG	A202560	001	May 14, 2013	Apr	NEWA
AB		5MG	A202560	002	May 14, 2013	Apr	NEWA
AB	ZYDUS PHARMS USA INC	2.5MG	A202890	001	May 15, 2013	Apr	NEWA
AB		5MG	A202890	002	May 15, 2013	Apr	NEWA
ZOMIG-ZMT							
AB	ASTRAZENECA	2.5MG	N021231	001	Feb 13, 2001	Apr	CFTG
AB	+	5MG	N021231	002	Sep 17, 2001	Apr	CFTG
<u>ZOLPIDEM TARTRATE</u>							
TABLET;ORAL							
ZOLPIDEM TARTRATE							
	@ DR REDDYS LABS LTD	5MG	A077985	001	Apr 23, 2007	Apr	DISC
	@	10MG	A077985	002	Apr 23, 2007	Apr	DISC
TABLET, EXTENDED RELEASE;ORAL							
ZOLPIDEM TARTRATE							
AB	ACTAVIS ELIZABETH	6.25MG	A078179	002	Oct 13, 2010	Apr	CAHN
AB		12.5MG	A078179	001	Jun 06, 2011	Apr	CAHN
AB	APOTEX INC	6.25MG	A200266	001	Sep 10, 2013	Aug	NEWA
AB		12.5MG	A200266	002	Sep 10, 2013	Aug	NEWA
AB	LUPIN LTD	6.25MG	A078970	001	Sep 11, 2013	Aug	NEWA
AB		12.5MG	A078970	002	Sep 11, 2013	Aug	NEWA
AB	WATSON LABS INC FL	6.25MG	A090153	001	Mar 25, 2013	Mar	NEWA
AB		12.5MG	A090153	002	Mar 25, 2013	Mar	NEWA
<u>ZONISAMIDE</u>							
CAPSULE;ORAL							
ZONISAMIDE							
	@ COREPHARMA	25MG	A077876	001	Feb 21, 2007	Feb	DISC
	@	50MG	A077876	002	Feb 21, 2007	Feb	DISC
	@	100MG	A077876	003	Feb 21, 2007	Feb	DISC
	@ DR REDDYS LABS LTD	25MG	A077645	002	Sep 29, 2006	Mar	DISC
	@	50MG	A077645	003	Sep 29, 2006	Mar	DISC
	@	100MG	A077645	001	Dec 22, 2005	Mar	DISC

ACETAMINOPHEN

TABLET, EXTENDED RELEASE;ORAL
 TYLENOL

+	MCNEIL CONS	650MG	N019872	001	Jun 08, 1994	Jul CTNA
+		650MG	N019872	002	Jan 11, 2001	Jul CTNA

ASPIRIN

CAPSULE;ORAL
 ASPIRIN

+	PLX PHARMA	325MG	N203697	001	Jan 14, 2013	Jan NEWA
---	------------	-------	---------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

@	APOTEX INC	5MG/5ML	A090188	002	Apr 22, 2008	Apr DISC
	BIO PHARM INC	5MG/5ML	A090474	002	Mar 30, 2009	May CAHN
	CARACO	5MG/5ML	A091327	001	Oct 17, 2011	May CAHN
	PERRIGO R AND D	5MG/5ML	A204226	001	Sep 09, 2013	Aug NEWA

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@	APOTEX INC	5MG/5ML	A090188	001	Apr 22, 2008	Apr DISC
	BIO PHARM INC	5MG/5ML	A090474	001	Mar 30, 2009	May CAHN
	CARACO	5MG/5ML	A091327	002	Oct 17, 2011	May CAHN

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

	CIPLA LTD	5MG	A077318	001	Jul 25, 2013	Jul NEWA
		10MG	A077318	002	Jul 25, 2013	Jul NEWA
	CONTRACT PHARMACAL	5MG	A076047	001	Dec 27, 2007	Oct CAHN
		10MG	A076047	002	Dec 27, 2007	Oct CAHN

TABLET, CHEWABLE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

+	SANDOZ	10MG	A078692	002	Feb 14, 2008	Apr CRLD
---	--------	------	---------	-----	--------------	----------

CHILDREN'S ZYRTEC ALLERGY

@	MCNEIL CONS	5MG	N021621	003	Nov 16, 2007	Apr DISC
+		5MG	N021621	003	Nov 16, 2007	Feb CRLD
@		10MG	N021621	004	Nov 16, 2007	Feb DISC

CHILDREN'S ZYRTEC HIVES RELIEF

@	MCNEIL CONS	5MG	N021621	005	Nov 16, 2007	Apr DISC
+		5MG	N021621	005	Nov 16, 2007	Feb CRLD
@		10MG	N021621	006	Nov 16, 2007	Feb DISC

CHLORHEXIDINE GLUCONATE

SOLUTION;TOPICAL

DYNA-HEX

	BAJAJ MEDICAL LLC	0.75%	N020111	001	Sep 11, 1997	Apr CAHN
--	-------------------	-------	---------	-----	--------------	----------

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SWAB;TOPICAL

PREVANTICS MAXI SWABSTICK

+	PROF DSPLS	3.15%;70% (5.1ML)	N021524	003	Jun 03, 2005	Mar CTNA
---	------------	-------------------	---------	-----	--------------	----------

PREVANTICS SWAB

+	PROF DSPLS	3.15%;70% (1ML)	N021524	001	Jun 03, 2005	Mar CTNA
---	------------	-----------------	---------	-----	--------------	----------

PREVANTICS SWABSTICK

+	PROF DSPLS	3.15%;70% (1.6ML)	N021524	002	Jun 03, 2005	Mar CTNA
---	------------	-------------------	---------	-----	--------------	----------

CIMETIDINE

TABLET;ORAL

TAGAMET HB

@	MEDTECH PRODS	100MG	N020238	001	Jun 19, 1995	Aug CAHN
+		200MG	N020238	002	Aug 21, 1996	Aug CAHN

CLOTTRIMAZOLE

CREAM;VAGINAL

MYCELEX-7

	BAYER	1%	N018230	002	Dec 26, 1991	Sep CAHN
--	-------	----	---------	-----	--------------	----------

CREAM, TABLET;TOPICAL, VAGINAL

MYCELEX-7 COMBINATION PACK

	BAYER	1%,100MG	N020389	002	Jun 23, 1994	Sep CAHN
--	-------	----------	---------	-----	--------------	----------

TABLET;VAGINAL MYCELEX-7 BAYER				100MG	N018182	002	Dec 26, 1991	Sep CAHN
<u>DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE</u>								
TABLET, EXTENDED RELEASE;ORAL DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE AVANTHI INC				6MG;120MG	A078648	001	Feb 27, 2013	Feb NEWA
<u>FAMOTIDINE</u>								
TABLET;ORAL PEPCID AC MCNEIL CONS				10MG	N020902	001	Aug 05, 1999	Jul CTNA
<u>FEXOFENADINE HYDROCHLORIDE</u>								
TABLET, ORALLY DISINTEGRATING;ORAL CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY DR REDDYS LABS LTD				30MG	A202978	001	Jan 18, 2013	Jan NEWA
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES DR REDDYS LABS LTD				30MG	A202978	002	Jan 18, 2013	Jan NEWA
<u>KETOTIFEN FUMARATE</u>								
SOLUTION/DROPS;OPHTHALMIC KETOTIFEN FUMARATE @ APOTEX INC				EQ 0.025% BASE	A077354	001	May 09, 2006	Apr DISC
<u>LEVONORGESTREL</u>								
TABLET;ORAL LEVONORGESTREL LUPIN LTD				0.75MG	A091328	001	Jan 23, 2013	Jan NEWA
NOVEL LABS INC				1.5MG	A202508	001	Feb 22, 2013	Feb NEWA
<u>LORATADINE</u>								
SYRUP;ORAL LORATADINE @ APOTEX INC				1MG/ML	A075565	001	Oct 05, 2004	Apr DISC
<u>LORATADINE; PSEUDOEPHEDRINE SULFATE</u>								
TABLET, EXTENDED RELEASE;ORAL LORATADINE AND PSEUDOEPHEDRINE SULFATE @ WATSON LABS INC FL				5MG;120MG	A076208	001	Jan 28, 2004	Feb DISC
<u>MICONAZOLE NITRATE</u>								
CREAM;VAGINAL MICONAZOLE NITRATE APHENA PHARMA MD				2%	A074366	001	Feb 22, 1996	Jan CAHN
G AND W LABS INC				2%	A074366	001	Feb 22, 1996	Sep CAHN
<u>MINOXIDIL</u>								
SOLUTION;TOPICAL MINOXIDIL (FOR MEN) @ APOTEX INC				2%	A074924	001	Apr 29, 1998	Apr DISC
MINOXIDIL (FOR WOMEN) @ APOTEX INC				2%	A074924	002	Apr 29, 1998	Apr DISC
MINOXIDIL EXTRA STRENGTH (FOR MEN) @ APOTEX INC				5%	A075839	001	Oct 01, 2001	Apr DISC
<u>NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE</u>								
SOLUTION/DROPS;OPHTHALMIC NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE AKORN INC				0.025%;0.3%	A202795	001	Jan 24, 2013	Jan NEWA
<u>OMEPRazole; SODIUM BICARBONATE</u>								
FOR SUSPENSION;ORAL ZEGERID OTC + MSD CONSUMER				20MG/PACKET;1.68GM/PACKET	N022283	001	Jun 17, 2013	Jun NEWA

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL
OXYTROL FOR WOMEN

+ MSD CONSUMER 3.9MG/24HR N202211 001 Jan 25, 2013 Jan NEWA

PIPERONYL BUTOXIDE; PYRETHRINS

AEROSOL;TOPICAL
RID MOUSSE

+ BAYER 4%;EQ 0.33% BASE N021043 001 Mar 07, 2000 Sep CAHN

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL
POLYETHYLENE GLYCOL 3350
PAR PHARM

17GM/SCOOPFUL A079214 001 Jan 31, 2013 Jan NEWA

RANITIDINE HYDROCHLORIDE

TABLET;ORAL
RANITIDINE HYDROCHLORIDE
@ WATSON LABS

EQ 75MG BASE A075212 001 Jan 14, 2000 Mar DISC

TRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL
NASACORT ALLERGY 24 HOUR

SANOFI AVENTIS US 0.055MG/SPRAY N020468 002 Oct 11, 2013 Oct NEWA

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 11 NOVEMBER 2013

NO NOVEMBER 2013 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO NOVEMBER 2013 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379 001	>A> 5604213	Dec 13, 2016	DS DP U-1126			
	>A> 5604213	Dec 13, 2016	DS DP U-1314			
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N 021539 001	8399445	Aug 24, 2025	U-1373			
<u>ACYCLOVIR - SITAVIG</u>						
N 203791 001					NP	Apr 12, 2016
<u>ADAPALENE - DIFFERIN</u>						
N 022502 001	8435502	Sep 15, 2026	DP U-1078			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N 022320 001	8445543	Jul 12, 2027	U-1078		NPP	Feb 01, 2016
<u>ADEFOVIR DIPIVOXIL - ADEFOVIR DIPIVOXIL</u>						
A 202051 001					PC	Mar 02, 2014
<u>AFATINIB DIMALEATE - GILOTRIE</u>						
N 201292 001	6251912	Jul 29, 2018	DS DP U-1067		NCE	Jul 12, 2018
	8426586	Oct 10, 2029	DS DP		ODE	Jul 12, 2020
	8545884	Dec 19, 2029	DP			
	RE43431	Jan 22, 2022	DS DP			
<u>AFATINIB DIMALEATE - GILOTRIE</u>						
N 201292 002	6251912	Jul 29, 2018	DS DP U-1067		NCE	Jul 12, 2018
	8426586	Oct 10, 2029	DS DP		ODE	Jul 12, 2020
	8545884	Dec 19, 2029	DP			
	RE43431	Jan 22, 2022	DS DP			
<u>AFATINIB DIMALEATE - GILOTRIE</u>						
N 201292 003	6251912	Jul 29, 2018	DS DP U-1067		NCE	Jul 12, 2018
	8426586	Oct 10, 2029	DS DP		ODE	Jul 12, 2020
	8545884	Dec 19, 2029	DP			
	RE43431	Jan 22, 2022	DS DP			
<u>ALBUTEROL SULFATE - PROVENTIL-HFA</u>						
N 020503 001	>A> 5775321	Jul 07, 2015	DP			
	>A> 6006745	Dec 28, 2016	DP			
<u>ALCAFTADINE - LASTACFT</u>						
N 022134 001	5468743	Apr 20, 2016	DS DP			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N 022217 001	8168616	Jul 03, 2026	DP			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N 022217 002	8168616	Jul 03, 2026	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 001	5965584	Jun 19, 2016	U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 002	5965584	Jun 19, 2016	U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 001	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 002	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 003	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 004	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 006	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
<u>ALVIMOPAN - ENTEREG</u>						
N 021775 001	8112290	Jul 31, 2030	DP U-1443		M-128	Oct 18, 2016
<u>AMBRISENTAN - LETAIRIS</u>						
N 022081 001	8349843	Oct 07, 2015	DS DP			
<u>AMBRISENTAN - LETAIRIS</u>						
N 022081 002	8349843	Oct 07, 2015	DS DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 001	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 002	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 003	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 004	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 005	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				
<u>AMOXICILLIN - MOXATAG</u>						
N 050813 001	8357394	Dec 08, 2026	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	6413980	Dec 22, 2019	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1323			
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	6413980	Dec 22, 2019	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1323			
<u>ARFORMOTEROL TARTRATE - BROVANA</u>						
N 021912 001	6589508	Apr 03, 2014	U-793			
	7348362	Jun 22, 2021	DP U-793			
	7462645	Jun 22, 2021	U-793			
	7465756	Jun 22, 2021	DP			
	7473710	Jun 22, 2021	U-793			
	7541385	Jun 22, 2021	U-793			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 001	>A> 7053092	Jan 28, 2022	U-839			
	>A> 8017615	Jun 16, 2024	DP			
	>A> 8017615*PED	Dec 16, 2024				
	>A> 8580796	Sep 25, 2022	DS			
	>A> 8580796*PED	Mar 25, 2023				
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 002	>A> 7053092	Jan 28, 2022				
	>A> 8017615	Jun 16, 2024	DP			
	>A> 8017615*PED	Dec 16, 2024				
	>A> 8580796	Sep 25, 2022	DS			
	>A> 8580796*PED	Mar 25, 2023				
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 003	>A> 7053092	Jan 28, 2022				
	>A> 8017615	Jun 16, 2024	DP			
	>A> 8017615*PED	Dec 16, 2024				
	>A> 8580796	Sep 25, 2022	DS			
	>A> 8580796*PED	Mar 25, 2023				
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 004	>A> 7053092	Jan 28, 2022				
	>A> 8017615	Jun 16, 2024	DP			
	>A> 8017615*PED	Dec 16, 2024				
	>A> 8580796	Sep 25, 2022	DS			
	>A> 8580796*PED	Mar 25, 2023				
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 005	>A> 7053092	Jan 28, 2022				
	>A> 8017615	Jun 16, 2024	DP			
	>A> 8017615*PED	Dec 16, 2024				
	>A> 8580796	Sep 25, 2022	DS			
	>A> 8580796*PED	Mar 25, 2023				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY</u>						
N 021436 006	>A> 7053092	Jan 28, 2022				
	>A> 8017615	Jun 16, 2024	DP			
	>A> 8017615*PED	Dec 16, 2024				
	>A> 8580796	Sep 25, 2022	DS			
	>A> 8580796*PED	Mar 25, 2023				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021713 001	>A> 7053092	Jan 28, 2022				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 002	>A> 7053092	Jan 28, 2022		U-839		
	>A> 8017615	Jun 16, 2024	DP			
	>A> 8017615*PED	Dec 16, 2024				
	>A> 8518421	Jan 24, 2021	DP			
	>A> 8518421*PED	Jul 24, 2021				
	>A> 8580796	Sep 25, 2022	DS			
	>A> 8580796*PED	Mar 25, 2023				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 003	>A> 7053092	Jan 28, 2022		U-839		
	>A> 8017615	Jun 16, 2024	DP			
	>A> 8017615*PED	Dec 16, 2024				
	>A> 8518421	Jan 24, 2021	DP			
	>A> 8518421*PED	Jul 24, 2021				
	>A> 8580796	Sep 25, 2022	DS			
	>A> 8580796*PED	Mar 25, 2023				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 004	>A> 7053092	Jan 28, 2022		U-839		
	>A> 8017615	Jun 16, 2024	DP			
	>A> 8017615*PED	Dec 16, 2024				
	>A> 8518421	Jan 24, 2021	DP			
	>A> 8518421*PED	Jul 24, 2021				
	>A> 8580796	Sep 25, 2022	DS			
	>A> 8580796*PED	Mar 25, 2023				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 005	>A> 7053092	Jan 28, 2022		U-839		
	>A> 8017615	Jun 16, 2024	DP			
	>A> 8017615*PED	Dec 16, 2024				
	>A> 8518421	Jan 24, 2021	DP			
	>A> 8518421*PED	Jul 24, 2021				
	>A> 8580796	Sep 25, 2022	DS			
	>A> 8580796*PED	Mar 25, 2023				
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	5006528	Apr 20, 2015	DS DP U-543		NDF	Feb 28, 2016
	7807680	Oct 19, 2024	DP			
	8030313	Oct 19, 2024		U-543		
	8338427	Mar 15, 2025	DP U-543			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Dec 29, 2023	DS			
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	5006528	Apr 20, 2015	DS DP U-543		NDF	Feb 28, 2016
	7807680	Oct 19, 2024	DP			
	8030313	Oct 19, 2024		U-543		
	8338427	Mar 15, 2025	DP U-543			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Dec 29, 2023	DS			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	5763476	Jun 09, 2020	DP U-326			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	5763476	Jun 09, 2020	DP U-326			
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 001	5846966	Sep 21, 2013	DP U-1400		NC	May 03, 2016
	5846966*PED	Mar 21, 2014				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 002	5846966	Sep 21, 2013	DP U-1400		NC	May 03, 2016
	5846966*PED	Mar 21, 2014				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 003	5846966	Sep 21, 2013	DP U-1400		NC	May 03, 2016
	5846966*PED	Mar 21, 2014				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 004	5846966	Sep 21, 2013	DP U-1400		NC	May 03, 2016
	5846966*PED	Mar 21, 2014				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203 001	8518919	Nov 22, 2025	U-1430		M-129 NPP	Aug 30, 2016 Aug 30, 2016
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022371 001	8518919	Nov 22, 2025	U-1430			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 002					NC NCE	Dec 20, 2014 Feb 25, 2016
<u>AZTREONAM - CAYSTON</u>						
N 050814 001	8399496	Dec 20, 2021	DP U-1377			
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N 022205 001	8497256	Jun 23, 2031	U-1229			
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247 001	5998402	Apr 04, 2017	DS DP U-594			
	6479535	May 06, 2019	DP U-594			
	6479535	May 06, 2019	DP U-904			
	7138392	Apr 04, 2017	DS DP U-594			
	7683051	Mar 10, 2027	DS DP U-594			
	7683051	Mar 10, 2027	DS DP U-904			
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001	7498343	Oct 02, 2024	DS DP U-1321		ODE	Dec 28, 2019
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 001	8436190	Oct 26, 2030	DP		>A> ODE	Oct 31, 2015
	8436190*PED	Apr 26, 2031			>A> PED	May 01, 2016
	8445524	Mar 26, 2029	DS DP U-1402			
	8445524*PED	Sep 26, 2029				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 002	8436190	Oct 26, 2030	DP		>A> ODE	Oct 31, 2015
	8436190*PED	Apr 26, 2031			>A> PED	May 01, 2016
	8445524	Mar 26, 2029	DS DP U-1402			
	8445524*PED	Sep 26, 2029				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 003	8344006	Sep 23, 2029	DP U-1402		ODE	Mar 20, 2015
	8344006*PED	Mar 23, 2030			>A> ODE	Oct 31, 2015
	8445524	Mar 26, 2029	DS		PED	Sep 20, 2015
	8445524*PED	Sep 26, 2029			>A> PED	May 01, 2016
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 004	8344006	Sep 23, 2029	DP U-1402		ODE	Mar 20, 2015
	8344006*PED	Mar 23, 2030			>A> ODE	Oct 31, 2015
	8445524	Mar 26, 2029	DS		>A> PED	May 01, 2016
	8445524*PED	Sep 26, 2029			PED	Sep 20, 2015
<u>BEPOTASTINE BESILATE - BEPREVE</u>						
N 022288 001	6780877	Sep 19, 2019	DS DP			
<u>BESIFLOXACIN HYDROCHLORIDE - BESIVANCE</u>						
N 022308 001	8415342	Nov 07, 2030	U-80			
	8481526	Jan 09, 2031	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BIMATOPROST - LUMIGAN</u>						
N 022184 001	8524777	Mar 16, 2025	U-1235			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	8541466	Jan 21, 2022	U-1217			
<u>BOCEPREVIR - VICTRELIS</u>						
N 022258 001					M-126 NPP	Feb 27, 2016 Feb 13, 2016
<u>BRIMONIDINE TARTRATE - MIRVASO</u>						
N 024708 001	7439241	Aug 25, 2025	U-1428		NDF	Aug 23, 2016
	8053427	Jun 13, 2031	DP U-1428			
	8163725	Jun 13, 2031	DP			
	8231885	May 24, 2025	DP			
	8410102	May 24, 2025	U-1428			
	8426410	May 24, 2025	U-1428			
	8513247	Mar 25, 2031	DP U-1428			
	8513249	Mar 25, 2031	DP U-1428			
<u>BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA</u>						
N 024251 001	6316441	Dec 07, 2019	U-778		NC	Apr 19, 2016
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N 021398 001	7323463	Jan 19, 2023	DP	Y		
	8354409	Apr 19, 2022	DP U-1371			
<u>BROMFENAC SODIUM - PROLENSA</u>						
N 023168 001	8129431	Sep 11, 2025	DS DP		NP	Apr 05, 2016
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	7888310	Jul 25, 2023	U-1433			
	8137992	Jul 25, 2023	U-1433			
	8137993	Jul 25, 2023	U-1433			
	8137994	Jul 25, 2023	U-1433			
	8431155	Apr 30, 2032	DP U-976			
<u>BUDESONIDE - UCERIS</u>						
N 023634 001	7410651	Jun 09, 2020	DP U-1325		NDF	Jan 14, 2016
	7431943	Jun 09, 2020	DP			
	8293273	Jun 09, 2020	DP			
	RE43799	Jun 09, 2020	DP U-1325			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	8387615	Nov 10, 2024	DP			
	8528545	Oct 16, 2028	DP			
>A>	8575137	Jan 29, 2023	DP U-1073			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	8387615	Nov 10, 2024	DP			
	8461211	Sep 09, 2018	U-1118			
	8528545	Oct 16, 2028	DP			
>A>	8575137	Jan 29, 2023	DP U-1073			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	8475832	Mar 26, 2030	DP U-1411			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	8475832	Mar 26, 2030	DP U-1411			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	8475832	Mar 26, 2030	DP U-1411			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	8475832	Mar 26, 2030	DP U-1411			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 024242 001	8454996	Sep 24, 2019	U-1421			
	8470361	Oct 14, 2029	DP U-1425			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 024242 002	8454996	Sep 24, 2019	U-1421			
	8470361	Oct 14, 2029	DP U-1425			
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 023756 001					ODE	Nov 29, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756 002					ODE	Nov 29, 2019
<u>CALCITONIN SALMON RECOMBINANT - FORTICAL</u>						
N 021406 001	RE43580	Feb 02, 2021	DP U-227			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001	7943582	Feb 26, 2029	DS DP U-493		NCE	Mar 29, 2018
	7943788	Jul 14, 2027	DS DP			
	8222219	Jul 30, 2024	U-493			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002	7943582	Feb 26, 2029	DS DP U-493		NCE	Mar 29, 2018
	7943788	Jul 14, 2027	DS DP			
	8222219	Jul 30, 2024	U-493			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANDESARTAN CILEXETIL - CANDESARTAN CILEXETIL</u>						
A 078702 001					PC	Jul 09, 2013
<u>CANDESARTAN CILEXETIL - CANDESARTAN CILEXETIL</u>						
A 078702 002					PC	Jul 09, 2013
<u>CANDESARTAN CILEXETIL - CANDESARTAN CILEXETIL</u>						
A 078702 003					PC	Jul 09, 2013
<u>CANDESARTAN CILEXETIL - CANDESARTAN CILEXETIL</u>						
A 078702 004					PC	Jul 09, 2013
<u>CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE - CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE</u>						
A 090704 003					PC	Jun 02, 2013
<u>CAPECITABINE - XELODA</u>						
N 020896 001	5472949	Dec 14, 2013	U-271			
	5472949*PED	Jun 14, 2014				
<u>CAPECITABINE - XELODA</u>						
N 020896 002	5472949	Dec 14, 2013	U-271			
	5472949*PED	Jun 14, 2014				
<u>CARBINOXAMINE MALEATE - KARBINAL ER</u>						
N 022556 001	8062667	Mar 29, 2029	DP			
<u>CELECOXIB - CELEBREX</u>						
N 020998 001	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1348			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1352			
	RE44048*PED	Dec 02, 2015				
<u>CELECOXIB - CELEBREX</u>						
N 020998 002	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1348			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1352			
	RE44048*PED	Dec 02, 2015				
<u>CELECOXIB - CELEBREX</u>						
N 020998 003	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1348			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1352			
	RE44048*PED	Dec 02, 2015				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CELECOXIB - CELEBREX</u>						
N 020998 004	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1348			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1352			
	RE44048*PED	Dec 02, 2015				
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832 002	7422388	Apr 25, 2027	DP U-1397			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832 005	7422388	Apr 25, 2027	DP U-1397			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832 007	7422388	Apr 25, 2027	DP U-1397			
<u>CICLESONIDE - ALVESCO</u>						
N 021658 002	8371292	Aug 25, 2027	U-1355		M-125	Dec 17, 2015
<u>CICLESONIDE - ALVESCO</u>						
N 021658 003	8371292	Aug 25, 2027	U-1355		M-125	Dec 17, 2015
<u>CICLESONIDE - OMNARIS</u>						
N 022004 001	8371292	Aug 25, 2027	U-1356			
	8383611	Oct 20, 2020	DP			
<u>CICLESONIDE - ZETONNA</u>						
N 202129 001	8371292	Aug 25, 2027	U-1357			
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u>						
N 021473 001	8187632	Jun 23, 2021	DP			
	8187632*PED	Dec 23, 2021				
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u>						
N 021473 002	8187632	Jun 23, 2021	DP			
	8187632*PED	Dec 23, 2021				
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - PREPOPIK</u>						
N 202535 001	8450338	Oct 10, 2028	DP			
	8481083	Oct 10, 2028	DP			
<u>CLOBAZAM - ONFI</u>						
N 203993 001					ODE	Oct 21, 2018
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A 201402 001					PC	Jul 31, 2013
<u>CLOBETASOL PROPIONATE - OLUX E</u>						
N 022013 001	8460641	Nov 05, 2028	DP U-1410			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	7635704	Oct 26, 2026	DS DP U-257			
<u>COLCHICINE - COLCRYS</u>						
N 022352 001	8415395	Oct 06, 2028	U-1007			
	8415396	Oct 06, 2028	U-1007			
	8440721	Feb 17, 2029	U-1007			
	8440722	Feb 17, 2029	U-1020			
<u>CROFELEMER - FULYZAQ</u>						
N 202292 001 >A>	8574634	Jan 11, 2018	U-1319			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	8026284	Sep 22, 2027	U-1399		NDF	Apr 30, 2016
	8129433	Jan 26, 2027	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	8026284	Sep 22, 2027	U-1399		NDF	Apr 30, 2016
	8129433	Jan 26, 2027	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	7994185	Jan 20, 2030	DS DP U-1406		NCE	May 29, 2018
	8415345	Jan 20, 2030	DS DP U-1406		ODE	May 29, 2020
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	7994185	Jan 20, 2030	DS DP U-1406		NCE	May 29, 2018
	8415345	Jan 20, 2030	DS DP U-1406		ODE	May 29, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DALFAMPRIDINE - AMPYRA</u>						
N 022250 001	5540938	Jul 30, 2018	U-1030			
	8354437	Dec 22, 2026	U-1030			
	8440703	Apr 08, 2025	U-1030			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 001	8518987	Feb 16, 2024	DS DP		D-135	Feb 01, 2016
	8518987*PED	Aug 16, 2024			PED	Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 002	8518987	Feb 16, 2024	DS DP		D-135	Feb 01, 2016
	8518987*PED	Aug 16, 2024			PED	Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 003	8518987	Feb 16, 2024	DS DP		D-135	Feb 01, 2016
	8518987*PED	Aug 16, 2024			PED	Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 004	8518987	Feb 16, 2024	DS DP		D-135	Feb 01, 2016
	8518987*PED	Aug 16, 2024			PED	Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 005	8518987	Feb 16, 2024	DS DP		D-135	Feb 01, 2016
	8518987*PED	Aug 16, 2024			PED	Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 006	8518987	Feb 16, 2024	DS DP		D-135	Feb 01, 2016
	8518987*PED	Aug 16, 2024			PED	Aug 01, 2016
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 020895 001	8518987	Feb 16, 2024	DS DP		D-135	Feb 01, 2016
	8518987*PED	Aug 16, 2024			PED	Aug 01, 2016
<u>DEFERASIROX - EXJADE</u>						
N 021882 001					I-665	Jan 23, 2016
<u>DEFERASIROX - EXJADE</u>						
N 021882 002					I-665	Jan 23, 2016
<u>DEFERASIROX - EXJADE</u>						
N 021882 003					I-665	Jan 23, 2016
<u>DESONIDE - VERDESO</u>						
N 021978 001	8460641	Nov 05, 2028	DP U-1412			
<u>DESOXIMETASONE - TOPICORT</u>						
N 0204141 001	5990100	Mar 24, 2018	DP U-1408		NDF	Apr 11, 2016
	8277780	Apr 23, 2028	DP U-1408			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 001	6673838	Feb 11, 2022	DS DP U-860		I-675	Feb 14, 2016
	6673838	Feb 11, 2022	DS DP U-1364			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 002	6673838	Feb 11, 2022	DS DP U-860		I-675	Feb 14, 2016
	6673838	Feb 11, 2022	DS DP U-1364			
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001	8506987	Jan 09, 2023	U-1204			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 001	4910214	Jul 15, 2013	DS DP U-421			
	4910214*PED	Jan 15, 2014				
	6716867	Mar 31, 2019	U-572			
	6716867*PED	Oct 01, 2019				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002	4910214	Jul 15, 2013	DS DP U-421			
	4910214*PED	Jan 15, 2014				
	6716867	Mar 31, 2019	U-572			
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003	4910214	Jul 15, 2013	DS DP U-421			
	4910214*PED	Jan 15, 2014				
	6716867	Mar 31, 2019	U-572			
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 202580 001					>A> PC	May 17, 2014
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 001					NP	Oct 18, 2016
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 002					NP	Oct 18, 2016
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 020947 001	8546450	Aug 09, 2030	U-1435			
	8546450	Aug 09, 2030	U-1436			
<u>DIFLUPREDNATE - DUREZOL</u>						
N 022212 001	6114319	May 18, 2019	DP		I-653	Jun 13, 2015
	6114319*PED	Nov 18, 2019			M-127	Mar 22, 2016
					ODE	Jun 13, 2019
					PED	Dec 13, 2015
					PED	Dec 13, 2019
					PED	Sep 22, 2016
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 001	6509376	Oct 29, 2019	DP		NCE	Mar 27, 2018
	7320999	May 18, 2020	U-1384			
	7619001	Apr 01, 2018	U-1384			
	7803840	Apr 01, 2018	U-1385			
	8399514	Feb 07, 2028	U-1384			
	8524773	Apr 01, 2018	U-1384			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 002	6509376	Oct 29, 2019	DP		NCE	Mar 27, 2018
	7320999	May 18, 2020	U-1384			
	7619001	Apr 01, 2018	U-1384			
	7803840	Apr 01, 2018	U-1385			
	8399514	Feb 07, 2028	U-1384			
	8524773	Apr 01, 2018	U-1384			
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 001	8129385	Oct 05, 2027	DS DP		NCE	Aug 12, 2018
<u>DONEPEZIL HYDROCHLORIDE - DONEPEZIL HYDROCHLORIDE</u>						
A 202542 001					PC	Jan 22, 2014
<u>DONEPEZIL HYDROCHLORIDE - DONEPEZIL HYDROCHLORIDE</u>						
A 202723 001					PC	Jan 22, 2014
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT</u>						
N 022568 001	8481565	Oct 04, 2026	DP			
<u>DOXEFIN HYDROCHLORIDE - SILENOR</u>						
N 022036 001	8513299	Apr 14, 2030	U-620			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 002	8513299	Apr 14, 2030	U-620			
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001	8394405	Apr 07, 2024	DP U-925			
	8394406	Apr 07, 2024	DP U-925			
	8470364	Apr 07, 2024	DP U-925			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 004	6958161	Dec 15, 2022	DP U-918			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 005	6958161	Dec 15, 2022	DP U-918		D-136 NS	Apr 11, 2016 Apr 11, 2016
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - DICLEGIS</u>						
N 021876 001	6340695	Jun 21, 2021	DP U-1382		NP	Apr 08, 2016
	7560122	Jan 25, 2019	DP			
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N 022425 001	5223510	Jul 26, 2016	DS DP U-992			
	5223510	Jul 26, 2016	DS DP U-1261			
	8410167	Apr 16, 2029	U-1387			
	8410167	Apr 16, 2029	U-1388			
<u>DROSPIRENONE; ETHINYL ESTRADIOL - YAZ</u>						
N 021676 001	RE43916	Jun 30, 2014	U-1326			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ</u>						
N 022532 001	RE43916	Jun 30, 2014	U-1326			
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 001					M-61 PED	Oct 18, 2015 Apr 18, 2016
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 002					M-61 PED	Oct 18, 2015 Apr 18, 2016
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 004					M-61 PED	Oct 18, 2015 Apr 18, 2016
<u>ECONAZOLE NITRATE - ECOZA</u>						
N 205175 001 >A>	5993830	Jan 16, 2018	DP U-1449		NDF	Oct 24, 2016
<u>EFAVIRENZ - SUSTIVA</u>						
N 020972 001	5519021	May 21, 2013	DS DP		NPP	May 02, 2016
	5519021*PED	Nov 21, 2013			PED	Nov 02, 2016
	5663169	Sep 02, 2014	U-257			
	5663169*PED	Mar 02, 2015				
	6238695	Apr 06, 2019	DP			
	6238695*PED	Oct 06, 2019				
	6555133	Apr 06, 2019	U-248			
	6555133*PED	Oct 06, 2019				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFAVIRENZ - SUSTIVA</u>						
N 020972 002	5519021	May 21, 2013	DS DP			
	5519021*PED	Nov 21, 2013				
	5663169	Sep 02, 2014	U-257			
	5663169*PED	Mar 02, 2015				
	6238695	Apr 06, 2019	DP			
	6238695*PED	Oct 06, 2019				
	6555133	Apr 06, 2019	U-248			
	6555133*PED	Oct 06, 2019				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EFAVIRENZ - SUSTIVA</u>						
N 020972 003	5519021	May 21, 2013	DS DP		NPP	May 02, 2016
	5519021*PED	Nov 21, 2013			PED	Nov 02, 2016
	5663169	Sep 02, 2014	U-257			
	5663169*PED	Mar 02, 2015				
	6238695	Apr 06, 2019	DP			
	6238695*PED	Oct 06, 2019				
	6555133	Apr 06, 2019	U-248			
	6555133*PED	Oct 06, 2019				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFAVIRENZ - SUSTIVA</u>						
N 021360 001	5519021	May 21, 2013				
	5519021*PED	Nov 21, 2013				
	5663169	Sep 02, 2014				
	5663169*PED	Mar 02, 2015				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFAVIRENZ - SUSTIVA</u>						
N 021360 002	5519021	May 21, 2013	DS DP		NPP	May 02, 2016
	5519021*PED	Nov 21, 2013			PED	Nov 02, 2016
	5663169	Sep 02, 2014	U-248			
	5663169*PED	Mar 02, 2015				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937 001	5519021	May 21, 2013	DS DP			
	5519021*PED	Nov 21, 2013				
	5663169	Sep 02, 2014	U-750			
	5663169	Sep 02, 2014	U-1170			
	5663169*PED	Mar 02, 2015				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>ENALAPRIL MALEATE - EPANED KIT</u>						
N 204308 001	8568747	Nov 06, 2032	DP			
<u>ENTECAVIR - BARACLUDE</u>						
N 021797 001	>A> 5206244	Feb 21, 2015	DS		>A> D-127	Oct 15, 2013
	>A> 5206244*PED	Aug 21, 2015			>A> NPP	Oct 12, 2015
					>A> NPP	Oct 12, 2015
					>A> PED	Apr 15, 2014
					>A> PED	Apr 12, 2016
					>A> PED	Apr 12, 2016
<u>ENTECAVIR - BARACLUDE</u>						
N 021797 002	>A> 5206244	Feb 21, 2015	DS		>A> D-127	Oct 15, 2013
	>A> 5206244*PED	Aug 21, 2015			>A> NPP	Oct 12, 2015
					>A> NPP	Oct 12, 2015
					>A> PED	Apr 12, 2016
					>A> PED	Apr 15, 2014
					>A> PED	Apr 12, 2016
<u>ENTECAVIR - BARACLUDE</u>						
N 021798 001	>A> 5206244	Feb 21, 2015	DS		>A> D-127	Oct 15, 2013
	>A> 5206244*PED	Aug 21, 2015			>A> NPP	Oct 12, 2015
					>A> NPP	Oct 12, 2015
					>A> PED	Apr 12, 2016
					>A> PED	Apr 12, 2016
					>A> PED	Apr 15, 2014

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N 022260 001	8318802	Mar 15, 2027	DP			
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N 022260 002	8318802	Mar 15, 2027	DP			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 001	6900221	Nov 09, 2020	DS DP U-659		I-671	May 14, 2016
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 002	6900221	Nov 09, 2020	DS DP U-659		I-671	May 14, 2016
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 003	6900221	Nov 09, 2020	DS DP U-659		I-671	May 14, 2016
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	>A> 5753646	Jun 27, 2016	DS DP U-1451		>A> NCE	Nov 08, 2018
	>A> 8372431	Apr 17, 2030	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	>A> 5753646	Jun 27, 2016	DS DP U-1451		>A> NCE	Nov 08, 2018
	>A> 8372431	Apr 17, 2030	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	>A> 5753646	Jun 27, 2016	DS DP U-1451		>A> NCE	Nov 08, 2018
	>A> 8372431	Apr 17, 2030	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	>A> 5753646	Jun 27, 2016	DS DP U-1451		>A> NCE	Nov 08, 2018
	>A> 8372431	Apr 17, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021153 001	8466175	May 25, 2018	U-1417			
	8466175*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021153 002	8466175	May 25, 2018	U-1417			
	8466175*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021957 001	8466175	May 25, 2018	U-1417			
	8466175*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021957 002	8466175	May 25, 2018	U-1417			
	8466175*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	8557285	May 31, 2022	DP			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 002	8557285	May 31, 2022	DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 001	5656286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	8231906	Jul 04, 2030	DS DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 002	5656286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	8231906	Jul 04, 2030	DS DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 003	5656286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	8231906	Jul 04, 2030	DS DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 004	5656286	Aug 12, 2014	DS DP			
	6024976	Jan 07, 2014	DS DP			
	8231906	Jul 04, 2030	DS DP			
<u>ESZOPICLONE - LUNESTA</u>						
N 021476 001					M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ESZOPICLONE - LUNESTA</u>						
N 021476 002					M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ESZOPICLONE - LUNESTA</u>						
N 021476 003					M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - QUARTETTE</u>						
N 204061 001	8415332	Mar 11, 2029	DP		NP	Mar 28, 2016
	8450299	Oct 07, 2025	U-1			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MINASTRIN 24 FE</u>						
N 203667 001	5552394	Jul 22, 2014	U-1		NDF	May 08, 2016
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>						
N 204426 001	5552394	Jul 22, 2014	U-1			
	6652880	Mar 29, 2020	DP			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO MINASTRIN FE</u>						
N 204654 001	5552394	Jul 22, 2014	U-1			
	6667050	Apr 06, 2019	DP U-1			
	7704984	Feb 02, 2029	U-1			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 001	5665772	Sep 09, 2019	DS DP U-1049		I-668	Feb 15, 2016
	5665772	Sep 09, 2019	DS DP U-1365			
	5665772*PED	Mar 09, 2020				
	6004973	Jul 12, 2016	DP U-1049			
	6004973	Jul 12, 2016	DP U-1365			
	6004973*PED	Jan 12, 2017				
	6440990	Sep 24, 2013	DP U-1049			
	6440990	Sep 24, 2013	DP U-1365			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518	Jul 29, 2017	U-1365			
	6455518*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 002	5665772	Sep 09, 2019	DS DP U-1049		I-668	Feb 15, 2016
	5665772	Sep 09, 2019	DS DP U-1365			
	5665772*PED	Mar 09, 2020				
	6004973	Jul 12, 2016	DP U-1049			
	6004973	Jul 12, 2016	DP U-1365			
	6004973*PED	Jan 12, 2017				
	6440990	Sep 24, 2013	DP U-1049			
	6440990	Sep 24, 2013	DP U-1365			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518	Jul 29, 2017	U-1365			
	6455518*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 003	5665772	Sep 09, 2019	DS DP U-1049		I-668	Feb 15, 2016
	5665772	Sep 09, 2019	DS DP U-1365			
	5665772*PED	Mar 09, 2020				
	6004973	Jul 12, 2016	DP U-1049			
	6004973	Jul 12, 2016	DP U-1365			
	6004973*PED	Jan 12, 2017				
	6440990	Sep 24, 2013	DP U-1049			
	6440990	Sep 24, 2013	DP U-1365			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518	Jul 29, 2017	U-1365			
	6455518*PED	Jan 29, 2018				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	8410131	May 22, 2025	DS DP U-1368			
	8410131*PED	Nov 22, 2025				
	8436010	Feb 22, 2022	DS DP U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	8410131	May 22, 2025	DS DP U-1368			
	8410131*PED	Nov 22, 2025				
	8436010	Feb 22, 2022	DS DP U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003	8410131	May 22, 2025	DS DP U-1368			
	8410131*PED	Nov 22, 2025				
	8436010	Feb 22, 2022	DS DP U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004	8410131	May 22, 2025	DS DP U-1368			
	8410131*PED	Nov 22, 2025				
	8436010	Feb 22, 2022	DS DP U-1396			
	8436010*PED	Aug 22, 2022				
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	8431685	Apr 13, 2025	DP U-412			
	8461105	Apr 13, 2025	DP U-412			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FAMOTIDINE; IBUPROFEN - DUEXIS</u>						
N 022519 001	8449910	Jul 18, 2026	DP			
	8501228	Jul 18, 2026	U-1196			
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 001	5614520	Mar 25, 2019	DS DP	U-954		
	8372872	Sep 08, 2031	U-1346			
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 002	5614520	Mar 25, 2019	DS DP	U-954		
	8372872	Sep 08, 2031	U-1346			
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695 004	8026281	Apr 22, 2025		U-1447		
	8026281	Apr 22, 2025		U-1448		
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695 005 >A>	8026281	Apr 22, 2025		U-1447		
	>A> 8026281	Apr 22, 2025		U-1448		
<u>FENOFIBRATE - FENOGLIDE</u>						
N 022118 001	8481078	Oct 01, 2024	DP	U-1416		
<u>FENOFIBRATE - FENOGLIDE</u>						
N 022118 002	8481078	Oct 01, 2024	DP	U-1416		
<u>FENTANYL - SUBSYS</u>						
N 020788 001	8486972	Apr 26, 2029	DP			
	8486973	Apr 26, 2029	U-55			
<u>FENTANYL - SUBSYS</u>						
N 020788 002	8486972	Apr 26, 2029	DP			
	8486973	Apr 26, 2029	U-55			
<u>FENTANYL - SUBSYS</u>						
N 020788 003	8486972	Apr 26, 2029	DP			
	8486973	Apr 26, 2029	U-55			
<u>FENTANYL - SUBSYS</u>						
N 020788 004	8486972	Apr 26, 2029	DP			
	8486973	Apr 26, 2029	U-55			
<u>FENTANYL - SUBSYS</u>						
N 020788 005	8486972	Apr 26, 2029	DP			
	8486973	Apr 26, 2029	U-55			
<u>FENTANYL - SUBSYS</u>						
N 020788 006	8486972	Apr 26, 2029	DP		NP	Jan 04, 2015
	8486973	Apr 26, 2029	U-55			
<u>FENTANYL - SUBSYS</u>						
N 020788 007	8486972	Apr 26, 2029	DP		NP	Jan 04, 2015
	8486973	Apr 26, 2029	U-55			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 020365 001	7612109	Feb 05, 2024	DS DP		NP	Jul 25, 2016
	7754702	Feb 13, 2027	DP	U-1432		
<u>FERUMOXYTOL - FERAHEME</u>						
N 022180 001	8501158	Mar 08, 2020		U-1422		
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030 001	8338478	May 11, 2019	DS DP	U-913		
	8501723	Jun 07, 2027	DP			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030 002	8338478	May 11, 2019	DS DP	U-913		
	8501723	Jun 07, 2027	DP			
<u>FIDAXOMICIN - DIFICID</u>						
N 021699 001 >A>	8586551	Apr 12, 2024	DS DP			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 020208 001	8506929	Apr 30, 2027	DS DP	U-1423		
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 020208 002	8506929	Apr 30, 2027	DS DP	U-1423		
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 020208 003	8506929	Apr 30, 2027	DS DP	U-1423		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUNISOLIDE - AEROSPAN HFA</u>						
N 021247 001	5980867	Dec 20, 2013	DP		M-128	Aug 28, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936 001					NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936 003					NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936 004					NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936 006					NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 001					NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 002					NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 003					NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 004					NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 005					NPP	Jul 26, 2016
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 001	>A> 8236282	May 21, 2024	DS DP			
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 002	>A> 8236282	May 21, 2024	DS DP			
<u>FLUTICASONE FUROATE - VERAMYST</u>						
N 022051 001	8347879	Apr 01, 2027	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	5873360	Feb 23, 2016	DP			
	6537983	Aug 03, 2021	DP U-1401			
	6759398	Aug 03, 2021	DP U-1401			
	6878698	Aug 03, 2021	U-1401			
	7101866	Aug 03, 2021	DS DP U-1401			
	7361787	Mar 23, 2023	DS DP U-1401			
	7439393	Sep 11, 2022	DS DP U-1401			
	7629335	Aug 03, 2021	DP			
	7776895	Sep 11, 2022	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8511304	Nov 11, 2025	DP U-1424			
	8534281	Aug 10, 2029	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 001	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 002	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 003	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
<u>FLUVOXAMINE MALEATE - FLUVOXAMINE MALEATE</u>						
A 091476 002					PC	Sep 09, 2013
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211 001	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1183			
	7563763	Aug 23, 2019	U-1367			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211 002	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1183			
	7563763	Aug 23, 2019	U-1367			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211 003	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1183			
	7563763	Aug 23, 2019	U-1367			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211 004	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1183			
	7563763	Aug 23, 2019	U-1367			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021273 001	5767251	Jun 16, 2015	DS			
	5929028	Jan 14, 2018	DP U-1366			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021273 002	5767251	Jun 16, 2015	DS			
	5929028	Jan 14, 2018	DP U-1366			
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518 001	7566705	May 21, 2020	DP U-1068			
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518 002	7566705	May 21, 2020	DP U-1068			
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	8466139	Jan 09, 2021	U-596			
	8466139*PED	Jul 09, 2021				
<u>GABAPENTIN - GRALISE</u>						
N 022544 001	8333992	Oct 25, 2022	DP U-1114			
<u>GABAPENTIN - GRALISE</u>						
N 022544 002	8333992	Oct 25, 2022	DP U-1114			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N 021711 001	8394356	Feb 01, 2015	U-1112			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N 021711 002	8394356	Feb 01, 2015	U-1112			
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 001					NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 002					NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 003					NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 004					NCE	Mar 20, 2018
<u>GADOXETATE DISODIUM - EOVI</u>						
N 022090 002					NCE	Jul 03, 2013
<u>GANIRELIX ACETATE - GANIRELIX ACETATE</u>						
N 021057 001	6653286	Jun 16, 2018	U-1354			
<u>GATIFLOXACIN - GATIFLOXACIN</u>						
A 202653 001					PC	Mar 30, 2014
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622 002	8367605	May 24, 2014	DS			
<u>GLIPIZIDE - GLUCOTROL XL</u>						
N 020329 001	RE44459	Mar 26, 2019	U-1431			
<u>GLIPIZIDE - GLUCOTROL XL</u>						
N 020329 002	RE44459	Mar 26, 2019	U-1431			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GLIPIZIDE - GLUCOTROL XL</u>						
N 020329 003	RE44459	Mar 26, 2019	U-1431			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	5968979	Feb 07, 2015	DS DP U-1378		NE	Feb 01, 2016
	8404215	Mar 09, 2032	U-1383		ODE	Feb 01, 2020
<u>GLYCOPYRROLATE - ROBINUL</u>						
N 012827 001	7091236	Apr 24, 2024	U-877	Y		
<u>GLYCOPYRROLATE - ROBINUL FORTE</u>						
N 012827 002	7091236	Apr 24, 2024	U-877	Y		
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001					NP	Oct 25, 2016
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002					NP	Oct 25, 2016
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003					NP	Oct 25, 2016
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004					NP	Oct 25, 2016
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005					NP	Oct 25, 2016
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006					NP	Oct 25, 2016
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001					>A> NCE >A> ODE	Nov 13, 2018 Nov 13, 2020
<u>IBUPROFEN LYSINE - NEOPROFEN</u>						
N 021903 001	8415337	Mar 02, 2032	DS DP			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	8357677	Feb 09, 2030	U-1287			
	8367652	Feb 09, 2030	U-1287			
	8377920	Feb 09, 2030	U-1287			
	8399446	Feb 09, 2030	U-1287			
	8415335	Feb 09, 2030	U-1287			
	8426399	Feb 09, 2030	U-1287			
	8431560	Feb 09, 2030	U-1287			
	8440650	Feb 09, 2030	U-1287			
	8445003	Apr 29, 2030	U-1287			
	8445013	Apr 29, 2030	U-1287			
	8501225	Apr 29, 2030	U-1287			
	8518929	Apr 29, 2030	U-1287			
	8524698	Apr 29, 2030	U-1287			
	8546372	Apr 29, 2030	U-1287			
	8551521	Apr 29, 2030	U-1287			
	8563608	Apr 29, 2030	U-1287			
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 001	7544799	Jan 16, 2019	DS DP	Y	I-666	Jan 25, 2016
	7544799*PED	Jul 16, 2019			ODE	Jan 25, 2020
	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 002	7544799	Jan 16, 2019	DS DP	Y	I-666	Jan 25, 2016
	7544799*PED	Jul 16, 2019			ODE	Jan 25, 2020
	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 001	>A> 8598196	Aug 18, 2029	U-172			
	>A> 8598196	Aug 18, 2029	U-1455			
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N 022383 001	8067437	Jun 02, 2020	U-1168			
	8479730	Oct 11, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INDIUM IN-111 PENTETREOTIDE KIT - OCTREOSCAN</u>						
N 020314 001	6123916	Sep 26, 2017	U-1125			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001	6844013	Dec 13, 2018	DS DP U-1221			
	8372827	Dec 18, 2026	DS DP			
	8372828	Dec 18, 2026	DS DP			
	8377919	Dec 18, 2026	DS DP			
	8536163	Dec 18, 2026	U-1440			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002	6844013	Dec 13, 2018	DS DP U-1221			
	8372827	Dec 18, 2026	DS DP			
	8372828	Dec 18, 2026	DS DP			
	8377919	Dec 18, 2026	DS DP			
	8536163	Dec 18, 2026	U-1440			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 75/25 KWIKPEN</u>						
N 021017 002	7291132	Aug 09, 2024	DP			
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 50/50 KWIKPEN</u>						
N 021018 002	7291132	Aug 09, 2024	DP			
<u>INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN</u>						
N 020563 003	7291132	Aug 09, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN - HUMULIN 70/30</u>						
N 019717 001 >A>	7291132	Aug 09, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN - HUMULIN 70/30 PEN</u>						
N 019717 002 >A>	7291132	Aug 09, 2024	DP			
<u>INSULIN SUSP ISOPHANE RECOMBINANT HUMAN - HUMULIN N</u>						
N 018781 001 >A>	7291132	Aug 09, 2024	DP			
<u>IOBENGUANE SULFATE I-123 - ADREVIEW</u>						
N 022290 001					I-669	Mar 20, 2016
<u>IRON SUCROSE - VENOFER</u>						
N 021135 005					NPP	Sep 21, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 001	8367102	Sep 21, 2021	U-1347			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 002	8367102	Sep 21, 2021	U-1347			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 003	8367102	Sep 21, 2021	U-1347			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 004	8367102	Sep 21, 2021	U-1347			
<u>ITRACONAZOLE - ONMEL</u>						
N 022484 001	8486456	Oct 03, 2028	DP U-1054			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	8410274	Dec 28, 2026	DP			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	8377982	May 28, 2024	U-1363			
	8377982*PED	Nov 28, 2024				
	8541463	May 28, 2024	U-1441			
	8541463*PED	Nov 28, 2024				
<u>KETOROLAC TROMETHAMINE - ACUVAIL</u>						
N 022427 001	8512717	Mar 07, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAPATINIB DITOSYLATE - TYKERB</u>						
N 022059 001	6391874	Jul 11, 2017	DS DP U-800			
	6391874	Jul 11, 2017	DS DP U-1429			
	6713485	Sep 29, 2020	DS DP U-800			
	6713485	Sep 29, 2020	DS DP U-1429			
	6727256	Jan 08, 2019	DS DP U-800			
	6727256	Jan 08, 2019	DS DP U-1429			
	6828320	Jul 11, 2017	U-800			
	6828320	Jul 11, 2017	U-1429			
	7157466	Nov 19, 2021	DS DP			
	8513262	Jan 08, 2019	DS DP			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	6281230	Jul 24, 2016	U-1212		I-672	Jun 05, 2016
	6281230	Jul 24, 2016	U-1414		ODE	Jun 05, 2020
	7468363	Oct 07, 2023	U-1414			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	6281230	Jul 24, 2016	U-1212		I-672	Jun 05, 2016
	6281230	Jul 24, 2016	U-1414		ODE	Jun 05, 2020
	7468363	Oct 07, 2023	U-1414			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	6281230	Jul 24, 2016	U-1212		I-672	Jun 05, 2016
	6281230	Jul 24, 2016	U-1414		ODE	Jun 05, 2020
	7468363	Oct 07, 2023	U-1414			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	6281230	Jul 24, 2016	U-1212		I-672	Jun 05, 2016
	6281230	Jul 24, 2016	U-1414		ODE	Jun 05, 2020
	7468363	Oct 07, 2023	U-1414			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	6281230	Jul 24, 2016	U-1212		I-672	Jun 05, 2016
	6281230	Jul 24, 2016	U-1414		ODE	Jun 05, 2020
	7468363	Oct 07, 2023	U-1414			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	5635517	Oct 04, 2019	DS DP U-1211		I-672	Jun 05, 2016
	6045501	Aug 28, 2018	U-1210		NS	Jun 05, 2016
	6281230	Jul 24, 2016	U-1212		ODE	Jun 05, 2020
	6281230	Jul 24, 2016	U-1414			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023	U-1414			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020	U-1249			
	8404717	Apr 11, 2023	U-1215			
	8530498	May 15, 2023	U-1216			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVALBUTEROL HYDROCHLORIDE - LEVALBUTEROL HYDROCHLORIDE</u>						
A 077756 001					PC	Feb 16, 2013
<u>LEVALBUTEROL HYDROCHLORIDE - LEVALBUTEROL HYDROCHLORIDE</u>						
A 077756 002					PC	Feb 16, 2013
<u>LEVALBUTEROL HYDROCHLORIDE - LEVALBUTEROL HYDROCHLORIDE</u>						
A 077756 003					PC	Feb 16, 2013
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140 001	6500829	Mar 07, 2022	DS DP			
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140 002	6500829	Mar 07, 2022	DS DP			
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140 003	6500829	Mar 07, 2022	DS DP			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 001	8481598	Mar 02, 2031	U-839		NCE*	Jul 25, 2018
	RE43879	Jun 03, 2023	U-839			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 002	8481598	Mar 02, 2031	U-839		NCE*	Jul 25, 2018
	RE43879	Jun 03, 2023	U-839			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 003	8481598	Mar 02, 2031	U-839		NCE*	Jul 25, 2018
	RE43879	Jun 03, 2023	U-839			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 004	8481598	Mar 02, 2031	U-839		NCE*	Jul 25, 2018
	RE43879	Jun 03, 2023	U-839			
<u>LEVONORGESTREL - PLAN B ONE-STEP</u>						
N 021998 001					RTO* RTO**	Apr 30, 2016 Apr 30, 2016
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001	5785053	Dec 05, 2015	DP		NP	Jan 09, 2016
	7252839	Nov 13, 2023	DP			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 001	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 002	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 003	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 004	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 005	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 006	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 007	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 008	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 009	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 010	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 011	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 012	7101569	Oct 02, 2023	U-759			
<u>LIDOCAINE HYDROCHLORIDE - ZINGO</u>						
N 022114 001	8540665	Oct 22, 2029	U-1438			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001 >A>	6268343	Aug 22, 2022	DS DP U-968			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	5712279	Feb 21, 2015	DS U-1317		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	5712279	Feb 21, 2015	DS U-1317		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	5712279	Feb 21, 2015	DS U-1317		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021251 001	8501219	Nov 28, 2021	DP			
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021906 001	8025899	Dec 14, 2027	DP			
	8025899*PED	Jun 14, 2028				
	8377952	Oct 22, 2027	U-1372			
	8377952*PED	Apr 22, 2028				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8470347	Sep 17, 2026	DP			
	8470347*PED	Mar 17, 2027				
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021906 002	8025899	Dec 14, 2027	DP			
	8025899*PED	Jun 14, 2028				
	8377952	Oct 22, 2027	U-1372			
	8377952*PED	Apr 22, 2028				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8470347	Sep 17, 2026	DP			
	8470347*PED	Mar 17, 2027				
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529 001	8367657	Apr 10, 2023	DS DP U-1252			
	8367657	Apr 10, 2023	DS DP U-1253			
	8367657	Apr 10, 2023	DS DP U-1254			
	8367657	Apr 10, 2023	DS DP U-1255			
	8546379	Apr 10, 2023	DS DP U-1252			
	8546379	Apr 10, 2023	DS DP U-1253			
	8546379	Apr 10, 2023	DS DP U-1254			
	8546379	Apr 10, 2023	DS DP U-1255			
>A>	8575149	Apr 10, 2023	U-1452			
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N 202872 001	5800807	Jan 29, 2017	DP			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	6716416	May 20, 2022	DP			
	7052679	Mar 20, 2022	DP			
	7078020	Oct 26, 2021	DP U-1375			
	7090830	Oct 26, 2021	DP			
	7458374	Aug 18, 2024	DP			
	7537009	Oct 26, 2021	DP			
	7585493	Oct 26, 2021	DP			
	7601337	Oct 26, 2021	DP			
	8074644	Oct 26, 2021	DP			
	8173107	Oct 26, 2021	DP			
	8235037	Oct 26, 2021	DP			
	8387612	Oct 23, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 001	6414016	Sep 05, 2020	U-717		I-670	Apr 19, 2016
	6414016	Sep 05, 2020	U-1392			
	6982283	Dec 04, 2022	U-1391			
	7064148	Aug 30, 2022	U-739			
	7064148	Aug 30, 2022	U-1404			
	8026393	Oct 25, 2027	DP			
	8071613	Sep 05, 2020	U-1203			
	8071613	Sep 05, 2020	U-1393			
	8097653	Nov 14, 2022	U-1214			
	8097653	Nov 14, 2022	U-1394			
	8389542	Nov 14, 2022	DP U-1345			
	8389542	Nov 14, 2022	DP U-1395			
<u>LULICONAZOLE - LUZU</u>						
N 204153 001 >A>	5900488	Jul 05, 2016	DS DP U-540		>A> NCE	Nov 14, 2018
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	5532372	Jul 02, 2018	DS		I-674	Jun 28, 2016
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	5532372	Jul 02, 2018	DS		I-674	Jun 28, 2016
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	5532372	Jul 02, 2018	DS		I-674	Jun 28, 2016
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	5532372	Jul 02, 2018	DS		I-674	Jun 28, 2016
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005					D-134 I-674 NCE	Apr 26, 2015 Jun 28, 2016 Oct 28, 2015
<u>MACITENTAN - OPSUMIT</u>						
N 204410 001	7094781	Oct 12, 2022	DS DP		NCE	Oct 18, 2018
	8268847	Apr 18, 2029	U-1446		ODE	Oct 18, 2020
	8367685	Oct 04, 2028	DP U-1445			
<u>MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE - SUCLEAR</u>						
N 203595 001					NC	Jan 18, 2016
<u>MECHLORETHAMINE HYDROCHLORIDE - VALCHLOR</u>						
N 202317 001	7838564	Mar 07, 2026	DP		NDF	Aug 23, 2016
	7872050	Jul 08, 2029	U-1427		>A> ODE	Aug 23, 2020
	8450375	Mar 07, 2026	DP			
	8501818	Mar 07, 2026	DP			
	8501819	Mar 07, 2026	U-1427			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 001	8168209	Nov 22, 2025	DP			
	8173708	Nov 22, 2025	U-539			
	8283379	Nov 22, 2025	U-539			
	8329752	Nov 22, 2025	DP			
	8362085	Nov 22, 2025	U-539			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 002	8168209	Nov 22, 2025	DP			
	8173708	Nov 22, 2025	U-539			
	8283379	Nov 22, 2025	U-539			
	8329752	Nov 22, 2025	DP			
	8362085	Nov 22, 2025	U-539			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 003	8168209	Nov 22, 2025	DP			
	8173708	Nov 22, 2025	U-539			
	8283379	Nov 22, 2025	U-539			
	8329752	Nov 22, 2025	DP			
	8362085	Nov 22, 2025	U-539			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 004	8168209	Nov 22, 2025	DP			
	8173708	Nov 22, 2025		U-539		
	8283379	Nov 22, 2025		U-539		
	8329752	Nov 22, 2025	DP			
	8362085	Nov 22, 2025		U-539		
<u>MESALAMINE - CANASA</u>						
N 021252 002	8217083	Jun 06, 2028	DP			
	8436051	Jun 06, 2028	DP			
<u>MESALAMINE - ASACOL HD</u>						
N 021830 001	8580302	Nov 15, 2021	DP			
<u>MESALAMINE - APRISO</u>						
N 022301 001	8496965	Apr 20, 2018	DP			
<u>MESALAMINE - DELZICOL</u>						
N 204412 001	5541170	Jul 30, 2013	DP	U-141		
	5541171	Jul 30, 2013	DP	U-141		
	6649180	Apr 13, 2020	DP			
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N 021574 001	8475841	Mar 20, 2018		U-604		
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N 021574 002	8475841	Mar 20, 2018		U-604		
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 001	8470368	Sep 19, 2023	DP			
	8475841	Mar 20, 2018		U-973		
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 002	8470368	Sep 19, 2023	DP			
	8475841	Mar 20, 2018		U-973		
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001	RE44186	Jul 31, 2023	DS DP	U-1097		
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002	RE44186	Jul 31, 2023	DS DP	U-1097		
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003	RE44186	Jul 31, 2023	DS DP	U-1097		
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001	7459428	Feb 02, 2019		U-1036		
	8414921	Jul 21, 2028	DP	U-1036		
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002	7459428	Feb 02, 2019		U-1036		
	8414921	Jul 21, 2028	DP	U-1036		
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	6746429	Apr 12, 2020	DP			
>A>	7744582	Aug 10, 2019	DP	U-1442		
	7776015	Aug 10, 2019	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP	U-1442		
	8562564	Jan 24, 2026	DP			
>A>	8579865	Mar 19, 2030	DP	U-1442		
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	6746429	Apr 12, 2020	DP			
>A>	7744582	Aug 10, 2019	DP	U-1442		
	7776015	Aug 10, 2019	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP	U-1442		
	8562564	Jan 24, 2026	DP			
>A>	8579865	Mar 19, 2030	DP	U-1442		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	6746429	Apr 12, 2020	DP			
	>A> 7744582	Aug 10, 2019	DP		U-1442	
	7776015	Aug 10, 2019	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP		U-1442	
	8562564	Jan 24, 2026	DP			
	>A> 8579865	Mar 19, 2030	DP		U-1442	
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	6746429	Apr 12, 2020	DP			
	>A> 7744582	Aug 10, 2019	DP		U-1442	
	7776015	Aug 10, 2019	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP		U-1442	
	8562564	Jan 24, 2026	DP			
	>A> 8579865	Mar 19, 2030	DP		U-1442	
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 001	8420663	Sep 30, 2029			U-1185	
	8552025	Apr 08, 2024	DP			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 002	8420663	Sep 30, 2029			U-1185	
	8552025	Apr 08, 2024	DP			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 003	8420663	Sep 30, 2029			U-1185	
	8552025	Apr 08, 2024	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR</u>						
N 202100 001	8062667	Mar 29, 2029	DP			
	8287903	Feb 15, 2031	DP			
	8465765	Feb 15, 2031	DP		U-1415	
	>A> 8563033	Feb 15, 2031	DP		U-1415	
<u>METRONIDAZOLE - METRONIDAZOLE</u>						
A 090903 001					PC	Dec 28, 2013
<u>MICONAZOLE - ORAVIG</u>						
N 022404 001	8518442	Sep 11, 2022	DP			
<u>MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE - VUSION</u>						
N 021026 001	8147852	Mar 30, 2028			U-1426	
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922 001	5908838	Feb 19, 2018			U-1376	
	7541347	Apr 02, 2027			U-917	
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025			U-124	
	7919483	Mar 07, 2027			U-124	
	8252776	Jun 24, 2025			U-124	
	8268804	Jun 24, 2025			U-124	
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922 003	5908838	Feb 19, 2018			U-1376	
	7541347	Apr 02, 2027			U-917	
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025			U-124	
	7919483	Mar 07, 2027			U-124	
	8252776	Jun 24, 2025			U-124	
	8268804	Jun 24, 2025			U-124	
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922 005	5908838	Feb 19, 2018			U-1376	
	7541347	Apr 02, 2027			U-917	
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025			U-124	
	7919483	Mar 07, 2027			U-124	
	8252776	Jun 24, 2025			U-124	
	8268804	Jun 24, 2025			U-124	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MIPOMERSEN SODIUM - KYNAMRO</u>						
N 203568 001	5914396	Jun 22, 2016	DS		NCE	Jan 29, 2018
	6166197	Dec 26, 2017	DS		ODE	Jan 29, 2020
	6222025	Mar 06, 2015	DS			
	6451991	Feb 11, 2017	DS			
	7015315	Mar 21, 2023	DS			
	7101993	Sep 05, 2023	DS			
	7407943	Aug 01, 2021		U-1353		
	7511131	Dec 13, 2025	DS			
<u>MOMETASONE FUROATE - ELOCON</u>						
N 019625 002					NP	Apr 19, 2016
<u>MOXIFLOXACIN HYDROCHLORIDE - MOXEZA</u>						
N 022428 001	8450311	May 29, 2029	DP			
<u>MUPIROCIN CALCIUM - BACTROBAN</u>						
N 050703 001	5569672	Oct 29, 2013		U-1358		
<u>MUPIROCIN CALCIUM - BACTROBAN</u>						
N 050746 001	5569672	Oct 29, 2013		U-1358		
<u>MYCOPHENOLIC ACID - MYFORTIC</u>						
N 050791 001	6306900	Feb 27, 2018	DP			
<u>MYCOPHENOLIC ACID - MYFORTIC</u>						
N 050791 002	6306900	Feb 27, 2018	DP			
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 204286 001					NP	Jun 27, 2016
<u>NEPAFENAC - ILEVRO</u>						
N 203491 001	5475034	Jun 06, 2014		U-100		
	6403609	Jul 17, 2018	DP			
	7947295	Jun 08, 2024	DP			
<u>NEVIRAPINE - VIRAMUNE XR</u>						
N 201152 001	8460704	Mar 12, 2029		U-1409		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 002	8455524	Apr 18, 2027		U-1029		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 003	8455524	Apr 18, 2027		U-1029		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 004	8455524	Apr 18, 2027		U-1029		
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 005	8455524	Apr 18, 2027		U-1029		
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360 001	8501164	Jun 14, 2029	DP			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360 002	8501164	Jun 14, 2029	DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068 001	8389537	Jul 18, 2026	DS DP	U-1374		
	8415363	Jul 18, 2026	DS DP	U-1407		
	8501760	Jul 18, 2026	DS DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068 002	8389537	Jul 18, 2026	DS DP	U-1374		
	8415363	Jul 18, 2026	DS DP	U-1407		
	8501760	Jul 18, 2026	DS DP			
<u>NIMODIPINE - NYMALIZE</u>						
N 203340 001					ODE	May 10, 2020
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 002	8431163	Jun 30, 2029		U-1286		
	8431163*PED	Dec 30, 2029				
	>A> 8573209	Jan 06, 2031	DP			
	>A> 8573209*PED	Jul 06, 2031				
	>A> 8573210	Jan 06, 2031	DP	U-1453		
	>A> 8573210*PED	Jul 06, 2031				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	8431163	Jun 30, 2029	U-1286			
	8431163*PED	Dec 30, 2029				
	>A> 8573209	Jan 06, 2031	DP			
	>A> 8573209*PED	Jul 06, 2031				
	>A> 8573210	Jan 06, 2031	DP U-1453			
	>A> 8573210*PED	Jul 06, 2031				
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 001					NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 002					NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 003					NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 004					NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 005					NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 006					NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086 001					NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086 002					NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086 003					NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086 004					NPP	Jul 26, 2016
<u>OLOPATADINE HYDROCHLORIDE - PATANASE</u>						
N 021861 001	8399508	Sep 17, 2022	U-726			
	8399508*PED	Mar 17, 2023				
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 001	6489346	Jul 16, 2016	DS DP U-588	Y		
	6645988	Jul 16, 2016	DS DP	Y		
	6699885	Jul 16, 2016	U-588	Y		
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 002	6489346	Jul 16, 2016	DS DP U-623	Y		
	6489346	Jul 16, 2016	DS DP U-624	Y		
	6645988	Jul 16, 2016	DS DP	Y		
	6699885	Jul 16, 2016	U-623	Y		
	6699885	Jul 16, 2016	U-624	Y		
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID OTC</u>						
N 022281 001	6489346	Jul 15, 2016	DP U-1025	Y		
	6645988	Jul 15, 2016	DP	Y		
	6699885	Jul 15, 2016	DP	Y		
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID OTC</u>						
N 022283 001	5840737	Jul 16, 2016	U-1025			
	6780882	Jul 16, 2016	DP			
	7399772	Jul 16, 2016	U-1025			
<u>ONDANSETRON - ZUPLENZ</u>						
N 022524 001	>A> 8580830	Nov 23, 2029	DP			
<u>ONDANSETRON - ZUPLENZ</u>						
N 022524 002	>A> 8580830	Nov 23, 2029	DP			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 001					NPP	Dec 21, 2015
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 002					NPP	Dec 21, 2015
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 003					NPP	Dec 21, 2015

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246 001					NPP	Dec 21, 2015
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246 002					NPP	Dec 21, 2015
<u>OSPEMIFENE - OSPHENA</u>						
N 203505 001	6245819	Jul 21, 2020	U-1369		NCE	Feb 26, 2018
	8236861	Aug 11, 2026	U-1369			
	8236861	Aug 11, 2026	U-1370			
	8470890	Feb 13, 2024	U-1369			
	8470890	Feb 13, 2024	U-1370			
<u>OXYBUTYNIN - OXYTROL FOR WOMEN</u>						
N 202211 001	5601839	Apr 26, 2015	DP U-1329		NP	Jan 25, 2016
	5834010	Apr 26, 2015	DP U-1329			
	6743441	Apr 26, 2020	DP U-1329			
	7081249	Apr 26, 2020	DP U-1329			
	7081250	Apr 26, 2020	DP U-1329			
	7081251	Apr 26, 2020	DP U-1329			
	7081252	Apr 26, 2020	DP U-1329			
	7179483	Apr 26, 2020	U-1329			
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N 202080 001	8409616	Nov 26, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N 202080 002	8409616	Nov 26, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OXYMORPHONE HYDROCHLORIDE</u>						
A 079087 006					PC	Jul 07, 2013
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001	7758891	Feb 21, 2026	U-1434		I-676	Sep 06, 2016
	7820788	Mar 03, 2024	DP U-1092		ODE	Sep 06, 2020
	7820788	Mar 03, 2024	DP U-1290			
	7820788	Mar 03, 2024	DP U-1434			
	7923536	Dec 09, 2023	U-1117			
	7923536	Dec 09, 2023	U-1290			
	7923536	Dec 09, 2023	U-1434			
	8138229	Dec 09, 2023	DP U-1092			
	8138229	Dec 09, 2023	DP U-1290			
	8138229	Dec 09, 2023	DP U-1434			
	8314156	Dec 09, 2023	U-1290			
	8314156	Dec 09, 2023	U-1434			
	RE41884	Aug 14, 2016	U-1117			
	RE41884	Aug 14, 2016	U-1290			
	RE41884	Aug 14, 2016	U-1434			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	8518981	Jan 30, 2024	DP			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	8518981	Jan 30, 2024	DP			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725 005					M-93 NCE	Jul 29, 2019 Apr 30, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 001	>A> 8562978	Feb 20, 2028	DP			
	>A> 8562979	Feb 20, 2028	DP			
	>A> 8562980	Feb 20, 2028	DP			
	>A> 8562981	Feb 20, 2028				
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 002	>A> 8562978	Feb 20, 2028	DP			
	>A> 8562979	Feb 20, 2028	DP			
	>A> 8562980	Feb 20, 2028	DP			
	>A> 8562981	Feb 20, 2028				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 003	>A> 8562978	Feb 20, 2028	DP			
	>A> 8562979	Feb 20, 2028	DP			
	>A> 8562980	Feb 20, 2028	DP			
	>A> 8562981	Feb 20, 2028				
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 004	>A> 8562978	Feb 20, 2028	DP			
	>A> 8562979	Feb 20, 2028	DP			
	>A> 8562980	Feb 20, 2028	DP			
	>A> 8562981	Feb 20, 2028				
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 005	>A> 8562978	Feb 20, 2028	DP			
	>A> 8562979	Feb 20, 2028	DP			
	>A> 8562980	Feb 20, 2028	DP			
	>A> 8562981	Feb 20, 2028				
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 006	>A> 8562978	Feb 20, 2028	DP			
	>A> 8562979	Feb 20, 2028	DP			
	>A> 8562980	Feb 20, 2028	DP			
	>A> 8562981	Feb 20, 2028				
<u>PARICALCITOL - PARICALCITOL</u>						
A 090829 001					PC	Dec 24, 2013
<u>PARICALCITOL - PARICALCITOL</u>						
A 090829 002					PC	Dec 24, 2013
<u>PARICALCITOL - PARICALCITOL</u>						
A 090829 003					PC	Dec 24, 2013
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	5874447	Jun 10, 2017	DS		NP	Jun 28, 2016
	7598271	Feb 12, 2023	DS			
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088 001	8440170	Mar 14, 2029	DP			
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088 002	8440170	Mar 14, 2029	DP			
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088 003	8440170	Mar 14, 2029	DP			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 001	8580298	May 15, 2029	DP			
	8580299	Jun 14, 2029			U-1262	
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 002	8580298	May 15, 2029	DP			
	8580299	Jun 14, 2029			U-1262	
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 003	8580298	May 15, 2029	DP			
	8580299	Jun 14, 2029			U-1262	
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 004	8580298	May 15, 2029	DP			
	8580299	Jun 14, 2029			U-1262	
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 001	5856336	Dec 25, 2020	DS		U-998	
	8557993	Feb 02, 2024	DP			
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 002	5856336	Dec 25, 2020	DS		U-998	
	8557993	Feb 02, 2024	DP			
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 003	5856336	Dec 25, 2020	DS		U-998	
	8557993	Feb 02, 2024	DS DP			
<u>PLERIXAFOR - MOZOBIL</u>						
N 022311 001	RE42152	Dec 10, 2018	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	5635517	Jul 24, 2016	U-1359		NCE	Feb 08, 2018
	6045501	Aug 28, 2018	U-1361		ODE	Feb 08, 2020
	6315720	Oct 23, 2020	U-1361			
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	5635517	Jul 24, 2016	U-1359		NCE	Feb 08, 2018
	6045501	Aug 28, 2018	U-1361		ODE	Feb 08, 2020
	6315720	Oct 23, 2020	U-1361			
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	5635517	Jul 24, 2016	U-1359		NCE	Feb 08, 2018
	6045501	Aug 28, 2018	U-1361		ODE	Feb 08, 2020
	6315720	Oct 23, 2020	U-1361			
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	5635517	Jul 24, 2016	U-1359		NCE	Feb 08, 2018
	6045501	Aug 28, 2018	U-1361		ODE	Feb 08, 2020
	6315720	Oct 23, 2020	U-1361			
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001					ODE	Dec 14, 2019
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002					ODE	Dec 14, 2019
<u>POSACONAZOLE - NOXAFIL</u>						
N 205053 001	>A> 5661151	Jul 19, 2019	DS DP U-1454			
	>A> 5703079	Aug 26, 2014	DS DP U-1454			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PRALATREXATE - FOLOTYN</u>						
N 022468 001	6028071	Jul 16, 2022	DS DP U-1004			
<u>PRALATREXATE - FOLOTYN</u>						
N 022468 002	6028071	Jul 16, 2022	DS DP U-1004			
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 001	8404703	Nov 12, 2022				
	8569325	Nov 12, 2022	U-1381			
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 002	8404703	Nov 12, 2022				
	8569325	Nov 12, 2022	U-1381			
<u>PREDNISONE - RAYOS</u>						
N 202020 001	8394407	Apr 23, 2024	DP U-1362		M-128	Jul 26, 2015
<u>PREDNISONE - RAYOS</u>						
N 202020 002	8394407	Apr 23, 2024	DP U-1362		M-128	Jul 26, 2015
<u>PREDNISONE - RAYOS</u>						
N 202020 003	8394407	Apr 23, 2024	DP U-1362		M-128	Jul 26, 2015
<u>PREGABALIN - LYRICA</u>						
N 022488 001					I-651	Jun 20, 2015
<u>PROPOFOL - DIPRIVAN</u>						
N 019627 002	8476010	Dec 01, 2024	DS DP			
	8476010*PED	Jun 01, 2025				
<u>RABEPRAZOLE SODIUM - ACIPHEX SPRINKLE</u>						
N 204736 001	5045552	May 08, 2013	DS DP U-385		NDF	Mar 26, 2016
	5045552*PED	Nov 08, 2013			PED	Sep 26, 2016
<u>RABEPRAZOLE SODIUM - ACIPHEX SPRINKLE</u>						
N 204736 002	5045552	May 08, 2013	DS DP U-385		NDF	Mar 26, 2016
	5045552*PED	Nov 08, 2013			PED	Sep 26, 2016
<u>RADIUM RA-223 DICHLORIDE - XOFIGO</u>						
N 203971 001	6635234	Jan 03, 2020	U-1405		NCE	May 15, 2018
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001	8470801	Jun 22, 2019	U-116			
	8536150	Jun 22, 2019	U-116			
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001					I-667 ODE	Feb 25, 2016 Feb 25, 2020
<u>REPAGLINIDE - REPAGLINIDE</u>						
A 077571 002					PC	Jan 20, 2014
<u>REPAGLINIDE - REPAGLINIDE</u>						
A 077571 003					PC	Jan 20, 2014
<u>REPAGLINIDE - PRANDIN</u>						
N 020741 002	6677358	Jun 12, 2018	DS DP U-1265	Y		
<u>REPAGLINIDE - PRANDIN</u>						
N 020741 003	6677358	Jun 12, 2018	DP U-1265	Y		
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 001	8518949	Mar 27, 2026	DP			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	8518949	Mar 27, 2026	DP			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 001	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
	7173037	Apr 25, 2023	DS DP		ODE	Oct 08, 2020
					ODE	Oct 08, 2020
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 002	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
	7173037	Apr 25, 2023	DS DP		ODE	Oct 08, 2020
					ODE	Oct 08, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIOCIQUAT - ADEMPAS</u>						
N 204819 003	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
	7173037	Apr 25, 2023	DS DP		ODE	Oct 08, 2020
					ODE	Oct 08, 2020
<u>RIOCIQUAT - ADEMPAS</u>						
N 204819 004	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
	7173037	Apr 25, 2023	DS DP		ODE	Oct 08, 2020
					ODE	Oct 08, 2020
<u>RIOCIQUAT - ADEMPAS</u>						
N 204819 005	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
	7173037	Apr 25, 2023	DS DP		ODE	Oct 08, 2020
					ODE	Oct 08, 2020
<u>RITONAVIR - NORVIR</u>						
N 022417 001	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8470347	Sep 17, 2026	DP			
	8470347*PED	Mar 17, 2027				
<u>RIVASTIGMINE - EXELON</u>						
N 022083 005					NPP	Jun 27, 2016
<u>RIZATRIPTAN BENZOATE - RIZATRIPTAN BENZOATE</u>						
A 078173 001					PC	Jun 29, 2013
<u>RIZATRIPTAN BENZOATE - RIZATRIPTAN BENZOATE</u>						
A 078173 002					PC	Jun 29, 2013
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001	8431154	Feb 19, 2023	DP			
	8536206	Mar 08, 2024	U-1115			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 001	5670524	Sep 23, 2014	DS DP U-833			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 003	5670524	Sep 23, 2014	DS DP U-833			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 004	5670524	Sep 23, 2014	DS DP U-833			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 005	5670524	Sep 23, 2014	DS DP U-833			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001	8415362	Dec 24, 2027	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002	8415362	Dec 24, 2027	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003	8415362	Dec 24, 2027	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	8415362	Dec 24, 2027	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	8415362	Dec 24, 2027	DS DP			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 022181 001	8318745	Nov 17, 2024	DP			
<u>SAQUINAVIR MESYLATE - INVIRASE</u>						
N 020628 001					M-61	Nov 30, 2015
					PED	May 30, 2016
<u>SAQUINAVIR MESYLATE - INVIRASE</u>						
N 021785 001					M-61	Nov 30, 2015
					PED	May 30, 2016
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001	RE44186	Jul 31, 2023	DS DP U-995			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002	RE44186	Jul 31, 2023	DS DP U-995			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SERTRALINE HYDROCHLORIDE - ZOLOFT</u>						
N 020990 001	7067555	Oct 11, 2019	DP			
	7067555*PED	Apr 11, 2020				
<u>SIMEPREVIR - OLYSIO</u>						
N 205123 001					>A> NCE	Nov 22, 2018
<u>SODIUM NITRITE - SODIUM NITRITE</u>						
N 203922 001	8568793	Dec 24, 2031	DS DP			
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE</u>						
N 201444 001	8496973	Mar 29, 2031	DS DP U-1419			
	8568793	Dec 24, 2031	DS DP			
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	8457988	Dec 17, 2022	U-1110			
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N 203923 001	8496973	Mar 29, 2031	DS DP U-1419			
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N 021923 001					>A> I-677	Nov 22, 2016
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N 022239 001	8343130	Oct 18, 2022	DP			
<u>SUMATRIPTAN SUCCINATE - ZECUITY</u>						
N 202278 001	6745071	Feb 21, 2023	DP		NDF	Jan 17, 2016
	7973058	Apr 12, 2027	U-1328			
	8155737	Apr 12, 2027	U-1328			
	8366600	Apr 21, 2029	U-1327			
	8470853	Apr 12, 2027	U-1328			
	>A> 8597272	Apr 12, 2027	DP			
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 001	6440458	Mar 25, 2019	DP		NDF	Jul 19, 2016
	6576259	Mar 25, 2019	DP U-1420			
	6884433	Mar 25, 2019	DP U-1420			
	8551522	Mar 25, 2019	DP			
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 002	6440458	Mar 25, 2019	DP		NDF	Jul 19, 2016
	6576259	Mar 25, 2019	DP U-1420			
	6884433	Mar 25, 2019	DP U-1420			
	8551522	Mar 25, 2019	DP			
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 003	6440458	Mar 25, 2019	DP		NDF	Jul 19, 2016
	6576259	Mar 25, 2019	DP U-1420			
	6884433	Mar 25, 2019	DP U-1420			
	8551522	Mar 25, 2019	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 001	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 002	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 003	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 004	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 005	8114383	Oct 10, 2024	DP	Y		
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N 202207 001					NCE	Mar 13, 2018
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	5789379	Apr 14, 2015	DS DP U-1320		ODE	Dec 21, 2019
	7056886	Sep 18, 2022	DP U-1320			
	7847061	Nov 01, 2025	U-1320			
<u>TELAPREVIR - INCIVEK</u>						
N 201917 001	8431615	May 30, 2028	U-1398			
	8529882	Aug 31, 2021	U-1398			
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N 022110 001	6635618	Sep 11, 2023	DS DP U-728		I-673	Jun 21, 2016
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N 022110 002	6635618	Sep 11, 2023	DS DP U-728		I-673	Jun 21, 2016
<u>TELBIVUDINE - TYZEKA</u>						
N 022011 001					M-124	Jan 28, 2016
<u>TELBIVUDINE - TYZEKA</u>						
N 022154 001					M-124	Jan 28, 2016
<u>TEMSIROLIMUS - TORISEL</u>						
N 022088 001	8455539	Jul 25, 2023	DP			
	8455539*PED	Jan 25, 2024				
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 001					M-128	Jul 24, 2016
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 002					M-128	Jul 24, 2016
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 003					M-128	Jul 24, 2016
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 004					M-128	Jul 24, 2016
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 022577 001					M-128	Jul 24, 2016
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 001	6794410	Apr 15, 2022	U-1285			
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 002	6794410	Apr 15, 2022	U-1285			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	8419307	Feb 26, 2027	U-1386			
	8435944	Jul 05, 2027	U-1390			
<u>TESTOSTERONE - TESTOSTERONE</u>						
N 203098 001					NP	Jan 31, 2016
<u>TESTOSTERONE - TESTOSTERONE</u>						
N 203098 002					NP	Jan 31, 2016
<u>TESTOSTERONE - TESTOSTERONE</u>						
N 203098 003					NP	Jan 31, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	8425934	Dec 18, 2029	DP			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	8372995	Oct 08, 2030	DP			
<u>TIMOLOL MALEATE - ISTALOL</u>						
N 021516 001	6645963	Nov 02, 2018	DP			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020912 001	6770660	May 01, 2023				
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 001	6770660	Jun 01, 2023				
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 002	6770660	Jun 01, 2023				
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 003	6770660	Jun 01, 2023				
<u>TOBRAMYCIN - TOBI PODHALER</u>						
N 201688 001	7097827	Apr 16, 2016	DP		NP	Mar 22, 2016
	7368102	Dec 19, 2022	DP U-909			
	7442388	May 10, 2020	DP			
	7516741	Jan 11, 2024	DP			
	7559325	Oct 27, 2025	DP			
	8069851	Sep 24, 2024	DP			
	8349294	May 10, 2020	DP			
<u>TOBRAMYCIN - BETHKIS</u>						
N 201820 001	6987094	Sep 22, 2022	DP			
	7696178	Mar 17, 2023	DP			
	7939502	Jun 14, 2022	U-1324			
<u>TOLTERODINE TARTRATE - DETROL LA</u>						
N 021228 001	6911217	Nov 11, 2019	DP U-544			
	6911217*PED	May 11, 2020				
<u>TOLTERODINE TARTRATE - DETROL LA</u>						
N 021228 002	6911217	Nov 11, 2019	DP U-544			
	6911217*PED	May 11, 2020				
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 001	5258510	Nov 02, 2013	DS DP			
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 002	5258510	Nov 02, 2013	DS DP			
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 003	5258510	Nov 02, 2013	DS DP			
	8501730	Sep 01, 2026	DS			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	8298576	Mar 18, 2029	DP U-106			
	8298580	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	8298576	Mar 18, 2029	DP U-106			
	8298580	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	8298576	Mar 18, 2029	DP U-106			
	8298580	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	8298576	Mar 18, 2029	DP U-106			
	8298580	Nov 16, 2027	DP U-106			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	7378423	Sep 13, 2025	DS DP		NCE	May 29, 2018
	>A> 8580304	Jan 28, 2032	DP		ODE	May 29, 2020
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	7378423	Sep 13, 2025	DS DP		NCE	May 29, 2018
	>A> 8580304	Jan 28, 2032	DP		ODE	May 29, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	7378423	Sep 13, 2025	DS DP		NCE	May 29, 2018
>A>	8580304	Jan 28, 2032	DP		ODE	May 29, 2020
<u>TRANEXAMIC ACID - TRANEXAMIC ACID</u>						
A 202093 001					PC	Jul 02, 2013
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N 022430 001	8487005	Mar 04, 2025	DP U-1182			
<u>TRAVOPROST - TRAVATAN Z</u>						
N 021994 001	8388941	Sep 20, 2027	DP			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001	7999007	Mar 29, 2029	DP U-1437			
	8497393	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002	7999007	Mar 29, 2029	DP U-1437			
	8497393	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003	7999007	Mar 29, 2029	DP U-1437			
	8497393	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	7999007	Mar 29, 2029	DP U-1437			
	8497393	Dec 15, 2028	DS			
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	8497393	Dec 15, 2028	DS			
<u>TRIAMCINOLONE ACETONIDE - NASACORT ALLERGY 24 HOUR</u>						
N 020468 002	>A> 5976573	Jul 03, 2016	DP			
	>A> 6143329	Jul 03, 2016	DP			
	>A> 7977045	Jul 03, 2016	DP			
<u>TROSPIMUM CHLORIDE - TROSPIMUM CHLORIDE</u>						
A 091289 001					PC	Apr 10, 2013
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	8426392	Jun 12, 2030	U-1389			
	8512745	Feb 14, 2030	DP			
<u>UNOPROSTONE ISOPROPYL - RESCULA</u>						
N 021214 001	6770675	Nov 24, 2018	DP U-1322			
<u>VELAGLUCERASE ALFA - VPRIV</u>						
N 022575 001					>A> M-130	Nov 21, 2016
<u>VELAGLUCERASE ALFA - VPRIV</u>						
N 022575 002					>A> M-130	Nov 21, 2016
<u>VEMURAFENIB - ZELBORAF</u>						
N 202429 001	8470818	Aug 02, 2026	U-1418			
<u>VIGABATRIN - SABRIL</u>						
N 020427 001					NCE	Aug 21, 2014
					>A> NPP	Oct 26, 2016
					PED	Feb 21, 2015
					>A> PED	Apr 26, 2017
<u>VIGABATRIN - SABRIL</u>						
N 022006 001					NCE	Aug 21, 2014
					>A> NPP	Oct 26, 2016
					ODE	Aug 21, 2016
					PED	Feb 21, 2015
					PED	Feb 21, 2017
					>A> PED	Apr 26, 2017
<u>VORICONAZOLE - VORICONAZOLE</u>						
A 202361 001					PC	Mar 24, 2014
<u>VORINOSTAT - ZOLINZA</u>						
N 021991 001	RE38506	Jul 07, 2015	DS DP			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 001	7144884	Jan 09, 2023	DS DP U-1439		NCE	Sep 30, 2018
	8476279	Oct 02, 2022	DP U-1439			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2013

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 002	7144884	Jan 09, 2023	DS DP U-1439		NCE	Sep 30, 2018
	8476279	Oct 02, 2022	DP U-1439			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 003	7144884	Jan 09, 2023	DS DP U-1439		NCE	Sep 30, 2018
	8476279	Oct 02, 2022	DP U-1439			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 004	7144884	Jan 09, 2023	DS DP U-1439		NCE	Sep 30, 2018
	8476279	Oct 02, 2022	DP U-1439			
<u>ZOLEDRONIC ACID - RECLAST</u>						
N 021817 001	8052987	Oct 27, 2023	U-1199			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 001	8512747	Sep 24, 2019	U-674			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 002	8512747	Sep 24, 2019	U-674			

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 33rd Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of exclusivity terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>